ISBN: 0-8247-0274-3 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New Y...
63 downloads
779 Views
3MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
ISBN: 0-8247-0274-3 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016 tel: 212-696-9000; fax: 212-685-4540 Eastern Hemisphere Distribution Marcel Dekker AG Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-261-8482; fax: 41-61-261-8896 World Wide Web http:/ /www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above. Copyright 2001 by Marcel Dekker, Inc. All Rights Reserved. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. Current printing (last digit): 10 9 8 7 6 5 4 3 2 1 PRINTED IN THE UNITED STATES OF AMERICA
To my wife, Tammy, my children, Shoshana, Avielle, Shira, and Aviva, and my parents, Sam and Sonia. Benjamin Movsas To my wife, Mindy, my children, Adina and Micah, and my parents, Leon and Rita. Corey Langer To my wife, Judith, and my children, Jennifer, Joanna, and Heather. Melvyn Goldberg
Series Introduction
The current volume, Controversies in Lung Cancer: A Multidisciplinary Approach, is Volume 25 in the Basic and Clinical Oncology series. Many of the advances in oncology have resulted from close interaction between the basic scientist and the clinical researcher. The current volume follows, expands on, and illustrates the success of this relationship as demonstrated by new therapies and promising areas for scientific research. As editor of the series, my goal has been to recruit volume editors who not only have established reputations based on their outstanding contributions to oncology, but also have an appreciation for the dynamic interface between the laboratory and the clinic. To date, the series has consisted of monographs on topics such as chronic lymphocytic leukemia, nucleoside analogs in cancer therapy, therapeutic applications of interleukin-2, retinoids in oncology, gene therapy of cancer, and principles of antineoplastic drug development and pharmacology. Controversies in Lung Cancer is certainly a most important addition to the series.
v
vi
Series Introduction
Volumes in progress include a work on chronic lymphoid leukemias. I anticipate that this and future volumes will provide a valuable contribution to the oncology literature. Bruce D. Cheson, M.D.
Foreword
Although progress is being made in the treatment of lung cancer, the long-term survival rate for lung cancer patients remains disappointing. In order to effect a major impact on lung cancer survival, the paradigm must shift. Currently, too many people develop lung cancer, too many people present with locally advanced or disseminated disease, and too many people have tumors that are refractory to available systemic treatment. Fortunately, there are potential ways to influence the frequency of lung cancer, the stage of the disease, and responsiveness to systemic therapy. First, optimism exists that educational efforts directed toward children will result in a decline in the prevalence of smoking. Second, low-dose rapid spiral CT scans of the chest may detect disease earlier in persons at risk and reduce the percentage of patients who present with advanced disease. Lastly, treatments directed at novel targets—including autocrine growth factors, angiogenesis, and defective programmed cell death—may provide new venues to treat locally advanced and disseminated disease and ultimately lead to less toxic, more effective adjuvant therapy. vii
viii
Foreword
Although we anticipate a favorable shift in the lung cancer paradigm, we must urgently confront our current challenge—to provide the most effective available treatment now for hundreds of thousands of lung cancer patients, who will be diagnosed in the next five years and who cannot wait for theoretical therapies. The editors of Controversies in Lung Cancer have carefully identified key areas where real progress has been achieved and where continued work is likely to result in further improvement. Equally important, they have gathered an impressive group of recognized experts in the field who are themselves directly involved in this task. The book begins with a refreshing discussion on lung cancer staging. TNM staging was adopted for lung cancer more than three decades ago, and the staging system has since been refined twice (1986 and 1997). The authors of Chapter 1 highlight the current inadequacies of the staging system and discuss possibilities for improving it. The next two chapters focus on the results achieved in limitedstage small cell lung cancer. In the year 2000, more than 25% of limited-stage small cell lung cancer patients treated with concurrent chemotherapy and radiation had survived for at least five years; this has truly ‘‘raised the bar’’ compared to results only 10 to 20 years ago. Using evidence-based medicine, the authors of subsequent chapters meticulously address dilemmas regarding local therapy (including the proper timing, volume, and fractionation schedule for radiation therapy) and revisit the heretofore dormant issue of surgical treatment. The potential drawbacks and benefits of prophylactic cranial radiation and chemotherapy dose intensification are also discussed in detail. The relative pros and cons are presented in a balanced manner that enables the reader to fully appreciate the subtleties behind each position. Other topics in the book include novel strategies to improve outcome in selected groups of locally advanced non–small cell lung cancer patients; the role of adjuvant postoperative chemotherapy and radiation therapy; surgery versus chemoradiation in patients with marginally resectable stage III disease; and opposing viewpoints on a recently emerging controversy—three-dimensional conformal radiation therapy versus conventional radiation in lung cancer. In addition to providing information in a pro/con format for the most controversial issues, this text presents comprehensive, state-of-the-art discussions of supportive care, chemoprevention, endobronchial therapy, economic and resource analyses, and the role of chemotherapy dose intensification in non–small cell lung cancer. For the clinician involved in the management of lung cancer, this book is an invaluable resource. Because of our increasing workloads, we have considerable difficulty in collecting and assimilating, on our own, the critical information necessary to provide the best possible care for patients. The well-organized and thoughtful presentations in Controversies in Lung Cancer will help the multidisciplinary team of lung cancer physicians and nurses to achieve their primary
Foreword
ix
objectives—to improve not only the quantity, but also the quality, of life for patients with lung cancer. Philip Bonomi, M.D. Director, Section of Medical Oncology Rush-Presbyterian-St. Luke’s Medical Center Chicago, Illinois
Preface
Lung cancer is the leading cause of cancer death in the United States for both men and women. Indeed, the number of deaths per year from lung cancer exceeds that of the second, third, and fourth leading causes of cancer death (viz., breast, prostate, and colorectal cancer) combined. It is not surprising, then, that many exhaustive textbooks have been written on this subject, encompassing a vast amount of intricate details about pathological factors, molecular markers, staging workup, and so forth. Despite the wealth of information available on lung cancer, many controversies and dilemmas still exist. Rather than focus on what is already known and accepted, we have decided to tackle challenging issues that remain unresolved. In this light, we have divided the chapters into ‘‘controversies’’ and ‘‘dilemmas.’’ For the chapters centering on controversies, both ‘‘pro’’ and ‘‘con’’ viewpoints are presented. Although similar material is sometimes presented in the opposing chapters, the key difference between the two lies in the interpretation of and emphasis placed on the studies discussed. We believe that it is important xi
xii
Preface
for the reader to be exposed to the subtleties behind both arguments in such controversies. Other topics do not lend themselves as readily to this format, but still constitute an ongoing dilemma worthy of discussion. For example, the opening chapter addresses current issues regarding staging. How are new techniques, such as PET scanning, to be incorporated into our staging algorithms? Leading national and international authorities on particular subjects have been selected to present their views. For example, a heated controversy still exists regarding the timing of thoracic radiotherapy for patients with limited-stage small cell lung cancer. Arguing for early administration of radiotherapy in Chapter 2 is Nevin Murray, first author of the NCI Canada randomized trial favoring early over delayed radiotherapy. The opposing argument is presented in Chapter 3 by Mark Bryer and Michael C. Perry, the lead author of the CALGB randomized trial suggesting a benefit to delayed radiotherapy. The authors (pro and con) of each chapter use evidence-based medicine to support the ‘‘bottom line’’ of why they favor one of two contrary approaches. Chapter 4 leads the reader through the ongoing dilemmas regarding radiotherapy fractionation and volume in small cell lung cancer. Chapter coauthor Andrew Turrisi was first author of the pivotal randomized trial (recently published in the New England Journal of Medicine) on radiation fractionation in lung cancer patients. Throughout this volume, not only are the authors leading experts in the treatment of lung cancer, but they have been specifically chosen to address issues about which they feel passionate. This applies not only to the chapters on small cell lung cancer, but also to the subsequent section on non– small cell lung cancer. The final section of the book investigates more global issues that apply to all patients with lung cancer. This book is geared toward the clinician who encounters these challenging problems in everyday oncologic practice. The management of lung cancer has become a multidisciplinary effort, requiring cooperation and communication among practitioners from various fields. Indeed, the specialization of the editors represent the three major modalities of treatment—radiation, medical, and surgical oncology. In our weekly Multidisciplinary Thoracic Oncology Tumor Board at Fox Chase Cancer Center, we have attempted to share our observations and thus highlight many of the dilemmas that confront us within and across disciplines. Controversies in Lung Cancer will prove a valuable resource, not only for oncologists and thoracic surgeons, but also for pulmonologists and general practitioners, who share the burden of caring for this large group of patients. Pulmonologists will find several chapters devoted to the supportive care of patients with lung cancer. These chapters include discussions of the preoperative pulmonary evaluation of patients, as well as the management of the key side effects of thoracic radiation and chemotherapy, pneumonitis, and esophagitis.
Preface
xiii
In the current era of second opinions, patients often lose their direction on the ‘‘information superhighway’’ and look toward their primary physician for guidance and assurance. This book helps crystallize the reasoning behind the opinions that patients often face, and it enables their physicians to make this information more understandable and accessible. The book will also be an indispensable reference for oncology nurses who are instrumental in taking care of patients with lung cancer. Finally, residents and medical students can glean countless insights regarding the management of lung cancer patients, and observe how evidence-based medicine can be used to formulate cogent arguments at chart rounds or tumor boards. We would like to take this opportunity to thank the many contributors who have worked diligently to present their perspectives in the prescribed format. We would also like to acknowledge Sandra Beberman and Michael Deters of Marcel Dekker, Inc., for their tireless efforts and Louise Marcewicz for her excellent secretarial support. We are deeply grateful to our families, who supported us wholeheartedly in this worthwhile project. Finally, we are forever indebted to our patients, whose courage and determination continue to inspire us. Benjamin Movsas Corey J. Langer Melvyn Goldberg
Contents
Series Introduction Foreword Preface Contributors
v vii xi xix
Part I Staging 1. Staging Dilemmas in Lung Cancer Swan S. Leong and Mark R. Green
1
Part II Small Cell Lung Cancer (SCLC) 2. Early Timing of Radiotherapy Is Critical in LimitedStage SCLC: Pro Nevin Murray
17 xv
xvi
Contents
3. Early Timing of Radiotherapy Is Critical in LimitedStage SCLC: Con Mark Bryer and Michael C. Perry 4. Limited-Stage SCLC: Radiotherapy Fractionation and Volume Issues Todd Williams, Charles Thomas, Jr., and Andrew Turrisi III
33
43
5. The Role of Prophylactic Cranial Irradiation: Pro Ce´cile Le Pe´choux, Thierry Le Chevalier, and Rodrigo Arriagada
59
6. The Role of Prophylactic Cranial Irradiation: Con Alan Sandler
79
7. Dose Intensification of Chemotherapy in SCLC: Pro Anthony Elias
91
8. Dose Intensification of Chemotherapy in SCLC: Con Russell F. Devore III
107
9. The Role of Surgery in SCLC Frances A. Shepherd
125
Part III Non–Small Cell Lung Cancer (NSCLC) 10. Adjuvant Therapy for Resected Stages II and IIIA NSCLC: Pro Ritsuko Komaki
149
11. Adjuvant Therapy for Resected Stages II and IIIA NSCLC: Con Steven M. Keller and Zvi Small
185
12. Surgery for Potentially/Marginally Resectable Pathological N2 NSCLC: Pro William H. Warren
197
Contents
13. Surgery for Potentially/Marginally Resectable Pathological N2 NSCLC: Con Elizabeth M. Gore and Roger W. Byhardt
xvii
213
14. Management of Superior Sulcus Tumors Garrett L. Walsh, Sunil Gandhi, and Ritsuko Komaki
225
15. Extended Resections in Stage T4 NSCLC: Pro Chong Hee Lim, Thomas W. Rice, and Eugene H. Blackstone
257
16. Extended Resections in Stage IIIB NSCLC: Con Richard I. Inculet
273
17. NSCLC: Value of Three-Dimensional Conformal Radiotherapy: Pro Mary V. Graham
279
18. NSCLC: Value of Three-Dimensional Conformal Radiotherapy: Con Eli Glatstein
299
19. Evolving Role of Chemotherapy in Stage IV NSCLC Desmond N. Carney 20. Chemotherapy Dose Intensification: Is There a Benefit in NSCLC? Primo N. Lara, Jr., Derick Lau, and David R. Gandara
309
327
Part IV Global Lung Cancer Dilemmas 21. Chemoprevention of Lung Cancer Daniel D. Karp and Mark D. Bergman 22. Supportive Care in Thoracic Oncology: Perioperative Pulmonary Concerns Earl King
349
373
xviii
Contents
23. Supportive Care in Thoracic Oncology: Chemoradiation Pneumonitis and Esophagitis—Characteristics and Management Sandra McDonald, Jan Dombrowski, Jacqueline Williams, and Philip Rubin
389
24. Supportive Care in Thoracic Oncology: Preemptive Management of Myelosuppression Jeffrey Crawford
421
25. Role of Laser, Photodynamic Therapy, Cryotherapy, and Electrocautery in Endobronchial Therapy Michael Unger
439
26. Endobronchial Brachytherapy: Its Niche in Lung Cancer Burton L. Speiser
449
27. Tumor Oxygenation and Radioresistance: From the Laboratory to the Clinic J. Donald Chapman and R. C. Urtasun
481
28. Economic Analysis in Lung Cancer Craig C. Earle, Douglas Coyle, and William K. Evans Index
499
521
Contributors
Rodrigo Arriagada, M.D. Department of Radiation Oncology, Instituto de Radiomedicina, Santiago, Chile Mark D. Bergman, M.D., Ph.D. Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Eugene H. Blackstone, M.D. Department of Thoracic and Cardiovascular Surgery, Department of Epidemiology and Biostatistics, Cleveland Clinic Foundation, Cleveland, Ohio Mark Bryer, M.D. Radiation Oncology, University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri Roger W. Byhardt, M.D. Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin xix
xx
Contributors
Desmond N. Carney, M.D., Ph.D. Department of Medical Oncology, Mater Hospital, and University College Dublin, Dublin, Ireland J. Donald Chapman, Ph.D. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania Douglas Coyle Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada Jeffrey Crawford, M.D. Director of Clinical Research, Duke Comprehensive Cancer Center, Durham, North Carolina Russell F. DeVore III, M.D.* Thoracic Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee Jan Dombrowski, M.D. Department of Radiation-Oncology, Genesee Hospital, Rochester, New York Craig C. Earle, M.D. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Anthony Elias, M.D. Adult Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts William K. Evans, M.D. Oncology Program, University of Ottawa, Cancer Care Ontario, Ottawa, Ontario, Canada David R. Gandara, M.D. Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Cancer Center, Sacramento, California Sunil Gandhi, M.D. University of Texas M. D. Anderson Cancer Center, Houston, Texas Eli Glatstein, M.D. Vice Chairman, Department of Radiation Oncology, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania Elizabeth M. Gore, M.D. Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
* Current affiliation: East Tennessee Oncology/Hematology, Knoxville, Tennessee.
Contributors
xxi
Mary V. Graham, M.D. Director, Radiation Oncology, Phelps County Regional Medical Center, Rolla, Missouri Mark R. Green, M.D. Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina Richard I. Inculet, M.D. Division of Thoracic Surgery, London Health Sciences Centre, London, Ontario, Canada Daniel D. Karp, M.D. Director, Cancer Clinical Trials Office, Department of Hematology/Oncology, Harvard Medical School, Boston, Massachusetts Steven M. Keller, M.D.* Chief, Division of Thoracic Surgery, Beth Israel Medical Center, New York, and Cardiothoracic Surgery, Albert Einstein College of Medicine, Bronx, New York Earl King, M.D. Director, Pulmonary Medicine and Respiratory Care, Fox Chase Cancer Center, Philadelphia, Pennsylvania Ritsuko Komaki, M.D. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas Primo N. Lara, Jr., M.D. Department of Internal Medicine, Division of Hematology-Oncology, University of California Davis Cancer Center, Sacramento, California Derick Lau, M.D., Ph.D. Department of Internal Medicine, Division of Hematology-Oncology, University of California Davis Cancer Center, Sacramento, California Thierry Le Chevalier, M.D. Department of Medicine, Institut GustaveRoussy, Villejuif, France Ce´cile Le Pe´choux, M.D. Department of Radiotherapy, Institut GustaveRoussy, Villejuif, France Swan S. Leong, M.D. Department of Medical Oncology, National Cancer Center, Singapore, Republic of Singapore
* Current affiliation: Montefiore Medical Center, Bronx, New York.
xxii
Contributors
Chong Hee Lim, M.D. Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio Sandra McDonald Department of Radiation Oncology, Genesee Hospital, Rochester, New York Nevin Murray, M.D. Department of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada Michael C. Perry, M.D. Division of Hematology/Oncology, University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri Thomas W. Rice, M.D. Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio Philip Rubin, M.D. Radiation Oncology, University of Rochester Cancer Center, Rochester, New York Alan Sandler, M.D. Department of Hematology/Oncology, Vanderbilt University, Nashville, Tennessee Frances A. Shepherd, M.D. Division of Medical Oncology, Princess Margaret Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada Zvi Small, M.D. Albert Einstein College of Medicine, Bronx, New York Burton L. Speiser, M.D. Medical Director, Department of Radiation Oncology, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona Charles Thomas, Jr., M.D.* Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina Andrew T. Turrisi III, M.D. Chairman, Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina
* Current affiliation: University of Texas Health Science Center at San Antonio, San Antonio Cancer Institute, San Antonio, Texas.
Contributors
xxiii
Michael Unger, M.D. Pulmonary Cancer Detection and Prevention Program, Fox Chase Cancer Center, and Thomas Jefferson Medical College, Philadelphia, Pennsylvania R. C. Urtasun, M.D. Professor Emeritus, Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada Garrett L. Walsh, M.D. Department of Thoracic and Cardiovascular Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas William H. Warren, M.D. Departments of Cardiovascular-Thoracic Surgery and Pathology, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois Jacqueline Williams, Ph.D. Radiation Oncology, University of Rochester Cancer Center, Rochester, New York Todd Williams, M.D. Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina
1 Staging Dilemmas in Lung Cancer Swan S. Leong National Cancer Center, Singapore, Republic of Singapore
Mark R. Green Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
INTRODUCTION The goals of a cancer staging system are to standardize the description of disease based on extent and severity; to reflect the different prognoses of each stage group; to direct management; and to facilitate conduct and comparison of clinical and translational research. Lung cancer staging, built upon this template, has undergone significant changes over the last two decades as more data on the behavior and outcome of disease have been accumulated and different management strategies, based on patterns of failure and treatment endpoints for different groups of patients, have been implemented. The accuracy of staging investigations has also improved as new tools and techniques have become available, enhancing the validity and usefulness of the lung cancer staging system. Issues and questions remain however. These issues continue to fuel discussion and reexamination of the International Lung Cancer Staging System. 1
2
Leong and Green
EVOLUTION OF LUNG CANCER STAGING Several classifications for lung cancer staging were proposed but none became widely accepted until the 1970s, when the American Joint Committee for Cancer Staging and End Results Reporting (AJCC) put forth an evidence-based proposal for staging. In 1973, the AJCC Task Force on Carcinoma of the Lung, adopting the TNM classification scheme as described by Denoix (1), recommended criteria for clinical staging of lung cancer. This staging system was based on information collected from 2155 patients with bronchogenic carcinoma (2). Variables such as size, location, and extent of primary tumor; association with obstructive pneumonitis, atelectasis, and pleural effusion; spread of tumor to different lymph node stations; and involvement of distant organs were analyzed against survival data. The T (T0–3 ), N (N 0–2 ), and M (M 0–1 ) categories were developed based on these data. In the 1973 system, the presence of pleural effusion (either with or without malignant cells) and the involvement of mediastinal structures by direct tumor invasion were placed in a heterogeneous T3 category. This grouping also included much more limited tumors, for example those involving only the chest wall. This arrangement was based on survival data that were available at the time and reflected the inadequate radiographic staging tools in use at the time. We now know that this diverse T3 category includes several subgroups with different treatment options and important outcome differences (3–6). Stage groupings were formed from analysis of more than 300 survival curves plotted for various combinations of T, N, and M descriptors. Three stage groups were defined, with stage I disease demonstrating the best outcome and stage III the worse. Stage I disease included T1–2 N 0 M 0 and T1 N 1 M 0 tumors. Stage II disease, the smallest category, included just T2 N 1 M 0 tumors. Stage III disease included all T3 , N 2 , or M 1 tumors. The stage III disease category, like the T3 category, was very broad and had patients ranging from those with locally infiltrative disease to patients with systemic metastasis. This staging system reflected the limited treatment options of that era. Essentially all of the stage III patients, with the exception of those with T3 N 0 disease, had a dismally poor outlook. Even in this early analysis, the survival estimates of patients with T3 N 0 M 0 disease, including some with superior sulcus tumors, demonstrated some chance for longterm survival (2,4). Yet in the 1973 staging system no stage III subgroups were defined to acknowledge that fact. Survival for patients with small cell carcinoma was also recognized to be exceptionally poor regardless of the demonstrated extent of disease. The proposed TNM guidelines were viewed as inappropriate for staging of small cell lung cancer. The 1973 staging system’s three stages generally reflected prognoses as appropriate for that period. However, with improvements in imaging techniques and treatment approaches, the deficiencies of the system became increasingly
Lung Cancer Staging
3
apparent. Various meetings held during 1985 by members of AJCC, Union Internationale Contre Cancer (UICC), and Japanese and German representatives culminated in the proposal for a revised International Staging System for Lung Cancer, published in 1986 (7). The database for this revision comprised records of 3753 lung cancer patients from M.D. Anderson Hospital and the North American Lung Cancer Study Group’s Reference Center for Anatomic and Pathologic Classification of Lung Cancer. Changes from the 1973 system were intended to better reflect prognoses and provide more meaningful guidelines for directing management. Tumors with invasion of mediastinal structures or vertebral bodies and tumors associated with a malignant pleural effusion were moved from T3 to a new category of T4 tumors. Malignant effusion was more fully defined to exclude pleural fluids that were cytologically negative, nonbloody, and not exudative. A footnote to the staging system defined superficial tumors limited to the bronchial wall as T1 , irrespective of the distance of involvement along the bronchial mucosa and proximity to the main bronchus. Mediastinal nodes were divided into two categories. N 2 disease was now limited to ipsilateral mediastinal and subcarinal lymph node involvement while a new N 3 descriptor, including supraclavicular, contralateral hilar (previously designated M 1 ), and contralateral mediastinal lymph nodes, was added. Although the prognosis of patients with contralateral hilar and supraclavicular lymph nodes (N 3 ) was recognized to be very poor, these areas of involvement were readily included in the field of radiation treatment and were considered regional spread by radiation oncologists. In the 1986 system, the stage groupings were also revised. Patients with T1 N 0 M 0 tumors, with 5-year survival rates of more than 60%, were recognized as a particularly favorable subgroup. The possibility of having a totally separate stage group was considered but ultimately this was not implemented. T1 N 1 M 0 disease, having a poorer prognosis than N 0 patients because of lymph node involvement (8,9), was combined with T2 N 1 M 0 disease as stage II. The heterogeneous stage III category of the first AJCC system was now separated into locally advanced disease (stage III) and disseminated disease (stage IV). Surgery was clearly the primary treatment approach for stage I and II disease while palliative management was indicated for stage IV disease. The new stage III category was too complex from the outset to uniformly define prognosis and direct therapy. Therefore, it was further subdivided into IIIA (T3 and/or N 2 ), where complete resection might still be feasible, and IIIB (T4 and/or N 3 ), where it usually was not feasible. The second major revision in the lung cancer staging system was implemented in 1997 (10), following a decade of working with the 1986 system. The 1997 revision was again based on patient data, an analysis of records from 5319 lung cancer patients treated at the M.D. Anderson Cancer Center from 1975 to 1988, and by the North American Lung Cancer Study Group from 1977 to 1982.
4
Leong and Green
TABLE 1 Primary Tumor (T)
Tx
T0 Tis T1
T2
T3
T4
1974
1986
Tumor proven by malignant cells in bronchopulmonary secretions but not visualized by imaging or bronchoscopically No evidence of tumor — Tumor 3 cm or less, surrounded by lung or visceral pleura, without invasion proximal to a lobar Tumor with any of the following: ⬎3 cm; involves main bronchus but ⱖ2 cm distal to carina; invades visceral pleura; assoc. with atelectasis or obstructive pneumonitis which involve ⬍1 lung Tumor that invades all adjacent structures including mediastinum and its contents; or ⬍2 cm from carina; or assoc. with atelectasis or obstructive pneumonitis that involves the whole lung; or pleural effusion
Same as 1974 ⫹ primary tumors that cannot be assessed
Same as 1986
Same as 1974 Carcinoma in situ Same as 1974
Same as 1974 Same as 1986 Same as 1974
Same as 1974
Same as 1974
—
1997
Tumor that invades: Same as 1986 chest wall; diaphragm, mediastinal pleura, parietal pericardium; main bronchus ⬍2 cm from carina but not involving it; assoc. with atelectasis or obstructive pneumonitis that involves the whole lung Tumor that invades: medi- Same as 1986 ⫹ satellite tumor astinal structures including heart, great vesnodule(s) within sels, trachea, ipsilateral priesophagus; vertebral mary-tumor lobe body; or presence of of lung malignant effusion
Source: Leong et al. Chest 1999; 115:242–248.
Lung Cancer Staging
5
Among the issues addressed by the 1997 revision were the varying prognoses of resectable tumors based on tumor diameter or the presence of multiple synchronous tumor ‘‘satellite’’ lesions in the same lung at diagnosis. In this most recent revision, stage I was divided into IA and IB, based on tumor size of 3 cm or less (T1 ) versus greater than 3 cm (T2 ) and the presence (T2 ) or absence (T1 ) of visceral pleural invasion. Stage II was also divided into IIA and IIB subgroups based on the same criteria. In addition, T3 N 0 M 0 patients were regrouped as stage IIB. Tumors with satellite nodules in the same lobe as the primary were designated T4 (stage IIIB). Synchronous lesions in a different lobe of the same lung as from the primary tumor were considered M 1 disease (Tables 1–4). Patients with T1 N 0 M 0 tumors have a significantly better outcome after complete resection compared to patients with T2 N 0 M 0 tumors. This had already been clear from the database of the 1986 staging proposal. In that database, the 5-year survival rate of patients with pathological T1 N 0 M 0 disease was 68.5% versus 59% for patients with T2 N 0 M 0 disease (7). Other series had also demonstrated the same finding. For example, of 461 patients with T1 N 0 M 0 or T2 N 0 M 0 disease treated with curative surgical resection between April 1972 and March 1978 at the Mayo Clinic, Williams et al. showed a 5-year survival rate of 80% for T1 N 0 M 0 disease compared to about 62% for T2 N 0 M 0 disease (8). Similar findings were noted by Naruke et al. (11) and Harpole et al. (12). Given the volume of data demonstrating a substantially superior survival outcome, T1 N 0 M 0 disease was given a separate subgroup heading of stage IA in the 1997 staging revisions,
TABLE 2 Regional Lymph Nodes (N) 1974
1986
1997
Nx
—
Same as 1986
N0
No regional lymph node metastasis Metastasis to ipsilateral hilar lymph nodes Metastasis to mediastinal lymph nodes —
Regional lymph nodes cannot be assessed Same as 1974
N1
N2
N3
Same as 1974
Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes Metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes
Same as 1986
Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral/ contralateral supraclavicular nodes
Same as 1986
Source: Leong et al. Chest 1999; 115:242–248.
Same as 1986
6
Leong and Green
TABLE 3 Distant Metastasis (M)
Mx
M0 M1
1974
1986
1997
—
Presence of distant metastasis cannot be assessed Same as 1974 Distant metastasis excluding scalene, cervical, and contralateral hilar nodes
Same as 1986
No distant metastasis Distant metastasis including involvement of scalene, cervical, and contralateral hilar lymph nodes
Same as 1974 Same as 1986
Source: Leong et al. Chest 1999; 115:242–248.
emphasizing the distinction from T2 N 0 M 0 disease. Watanabe et al. have demonstrated a continuous effect of tumor size on survival, finding not only a difference in 5-year survival between T1 N 0 M 0 disease (77.6%) and T2 N 0 M 0 disease (60.1%), but also a difference when comparing survival rates of patients with tumors measuring 3–5 cm in diameter (61%) and those with tumors greater than 5 cm (46%) TABLE 4 Stage Grouping (TNM Combinations) 1974 Occult Stage 0 Stage I
Stage II
1986 Tx N 0 M 0 Tis N 0 M 0 T 1 N 0 M0 T2 N 0 M 0 T1 N 1 M 0 T2 N 1 M 0
Stage III T3 , any N, any M Any T,N 2 , any M Any T, any N,M 1
—
1997
Occult Stage 0 Stage I
Tx N 0 M 0 Tis N 0 M 0 T1 N 0 M 0 T2 N 0 M 0
Occult Stage 0 Stage IA Stage IB
Stage II
T1 N 1 M 0 T2 N 1 M 0
Stage IIA Stage IIB
Stage IIIA T3 N 0 M 0 T3 N 1 M 0 T1 N 2 M 0 T2 N 2 M 0 T3 N 2 M 0 Stage IIIB T4 , any N,M 0 , any T,N 3 ,M 0 Stage IV Any T, any N,M 1
Source: Leong et al. Chest 1999; 115:242–248.
Txs N 0 M 0 Tis N 0 M 0 T1 N 0 M 0 T2 N 0 M 0
T1 N 1 M 0 T2 N 1 M 0 T3 N 0 M 0 Stage IIIA T3 N 1 M 0 T1 N 2 M 0 T2 N 2 M 0 T3 N 2 M 0
Stage IIIB T4 , any N,M 0 , any T,N 3 ,M 0 Stage IV Any T, any N,M 1
Lung Cancer Staging
7
(13). However, only two subgroups of stage I disease are designated in the current staging scheme. In the 1997 staging revision, stage II disease has also been divided into stage IIA and stage IIB subgroups based on T characteristics. A difference in prognosis is demonstrable between patients with T1 N 1 M 0 disease and those with T2 N 1 M 0 disease (7,11). However, the available data do not show as great a survival disparity between the two stage II subgroups as is seen in stage IA and IB patients. For example, Naruke et al. demonstrated a 5-year survival rate of 43.6% for patients with T1 N 1 M 0 disease and 37.6% for patients with T2 N 1 M 0 disease (11). Mountain found survival rates of 54.1% and 40%, respectively (7). In the current revision, T3 N 0 M 0 disease, which has shown a survival comparable to T2 N 1 M 0 disease, was also added to the stage IIB category. The 5-year survival rate for T3 N 0 patients was 31.6% in the Naruke series (11) and 44.2% in data presented by Mountain (7). Significant differences in survival rates following complete surgical resection have been shown between patients with T3 N 0–1 and T1–3 N 2 disease (14,15). Patients with T3 N 0 disease due to chest wall invasion do especially well after complete resection of their tumor (3,4). In such individuals, McCaughan et al. were able to show a 5-year survival rate of 56% (3). In retrospect T3 N 0 M 0 patients had been recognized as having a superior outcome at least since the 1974 staging system was proposed (2). In the survival data of the 1997 staging proposal, the 5-year survival rate for T3 N 0 patients was almost identical to that of patients with T2 N 1 M 0 disease (10), in contrast to the much poorer outcome for patients with N 2 disease (16,17), cementing the move of the T3 N 0 group from stage IIIA to stage IIB, where surgery represents the primary treatment approach. AREAS OF CONTROVERSY While the 1997 staging revision addressed several important issues already discussed, other compelling issues were either incompletely addressed or ignored. This means that the international lung cancer staging scheme will remain dynamic. Within a decade, as a broad experience with the 1997 system becomes available, additional discussion will inevitably lead to yet further revision of the current TNM staging classification. Some of the important questions less than fully addressed in the current staging system are discussed below. Pulmonary Nodules The 1986 staging system did not provide strong, evidence-based information for categorizing patients with synchronous satellite lesions or pulmonary nodules in the ipsilateral lung. However, in the footnotes of the fourth edition of the AJCC staging manual published in 1993, satellite lesions in the same lobe led to upstag-
8
Leong and Green
ing of the primary by one T category while the presence of a synchronous ipsilateral lesion in a separate lobe was categorized as T4 . The notion that ipsilateral synchronous nodules in a separate lobe should be considered T4 (stage IIIB) rather than hematogenous M 1 disease was questioned by many investigators. Some considered them as locally advanced disease while others considered them metastases. Deslauriers et al. retrospectively reviewed the records of 84 patients with primary lung cancer accompanied by one or more satellite nodules, and 1021 patients who had a primary lung cancer but no satellite nodules. All had undergone pulmonary resection between January 1969 and December 1986 (18). In most of the patients, the satellite nodule(s) occurred in the same lobe as the primary tumor (68 of 84). Disease was staged according to the 1974 guidelines, and survival was compared, stage for stage, in patients with and without satellite nodules. For patients without satellite nodules, the 5-year survival rates were 54.4% for stage I, 40.4% for stage II, and 20.3% for stage III disease. For patients with satellite nodules, the 5-year survival rates were 32%, 12.5%, and 5.6%, respectively, for stages I, II, and III disease. Since over 80% of the patients had their satellite nodules in the same lobe as the primary, no exploratory subset analysis of nodules occurring in the same lobe as the primary tumor versus those occurring in a different lobe was carried out. The work of Deslauriers did demonstrate that the presence of satellite nodules connoted a poorer prognosis. However, it also showed that some patients with satellite lesions in the same lobe as the primary tumor were able to achieve long-term survival with resection. In another retrospective review by Shimizu et al., 42 patients with lung cancer were found to have intrapulmonary satellite nodules in the pathology specimen obtained at the time of pulmonary resection (19). The 2-year survival rate was significantly better in patients with satellite lesions in the same lobe as the primary tumor (41.5%) than in patients with lesions in different lobes (20%). The presence of satellite nodules in the same lobe as the primary tumor did not necessarily preclude long-term survival following surgery. Watanabe et al., in an evaluation of 49 patients with ipsilateral intrapulmonary lesions, suggested that the survival of patients with satellite lesions was similar to that of stage IIIA patients without satellite lesions and superior to that of stage IIIB patients without satellite lesions (13). There was no breakdown as to how many of these individuals had lesions in the same lobe as the primary tumor and how many had them in different lobes, but clearly, the survival following surgery was better than would be expected from M 1 disease. In the 1997 revision of the staging system, satellite lesions in the same lobe as the primary tumor are categorized as T4 stage IIIB disease. Synchronous lesions outside the primary tumor lobe but in the ipsilateral lung are considered metastatic spread (M 1 ). This distinction is based in part on the proposed difference in the mechanisms of disease, with lesions in the same lobe thought to represent tumor emboli and lesions in different lobes considered hematogenous
Lung Cancer Staging
9
metastases. However, the T4 designation for satellite lesions in the same lobe suggests a poorer prognosis than appears warranted by the available data. Many surgeons continue to offer surgery to patients with T4 satellite lesions if the N and M status of their presentation do not preclude curative surgery. Pleural Effusion In the 1986 staging system, a malignant pleural effusion was defined as one containing malignant cells and/or one that was either bloody or exudative. In patients with lung cancer, the presence of a malignant pleural effusion confers a poor prognosis. Naruke et al. (11) compared the postoperative survival of 1298 lung cancer patients without a pleural effusion, 112 patients with a nonmalignant effusion, and 48 patients with malignant pleural fluid at surgery. Five-year survival rates for the three groups were 40%, 39.2%, and 10.7%, respectively. In the Naruke series, the survival of the patients with malignant pleural effusion was similar to that of all operated patients with T4 disease (8.4%) seen in the database for the 1986 staging system. This suggested at the time that it was reasonable to include malignant pleural effusion within the T4 stage IIIB category. As management strategies have evolved to include multimodality treatment for T4 stage IIIB disease, the inclusion of malignant pleural effusion in the T4 category has become more problematic. The substantial advances made over the last decade for managing patients with stage III disease all involve local or regional treatment modalities designed to eradicate intrathoracic disease (20,21). The presence of a malignant effusion implies involvement of the pleural cavity, limiting the curative potential of radiotherapy or surgery. Recent data demonstrate that the survival of patients with malignant pleural effusion approximates that of stage IV disease. Sugiura et al. investigated the impact of pleural effusion in patients with advanced non–small cell lung cancer (6). A total of 197 patients with stage IIIB or IV non–small cell lung cancer were studied. The median survival for patients with stage IIIB disease without pleural effusion, stage IIIB disease with pleural effusion, and stage IV disease was 15.3, 7.5, and 5.5 months, respectively. The survival of patients with stage IIIB disease with effusion was significantly worse than that of IIIB patients without effusion, but not significantly different from that of stage IV patients. In this study, there was no significant difference in survival between patients with cytologically positive and cytologically negative pleural effusions provided the effusion was as exudate. Mountain (22) also came to a similar conclusion when he found no difference in survival for patient with malignant cells present in the pleural fluid, those with negative cytology, and those with clinically evident pleural fluid not further analyzed but thought to be the result of the underlying malignancy. These data suggest that patients with malignant pleural effusion should be considered to have stage IV disease, perhaps stage IVA versus stage IVB for
10
Leong and Green
those with frank metastatic disease, to reflect the current incurability of such patients and the palliative nature of treatment. Pleural Nodules Pleural nodules in the absence of pleural effusion constitute a vexing staging problem. Nodular pleural involvement was classified as T4 disease in the footnotes to the 1986 staging classification. However, information on the outcome of patients with pleural dissemination without pleural effusion is scarce. Might there not be a distinction between a more limited involvement of visceral pleura overlying the primary tumor, suggesting spread by tumor emboli, versus extensive, multifocal, visceral, and/or parietal pleural involvement suggesting true metastasis? Such an approach would be analogous to the current categorization of ipsilateral pulmonary nodules. Akaogi et al. (23) retrospectively assessed the distribution of pleural nodules in 23 patients with pleural dissemination but no distant metastasis who underwent pleuropulmonary resection. Thirteen patients had small pleural nodules but either no effusion or only a small amount of effusion. All 13 had involvement of the visceral pleura and 10 of these 13 also had involvement of the parietal pleura. In 10 of 13 patients, visceral involvement was considered ‘‘local and limited,’’ while in the majority (6 of 10) with parietal pleural involvement, the parietal disease was extensive. Although it is difficult to draw any definite conclusions from these findings, they suggest different patterns of spread leading to different distributions of pleural involvement. Whether this translates into survival differences cannot be discerned from this small series. Of interest, all 13 patients with pleural involvement did poorly except for those who did not have N 2 node involvement. In another small series reported by Shimizu et al., 38 patients with pleural dissemination without pleural effusion were studied (24). The overall 5-year survival rate was found to be 19.4%. This survival outcome is better than would have been expected from patients with pleural dissemination with effusion. Once again, the survival rate of the patients appeared to correlate with nodal stage and tumor size. The correlation of survival with the extent of pleural involvement was not discussed. Clearly, more data will be required before an evidence-based classification of visceral and parietal pleural involvement can be provided within the staging system. NEW STAGING INVESTIGATIONS Improvement in staging investigations have complemented the development of the staging system for lung cancer. Since the 1970s, staging of lung cancer patients has relied heavily on computed tomography (CT) of the chest and upper abdomen. Though invaluable for the evaluation of the primary tumor, staging of lymph nodes with CT has its limitations (25). Glazer et al., after studying CTs
Lung Cancer Staging
11
of 56 normal subjects and reviewing a previous set of data on patients with non– small cell lung cancer, suggested a measurement of 1.0 cm in the short axis of a lymph node as the threshold for defining pathological enlargement (26,27). McLoud et al. studied 143 patients prospectively with CT using the same criteria and compared the results with surgical staging (28). The sensitivity of CT was found to be 64% and specificity 62%. Thirteen percent of normal-sized lymph nodes and 25% of lymph nodes measuring 1–1.9 cm in short-axis diameter were found to contain metastatic disease. The likelihood of lymph nodes being involved with tumor increased with increasing nodal size. However, Gallardo et al. found, in a series of 167 patients, that only 23% of enlarged lymph nodes had neoplastic involvement (29). This high false positive rate dictates the need for an adjunctive staging instrument or procedure to further assess enlarged lymph nodes shown on chest CT. The current procedure of choice for this additional assessment is mediastinoscopy. European investigators have recently reported the sensitivity and specificity of mediastinoscopy to be 89% and 100%, respectively, in the staging of 100 consecutive patients with non–small cell lung cancer. In the same series the sensitivity and specificity of CT among the same patients were 63% and 57%, respectively (30). Such data have led to routine use of mediastinoscopy (cervical or parasternal) prior to thoracotomy, to evaluate enlarged lymph nodes found on chest CT. The role of mediastinoscopic staging when lymph nodes are normal in size on a staging chest CT is more controversial. In this setting the false negative rate ranges from approximately 10 to 13% (25,28). Some have suggested that microscopic involvement of a normal-sized lymph node may not have the same prognostic significance as nodes enlarged with tumor. Daly et al. reviewed data on 681 patients who had both CT and surgical staging (31). A total of 501 patients had normal-sized mediastinal lymph nodes. Thirty-seven of these were subsequently found to have positive lymph nodes at mediastinoscopy or thoracotomy. Thirty-one patients underwent definitive resection. For these 31 patients, the 5year survival was 31%. Among patients with negative CT scans later found to have mediastinal lymph node involvement, prognosis was worse if the primary tumor was central rather than peripheral. The authors concluded that definitive thoracotomy without mediastinoscopy is justified in most patients with a normal mediastinum on CT. For central tumors, however, mediastinoscopic examination may prove helpful (15,31). Endoscopic ultrasound (EUS) examination of mediastinal lymph nodes has improved staging accuracy in centers where expertise with the technique is available. It has the advantage of being able to evaluate lymph nodes based on thickness, contour, and internal architecture rather than size alone. Kondo et al. tested the sensitivity and specificity of EUS mediastinal staging in 101 Japanese patients with lung cancer (32). The sensitivity was found to be 53.6% and specificity 97.5%. Endoscopic ultrasound can also be used to perform fine-needle aspiration biopsies of abnormal lymph nodes either poorly accessible or completely inacces-
12
Leong and Green
sible to cervical mediastinoscopy, especially the level 5 and 7 lymph nodes. Silvestri et al. evaluated the sensitivity of EUS in 27 patients with lung cancer (33). Twenty-two of the 27 patients had mediastinal lymph node enlargement on chest CT. Only 16 had a positive EUS evaluation. In 15 of the 16, the positive EUS was confirmed by FNA. Of the remaining 12 patients, two had lymph nodes found to be involved at operation. Overall sensitivity was 89%. One limitation of endoscopic ultrasound is that it can only be used to assess lymph nodes adjacent to the esophagus. Clearly it can complement, but does not replace, chest CT and mediastinoscopy in the staging of lung cancer. Small pulmonary nodules are frequently detected during CT staging for lung cancer. This is especially true with the newest generation of spiral scanners. If these lesions are not calcified, it is often difficult to distinguish between malignant disease and benign changes. For example, among 551 patients with lung cancer who underwent preoperative CT scanning, Keogan et al. reported that 88 patients (16%) had small, noncalcified nodules separate from the lung primary (34). Of the 88 patients, 25 had adequate radiological follow-up of at least 24 months or pathological examination of the nodules at surgery. Seventy percent were eventually determined to be benign, 11% malignant, and 19% remained indeterminate. The development of positron emission tomography (PET) is an exciting advance in radiological imaging. However, its true effectiveness in diminishing staging ambiguity in lung cancer is still being defined. Nonetheless, in the United States the Health Care Financing Administration (HCFA) has recently authorized Medicare to pay for PET scans in the staging of patients with non–small cell lung cancer (35). Glycolysis is increased in tumor tissue and PET detects increased uptake of 18 F-fluoro-2-deoxy-d-glucose (FDG), a glucose analog radiopharmaceutical, in malignant tissue. It can be useful in evaluating both parenchymal lung nodules and mediastinal nodes. It has stronger negative than positive predictive value because nonmalignant diseases may also result in an increase in FDG uptake. However, small parenchymal lesions (⬍7–10 mm) may be falsely negative with PET scanning. Sazon et al. have reported that PET is 100% sensitive and 52% specific in predicting the malignant nature of radiographic abnormality (36). Others have reported less impressive findings but a 90% or greater sensitivity for PET in detecting primary lung cancer is well accepted. Positron emission tomography has also been found to be superior to CT in both sensitivity and specificity in the staging of mediastinal lymph nodes (37–39). A sensitivity of 93% and specificity of 97% have been reported (39) when combined CT-PET scanning was used for evaluation, versus 91% and 86%, respectively, with PET alone (38). Whole-body PET may also be useful in detecting distant metastasis (37). Nabi et al. reported their experience with PET in 12 patients deemed resectable for cure after conventional workup (40). Eight patients showed increased mediastinal uptake, confirmed by mediastinoscopy or thoracotomy; one showed in-
Lung Cancer Staging
13
creased uptake in the thoracic vertebrae, confirmed later by bone scan; and one showed increased uptake in the liver, borne out later by clinical course. In contrast, two patients found to have adrenal enlargement radiologically turned out to have negative PET scans. In a recent study with 102 patients, PET scanning resulted in a different stage than the one determined by standard imaging (e.g., CT, ultrasound, bone scan, needle biopsy) in 62 patients; the stage was lowered in 20 and raised in 42 (38). In time, PET may prove to be the most cost-effective method for detecting both intrathoracic disease extent and the presence of extrathoracic metastasis. The potential that PET has, not just for staging, but in guiding management as well, is encouraging. With the advent of combined modality management in stage III non–small cell lung cancer, prethoracotomy evaluation of response to induction chemotherapy or combined chemotherapy and radiotherapy may give important predictive information for resectability and outcome. The difficulty in assessing patients who have been treated with chemo/RT has long been appreciated, as it can be impossible to distinguish between persistent/recurrent disease and fibrosis. In a prospective study, FDG-PET response (but not CT response) was a powerful predictor of survival (p ⫽ 0.0004) (41). Eberhardt et al. have advocated repeat mediastinoscopy in guiding further management after induction chemotherapy and radiation (42). Positron emission tomography is being evaluated as an alternative approach for this restaging. Venugopal et al. have shown a significant correlation between the final pathological status and the differential uptake ratios of preoperative PET scans in 11 patients treated with chemoradiation followed by surgery (43). These provocative studies suggest that functional imaging may become a critical component of treatment algorithms, not only in defining the target, but also in assessing its response to therapy. Clearly, further defining the true capabilities of PET scanning in each of these settings is critically important. SUMMARY Over the past quarter century, the staging system for non–small cell lung cancer has evolved into a widely employed structure for defining prognosis, directing therapy, and facilitating communication and further clinical investigation. However, several issues remain incompletely addressed by the current staging scheme. The designation T4 (stage IIIB) for satellite nodules in the same lobe as the primary tumor suggests a worse prognosis for these lesions than may be warranted. Long-term survival following definitive surgery can be achieved in some such patients (18,19) and they should not be excluded from consideration of surgery. Conversely, the designation of T4 (stage IIIB) for malignant pleural effusion may not adequately convey the adverse prognosis of this extent of disease. Treatment of such patients is usually palliative, with symptomatic treatment of the effusion and systemic chemotherapy as appropriate for advanced disease. In addition to
14
Leong and Green
these concerns with the 1997 staging revision, rational staging of visceral and parietal pleural studding without effusion has yet to be defined. New staging procedures such as EUS and PET are expanding the prethoracotomy options for defining the true extent of disease in patients with lung cancer. Each has great potential to help guide management. However, like any new technology, more experience will be required before we can understand their true role in standard staging approaches to patients with lung cancer. REFERENCES 1. Denoix PF. Enquete permanent dans les centres anticancereux. Bull Inst Nat Hyg 1946; 1:70–75. 2. Mountain CF, Carr DT, Anderson WAD. A system for the clinical staging of lung cancer. Am J Roentgenol 1974; 120:130–138. 3. McCaughan BC, Martini N, Bains MS, et al. Chest wall invasion in carcinoma of the lung: therapeutic and prognostic implications. J Thorac Cardiovasc Surg 1985; 89:836–841. 4. Paul DL. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg 1975; 70(6):1095–1104. 5. Martini N, Yellin A, Ginsberg RJ, Bains MS, Burt ME, McCormack PM, Rusch VW. Management of non–small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg 1994; 58:1447–1451. 6. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non–small cell lung cancer. Clin Cancer Res 1997; 3:47–50. 7. Mountain CF. A new International Staging System for Lung Cancer. Chest 1986; 89(4):225s–231s. 8. Williams DE, Pairolero PC, Davis CS, Bernatz PE, Payne WS, Taylor WF, Uhlenhopp MA, Fontana RS. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82:70–76. 9. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz, PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38:331–336. 10. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710–1717. 11. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new International Staging System. J Thorac Cardiovasc Surg 1988; 96:440–447. 12. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non–small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55:51–56. 13. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Iwa T, Nonomura A, Kamimura R, Takashima T. Proposals regarding some deficiencies in the New International Staging System for non–small cell lung cancer. Jpn J Clin Oncol 1991; 21:160–168. 14. Mountain CF. Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIa disease. Chest 1990; 97:1045–1051.
Lung Cancer Staging
15
15. Watanabe Y, Shimizu J, Oda M, et al. Results of surgical treatment in patients with stage IIIA non–small-cell lung cancer. Thorac Cardiovasc Surgeon 1991; 39:44– 49. 16. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67(5):1037–1049. 17. Pearson FG, Delarue NC, Ilves R, Todd TRJ, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83:1–11. 18. Deslauriers J, Brisson J, Cartier R, Marcien F, Gagnon D, Piraux M, Beaulieu M. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989; 97:504–512. 19. Shimizu N, Ando A, Date H, Teramoto S. Prognosis of undetected intrapulmonary metastases in resected lung cancer. Cancer 1993; 71(12):3868–3872. 20. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA(N2) ad IIIB non–smallcell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 1995; 13(8):1880–1892. 21. Dillman RO, Hercon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non–small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 1996; 88(17):1210–1215. 22. Mountain CF. Prognostic implications of the International Staging System for Lung Cancer. Semin Oncol 1988; 15(3):236–245. 23. Akaogi E, Mitsui K, Onizuka M, Ishikawa S, Tsukada H, Mitsui T. Pleural dissemination in non–small cell lung cancer: results of radiological evaluation and surgical treatment. J Surg Oncol 1994; 57:33–39. 24. Shimizu J, Oda M, Morita K, Hayashi Y, Arano Y, Matsumoto I, Kobayashi K, Nonomura A, Watanabe Y. Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. J Surg Oncol 1996; 61:1–6. 25. Broderick LS, Tarver RD, Conces DJ Jr. Imaging of lung cancer: old and new. Semin Oncol 1997; 24:411–418. 26. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol 1985; 144:261–265. 27. Glazer GM, Orringer MB, Gross BH, Quint LE. The mediastinum in non–small cell lung cancer: CT-surgical correlation. Am J Roentgenol 1984; 142:1101–1105. 28. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JO, Moore EH, Wain JC, Mathisen DJ, Grillo HC. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319–323. 29. Gallardo JFM, Naranjo FB, Cansino MT, Rodriguez-Panadero F. Validity of enlarged mediastinal nodes as markers of involvement by non–small cell lung cancer. Am Rev Respir Dis 1992; 146:1210–1212. 30. Gdeede A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 1997; 10:1547–1551.
16
Leong and Green
31. Daly BDT, Mueller JD, Faling LJ, Diehl JT, Bankoff MS, Karp DD, Rand WM. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 1993; 105(5):904–911. 32. Kondo D, Imaizumi M, Abe T, Naruke T, Suemasu K. Endoscopic ultrasound examination for mediastinal lymph node metastases of lung cancer. Chest 1990; 98:586– 593. 33. Silvestri GA, Hoffman BJ, Bhutani MS, Hawes RH, Coppage L, Sanders-Cliette A, Reed CE. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61:1441–1446. 34. Keogan MT, Tung KT, Kaplan DK, Goldstraw PJ, Hansell DM. The significance of pulmonary nodules detected on CT staging for lung cancer. Clin Radiol 1993; 48:94–96. 35. McCann J. PET scans approved for detecting metastatic non–small-cell lung cancer. J Natl Cancer Inst 1998; 90(2):94–96. 36. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, Blahd W, Williams AJ. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153:417– 421. 37. Wahl RL, Siegal BA. Positron emission tomography imaging in cancer staging and therapy assessment: basic principals and clinical applications. ASCO Educational Book Spring 1999; 604–613. 38. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vallburg W, Koeter GH, Fidler V, Pruin J, Groen HJM. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Eng J Med 2000; 343:254–261. 39. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nacckaerts KL, Mortelmans LA, Leuven Lung Cancer Group. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non–small cell lung cancer: a prospective analysis of 50 cases. Chest 1997; 112:1480–1486. 40. Nabi HA, Steinbrenner L, Lamonica D, Spaulding M. The use of positron emission tomography. Proc Ann Meet Am Soc Clin Oncol 1996; 15:A1204. 41. MacManus MP, Hicks RJ, Wada M, Hogg A, Matthews J, Wirth A, Rischin D, Ball DL. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in unresectable non–small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19:483a. 42. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Udach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non–small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16(2):622–634. 43. Venugopal P, Bonomi P, Ali A, Patel S, Faber LP, Lincoln S, LaFollette S, Priesler H. Correlation of positron emission tomography (PET) scan, computerized tomographic (CT) scan and histologic response to combined modality chemo-radiotherapy (CT/RT) in stage III non–small cell lung cancer (NSCLC). Proc Ann Meet Am Soc Clin Oncol 1997; 16:A1750.
2 Early Timing of Radiotherapy Is Critical in Limited-Stage SCLC: Pro Nevin Murray University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
INTRODUCTION Cancer treatment is many things. It is not just biochemistry, cell population kinetics, pharmacology, or sophisticated therapeutics in model systems and man. It is all these things and many more, but most of all it is discovery, development, cooperation across disciplines, and application to man with a prevailing sense of urgency. We want and need and seek better guidance and are gaining it, but we cannot sit and wait for the promise of tomorrow so long as stepwise progress can be made with the tools at hand today. —Howard Skipper, 1979 (1)
For patients with limited-stage small cell lung cancer (LS-SCLC), it is usually easy to produce an impressive improvement in symptoms and chest radiographs within a short period of time with multiagent chemotherapy or thoracic irradiation. Unfortunately, the natural history of LS-SCLC is that despite impressive 17
18
Murray
tumor regression, the majority of patients harbor resistant elements of disease that persist after induction therapy and cause an incurable relapse. The challenge in the treatment of LS-SCLC is to combine chemotherapy and thoracic irradiation in an optimal fashion resulting in an improvement in median survival and the proportion of long-term survivors. A consensus on the most effective sequence of chemotherapy and thoracic irradiation (early versus delayed thoracic irradiation) has not been reached. This topic is the subject of this debate. The Veterans Administration Lung Group system (2) that divided patients into either limited or extensive stages has endured for SCLC because of its simplicity, reliable prognostic value, and practical utility (3,4). LS-SCLC is defined as tumor confined to one hemithorax and the regional lymph nodes, whereas extensive-stage small cell lung cancer (ESCLC) patients have disease spread beyond this definition. The original operational definition of limited disease was tumor quantity and configuration that could be encompassed by a ‘‘reasonable’’ radiotherapy treatment volume. Because long-term survival is uncommon (9%) when chemotherapy alone is used to treat LS-SCLC (5,6), the reasonable radiotherapy port rule continues to be a practical guide in the design of combinedmodality therapy. The necessity for accurate staging may be influenced by the sequence of treatment modalities. Since complete staging workup may delay symptomrelieving treatment, and because chemotherapy is recommended for all fit patients anyway, some clinicians may prefer not to bother with standard staging procedures outside the context of clinical trials. This pattern of practice may not be associated with serious negative consequences if the best treatment paradigm consisted of initial treatment with multiple chemotherapy cycles followed sequentially by administration of consolidative thoracic irradiation after drug treatment was finished. However, if patients with bona fide LS-SCLC benefit from early delivery of thoracic irradiation concurrent with combination chemotherapy, the importance of modern staging technology is crucial. The enhanced curative power of such integrated modality protocols would justify their increased complexity and toxicity in LS-SCLC but not ESCLC. STRATEGIC FACTORS FOR OPTIMAL SEQUENCING OF RADIOTHERAPY AND CHEMOTHERAPY Arbitrary assembly of chemotherapy and thoracic irradiation is unlikely to yield the best results. Previous experience with treatment protocols for LS-SCLC make it difficult to explore the scientific rationale of combining therapeutic modalities in an unprejudiced manner. Before review of clinical data, it would be useful to examine the fundamental principles for various sequences of therapeutic modalities. The goal of optimal treatment modality assembly is to maximize the proba-
Early Timing of Radiotherapy: Pro
19
bility of elimination of the last cancer stem cell thereby attaining a durable complete remission. A simplified overview of strategic considerations for combined-modality therapy would identify two distinct plans for combining chemotherapy and thoracic irradiation (Table 1). The strategy of the first plan must be to attempt to destroy as many cancer cells as possible in the shortest period of time. Such front-end-loaded therapy would involve using the most effective modalities early in the treatment program. Four concepts support early chemoradiation including decreased probability of metastatic events, lower probability of development of chemotherapy resistance, lower probability of development of resistance to radiotherapy, and diminished accelerated repopulation. The alternative method would require rationalization of the strategic superiority of deploying modalities in a more sequential fashion, via delayed administration of thoracic radiation (after chemotherapy) (Table 1). Sequential rather
TABLE 1 Conceptual Basis for Early Integration Versus Sequential Delivery of Therapeutic Modalities in the Assembly of Multimodality Cancer Treatment Programs A.
B.
Early integration of modalities Characteristics Eliminate as many cancer cells as possible in the shortest period of time Deploy multiple modalities quickly More complex logistically: requires early multidisciplinary involvement More toxic Scientific rationale 1. Decreased probability of metastatic events 2. Lower probability of chemotherapy resistance 3. Lower probability of resistance to radiotherapy 4. Minimize accelerated repopulation Sequential assembly of therapy Characteristics Modalities deployed with temporal separation Tumor burden destroyed in phases Logistically less complex: disciplines involved sequentially Chemotherapy nonresponders spared toxicity of radical local therapy Less toxic Scientific rationale 1. Originally impossible local therapy made feasible in subset with good response to neoadjuvant chemotherapy 2. Requires treatment modality (chemotherapy or radiotherapy) resistance to reverse at time of planned modality deployment
20
Murray
than concurrent use of modalities in oncology has been prevalent for obvious logistical reasons including simplicity and diminished toxicity. Existence of reversible resistance is a concept that could support sequential therapy. If a definitive local therapy was originally impossible but was rendered feasible by neoadjuvant therapy, this concept would also support the sequential therapy model. Concepts that Favor Early Integrated Combined-Modality Therapy The concepts that scientifically favor early integration of effective therapeutic modalities have clear-cut characteristics. The probability of treatment failure events associated with these concepts occurring must increase fairly quickly with the elapse of time. Therefore, the chance of avoiding treatment failure should be minimized with elimination of as many tumor cells as possible in the shortest period of time. Rapid eradication of tumor cells requires the early integration of definitive local treatment(s) with systemic chemotherapy. Decreased Probability of Metastatic Events Experimental work by Hill et al. (7,8) indicates that tumor cells mutate spontaneously and randomly to acquire metastatic potential. Moreover, once tumors reach a critical size or volume, metastatic phenotypes are generated ‘‘explosively.’’ The cumulative probability of the existence of metastases and the number of metastases increase in proportion to elapsed time. The best way to decrease metastatic events is to quickly eliminate as much tumor as possible. Lower Probability of Chemotherapy Resistance A large body of experimental and clinical data exists that support the observation that variability exists for chemosensitivity within tumor cell populations (9,10). Moreover, tumor cells display a capacity to be resistant to many drugs concurrently (11). The biological basis of this evolution of resistance originates during tumor growth from mutations in the cancer genome (12). The development of resistant mutants is a random process, and the probability of their appearance increases with time in proportion to the total number of cell divisions the neoplastic burden has undergone. The somatic mutation theory of drug resistance (13) predicts that once a tumor has reached a critical size, the probability of cure is lost over a small additional size increase in a short time period. The best way to minimize the probability of chemotherapy resistance is to eliminate as many cancer cells as possible in the shortest time. Lower Probability of Resistance to Radiotherapy Local control rates with radiotherapy are inversely related to tumor size (14,15). Although microenvironmental effects such as hypoxia (16) may be relevant, in-
Early Timing of Radiotherapy: Pro
21
creasing evidence indicates that tumor cell populations are heterogeneous with respect to inherent radiosensitivity, and like chemotherapy resistance, resistance to ionizing radiation may be genetically determined and a stochastic process (17). Epigenetic mechanisms for radiotherapy resistance also exist including upregulation of DNA repair enzymes (17). Induction of DNA repair enzymes by chemotherapy is a plausible reason why thoracic irradiation delivered after chemotherapy may be less effective. SCLC is less responsive to irradiation when recurrent after chemotherapy and mechanisms of resistance may overlap; however, cross-resistance is not complete (18). The probability of mutation to radiotherapy resistance or radioresistance as a consequence of enhanced DNA repair efficiency secondary to previous chemotherapy should be minimized by the early deployment of both modalities. Diminished Accelerated Repopulation Accelerated proliferation of tumors undergoing radiotherapy has been proposed (19,20) to explain the clinical observation that extended therapy regimens often require increased radiation dosages to achieve an isoeffective result (21,22). Accelerated tumor growth has been reported after surgery (23) and chemotherapy (24) in animal models. Accelerated repopulation will decrease local control, but additionally increased mitotic activity with larger burden of residual tumor may also hasten the tempo of metastatic events and increase the probability of developing drug and radiation resistance. Noncurative perturbation of the primary tumor may have detrimental effects (possibly mediated by cytokines) on existing metastatic lesions (25). Accelerated repopulation is independent of modalities and an obvious form of crossresistance. This phenomenon has not been mathematically modeled but it appears to be well established within a few weeks after initiation of therapy (19). Rapid destruction of tumor by early integration of chemoradiation should minimize the amount of tumor capable of repopulation. Concepts that Favor Sequential Application of Radiotherapy and Chemotherapy Simplicity has great appeal. The model of a medical oncologist administering a series of chemotherapy treatments, assessing response, and subsequently referring the LS-SCLC patient for consolidative thoracic irradiation when toxicity has subsided is undoubtedly simple. This approach is also associated with less toxicity. However, is sequential or delayed administration of thoracic irradiation after chemotherapy credible scientifically? The strategic concepts favoring early combined modality have a simple rule for the timing of effective modalities: any delay is potentially detrimental because the probability of treatment failure increases as a function of time. The
22
Murray
rules are more arcane for concepts that favor sequential modalities because an additional element of information is required. It is necessary to know the most advantageous amount of delay required for the optimum sequence of modalities. This crucial knowledge must be supplied by the concept itself or learned by the conduct of controlled clinical trials. Other than simplicity and diminished toxicity, there are two strategic concepts that may favor sequential therapy. Originally Impossible Local Therapy Rendered Feasible by Neoadjuvant Therapy An unambiguous scenario where sequential therapy would offer an advantage would be when a locally advanced tumor was originally untreatable by a definitive local therapy but such therapy was rendered feasible by downstaging. This is a classic rationale for neoadjuvant chemotherapy before surgery. However, LS-SCLC is rarely considered for surgery and the definition of this stage indicates that all original tumor should be encompassable within a reasonable radiotherapy treatment volume at the outset. There is no obvious scientific reason why chemotherapy-resistant residual tumor should be confined to the postchemotherapy tumor volume. Reversible Resistance Sequential application of modalities could be strategically superior if resistance to a particular therapy (chemotherapy or radiotherapy) was present at one point in the treatment program, but the resistance reversed later allowing successful use of that modality. Once genetically determined resistance to chemotherapy has been acquired by a tumor, it is improbable that such elements would disappear by spontaneous mutation (12). However, resistance to chemotherapy with an epigenetic basis could occur and would be a possible form of reversible resistance. Kinetic resistance is another type of reversible resistance. The potential superiority of sequential therapies as predicted by the Norton-Simon hypothesis (26) is based on the possible existence of kinetic resistance. The arguments supporting either early integration of chemoradiation or sequential utilization of chemotherapy and thoracic irradiation are hypothetical and must be supported by clinical data. Clinical data to be examined will be classified under the following categories: meta-analysis of randomized trials of chemotherapy versus chemoradiation and randomized trials of thoracic irradiation timing. META-ANALYSES OF PHASE III TRIALS OF CHEMOTHERAPY WITH OR WITHOUT THORACIC IRRADIATION Thirteen randomized studies investigated this question. Two meta-analyses have been published that examine the trials to determine the role of thoracic radiother-
Early Timing of Radiotherapy: Pro
23
apy in LSCLC (5,6). One was based on published data (1911 patients) and looked at 2-year survival rates, local control, and toxicity (5). The other (6) included 2140 patients and examined survival at 3 years and prognostic factors for survival. Because most data in each meta-analysis were derived from the same studies, the conclusions are consistent and complementary despite differences in the methods used in the meta-analyses. Both show a modest improvement in survival rates in those patients given thoracic radiotherapy. The survival benefit becomes evident at about 15 months after start of treatment and persists beyond 5 years. At 3 years, 8.9% of the chemotherapy-only group are alive, compared with 14.3% of the combined-modality group. The relative rate of death in the combinedmodality group as compared with the chemotherapy group was 0.86 (95% confidence interval, 0.78–0.94; p ⫽ 0.001), corresponding to a 14% reduction in the mortality rate. The analysis of local control was based on 1521 patients for whom data were reported and showed a marked reduction in the absolute 2-year local failure rate comparing the irradiated patients (23%) to the nonirradiated patients (48%) ( p ⫽ 0.0001). These benefits were obtained at the cost of an increase in treatment-related deaths of 1%. Most of these studies were designed to permit a chemotherapy response evaluation, which allows the possibility of a reduction in the radiotherapy field size. The timing of thoracic irradiation was most often after three to six cycles of chemotherapy but was concurrent with the first cycle of chemotherapy in four studies. Treatment factors, such as radiotherapy timing and chemoradiation integration (sequential, concurrent, or alternating), were not significant in the metaanalyses, but the heterogeneity of trial design did not allow a precise assessment of these issues. An additional explanation for not demonstrating the importance of timing or integration of thoracic irradiation may be found in the shape of the survival curve and the statistical methodology used in this analysis. Initially, the overall survival graph begins in favor of chemotherapy but the curves cross at about 1 year and later demonstrate a long-term survival advantage for chemoradiation. The initial separation of the curves is not large, but many events occur on this steep portion of the curves. Because thoracic irradiation adds toxicity that may diminish chemotherapy delivery, the relative risk of death is not constant over time. The short-term mortality increase may cancel out the long-term survival gain as measured by relative risk. Reexamination of this data set for an effect of thoracic irradiation timing on long-term survival rather than relative risk of death may be useful. Most studies in the meta-analyses were initiated before 1981 and did not deliver cisplatin and etoposide concurrently with thoracic irradiation. The safety and efficacy of early concurrent chemoradiation has been markedly improved with the administration of etoposide/cisplatin chemotherapy rather than cyclophosphamide-, nitrosourea-, or doxorubicin-based regimens. From the earliest report (27), it was clear that etoposide and cisplatin could be delivered concur-
24
Murray
rently with thoracic irradiation without dire normal tissue toxicity or the need to compromise the dose of either modality. Concurrent etoposide plus cisplatin or carboplatin with thoracic irradiation has become a prevalent theme in current LSCLC regimens. Lack of data of this type in the meta-analyses (5,6) reduces the capacity of these reports to provide guidance on optimal integration of chemoradiation that is relevant to the modern era. RANDOMIZED TRIALS OF THE TIMING OF THORACIC IRRADIATION The highest standard of evidence for the optimal timing of chemotherapy and thoracic irradiation for LSCLC comes from prospective randomized trials directly addressing this question. To date, five trials (28–33) of thoracic irradiation timing have been performed; four trials are published in peer-reviewed journals (28–32) and one is currently available as an abstract (33). Because of the importance of these trials, each study is discussed separately and summarized in Table 2. The Cancer and Leukemia Group B Trial This large trial (28,29) performed from 1981 to 1984 included 399 evaluable LSCLC patients distributed between three arms including chemotherapy alone (cyclophosphamide, etoposide, vincristine, and doxorubicin), initial chemoradiation (50 Gy thoracic irradiation and whole-brain irradiation concurrently with the initial cycle of chemotherapy), and delayed chemoradiation (chest and brain irradiation concurrently with the fourth cycle of chemotherapy at week 9). Both arms that included thoracic irradiation had significantly superior response rates, time to progression, and overall survival rates compared with chemotherapy alone. However, no significant differences were found between the initial and delayed thoracic irradiation arms; an insignificant trend favored the delayed thoracic irradiation arm. The rationale of a randomized trial is to hold all variables constant, except the experimental one. Unfortunately, the interpretation of the CALGB study is confounded by the fact that potential differences in outcome from thoracic irradiation timing may be obscured by unequal chemotherapy delivery. Myelosuppression from initial thoracic irradiation, brain irradiation, and concurrent CEV chemotherapy resulted in an unplanned attenuation (50% reduction) in the doses of cyclophosphamide, etoposide, and doxorubicin after the first cycle. This trial clearly supports the addition of thoracic irradiation to chemotherapy in LS-SCLC, but the utility of the study to provide guidance for optimal integration of chemoradiation is doubtful. The long-term survival rates for chemoradiation in the CALGB study are low (⬍13%) (29).
Thoracic irradiation Number of patients
Start time
1. 2. 3. 4. 5.
Study
Drugs
Dose
CALGB (28,29) Aarhus (31) NCIC (30) Yugoslavian (32) JCOG (33)
CEVA CAV/EP CAV/EP Carbo/EP EP
50 Gy/25F/5 wk 40–45 Gy/22F/6 wk a 40/15F/3 wk 54 Gy/36F/3 1/2 wk b 45 Gy/30F/3 wk b
Early Week Week Week Week Week
Late 1 1 3 1 1
Week Week Week Week Week
9 18 15 6 15
Survival, median (mo.)
Survival 5-year (%)
Early
Late
Early
Late
Early
Late
p-Value
125 99 155 52 114
145 100 153 51 114
13.04 10.7 21.2 34 31.3
14.54 12.9 16.0 26 20.8
6.6 10.0 22.0 30 30
12.8 10.0 13.0 15 15
NS NS 0.013 0.027 ⬍0.05
Early Timing of Radiotherapy: Pro
TABLE 2 Randomized Trials of Thoracic Irradiation Timing in Limited-Stage Small Cell Lung Cancer
CALGB ⫽ Cancer and Leukemia Group B; NCIC ⫽ National Cancer Institute of Canada; JCOG ⫽ Japan Clinical Oncology Group; C ⫽ cyclophosphamide; E ⫽ etoposide; V ⫽ vincristine; A ⫽ doxorubicin; P ⫽ cisplatin; Carbo ⫽ carboplatin. a Split course. b 1.5 Gy twice daily.
25
26
Murray
The Aarhus Lung Cancer Group Trial In this Danish trial (31) performed between 1981 and 1989, 199 patients with LSCLC were randomly allocated to initial chest irradiation or late chest irradiation delayed by 18 weeks. Both groups received nine cycles of combination chemotherapy: three cycles of EP and six cycles of CAV. The timing of radiotherapy (40–45 Gy) had no significant effect on the median survival (about 1 year) or long-term survival (about 10%). However, thoracic irradiation was delivered sequentially rather than concurrently with EP. In addition, the thoracic radiation was administered as a split course. Radiobiologically, this is a disadvantage in tumors that have the potential for accelerated repopulation. The National Cancer Institute of Canada Trial In 1993, the NCIC published results of a randomized trial (30) (accrual period 1985–88) comparing early versus late thoracic irradiation (Figure 1) that demonstrated a significant improvement in survival for early thoracic irradiation in the combined modality therapy of LS-SCLC. All 308 eligible patients received CAV alternating with EP for three cycles of each regimen. Patients randomized to early thoracic irradiation received 40 Gy/15F to the primary site concurrent with the
FIGURE 1
Schema of the National Cancer Institute of Canada BR6 trial (30).
Early Timing of Radiotherapy: Pro
27
first cycle of EP (week 3), and the late thoracic irradiation arm received the same radiation concurrent with the last cycle of EP (week 15). Dose intensity and total dose of chemotherapy were uniform in both arms (85–90% delivery according to protocol). Although complete response rates were not significantly different (CR early arm 64%, CR late arm 56%, p ⫽ 0.14), the overall survival was significantly superior ( p ⫽ 0.013) in the early thoracic irradiation arm (Figure 2). Median survival was 21.2 months in the early arm and 16.0 months in the late arm; actual survival at 5 years was 22% in the early arm and 13% in the late arm. A delay of thoracic irradiation by 12 weeks was associated with a 50% decrease in the probability of long-term survival. This was the first phase III study to demonstrate that actual 5-year survival rates of over 20% were achievable using early integrated chemoradiation in LS-SCLC. The Yugoslavian Trial This extraordinary phase III study (32) performed between 1988 and 1992 has achieved outcomes in LS-SCLC that are not only superior to any other phase III study, but survival is also better than in any published phase II trial. All patients received accelerated hyperfractionated thoracic irradiation with 1.5 Gy twice
FIGURE 2 Final analysis for overall survival of the National Cancer Institute of Canada BR6 study (30).
28
Murray
daily to 54 Gy plus concurrent daily carboplatin/etoposide and four sequential cycles of EP. Early thoracic irradiation was delivered between weeks 1 and 4 and late thoracic irradiation patients received concurrent chemoradiation between weeks 6 and 9. The difference in timing of the initiation of thoracic irradiation between the two arms was only 5 weeks. The median survival was 34 months for initial chemoradiation versus 26 months for delayed chemoradiation; 5-year survival was 30% and 15%, respectively. The difference was significant on multivariate analysis (p ⫽ 0.027). This study by Jeremic and colleagues (32) shows that early integration of chemotherapy with intensive radiation for LS-SCLC may generate median survival times of almost 3 years and long-term survival rates may approach 30%. The Japan Clinical Oncology Group Trial This study (33) also examined the optimal sequence of chemoradiation for LSCLC by randomizing patients to initial concurrent versus delayed sequential chemoradiation. The chemotherapy prescription was EP (four cycles) and thoracic irradiation consisted of 45 Gy over 3 weeks (two daily fractions of 1.5 Gy). A total of 228 patients were entered between 1991 and 1995. Initial concurrent chemoradiation was significantly superior (p ⬍ 0.05) to sequential therapy with median survivals of 31.3 months and 20.8 months and projected 5-year survival rates of 30% and 15%, respectively. These results strengthen the conclusion that long-term survival rates of ⬎20% for LS-SCLC are obtainable with early chemoradiation. Why Are the Randomized Trials of Thoracic Irradiation Timing Discordant? Of the five controlled trials of thoracic irradiation timing performed, three [NCIC (30), Yugoslavian (32), JCOG (33)] support the concept that the optimal integration of chemotherapy and thoracic irradiation is early concurrent chemoradiation; the CALGB (28,29) and the Aarhus (31) studies suggest that the timing of thoracic irradiation does not influence outcome. Why are the results discordant? There are three possible reasons: 1. 2. 3.
The timing of thoracic irradiation is unimportant and the discordant results are due to the play of chance. Delivery of chemotherapy or thoracic irradiation was inadequate in the negative trials. The patient populations differ.
The influence of chance cannot be discounted, but other explanations may be more plausible. The CALGB study (28,29) and the Aarhus trial (31) were associated with issues related to the adequate delivery of chemotherapy or tho-
Early Timing of Radiotherapy: Pro
29
racic radiotherapy, respectively. Thoracic irradiation can improve the long-term prognosis of LSCLC only in those cases in which the systemic therapy successfully controls distant subclinical disease, but fails to eliminate regional residual tumor. Suboptimal systemic therapy (e.g., secondary to marked dose attenuation in the CALBG trial) will unavoidably decrease the impact of a change in the timing of local therapy for a systemic disease. Similarly, suboptimal radiotherapy (e.g., split-course as in the Aarhus trial) may dampen the benefit of this modality. However, the most important reason for discordance of results probably is associated with differences in the trial patient populations. The prevalence of metastatic drug-resistant tumor outside the thoracic irradiation volume in the study population strongly affects the likelihood that thoracic irradiation or an innovation of it (timing or dose) will be associated with a survival advantage. If a poor prognosis LS-SCLC population (as evidenced by short median survival) is studied, the proportion of cases that can have their prognosis improved by better integration of chemoradiation will be low and the benefit of early thoracic irradiation timing will be diluted out by the presence of incurable cases. That the study populations in the CALGB (28,29) and Aarhus (31) trials, which fail to show superiority of early chemoradiation, were a poor prognostic group is strongly suggested by the short median survivals reported (Table 2). Long-term survival in these reports is also low. Adverse prognostic factors in these studies that commenced in 1981 may have been due to staging procedures that were less accurate than more recently reported trials. Median survival in the early chemoradiation arms of the NCIC (30), Yugoslavian (32), and JCOG (33) trials ranges from 21.2 to 34 months, which is two to three times longer than the median survival times in the CALGB (28) and Danish (31) studies. Median survival in the delayed chemoradiation arms of the trials that support early chemoradiation (30,32,33) ranges from 16 to 21 months, indicating that all patients in these trials had better prognostic factors than the negative trials (28,31). More importantly, long-term survival for early chemoradiation in the positive trials consistently exceeds 20% at 5 years (30,32,33). Delayed chemoradiation has never approached the 20% long-term survival milestone, which should be considered the minimum standard for LS-SCLC at this time. Delayed chemoradiation usually is associated with a long-term survival rate of approximately 10% (Table 2), which is not much different than the 9% rate expected from chemotherapy alone, as reported in the meta-analysis (6) of randomized trials performed in a similar era. CONCLUSION The available data from modern randomized trials of thoracic irradiation timing indicate that the typical patient with LS-SCLC staged with modern technology has a median survival expectation of 16–26 months and long-term survival of 10–13% when treated with standard chemotherapy and late thoracic irradiation.
30
Murray
Combining early thoracic irradiation concurrently with etoposide-cisplatin chemotherapy improves that median survival expectation to 21–34 months and longterm survival to more than 20%. The addition of more intensive thoracic irradiation has recently been associated with improved outcome in LS-SCLC when such radiotherapy is delivered with early concurrent etoposide-cisplatin (34). Turrisi et al. (34) demonstrated that 45 Gy delivered twice daily in 3 weeks (5-year survival 26%) was superior to 45 Gy once daily over 5 weeks (5-year survival 16%). Notably, twice-daily thoracic irradiation had no impact on median or long-term survival in a randomized trial by Bonner et al. (35) that delivered radiotherapy in a delayed fashion (beginning concurrently with the fourth etoposide-cisplatin chemotherapy cycle). An increase in long-term survival from 10% to ⬎20% is a modest, albeit worthwhile, advance in a common condition such as LS-SCLC. This gain is a least as large as the improvement in stage III NSCLC outcome associated with integrated chemoradiation (36) that changed the treatment paradigm for this condition. Moreover, a consensus (37) now exists that patients with stage III NSCLC, who may benefit from combined modality therapy, must be carefully staged and have good prognostic factors. It is unlikely that similar guidelines for accurate staging and patient selection can be relaxed when innovations of local therapy (timing or dose of radiotherapy) are tested in a systemic disease such as LSSCLC. That survival improvement from early chemoradiation in LS-SCLC is difficult to detect in inadequately staged patient populations with adverse prognostic factors should not be interpreted as either surprising or particularly relevant to the question of whether early chemoradiation is more efficacious. Now that early concurrent chemoradiation has been demonstrated superior to delayed chemoradiation for stage III NSCLC (38), persistence of controversy on this therapeutic principle should not be acceptable to physicians who treat local-regional small cell or non–small cell lung cancer. More randomized trials of local and systemic treatment modality sequencing are urgently needed. Such investigations probe fundamental issues in cancer biology and are likely to be relevant to other common malignancies where local and systemic therapies are combined with curative intent.
REFERENCES 1. Skipper HE. Historic milestones in cancer biology: a few that are important in cancer treatment (revisited). Semin Oncol 1979; 6:506–513. 2. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46:516–525. 3. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8:1563–1574.
Early Timing of Radiotherapy: Pro
31
4. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61:597–604. 5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890–895. 6. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327:1618–1624. 7. Hill RP, Chambers AF, Ling V. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B 16 melanoma cells. Science 1984; 224:998–1001. 8. Hill RP, Young SD, Ling V, et al. Metastatic cell phenotypes: quantitative studies using the experimental metastasis assay. Cancer Rev 1986; 5:118–151. 9. Claes Trope. Different susceptibilities of tumor cell subpopulations to cytotoxic agents and therapeutic consequences. In: Owens AH, Coffey DS, Baylin SB, eds. Tumor Cell Heterogeneity: Origins and Implications. New York: Academic Press, 1982:147. 10. Young RC. Drug Resistance: the clinical problem. In: Ozols RF, ed. Drug Resistance in Cancer Therapy. Norwell, MA: Kluwer Academic Publishers, 1989:1. 11. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650–1654. 12. Goldie JH, Coldman AJ. Genetic origin of drug resistance in neoplasms. Cancer Res 1984; 44:3643–3653. 13. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727–1733. 14. Tubiana M. The role of local treatment in the cure of cancer. Eur J Cancer 1992; 28:2061–2069. 15. Suit H. Local control and patient survival. Int J Radiat Oncol Biol Phys 1992; 23: 653–660. 16. Tomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9:539–549. 17. Yaes RJ. Tumor heterogeneity, tumor size, and radioresistance. Int J Radiat Oncol Biol Phys 1989; 17:993–1005. 18. Ochs JJ, Tester WJ, Cohen MH, et al. ‘‘Salvage’’ radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 1983; 67:1123–1126. 19. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131–146. 20. Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990; 19:1071–1075. 21. Maciejewski B, Preuss-Bayer G, Trott KR. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983; 9:321–328. 22. Holsti LR, Mantyla M. Split-course versus continuous radiotherapy. Analysis of a randomized trial from 1964 to 1967. Acta Oncol 1988; 27:153–161. 23. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976; 60:1749–1760.
32
Murray
24. Stephens TC, Steel GG. Regeneration of tumors after cytotoxic treatment. In: Meyn RE, Withers HR, eds. Radiation Biology in Cancer Research. New York: Raven, 1980:385–395. 25. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49:1996–2002. 26. Norton L, Simon R. Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 1977; 61:1307–1317. 27. Murray N, Hadzic E, Shah A, et al. Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited stage small cell lung cancer. Proc Am Soc Clin Oncol 1984; 3:214 (abstr 835). 28. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912–918. 29. Perry MC, Herndon JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of cancer and leukemia group B study 8083. J Clin Oncol 1998;16:2466–2467. 30. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336–344. 31. Work E, Nielsen O, Bentzen S, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol 1997; 15:3030–3037. 32. Jeremic B, Shibamato Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893–900. 33. Takada M, Fukuoka M, Furuse K, Ariyoshi Y, Ikegami H, Kurita Y, Nishiwaki Y, Nishikawa H, Wantanabe K, Noda K, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: preliminary results of the Japan Clinical Oncology Group (JCOG). Proc Am Soc Clin Oncol 1996; 15:372 (abstr 1103). 34. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Eng J Med 1999; 340(4):265–271. 35. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krooks JE, Gerstner JB, et al. Phase III comparison of twice-daily split-course irradiation versus oncedaily irradiation for patients with limited stage small-cell lung cancer. J Clin Oncol 1999; 17(9):2681–2691. 36. Dillman RO, Seagren SL, Herndon J, et al. Improved survival in stage III non–small cell lung cancer: seven year follow-up of CALGB 8433. J Natl Cancer Inst 1996; 88:1210–1215. 37. Non–small Cell Lung Cancer Expert Panel: Clinical practice guidelines for the treatment of unrespectable non-small cell lung cancer. J Clin Oncol 1997; 15:2996–3018. 38. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non–small-cell lung cancer. J Clin Oncol 1999; 17(9):2692–2699.
3 Early Timing of Radiotherapy Is Critical in Limited-Stage SCLC: Con Mark Bryer and Michael C. Perry University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri
INTRODUCTION The decade of the 1970s recognized the uniqueness of small cell lung cancer (SCLC) and saw the adoption of combination chemotherapy as a standard therapy (1). In the 1980s, the primary topic of debate was the need for thoracic radiation therapy in limited stage SCLC (2,3). Two meta-analyses were published in the 1990s evaluating the role of thoracic radiation therapy in addition to chemotherapy in the management of limited-stage SCLC (4–6). These two meta-analyses showed an improvement in 3-year survival rates of about 5% in those receiving chemotherapy and radiotherapy compared to those receiving chemotherapy alone. The Pignon et al. meta-analysis involved 13 randomized trials including 2140 patients (4,6). At 3 years, the survival advantage for the addition of radiation therapy was 5.4% ⫾ 1.4%. The improvement in survival was even greater for patients ⬍ 55 years of age who received thoracic irradiation, but was not observed in patients ⬎ 70 years of age. 33
34
Bryer and Perry
Thoracic radiation therapy offered the possibility of more complete responses, reduced recurrences at the primary site and improved survival, but at a potential cost of increased toxicity. Many questions remain to be answered with regard to the optimal sequencing, timing, dose, treatment volume, and fractionation of thoracic radiation therapy in the management of limited stage SCLC. An in-depth review of the radiation fractionation and volume issues is found in another chapter. Certainly, there is no consensus at this time regarding these factors. Many investigators have championed the cause of early thoracic radiation therapy in limited-stage SCLC, but analysis of the data suggests that delayed thoracic radiation therapy may be equally efficacious. EARLY STUDIES In 1980, the Cancer and Leukemia Group B addressed both the role and optimal timing of thoracic radiation in a randomized, prospective trial of chemotherapy with or without radiation therapy in limited-stage SCLC (7). After stratification for gender and performance status, patients were randomly assigned to receive initial chemotherapy and thoracic radiation therapy starting on day 1, chemotherapy with radiation therapy starting with cycle 3 (day 63), or chemotherapy alone. The chemotherapy was the same in all three arms: cyclophosphamide, vincristine, and etoposide every 3 weeks for 18 cycles. Starting at cycle 7 for odd-numbered cycles, doxorubicin replaced the 3 days of etoposide. The radiation therapy was directed at the primary tumor at a dose of 4000 cGy in 4 weeks, followed by a 1000-cGy ‘‘boost’’ directed against residual disease as demonstrated on a midcourse chest film taken after the first 2 weeks of initial therapy. The initial field included the primary disease site with a 2-cm margin around the mass and the ipsilateral hilum, the whole width of the mediastinum, and both supraclavicular fossae. The whole brain was simultaneously treated prophylactically with 3000 cGy in 10 fractions. A total of 399 patients were enrolled, and at the conclusion of the study, there was a statistically significant difference in the frequency of complete responses in favor of the two thoracic radiation therapy arms ( p ⫽ 0.0013). These two regimens also yielded better failure-free survival ( p ⬍ 0.001), treatment failure-free interval in the chest (p ⬍ 0.001), and overall survival ( p ⫽ 0.0099). As anticipated, toxicity was worse in the combined-modality arms, but was generally tolerable. In regimen 1, in which radiation therapy and chemotherapy both started on day 1, the incidence of neutropenia and neutropenic fever prompted reductions of the chemotherapy that were maintained throughout treatment, resulting in less chemotherapy being administered in this arm. For this reason, CALGB adopted the second arm (with radiation therapy starting with cycle 4) as its standard.
Early Timing of Radiotherapy: Con
35
These findings were confirmed in a recent update (8). It should be noted, however, that the staging and chemotherapy used in this study are not what we would choose in the 1990s. More aggressive staging would likely produce better results as more patients with extrathoracic disease would be identified. The results of more modern chemotherapy would likely be better as well. RECENT STUDIES Investigators in Aarhus, Denmark have also evaluated the timing of thoracic irradiation in a phase III trial in patients with limited-stage SCLC (9). From 1981 to 1989, 199 patients with limited-stage SCLC were randomized to early chest irradiation (n ⫽ 99) or delayed chest irradiation (n ⫽ 100) starting at week 18 of chemotherapy. All patients received the same chemotherapy, consisting of three cycles of cisplatin, etoposide (PE), and six cycles of cyclophosphamide, doxorubicin, and vincristine (CAV). The patients received 40 or 45 Gy of radiation to the chest. Chest irradiation was given as a split-course treatment of two treatment courses (of 20 or 22.5 Gy in 11 fractions) separated by an interval of 21 days, during which PE chemotherapy was administered. In the early thoracic radiation therapy group, irradiation was started prior to the first cycle of PE chemotherapy. Prophylactic cranial irradiation (PCI) was initially given to patients randomized to early radiation therapy, but after the first 42 patients were treated in the delayed-radiation-therapy arm, the protocol was amended so that all patients received PCI. Based on the recent meta-analysis showing a survival advantage to PCI, excluding PCI from the treatment of the first 42 patients in the delayedradiation-therapy arm may have biased the results in favor of the early-radiationtherapy arm. However, at 2 years, the timing of radiation therapy did not significantly affect the overall survival, in-field recurrence rate, or median survival durations (Table 1). While bone marrow toxicity was felt to be acceptable with 15% of patients in both groups developing World Health Organization (WHO) grade 4 leukopenia
TABLE 1 Results of Randomized Trial of Timing of Thoracic Radiation Therapy in 199 Patients with Limited-Stage SCLC (Aarhus Lung Cancer Group)
2-year overall survival 2-year in-field recurrence Median survival
Early RT
Late RT
p
20% 72% 10.5 m
19% 68% 12.0 m
0.4 0.2
36
Bryer and Perry
and 4% grade 4 thrombocytopenia, grade 4 leukopenia was noted to be more pronounced in the early-radiation-therapy group. The authors concluded that the timing of chest irradiation did not influence survival or local control in the chest. Since grade 4 leukopenia was higher in the early-radiation-therapy group, this study also suggests that delayed radiation therapy may be preferable. A third randomized trial examining the timing of thoracic irradiation in patients with limited-stage SCLC has been reported by Shultz et al. (10). Patients were treated with alternating cycles of etoposide, cisplatin, and cyclophosphamide, doxorubicin (Adriamycin), vincristine chemotherapy. Patients were randomized between early thoracic irradiation starting day 1 and delayed thoracic irradiation starting day 120. The thoracic radiation therapy given was 40 Gy in 22 fractions or 45 Gy in 22 fractions using a split-course technique. These doses and the use of a split-course technique would not be considered standard therapy in the United States. There was a nonstatistically significant trend toward improved median survival in patients receiving late thoracic radiation therapy (Table 2). Results for local control and toxicity were not reported. A phase III randomized trial performed by the European Organization for Research and Treatment of Cancer (EORTC) and the United Kingdom Coordinating Committee on Cancer Research compared cyclophosphamide, doxorubicin, and etoposide chemotherapy with either thoracic radiation therapy (10 Gy in four fractions over 1 week) alternating between chemotherapy cycles 2, 3, 4, and 5 or postchemotherapy radiation in patients with limited-stage SCLC (11). At 3 years, survival was not significantly different between the two treatment arms (Table 3). Severe acute hematological toxicity was observed in the alternating chemotherapy/radiotherapy arm resulting in about a 25% reduction in chemotherapy dose intensity. Ninety-three percent of the patients in the sequential arm completed their radiation, versus only 77% in the alternating arm. The most commonly quoted phase III randomized trial on the timing of thoracic radiation therapy in patients with SCLC showing a benefit to early thoracic radiation therapy was published by Murray et al. from the National Cancer Institute of Canada (NCIC) (12). The NCIC treated 308 eligible patients with six cycles of alternating cisplatin, etoposide (PE), and cyclophosphamide, doxorubi-
TABLE 2 Results of Randomized Trial of Timing of Thoracic Radiation Therapy for Patients with Limited-Stage SCLC (10)
Median survival
Early RT
Late RT
10.7 m
12.9 m
Early Timing of Radiotherapy: Con
37
TABLE 3 Survival Results from EORTC Randomized Trial Comparing Sequential to Alternating Chemo/radiotherapy for Limited-Stage SCLC
3-year survival
Alternating
Sequential
12%
15%
cin (Adriamycin), etoposide chemotherapy. Patients were randomized to concurrent thoracic irradiation starting with the first cycle of PE chemotherapy (week 3) or the third cycle of PE (week 15). Thoracic irradiation consisted of 40 Gy in 15 fractions. Thoracic irradiation was administered in 149 of 155 (96.1%) patients on the early-radiation-therapy arm and 133 of 153 (86.9%) patients on the late-thoracic-radiation-therapy arm. Overall survival was improved in patients receiving early-thoracic-radiation therapy (Table 4). When patterns of failure were analyzed, however, there was no difference in local control or the overall metastatic rate. There was a reduction in the frequency of brain metastases in the early-radiation-therapy group (18%) versus the late-radiation-therapy group (28%). PCI was delayed for 19 weeks in this trial and was only given if there was no progression at any site. Thus, 85.8% of the early-thoracic-radiation-therapy patients and 79.7% of the late-thoracic-radiationtherapy patients received PCI. With no differences in local control or overall metastatic failure rate, it is difficult to explain the observed differences in survival in the two groups. Jeremic et al. treated 107 limited-stage small cell lung cancer patients with accelerated hyperfractionated radiation therapy with 1.5 Gy twice daily to 54 Gy plus concurrent daily carboplatin/etoposide and four sequential cycles of cisplatin/etoposide on days 1–3 (13). One-half of the patients received concurrent chemoradiation at weeks 1–4 (group 1) and the other half (group 2) at weeks 6–9. Median survival was better in group 1 (34 months versus 26 months, p ⫽ .027 on multivariate analysis), and local control was better, but there was no
TABLE 4 NCIC Study of Radiation Therapy Timing in Patients with Limited-Stage SCLC
Overall median survival 4-year survival
Early RT
Late RT
21.2 m 25%
16 m 15%
38
Bryer and Perry
difference in distant metastasis rate or toxicity. This is a small study of an unusual regimen and the results must be confirmed in a larger trial. The meta-analysis by Pignon et al. of trials of chemotherapy with or without radiation therapy could not identify the optimal timing for thoracic irradiation (4). A direct comparison of early to late radiotherapy and of sequential to nonsequential radiotherapy did not demonstrate any significant differences. The relative risk of early thoracic irradiation (defined as ⬍ 60 days after starting chemotherapy) was not significant. While many phase II trials have reported excellent results with combinedmodality therapy utilizing early-thoracic-radiation therapy (14,15), equally good results have been reported by other groups utilizing thoracic irradiation starting later in the chemotherapy course. The Mayo Clinic reported the results of a phase II trial for the treatment of limited-stage SCLC patients with three cycles of cyclophosphamide, etoposide, and infusion cisplatin chemotherapy followed by concurrent cyclophosphamide and etoposide chemotherapy and hyperfractionated radiation therapy (4800 cGy in 32 fractions of 150 cGy twice daily) and PCI (16). Twenty-nine patients with limited-stage SCLC were treated with this regimen. Median survival was 26.5 months and 2-year survival was 55%. Only seven of the 29 patients failed in the chest. These excellent results are similar to the best single-institution studies using early thoracic irradiation. There remains considerable uncertainty regarding the optimal timing of thoracic irradiation in patients with limited-stage SCLC. Review of the literature shows that regimens utilizing late thoracic irradiation with concurrent chemotherapy produce results as good as those seen with early radiation therapy. While most studies favor concurrent administration of chemotherapy and radiation, alternative regimens, including alternating chemo/radiation therapy, have produced very good results. However, overall survival remains poor with late relapses occurring after 5 years and long-term survivors experiencing a high rate of new lung cancers (17,18). The above studies have mixed results regarding the timing of thoracic radiotherapy. While a few of the studies suggest a benefit to early rather than delayed radiation, others do not substantiate this advantage. Without a clear benefit in terms of efficacy, the next critical issue relates to the impact of timing regarding toxicity. There is a benefit in delaying thoracic radiotherapy after several cycles of chemotherapy that is not often addressed. This benefit directly relates to the size of the radiotherapy field that is required. While limited-stage disease may be confined to one hemithorax, patients often present with bulky disease. As the required radiation dose for small cell lung cancer exceeds lung tolerance, encompassing the initial volume of disease can lead to more radiation fibrosis and increase the risk of radiation pneumonitis. Yet, there is compelling evidence that there is no need to treat such large prechemotherapy volumes. Indeed, in a randomized trial, there was no difference in outcome whether prechemotherapy
Early Timing of Radiotherapy: Con
39
volume was treated versus the postchemotherapy volume (19). Other studies also support this strategy (20,21). This issue is discussed in further detail in another chapter. While the use of smaller postchemotherapy volumes has not translated into more local failures or compromised outcome, it clearly has the potential to reduce toxicity, not only in terms of sparing normal lung tissue, but also by reducing the length of the esophageal irradiation. Prior studies have documented that the length of esophagus in the radiotherapy field significantly impacts on the rate of radiation esophagitis (22). Thus, an argument can be made that delayed radiotherapy, by allowing reduced field sizes, has the potential to substantially reduce toxicity and thereby enhance the therapeutic ratio. The shrinkage of disease in small cell lung cancer with chemotherapy is often dramatic and the benefit in terms of reducing radiation exposure to normal tissue can be significant. This strategy of delayed radiotherapy has other important advantages. Despite the current staging workup, there is still a significant percentage of patients deemed ‘‘limited stage’’ who harbor metastatic disease. Delaying the radiotherapy will select out a proportion of these patients who will not benefit from intensive combined-modality therapy and can be spared the toxicity of this aggressive approach. There is nothing more upsetting than having to counsel a patient who is still suffering from chemoradiation esophagitis that there is now evidence of metastatic disease, not previously appreciated. Rather, several cycles of chemotherapy has the advantage of a ‘‘tincture of time’’ to test the natural history of the disease and ensure that the patient continues to have limited-stage disease and actually benefits from the thoracic radiation. Even the best results reported to date utilizing concurrent chemotherapy and early radiotherapy have 5-year survival rates of only 20–25%, with the majority of the failures being due to distant metastatic disease. Better prognostic indicators and improved systemic therapy are needed before we mandate early intensive thoracic radiotherapy to all patients. Delayed radiotherapy also benefits another cohort of patients whose disease is initially too bulky or locally extensive for a ‘‘tolerable’’ radiotherapy field, but then responds well to chemotherapy, thereby facilitating combinedmodality treatment. In summary, delayed radiotherapy allows both those who respond poorly to chemotherapy and those who respond well to chemotherapy to benefit from this strategy. During the first half of the 1990s, new agents have been identified with activity in SCLC, including Gemcitabine, Irinotecan, Topotecan, Docetaxol, and Paclitaxel. Studies will need to be performed to determine the role of these agents in the management of SCLC compared to currently used agents. Several of these agents, including Gemcitabine, are potent radiation sensitizers and combining them with radiation will need to proceed carefully to limit toxicity, while hopefully improving the results currently obtained. The timing of radiation therapy will continue to be an important issue in the management of these patients. It is likely that specific issues, such as treatment volume, dose, fractionation, and tim-
40
Bryer and Perry
ing of thoracic irradiation, as well as the chemotherapy used, will prove important in providing optimal results. In addition, newer radiation planning techniques, such as conformal radiation therapy, which can limit the volume of normal tissues (e.g., esophagus, lung, and heart) irradiated, may further improve the results of treatment by limiting toxicity and allowing treatment to be delivered with fewer interruptions and dose reductions. It may also be important for treating physicians and patients to accept severe acute toxicities without interrupting radiation treatments or reducing the doses of chemotherapy to produce optimal survival results.
CONCLUSION These authors conclude, that at the current time, the optimal timing of thoracic radiation therapy in limited-stage SCLC is unknown. Early administration of thoracic radiation, with the likelihood of resultant reduced chemotherapy doses, has no clear advantage. What is important is finding the optimal combination of chemotherapy for distant disease and optimal dose and schedule of thoracic radiotherapy for local disease.
REFERENCES 1. Weiss RB. Small cell carcinoma of the lung: therapeutic management. Ann Intern Med 1978; 88:522–531. 2. Cohen MH. Is thoracic radiation therapy necessary for patients with limited stage small cell lung cancer? No. Cancer Treat Rep 1983; 67:217–221. 3. Byhardt RW, Cox JD. Is thoracic radiation therapy necessary for patients with limited stage small cell lung cancer? Yes. Cancer Treat Rep 1983; 67:209–215. 4. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tattersall MHN, Wagner H. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327(23):1618–1624. 5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10(6):890–895. 6. Arriagada R, Pignon JP, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tattersall MHN, Wagner H. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994; 14:333–335. 7. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner C, Comis R, Green MR. Chemotherapy with or without radiation therapy in limited small cell lung carcinoma of the lung. N Engl J Med 1987; 316:912–918. 8. Perry MC, Herndon JE III, Eaton WL, Green MR. Thoracic radiation therapy added
Early Timing of Radiotherapy: Con
9.
10.
11.
12.
13.
14.
15.
16.
17. 18. 19.
20.
21.
41
to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B study 8083. J Clin Oncol 1998; 16:2466–2467. Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. for the Aarhus Lung Cancer Group. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited stage small cell lung carcinoma. J Clin Oncol 1997; 15(9): 3030–3037. Shultz HO, Nielson O, Sell A, Steenholdt S, Bentzen S. Timing of chest irradiation with respect to combination chemotherapy in small cell lung cancer, limited disease. Lung Cancer 1988; 4:153 (abstract). Gregor A, Drings P, Sahmoud T, Giaccone G. Sequential versus alternating chemoradiotherapy in limited small cell lung cancer—the EORTC Lung Cancer Cooperative Group experience. International Association for the Study of Lung Cancer, Bruges, Belgium, 1996 (abstr). Murray N, Coy P, Pater JL, Hudson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun JA, Wilson KS for the National Cancer Institute of Canada Clinical Trials Group. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 1993; 11:336–344. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893–900. Turrisi AT, Glover DJ. Thoracic radiotherapy variables: Influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 1990; 19: 1473–1479. Johnson DH, Salem C, Nesbitt J. Limited stage small cell lung cancer treated with concurrent BID chest radiotherapy and etoposide-cisplatin followed by chemotherapy selected by in vitro drug sensitivity testing (DST). Proc Am Soc Clin Oncol 1991; 10:240 (abstr). Frytak S, Shaw EG, Jett JR, Richardson RL, Foote RL, Creagan ET, Eagan RT, Su JQ. Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small cell lung cancer. Am J Clin Oncol (CCT) 1996; 19:193–198. Wagner H Jr. Thoracic irradiation of limited small cell lung cancer: have we defined optimal dose, time, and fractionation? Lung Cancer 1997; 17(Suppl):S137–148. Wagner H Jr. Radiation therapy in the management of limited small cell lung cancer: when, where, and how much? Chest 1998; 113(Suppl):S92–100. Kies M, Mira J, Crowley J. Multimodal therapy for limited small cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol 1987; 5: 592–600. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ. Limited stage small cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994; 12(3):496–502. Arriagada R, Pallae-Cosset B, Ladron de Guevara JC, el Bakry H, Benna F, Martin M, de Cremoux H, Baldeyrou P, Cerrina ML, Le Chevalier T. Alternating radiother-
42
Bryer and Perry
apy and chemotherapy schedules in limited small cell lung cancer: analysis of local chest recurrences. Radiother Oncol 1991; 20(2):91–98. 22. Hudes RS, Langer C, Movsas B, Nicolauo N, Litwin S, Schol J. Keenan E, Curran WJ. Induction paclitaxel-carboplatin followed by concurrent radiotherapy and dose escalation of paclitaxel-carboplatin in unresectable, locally advanced non-small cell lung carcinoma: a report of FCCC 94-001. Int J Radiat Oncol Biol Phys 1999; 45(3): 243.
4 Limited-Stage SCLC: Radiotherapy Fractionation and Volume Issues Todd Williams, Charles Thomas, Jr.,* and Andrew Turrisi III Medical University of South Carolina, Charleston, South Carolina
INTRODUCTION Thoracic radiotherapy has been demonstrated to be a valuable component in the treatment of limited-stage small cell lung cancer (LS-SCLC) (1,2). Yet the method of its delivery continues to pose challenges to radiation oncologists. Despite high response rates to both radiotherapy and chemotherapy, failure rates remain unacceptably high. In an attempt to improve local control and survival, radiation treatment parameters have been altered. They include treatment volumes and fractionation schedules. FRACTIONATION Fractionation refers to the dividing of the total radiation dose into multiple segments. The most frequent schedule utilized in the United States delivers one treatment per day, 5 days a week. *Current affiliation: University of Texas Health Science Center at San Antonio, San Antonio Cancer Institute, San Antonio, Texas.
43
44
Williams et al.
Generally, tissues in the body can be divided into late responding (slowly or nonproliferating) or early responding (rapidly proliferating). Examples of lateresponding, normal tissues include the central nervous system, lung, and kidney. The gastrointestinal tract, skin, and gonads are considered early-responding normal tissues; they behave differently when exposed to ionizing radiation. Earlyresponding tissue effects are more related to overall treatment time and less dependent on fraction size. In contrast, late-responding tissues are mainly dependent on the fraction size. Increasing the dose per fraction (⬎2.5–3.0 Gy) will result in more severe late effects (fibrosis, necrosis, etc.) for equivalent early effects (skin erythema, esophagitis, etc.). Conceptually, two distinct altered fractionation strategies can be utilized in the hope of improving local control or survival. Hyperfractionation involves smaller-than-conventional RT doses (e.g., 1–1.2 Gy) administered multiple times daily (typically two to three times) to achieve a higher cumulative dose over the course of therapy. Radiobiologically, hyperfractionation yields differential sparing of late-reacting normal tissue compared with acute-reacting malignant tissues. By contrast, with accelerated (hyperfractionated) RT, a more conventional radiation fraction size is utilized (e.g., 1.5–2 Gy), but as multiple fractions are administered daily, the overall treatment time is significantly shorter. Unlike hyperfractionated radiotherapy (HFRT), the aim of accelerated RT is to reduce the tumor cell repopulation in rapidly proliferating neoplasms by shortening the overall treatment time. The rationale for altered fractionation is based on several radiobiological principles (3). One is that repair of sublethal radiation damage in aerobic cells is essentially complete within 2–4 hr. Therefore, if several treatments per day are delivered, separated by 4–6 hr to allow for normal tissue repair, it would theoretically be more effective on rapidly proliferating tumors (e.g., small cell carcinoma) and improve the therapeutic ratio. Another observation is that the shape of the dose-response relationships for early- and late-responding tissues is different. The fraction size dependence of most tumors, including small cell carcinoma, mimics that of rapidly proliferating tissues (although there are exceptions, e.g., malignant melanoma). The optimal dose per fraction for cancer in general, as well as small cell lung cancer, continues to be a hotly debated subject. The ‘‘standard’’ regimens vary from institution to institution but are most often in the range of 1.8–2.5 Gy per fraction delivered once a day. There are data that this may not be optimal for small cell lung carcinoma. It has been demonstrated in in vitro studies to exhibit exponential cell killing with small fraction sizes as well as with the ‘‘standard’’ daily doses. As noted previously, the larger the dose per fraction, the greater the chance for longterm side effects (fibrosis, pneumonitis). Accelerated, hyperfractionated treatment would potentially allow continued exponential tumor kill, with lower prospects of long-term side effects. Finally, it is theorized that fractionation allows
Radiotherapy Fractionation and Volume
45
time for reassortment of tumor cells into more radiosensitive phases of the cell cycle [gap 2 (G2) and mitosis (M)]. Several pilot studies performed in the 1980s and early 1990s tested the hypothesis of using accelerated hyperfractionated radiotherapy along with concurrent chemotherapy in limited-stage small cell lung cancer (4–12). As these studies suggested superior responses and survival rates, this concept was tested in a large, cooperative group, phase III, prospective randomized trial (13). A total of 417 patients with limited-stage disease were randomized. Patients on both arms received four cycles of cisplatin (60 mg/m 2, day 1) and etoposide (120 mg/ m 2, days 1, 2, and 3) chemotherapy. The radiotherapy consisted of 45 Gy in both treatment arms and was started on day 1 of chemotherapy cycle 1. The oncedaily arm received 1.8 Gy/day, treated Monday through Friday, for 5 weeks. The accelerated, hyperfractionated arm received 1.5 Gy twice a day for 3 weeks. The twice-daily fractions were separated by a 4–6-hr interval. The volume of lung and mediastinum irradiated was defined by chest CT scan. Clinical treatment volumes incorporated gross tumor, mediastinum, and ipsilateral hilum. The contralateral hilum and supraclavicular regions were excluded. Prophylactic cranial irradiation, consisting of 25 Gy in 10 fractions, was recommended for patients achieving a complete clinical response. The primary endpoint of the study was overall survival measured from the date of study entry to the date of death from any cause. The median follow-up was approximately 8 years, with a minimum of 5 years. Final analysis revealed the median survival to be 20 months for all patients. For the once-daily and twice-daily arms, it was 19 and 23 months, respectively. The 2- and 5-year overall survivals are as follows:
Once-daily XRT Twice-daily XRT
2-year overall survival (%)
5-year overall survival (%)
41 47
16 26
The survival differences were statistically significant (p ⫽ 0.04). A pattern of failure analysis divulged a substantial reduction in local failure in the investigational arm, 36%, compared to 52%, in the standard, once-daily treatment arm ( p ⫽ 0.06). There was a statistically significant increase in grade 3 esophagitis in the twice-daily treatment arm, 27% versus 11% for those receiving chest radiotherapy once daily (p ⬍ 0.001). The duration of esophagitis was not measured, but there were no cases of esophageal stricture or long-term dysphasia. A criticism of this trial is that the dose of radiotherapy used in the standard arm was too low (14). There are dose-response data for small cell carcinoma
46
Williams et al.
suggesting improved local control with higher total doses; likewise, higher doses have recently been shown to be tolerable with concurrent cisplatin-based chemotherapy (15–17). Choi et al. performed a phase I trial to determine the maximum tolerated dose (MTD) of thoracic radiotherapy for both standard and twice-daily schedules in patients with LS-SCLC (18). All patients received concurrent cisplatin/etopside chemotherapy. Esophagitis was found to be the dose-limiting toxicity in both arms. For the field sizes and chemotherapy used, the MTD was 45 Gy and 70 Gy in the twice-daily and standard treatment arms, respectively. These patients received three cycles of PCE chemotherapy (cisplatin, cytoxan, etoposide) prior to receiving the concurrent treatment. Thus, their radiotherapy was delivered as later concurrent (like the CALGB standard) as compared to early concurrent, with cycle 1 or 2. Other investigators have demonstrated superior results with earlier concurrent treatment (19,20). It is yet unproven whether higher doses delivered with a standard once-daily regimen are superior to 45 Gy delivered twice daily. Higher total doses (60 and 70 Gy, delivered with a oncea-day fraction regimen) are now being investigated by several U.S. cooperative groups. It is also unknown whether using smaller treatment volumes, which exclude regions that have historically been treated ‘‘prophylactically,’’ will allow further dose escalation or compromise local control. Data for non–small cell lung cancer suggest the dose can be dramatically increased to smaller volumes, without a concordant rise in regional failure (21). Other investigators have also compared once-daily versus twice-daily therapy. Bonner et al. randomized 262 patients to standard chest radiotherapy (50.4 Gy/1.8 Gy fractions) versus twice-daily (48 Gy/1.5 Gy fractions) (22). Similar to Choi’s dose escalation trial, these patients received late concurrent therapy beginning with cycle 4. The chemotherapy consisted of cisplatin (30 mg/m 2, days 1, 2, 3, cycles 1–6) and etoposide (130 mg/m 2, days 1, 2, 3, cycles 1, 2, 3). During the concurrent treatment, the etoposide dose was reduced to 100 mg/ m 2. All twice-daily patients had a planned 2-week interruption of the thoracic radiotherapy after receiving 24 Gy. Prophylactic cranial irradiation was administered after the completion of six cycles of chemotherapy, if a complete response had been observed. This consisted of 30 Gy in 15 fractions. Esophageal toxicity was statistically different between the two arms, with the twice-daily patients experiencing 13% ⱖ grade 3 esophagitis versus 5% for the once-daily patients ( p ⫽ 0.027). No statistically significant difference in median survival between the two arms was found. Owing to the difference in toxicities, a quality-of-life evaluation was performed (23). Quality-adjusted life-years (QALY) were calculated using the Q-TWiST methodology and found to be greater for the oncedaily thoracic radiation arm than for the twice-daily treatment arm. However, the difference was not statistically significant and the benefit was restricted to the time of therapy, not subsequent years. It was the authors’ opinion that in evaluat-
Radiotherapy Fractionation and Volume
47
ing both survival and treatment toxicity, there was no significant difference between the two treatments. Several caveats should be kept in mind regarding this study. While the split course in the twice-daily arm was intended to decrease esophageal toxicity, it also defeats the purpose of this regimen, which is to combat accelerated tumor repopulation. Such a break does not fit with known radiobiological principles. Moreover, unlike the Intergroup Trial (13), the radiotherapy in this study was delayed until cycle 4. While the timing of radiotherapy remains controversial, many studies support the use of earlier, rather than delayed, radiotherapy (24,25). These key distinctions between these two studies (13,22) may account for the differences reported regarding the benefit of twice-daily radiotherapy. As this disease often presents in older patients, it is important to assess whether twice-daily therapy is tolerable in this patient population. A retrospective analysis of elderly patients ⱖ 70 years of age was performed from data collected from intergroup trial 0096 (26). It was found that severe (grade 4–5) hematological toxicity was more common in this group (85% in the twice-daily arm versus 60% in the daily arm, p ⬍ 0.01), although no significant difference in the frequency of nonhematological toxicities was observed. In particular, neither esophageal toxicity nor survival was different when compared with younger patients. Experiences in altered fractionation in both LS-SCLC and non–small cell lung carcinoma (NSCLC) may be useful in defining the current limits of combined therapy. In an Australian study by Ball and colleagues, 50 patients were treated with 2 Gy twice daily to a total of 60 Gy over the 3-week span with or without carboplatin chemotherapy (27). Patients experienced esophagitis lasting a median of 2–3 months. The multivariate analysis showed carboplatin did not influence the duration of symptoms. Locally advanced NSCLC patients received similar therapy in a trial reported by Kelly and colleagues (28). Instead of 2 Gy twice daily, they received 1.5 Gy twice daily, also to a total of 60 Gy. Esophageal toxicity was significant and was felt to be near the tolerable limits by the authors. In LS-SCLC patients Ali et al. delivered 1.1 Gy three times daily to a total dose of 66 Gy (6). This accelerated hyperfractionated regimen was started on day 1 of chemotherapy. Only 12 patients were treated on this phase II trial with a median survival of 20 months; the 2- and 5-year survival was 50 and 17%, respectively. Toxicity was severe with 65% grade 3–4 esophageal and 85% hematological toxicity. This prompted the early termination of the trial. Current Recommendations The addition of thoracic irradiation to systemic therapy significantly improves the local control rates and provides a modest improvement in survival. The optimal dose and fractionation schemes are unknown. However, previously standard
48
Williams et al.
doses of 45–50 Gy delivered in a once-daily scheme are known to result in unacceptably high local failure rates (ⱖ50%). Hyperfractionated radiotherapy, incorporating biological data in their design, to the same total dose has been shown in recent phase III trials to be tolerable and efficacious (though more toxic). The larger of the two reported trials demonstrated statistically significant improved 5-year survival and local control rates. Is this superior to higher doses of radiotherapy delivered in a once-daily regimen? The answer to that question is unknown and will need to be answered in future prospective randomized trials. The available data do strongly suggest that the current doses used in twice-daily fractionation schemes are close to or at tolerance. It may be possible to escalate doses using smaller volumes. With modern chemotherapy, this may be feasible. There are plans to design a randomized trial comparing 45 Gy twice daily to 66 Gy once daily (each with four cycles of platinum-etoposide chemotherapy). VOLUME The irradiated volume is a crucial variable. Limited-stage disease has been defined as the extent of disease that can be incorporated into a tolerable radiation portal. With the doses used at the time (40–45 Gy), this volume included most of the ipsilateral hemithorax and regional lymph nodes. The mediastinal, bilateral hilar, and ipsilateral supraclavicular regions were typically encompassed. In the 1970s and 1980s, the majority of authors emphasized the need to utilize such large radiation portals. They encompassed not only clinically involved areas, but all regional lymphatic drainage sites, regardless of whether they showed evidence of disease or not. This design likely arose from the treatment of Hodgkin’s lymphoma, in which adjacent nodal areas are included, because of its propensity for contiguous spread. Moreover, confidence may have been lacking concerning pre–cisplatin chemotherapy’s ability to eradicate subclinical disease. To counter that presumed deficit, extremely large fields have been attempted, including even hemibody and total-body radiation (29,30). A small trial reported by Byhardt et al. attempted to answer the question: could total-body irradiation (TBI) replace chemotherapy as a more effective systemic treatment? (29). Sixteen patients with limited-stage disease received 30 Gy/10 fractions thoracic radiotherapy and were then randomized to receive 1 Gy/10 fractions TBI versus CAV chemotherapy (cyclophosphamide, Adriamycin, vincristine). Although the toxicity related to the TBI was tolerable, it demonstrated no improvement over chemotherapy. A later trial attempted to incorporate TBI (same regimen) in the treatment of extensive-stage-disease patients (30). In that pilot, 19 patients received induction chemotherapy consisting of four cycles of VOCA (VP-16, vincristine, cyclophosphamide, and Adriamycin) followed by TBI and prophylactic cranial irradiation delivered concurrently. ‘‘Responding’’ partici-
Radiotherapy Fractionation and Volume
49
pants then went on to receive further CMH chemotherapy (cyclophosphamide, methotrexate, and hexamethylmelamine). Owing to toxicity, only eight of 19 patients received the consolidative chemotherapy and four of those required a delay before resuming chemotherapy. No improvement was noted in response or median survival with the addition of the low-dose TBI over chemotherapy alone compared to historical controls. A larger randomized trial compared systemic chemotherapy (pre–cisplatin era) plus locoregional thoracic radiotherapy versus that plus additional upper-abdominal and prophylactic cranial radiation (31). A total of 114 patients were randomized and the final analysis showed no local control or survival benefit to the larger-field radiotherapy, but rather a trend toward worse survival. Toxicity was not statistically different between the treatment arms. These series suggest that large-field radiotherapy for small cell carcinoma appears to be of limited use. In 1981, Perez and colleagues reported results of a prospective, randomized, combined therapy trial of the Southeastern Cancer Study Group (SECSG) (32). They established decreased intrathoracic failures (32.5%) in patients treated with large portals as compared with those where fields did not include the contralateral hilum or entire mediastinum (69.2%). However, it was not clear if the locoregional failures actually occurred in the unirradiated areas. Pre–cisplatin era chemotherapy was used. Typical radiation fields of the era are shown in Figure 1.
FIGURE 1 Traditional (large) radiotherapy portals used in the past.
50
Williams et al.
Other investigators also found the vast majority of intrathoracic failures occurred in the radiation ports, but suggested inadequate dose and resistant disease may have been the problem, rather than the volume treated (33). More recently, investigators have advocated using smaller postchemotherapy tumor volumes in designing fields rather than prechemotherapy volumes. Mira and Livingston evaluated 17 patients treated with reduced, postchemotherapy volume portals (34). They found that the majority of chest failures were outside the highdose volume, such as the development of lung parenchymal metastases and/or pleural effusions. They suggested that the systemic therapy might have left subclinical disease that was not included in the radiation portals. Liengswangwong et al. retrospectively compared 31 patients who had been treated with prechemotherapy tumor volumes to 28 patients who had been treated with postchemotherapy volumes (35). Thirty-two percent of patients experienced intrathoracic recurrence; however, the incidence was equally distributed between the two groups. No convincing evidence was found that treating postchemotherapy volumes placed patients at higher risk for intrathoracic or marginal failure. Investigators at the Institut Gustave-Roussy analyzed the chest recurrences in 72 patients with limited-stage disease treated in several phase II trials of combined modality therapy (36). The in-field recurrence rate was 33% in the group of patients treated with prechemotherapy volumes versus 36% for those treated with postchemotherapy fields. The difference was not statistically significant. Owing to the low number of patients in this analysis, the authors were only able to suggest that postchemotherapy volumes may be adequate and thereby reduce the treatment toxicity. After assessing the local failure in 117 patients with LSSCLC treated with combined modality therapy (83% receiving cisplatincontaining regimens), Tada and colleagues suggested that treatment volumes should be enlarged for patients with N 2 or N 3 involvement (37). Typical treatment field arrangements included the primary lung lesion with a 1.5-cm margin and all enlarged lymph nodes and the entire mediastinum down to the level of the subcarinal nodes (Figure 2). Marginal failures were noted in 13% and 27% of patients presenting with N 2 and N 3 disease, respectively. A marginal failure was defined as locoregional relapse (including cervical lymph nodes) outside or on the edge of the initial radiation port. They detected a majority of the marginal failures to occur in the superior mediastinum, supraclavicular, and cervical regions. Only one prospective, randomized trial has attempted to answer the preversus postchemotherapy volume question. The Southwest Oncology Group (SWOG) trial reported by Kies and colleagues randomized 191 patients with partial responses to chemotherapy to receive either wide-volume prechemotherapy or reduced-volume postchemotherapy radiotherapy after several cycles of induction chemotherapy (38). No appreciable difference emerged in either relapse pattern or survival. Patients receiving the wide-field radiotherapy had a slightly
Radiotherapy Fractionation and Volume
51
FIGURE 2 Radiotherapy portal of such a classic radiation treatment field (anterior view).
longer median survival and remission duration, but this was not statistically significant ( p ⫽ 0.73 and 0.32, respectively). It is important to note that in the previously mentioned studies, only the volume around primary disease changed. All these studies treated regional lymphatic sites prophylactically. The literature is silent about treating clinically involved areas alone, without treating radiographically uninvolved nodes. Three dimensional (3D) treatment planning systems are now widely available. Utilizing computerized tomography (CT) imaging, it is possible to better define gross tumor volumes and plan treatments that are no longer confined to two dimensions (Figure 3). One clear advantage of the 3D technique is its ability to treat less normal tissue (Figures 4 and 5). Using multiple noncoplanar beam arrangements, the dose to the surrounding normal tissue can be reduced. With the advent of intensity-modulated radiation therapy (IMRT), even more sophisticated conformal treatments are now possible. Using this new technology it is possible to adjust the radiation flux across the beam to confine the radiation dose tightly around critical structures, while maintaining high doses to the tumor volume. This
FIGURE 3
Beam’s-eye view of a three-dimensional conformal radiotherapy field.
FIGURE 4 Axial CT slice showing the radiation isodose curves conforming to the shape of the target.
Radiotherapy Fractionation and Volume
53
FIGURE 5 Three-dimensional reconstruction demonstrating the location of the tumor in the context of the surrounding anatomy.
technology has shown promise in several body sites, but its use is still considered investigational (39,40). It is a well-recognized tenet in radiotherapy that treating larger volumes requires a corresponding decrease in the deliverable dose. It is therefore reasonable to hypothesize that by decreasing the treated volume, dose escalation would be allowed, possibly leading to an increase in local control and survival. Supporting data include several studies in which the entire mediastinum was not treated, and the contralateral hilum and supraclavicular fossae were omitted. Excellent local control and survival were verified (8,11,13).
54
Williams et al.
It is also reasonable to hypothesize that as diagnostic capabilities improve, with more effective evaluation of the mediastinum, including esophageal ultrasound (41–43) and positron emission tomography (PET) (44–46), marginal or locoregional failures can hopefully be avoided. Current Recommendations Most modern radiotherapy series indicate that failure occurs within the irradiated volume at the primary site, and the problem appears to be intrinsic tumor resistance, rather than marginal miss. Reducing the irradiated volume may allow for significant dose escalation without an attendant rise in toxicity. Recent dose escalation trials in both LS-SCLC and NSCLC have borne this out. Modern chemotherapy will hopefully aid in this goal by sterilizing subclinical disease and allowing omission of lymphatic regions previously treated prophylactically. Field size reduction can be exploited to increase dose and decrease toxicity. Developing technologies, including 3D treatment planning and IMRT, will also assist in this goal and hopefully lead to an improvement in local control and survival. REFERENCES 1. Pignon JP, Arriagada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618–1624. 2. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small-cell carcinoma of the lung? J Clin Oncol 1992; 10:890–895. 3. Choi N. Accelerated radiation therapy in small cell lung cancer: rationale and limitation in its utility. Int Radiat Oncol Biol Phys 1990; 19:1623–1625. 4. Johnson D, Turrisi A, Chang A, Blum A, Bonomi P, Ettinger D, Wagner H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11(5):879–884. 5. Johnson BE, Bridges JD, Sobezeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg S, Edison M, Frame J, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14(3):806–813. 6. Ali M, Kraut M, Valdivieso M, Herskovic A, Du W, Kalemkerian G. Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer. Lung Cancer 1998; 22:39–44. 7. Johnson BE, Salem C, Nesbitt J, Gazdar A, Lesar M, Phelps R, Edison M, Linnoila R, Phares J, Pass H, Mulshine J, Minna J, Glatstein E, Ihde D. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin. Lung Cancer 1993; 9(suppl. 1):S21–S26. 8. Turrisi AT, Glover DJ, Mason B, Tester W. Long term results of platinum etoposide
Radiotherapy Fractionation and Volume
9.
10.
11.
12.
13.
14. 15.
16.
17.
18.
19.
20.
55
(PE) ⫹ twice-daily (BID) thoracic radiotherapy (TRT) for limited small-cell lung cancer (LSCLC): results on 32 patients with 48 month minimum F/U. Proc ASCO 1992; 11:292. Turrisi A, Wagner H, Glover D, Mason B, Oken M, Bonomi P. Limited small cell lung cancer (LSCLC): concurrent BID thoracic radiotherapy (TRT) with platinumetoposide (PE): an ECOG study. Proc ASCO 1990; 9:230. Mornex F, Trillet V, Chauvin F, Ardiet JM, Schmitt T, Romestaing P, Carrie C, Mahe M, Mornex JF, Fournel P, Souquet PJ, Boniface E, Vincent M, Piperno D, Rebattu P, Gerard JP, and the Groupe Lyonnais d’Oncologie Thoracique. Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 1990; 19:23– 30. Turrisi AT, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 15(1):183–187. Armstrong JG, Rosenstein MM, Kris MG, Shank BM, Scher HI, Fass DE, Harrison LB, Leibel SA, Fuks ZY. Twice daily thoracic irradiation for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1991; 21:1269–1274. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340(4):265–271. Abadir R, Orton C. Radiotherapy for small-cell lung cancer. Correspondence. N Engl J Med 1999; 340(25):2002–2003. Coy P, Hodson I, Payne D, Evans W, Feld R, MacDonald A, Osoba D, Pater J. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys 1987; 14:219–236. Choi N, Carey R. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 1989; 17:307–310. Papac R, Son Y, Bien R, Tiedemann D, Keohane M, Yesner R. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys 1987; 13:993–998. Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16(11):3528–3536. Jeremic B, Shibamoto Y, Acimovic L, Millsavijevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15(3):893–900. Goto K, Nishiwaki Y, Takada M, Fukuoka M, Kawahara M, Sugiura T, Kurita Y, Watanabe K, Noda K, Yoshimura K, Tamura T, Saijo N. Final results of a Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-
56
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Williams et al. SCLC): the Japan Clinical Oncology Group (JCOG) study. Proc ASCO 1999; 18: 468a. Hayman J, Martel M, Ten Haken R, Todd R, Turrisi A, Lichter A, University of Michigan Health System, Ann Arbor, MI. Dose escalation in non-small cell lung cancer (NSCLC) using conformal 3-dimensional radiation therapy (C3DRT): update of a Phase 1 Trial. Proc ASCO 1999; 18:459a. Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Sloan JA. Phase III comparison of once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer. Proc ASCO 1998; 17:456a. Bonner JA, Sloan JA, Hillman SH, Shanahan TG, Brooks BJ, Marks RS, Ochsner Clinic CCOP, New Orleans, LA, and North Central Cancer Treatment Group (NCCTG). A quality adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation therapy versus twice-daily thoracic radiation therapy in patients with limited stage small cell lung cancer. Proc ASCO 1999; 18:466a. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336–344. Jeremic B, Shibamato Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893–900. Yuen A, Zou G, Turrisi A, Sause W, Komaki R, Wayner H, Aisner S, Livingston R, Blum R, Johnson D. Similar outcome of elderly patients in intergroup trail 0096: cisplatin (P), etoposide (E), and thoracic radiotherapy (TRT) administered once (QD) or twice daily (BID) in limited stage small cell lung cancer (SCLC). Proc ASCO 1999; 18:467a. Ball D, Bishop J, Smith J, et al. A phase III study of accelerated radiotherapy (RT) with and without carboplatin in non-small cell lung cancer (NSCLC): interim toxicity analysis. Lung Cancer 1994; 11(suppl 2):54–55. Kelly K, Bunn PA, Hazuka MB, et al. A phase I-II study of daily carboplatin in patients with regionally inoperable non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11(suppl):693 (abstr). Byhardt R, Cox J, Wilson J, Libnoch J, Stein R. Total body irradiation vs. chemotherapy as a systemic adjuvant for small cell carcinoma of the lung. J Radiat Oncol Biol Phys 1979; 5:2043–2048. Dillman R, Seagren S, Taetle R. Failure of low-dose, total-body irradiation to augment combination chemotherapy in extensive-stage small cell carcinoma of the lung. J Clin Oncol 1983; 1(4):242–246. Hansen H, Dombernowsky P, et al. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma: a comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer 1980; 46:279–284. Perez C, Krauss S, Bartolucci A. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung. Cancer 1981; 47:2407–2413. Brodin O, Arnbert H, Bergh J, et al. Increased radioresistance of an in vitro transformed human small cell lung cancer cell line. Lung Cancer 1995; 12:183–198.
Radiotherapy Fractionation and Volume
57
34. Mira JG, Livingston RB. Evaluation and radiotherapy implications of chest relapse patterns in small cell lung carcinoma treated with radiotherapy-chemotherapy: study of 34 cases and review of the literature. Cancer 1980; 46:2557–2565. 35. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994; 12(3):496–502. 36. Arriagada R, Pallae-Cosset B, Ladron de Guevara JC, el Bakry H, Benna F, Martin M, de Cremoux H, Baldeyrou P, Cerrina ML, Le Chevalier T. Alternating radiotherapy and chemotherapy schedules in limited small cell lung cancer: analysis of local chest recurrences. Radiother Oncol 1991; 20(2):91–98. 37. Tada T, Minakuchi K, Koda M, Masuda N, Matsui K, Kawase I, Nakajima T, Nishioka M, Fukuoka M, Kozuka T. Limited-stage small cell lung cancer: Local failure and chemotherapy and radiation therapy. Radiology 1998; 208:511–515. 38. Kies M, Mira J, Crowley J. Multimodal therapy for limited small cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol 1987; 5: 592–600. 39. Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999; 9(1):78– 98. 40. Meeks SL, Buatti JM, Bova FJ, Friedman WA, Mendenhall WM, Zlotecki RA. Potential clinical efficacy of intensity-modulated conformal therapy. Int J Radiat Oncol Biol Phys 1998; 40(2):483–495. 41. Silvestri GA, Hoffman BJ, Bhutani MS, Hawes RH, Coppage L, Sanders-Cliette A, Reed CE. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61(5):1441–1445. 42. Serna DL, Aryan HE, Chang KJ, Brenner M, Tran LM, Chen JC. An early comparison between endoscopic ultrasound-guided fine-needle aspiration and mediastinoscopy for diagnosis of mediastinal malignancy. Am Surg 1998; 64(10):1014–1018. 43. Hunerbein M, Ghadimi BM, Haensch W, Schlag PM. Transesophageal biopsy of mediastinal and pulmonary tumors by means of endoscopic ultrasound guidance. J Thorac Cardiovasc Surg 1998; 116(4):554–559. 44. Coates G, Skehan SJ. Emerging role of PET in the diagnosis and staging of lung cancer. Can Respir J 1999; 6(2):145–152. 45. Saunders CA, Dussek JE, O’Doherty MJ, Maisey MN. Evaluation of fluorine-18fluorodeozxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67(3):790–797. 46. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz EF. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212(3):803–809.
5 The Role of Prophylactic Cranial Irradiation: Pro Ce´cile Le Pe´choux and Thierry Le Chevalier Institut Gustave-Roussy, Villejuif, France
Rodrigo Arriagada Instituto de Radiomedicina, Santiago, Chile
INTRODUCTION Small cell lung cancer (SCLC) represents 20% of all lung cancer cases. Specific characteristics distinguish it from other cell types: the risk of early hematogenous dissemination, and its marked radiosensitivity and chemosensitivity (1). About two-thirds of these patients, and particularly those presenting limited disease, and treated with aggressive induction therapy combining multidrug chemotherapy and thoracic radiation therapy, will achieve a complete remission. Yet only 15– 20% of complete responders will be long-term survivors. Indeed, the majority of these patients relapse. A consequence of improved local control is that brain metastases have now become a significant cause of treatment failure (2,3). Even if SCLC is chemosensitive, unless they are highly liposoluble, drugs find it difficult to cross the bloodbrain barrier. In the seventies, Hansen proposed central nervous system (CNS) prophylaxis given that the brain was considered a pharmacological sanctuary where metastases could be protected from cytostatic agents due to the blood59
60
Le Pe´choux et al.
brain barrier (4). Here pediatric acute lymphoblastic leukemia (ALL) served as a paradigm of successful CNS prophylaxis; meningeal leukemia had been significantly reduced and the cure rate of ALL improved as a result of such treatment. These observations were part of the rationale underlying a number of clinical trials investigating prophylactic cranial irradiation (PCI) over the last two decades, in an attempt to prevent the development of brain metastases and reduce the risk of CNS relapses. Many of these trials were too small to detect significant benefits in terms of the prevention of brain metastases or enhanced survival. However, by the mid-1980s, PCI had been demonstrated to significantly reduce the incidence of CNS relapses compared to no PCI, although doubts persisted as to whether such treatment would be beneficial for survival. Physicians were also concerned about the best ways to preclude recurrences without generating unacceptable toxicity and without impairing the patient’s quality of life. More recent studies have tested PCI in patients achieving a good response to induction therapy, and have confirmed that PCI significantly decreases the likelihood of developing brain metastases by at least 30%. Despite several retrospective and prospective studies, the usefulness of PCI has remained controversial owing to the lack of improvement in survival in individual trials and possible neurotoxicity in long-term survivors (5–8). However, data have recently been published that help clarify the role of PCI in SCLC. INCIDENCE OF CENTRAL NERVOUS SYSTEM METASTASES IN SCLC Neurological disorders, either at the time of presentation or during the subsequent clinical course of SCLC, are frequent. They include brain metastases, meningeal carcinomatosis, intramedullary metastases, epidural metastases, and hyponatremia producing CNS symptoms. However, carcinomatous leptomeningitis or spinal cord lesions are usually found in patients who develop recurrent disease (9). Brain metastases are the most common forms of CNS involvement, and are the only lesions shown to be potentially preventable. At initial diagnosis, 10– 15% of patients have brain metastases; the incidence varies between 50 and 65% in autopsy series (3,4,10,11). Indeed, brain metastases are present in 50–80% of 2-year survivors (2,3,12). The incidence of brain metastasis as the first site of treatment failure varies between 14 and 45% at 2 years, even in patients who achieve a complete response (13,14). With the improvement in local control in SCLC, brain metastases have become a common cause of treatment failure. TREATMENT OF BRAIN METASTASES Historically, cytotoxic agents have played a limited role in the treatment of brain metastases, since cytostatic drugs were generally unable to cross the blood-brain barrier of the normal brain in tumoricidal concentrations. However, more recent
Prophylactic Cranial Irradiation: Pro
61
studies have reported a better response in brain metastases after treatment with chemotherapy alone, with rates ranging from 40 to 76% (15–18). Although these small studies have shown that brain relapses are quite responsive to systemic therapy, radiation therapy has remained the most widely accepted treatment modality for brain metastases. According to retrospective studies, cranial irradiation significantly improves neurological symptoms in 56–92% of patients with SCLC brain metastases (3,19–22). Both initial and delayed brain metastases are included in most studies, and about 70–75% of patients have some improvement of their symptoms and 40% achieve a complete remission. Success, however, is inversely proportional to the severity of the neurological symptoms; in effect, all patients who had minimal symptoms had complete palliation, whereas only 45% of patients with severe symptoms had complete palliation (19). The response rate for initial metastases (73–74%) is higher than for delayed metastases (56–58%) (19,21). Whereas systemic chemotherapy may be appropriate for patients with brain metastases at initial diagnosis, therapeutic cranial irradiation appears preferable for patients who develop brain metastases after induction treatment. Although relief of symptoms with therapeutic brain radiation is clearly beneficial, overall survival after development of brain metastases is low, with median survival ranging from 1.5 to 4.5 months (20,22–25). Brain metastases are also associated with considerable morbidity, which has been shown to be worse in terms of days spent in hospital than in patients with SCLC liver involvement (26). As brain metastases are so difficult to treat, and are accompanied by distressing and sometimes life-threatening symptoms, prophylactic treatment seems a reasonable alternative. It has been suggested that prophylactic cranial irradiation could confer an advantage over therapeutic brain irradiation by preserving a better quality of life (QoL) (27). In one early study, the QoL was evaluated with the Karnofsky performance status. The mean survival, with a Karnofsky score of 60 or greater, was superior in patients who had prophylactic cranial irradiation (10 months) compared to patients who had no PCI and who subsequently developed brain metastases (6 months) (27). Thus historically, one of the first arguments of the proponents of PCI was that the development of brain metastases gave rise to considerable morbidity, and such morbidity could be prevented with elective irradiation. Furthermore, brain failure is a rapidly fatal event once CNS metastases have emerged (20,23–25). Alternatives to prophylactic cranial irradiation have been proposed. Chemoprophylaxis of brain metastases, even with lipophylic agents, has failed in past studies (3,28). Regular follow-up of the brain (CT scan every 3 months for 2 years) was also proposed as an alternative to PCI in a study that included 127 patients (29). There, the objective was to detect brain metastases at an early asymptomatic stage in the hope of achieving long-term control with immediate therapeutic radiotherapy and thus avoid possible long-term morbidity due to PCI. Among the 56 patients (44%) who had a CNS relapse, it emerged between scans in 20 of them. Despite cranial irradiation, about 60% of the patients who devel-
62
Le Pe´choux et al.
oped brain metastases died with active CNS disease. The authors concluded that PCI could not be replaced by regular follow-up with CT scans. EFFICACY OF PROPHYLACTIC CRANIAL IRRADIATION Older Trials Several retrospective studies have shown that PCI could reduce CNS relapse; only 2–5% of patients thus treated would develop brain metastases as the first site of relapse (19,30). Other studies have reported higher rates of CNS relapse. Some of the difficulties in assessing the value of PCI have come from statistical ambiguities in the definition of a brain relapse, i.e., sole site of first relapse, cumulative rate of brain failure at a given time, crude rate of brain metastases or actuarial rate. Furthermore, as the duration of survival has increased due to increasingly effective systemic therapy, combined or not with thoracic radiotherapy in localized disease, so has the frequency of brain metastases (2,3,31). Many investigators have routinely used PCI during the past 20 years, since it was generally accepted that it would delay the onset of symptomatic brain metastases and reduce by 30–50% the lifetime risk of CNS relapse (2,3). Since then, several randomized trials have been published (32–38). However, they included very heterogeneous patient populations: patients who failed to achieve a complete remission, patients with limited and extensive disease, patients who had concomitant chemotherapy and different PCI doses and fractionation, which may account for the differences observed in the reduction of brain failure. Table 1 summarizes the results of several randomized trials that show that the incidence of CNS metastases varies between 13% and 67% in patients not receiving PCI. Almost all these studies showed a significant two- to threefold decrease in the incidence of brain metastases, but no impact on the survival rate. However, in 1983, Rosen et al. were the first to report that PCI could have an impact on survival in a subgroup of patients. Since then, several retrospective studies have suggested that PCI not only reduced brain failure rates, but could also improve survival in complete responders to induction treatment (12,41–43). In other studies, increased survival with PCI was also observed in patients with other favorable characteristics, such as a good performance status, moderate weight loss, young age, and a serum sodium value that could be predictive of a relatively long life expectancy (44). Furthermore, brain metastases were the only cause of death in only a minority of patients (10%) (45). This may also contribute to the fact that these randomized studies did not show any impact on survival. Recent Randomized Trials More recent randomized trials have enrolled only patients considered to be in complete remission, as shown in Table 2 (12,46–49). When PCI is restricted to
Study Aroney (40) 1983 Beiler (32) 1979 Cox (33) 1978 Eagan (23) 1981 Hansen (34) 1980 Jackson (35) 1983 Katsenis (36) 1982 Maurer 1980 Niiranen (37) 1989 Seydel (39) 1985
No. of patients 29 54 45 30 110 29 35 163 51 217
PCI dose, Gy/fraction, timing of PCI 30/10 CR 24/8 3 rd week 20/10 D1 36/10 20 th week 40/20 12 th week 30/10 D1 40/25 D1 30/10 9 th week 40/20 4 th week 30/10 D1
Rate of brain metastases (%)
Median survival
PCI(⫹)
PCI(⫺)
p value
PCI(⫹)
PCI(⫺)
0
27
NS
NR
NR
0
16
⬍0.05
17
24
NS
⬎104 wk LD NR
58 wk LD NR
13
73
⬍0.05
13.6 mo
12.9 mo
9
13
NS
9.2 mo
10.2 mo
0
27
⬍0.05
9.8 mo
7.2 mo
12
44
⬍0.05
NR
NR
4
18
⬍0.01
8.4 mo
8.8 mo
0
26
⬍0.05
13 mo
10 mo
5
21
⬍0.005
53 wk
Prophylactic Cranial Irradiation: Pro
TABLE 1 Randomized Trials Evaluating PCI in SCLC Patients
52 wk
63
NS: No significant difference in terms of overall survival; CR: PCI given when patients are in complete remission; D1: PCI given on the first day of induction treatment.
64
TABLE 2 Randomized Trials Evaluating PCI in SCLC Complete Responders
Study Arriagada (13) 1995 Gregor (46) 1997 Laplanche (47) 1998 Ohonoshi (48) 1993 Wagner (49) 1996
No. of patients 300 314 211 46 31
PCI dose, Gy/fraction, timing of PCI 24/8 CR Various CR 24/8–30/10 CR 40/20 CR 25/10 CR
Rate of brain metastases (%)
Median survival
p value
PCI(⫹)
PCI(⫺)
40
67
⬍10 ⫺13
30
54
0.00004
44
51
0.14
22
52
⬍0.05
20
50
PCI(⫹)
PCI(⫺)
NR
NR
305 days
300 days
NR
NR
21 mo
15 mo
15.3 mo
8.8 mo
Le Pe´choux et al.
NS: No significant difference in terms of overall survival; CR: PCI given when patients are in complete remission.
Prophylactic Cranial Irradiation: Pro
65
this favorable group of patients, brain metastases appear to be a major cause of failure. Virtually all the oldest randomized trials demonstrated a decreased rate of brain metastases from 22% to 6% for the groups not receiving and receiving PCI, respectively (32–40). These were crude brain metastasis rates. In the more recent trials, the rates seem higher, but are reported as actuarial rates (13,46– 49). The overall 2-year actuarial brain failure rates are 40% and 67% (for PCI⫹ and PCI⫺, respectively) in the trial reported by Arriagada and colleagues and 30% and 54%, respectively, in the trial reported by Gregor and colleagues (Table 3) (13,46). In both the French and the EORTC trials, a plateau was observed after 2 years in the brain metastasis rate, suggesting that brain metastases can potentially be prevented, and not simply delayed, with PCI. This can be considered a second strong argument for the advocates of PCI. None of these randomized trials were large enough to confirm statistically the survival benefit suggested in retrospective studies (12,42–44). Since the probability that a patient might have the brain as the only site of failure ranges from 5 to 10%, only a small gain in long-term survival could be expected from PCI (19,45). Meta-Analysis A meta-analysis of individual patient data collected from seven trials, including a total of 987 patients randomized from 1977 to 1995, compared PCI to no PCI in patients with SCLC in complete remission (Table 4). The primary endpoint was overall survival (50). The results, which have recently been reported, showed PCI led to a 16% reduction in the mortality rate corresponding to an absolute increase of 5.4% in the 3-year survival rate (from 15.3% observed in the control group to 20.7%). PCI, therefore, not only decreased the risk of developing brain metastases significantly (from 58.6% to 33.3% at 3 years), as shown in other individual trials, but also improved overall survival and disease-free survival (50). Optimal PCI Dose? Although the dose-response relationships for PCI in SCLC are a fundamental element in planning the optimal treatment schedule, they have not been well established. In most studies, the prescribed PCI dose is about 24–30 Gy. One study has reported interesting results with one fraction of 8 Gy (51). However, large PCI fractions should be avoided because of late neurotoxicity. It has been demonstrated by Withers et al. that the dose-response relationship for subclinical metastatic disease is usually linear and within the 20–50-Gy dose range (52). Only one randomized trial has directly addressed this issue (46). The first part of this three-arm trial compared two PCI doses (24 Gy and 36 Gy) to no PCI. The hazard ratio between the group of patients treated with 24 Gy and the noPCI group was 0.71 whereas it was 0.16 between the 36-Gy and no-PCI groups, and highly significant. Thus, the higher dose reduced the risk of brain metastasis
66
TABLE 3 Results at 2 Years (except for the IPC 88) of the Three Main PCI Randomized Studies in SCLC Complete Responders
IPC 85 (13) ICP 88 (47) UKCCCR-EORTC (46)
No. of patients, PCI⫹/PCI⫺
PCI(⫹)
PCI(⫺)
OS, PCI(⫹)
OS, PCI(⫺)
149/151 100/111 194/120
40% 44% (4 years) 30%
67% 51% (4 years) 54%
29% 22% (4 years) 25%
21.5% 16% (4 years) 19%
Rate of brain metastases
Le Pe´choux et al.
Prophylactic Cranial Irradiation: Pro
67
TABLE 4 Randomized Studies Included in the Meta-Analysis Study
Stage
Aroney (40) Danish/NCI Ohonoshi (48) Wagner ECOG 3589 RTOG 9201 (49) Arriagada IPC 85 (13) Laplanche IPC 88 (47) Gregor UKCCCR/ EORTC (46)
All All All All All All Limited
PCI dose, Gy/fractions
Number of patients
Years of accrual
30/10 24/8 40/20 25/10
32 48 46 32
1977–80 1986–91 1981–86 1991–94
24/8 24–30/8–10 8–40/1–18
300 211 314
1985–93 1988–94 1987–95
more effectively. In the study by Work et al., among the 199 patients with limited SCLC who were randomized to initial chest irradiation versus late (18 weeks) chest irradiation, 157 received PCI. The PCI dose was 33 Gy in 11 fractions for 45 patients and 25 Gy in 11 fractions for the other 112. The 5-year incidence of CNS recurrences was 15% after 33 Gy and 23% after 25 Gy. Although the difference was not significant, there was a trend toward a dose-response relationship, which was also apparent in the meta-analysis (44). The effect of PCI on brain metastases increased with the total PCI dose when four dose groups (8 Gy, 24– 25 Gy, 30 Gy, 36–40 Gy) were analyzed in the meta-analysis (trend p ⫽ 0.02). Hence the reduction of the relative risk of developing brain metastasis as compared to the control group was 24% in the 8-Gy group, 48% in the 24–25-Gy group, 68% in the 30-Gy group, and 73% in the 36–40-Gy group, but the effect on survival did not differ significantly according to the dose. A dose-response relationship was also found in a recent review that collected data from 12 nonrandomized studies and 12 randomized studies comparing brain relapse rates with and without PCI (53). The dose-response curve was almost linear within the 20– 35-Gy dose range. Optimal Timing? The optimal timing for PCI in limited-stage SCLC has not been firmly determined either. Many relapses probably reflect an uninterrupted metastatic process, given the tumor doubling time in SCLC and the short life-span. Even if PCI is administered early to avoid reseeding in the brain, it has been recommended that it be administered preferably following documentation of complete remission, after 2–4 months of follow-up, but before 6 months from initiation of chemotherapy (54). Rarely is brain metastasis observed within 6 months from the initiation of
68
Le Pe´choux et al.
chemotherapy (12). In the study by Lee et al., the overall incidence of brain metastasis was higher in patients who received PCI after five to six cycles of chemotherapy than in patients who received PCI after two to three courses of induction and maintenance chemotherapy (54). Only one trial has directly addressed the optimal timing of PCI. In the Perez study, comparing the effectiveness of concomitant versus delayed chemotherapy combined with irradiation to the mediastinum and to the brain in 70 patients with localized disease, PCI was administered either during the first week (early-PCI group) or during the seventh week (late-PCI group). There was no difference in the incidence of brain metastases (7% in both groups). However, the induction treatment would now be considered inadequate as patients in the early-PCI group received chemotherapy only in case of relapse or in case of no response to mediastinal radiotherapy (38). Therefore, no firm conclusions can be drawn from this trial. In the study by Murray et al., a delay of 12 weeks in the initiation of chest irradiation (PCI being delivered on the nineteenth week at a dose of 25 Gy) was associated with a significant increase in the incidence of CNS recurrences. The total proportion of brain metastases in the early arm (18.1%) was significantly less than in the late-mediastinal-irradiation arm (28.1%) (55). The authors explained that although SCLC is chemosensitive, about 30–40% of patients have a chemoresistant tumor confined to the primary site. Thus, early mediastinal radiotherapy would decrease the probability of growth of a chemoresistant tumor during treatment in sites such as the brain. In the Aarhus Lung Cancer Group study, there was no difference in CNS recurrences whether chest irradiation was given at the beginning of treatment or delayed, but PCI was delivered initially, together with early mediastinal irradiation or with the first cycle of chemotherapy (44). Recently Suwinski et al. have conducted an interesting analysis of PCI dose response according to its timing (53). They showed that the delay between the initiation of induction treatment and PCI introduces a 20-Gy threshold in the dose-response curve, which would otherwise have been linear. If only studies during which PCI was initiated less than 60 days after the first day of induction treatment are considered, there was almost a linear relationship between the dose delivered in 2-Gy fractions equivalent and the percentage reduction in total brain relapse rates within the 8–30-Gy dose range. In the studies in which PCI was initiated later, higher doses appeared to be necessary to obtain the same prophylactic effect. Effective induction treatment may arrest the development of new metastases to the brain, but it probably does not affect existing brain metastases. Thus, increasing the delay between induction treatment and PCI may increase the burden of metastatic disease to the brain. The meta-analysis has shown that PCI influences long-term survival of patients who achieve a complete response to therapy (50). However, PCI is directly suspected in the onset of neurotoxicity in long-term survivors. Several studies
Prophylactic Cranial Irradiation: Pro
69
have reported neurological and intellectual impairment and abnormalities on brain CT scan potentially related to PCI (56–70). However, neurological sequelae are difficult to assess in this subset of patients and there is a wide variety of interpretations regarding the etiology of the morbidity in all of these retrospective studies. This confusion has contributed largely to the controversy regarding PCI. Age, the effects of chronic cigarette abuse, possible paraneoplastic syndromes, and micrometastases may also contribute to neurotoxicity (69,71–73). Several studies, however, have reported that it was dependent on the total dose, the dose per fraction, the timing of chemotherapy (concomitant with PCI), and the type of chemotherapy. NEUROTOXICITY In the past, neurotoxicity was the overriding argument against PCI, particularly as no improvement was demonstrated in survival, until now. Early toxicity is minimal with the exception of transitory alopecia, although varying degrees of headache, mild nausea, and fatigue are observed. Most data on late neurotoxicity are based on small retrospective studies (57,58,61–67). There has been much concern about the possible long-term damaging effects of PCI: ataxia, seizures, and even dementia (57,59,62,63,65). Some sequelae are shown in Table 5. Lishner et al. analyzed 58 long-term survivors and found that nine of 48 patients (19%) who had had PCI had neurological complications (66). However, PCI was responsible for progressive dementia in only two patients. Laukkanen et al. evaluated 12 patients who had PCI and who were alive at 2 years for clinical, neuropsychological, and brain CT scan sequelae (65). All were capable of looking after
TABLE 5 Retrospective Studies Reporting Neurotoxicity After PCI
Author Catane (57) Cull (60) Craig (58) Frytak (61) Johnson (62) Lee (64) Laukkanen (65) Lishner (66) Twijnstra (67)
No. of patients 16 64 13 283 20 25 12 58 21
Neuropsychological abnormalities PCI(⫹) 4/13 25% 4/13 28/160 (17%) 11/17 3/20 8/12 9/48 12/14
PCI(⫺) 2/3
0/123 1/3 0/5 2/10 0/7
Brain CT abnormalities PCI(⫹)
PCI(⫺)
9/13 60% 13/13 Present 10/17 14/20 12/12
2/3
1/3 0/5
70
Le Pe´choux et al.
themselves and none had dementia, as described in other studies. As suggested by Johnson, patients who were given high-dose induction chemotherapy while receiving cranial irradiation or large radiotherapy fractions (more than 3 Gy) were more likely to have abnormal neuropsychological tests and abnormal mental status examinations (62,63). Brain CT scan abnormalities are common: cerebral atrophy, ventricular dilatation, and periventricular and subcortical white matter changes, which seem to worsen after completion of treatment (62). These abnormalities seem to occur more frequently in patients with abnormal neuropsychological function (63). To determine the specific causes of CNS abnormalities occurring in patients with SCLC is difficult: metastases, paraneoplastic syndromes, infections, metabolic effects, a chronic smoking habit, psychological stress, and chemotherapy may contribute to these complications (69–73). PCI has often been delivered with chemotherapeutic agents, some of which are potentially neurotoxic, either due to synergism with PCI or via independent mechanisms. Patients who receive methotrexate, nitrosoureas, and procarbazine after whole-brain irradiation are at high risk for clinical CNS neurotoxicity and for the development of periventricular white matter changes depicted on CT brain scans (64). Methotrexate is known to interact with PCI to produce necrotizing leukoencephalopathy, mineralizing microangiopathy, and cognitive impairment (74). Among 13 patients who received concomitant chemotherapy and PCI, posttreatment scans documented cerebral atrophy (100%), ventricular dilatation (70%), and decreased coefficient of absorption in the white matter (15%) (58). Van Oosterhout et al. reported neurological sequelae in a series of 51 long-term SCLC survivors who were treated with chemotherapy alone (group 1), with sequential PCI (group 2), or with concurrent chemotherapy and PCI (group 3) (75). Mental impairment, motor abnormalities, and visual complaints were observed in 24% of group 1 patients, 42% of group 2 patients, and 73% of patients in group 3. White matter abnormalities were found more frequently in group 3, whereas there was no significant difference in the analysis of brain atrophy. No significant differences existed between groups with respect to their neuropsychological status. The authors concluded that there was no statistical evidence for additional neurotoxicity of PCI. However, they did observe marked neuropsychometric differences between patients and matched controls, so cognitive impairment may be partly related to disease, but also to a deteriorated physical condition and emotional distress (75). A small prospective study has evaluated the magnitude of neuropsychological deficits thoroughly in 30 patients with SCLC who had PCI. Almost all the patients with favorable responses to combination chemotherapy had specific cognitive deficits before receiving PCI (29 of 30 patients) (69). A recent study by Cull et al., also reported neurological and cognitive impairment in 64 long-term survivors (ⱖ2 years) (60). The authors emphasized how difficult it was to assess these patients, but used validated scales for toxicity
Prophylactic Cranial Irradiation: Pro
71
and the performance status; 75% of these patients were well, 11% had cognitive deficits, and 16% had ataxia that could be attributed to late neurotoxicity. These data contrast with those reported in older studies where up to 85% of patients were found to have clinically detectable neurological problems (62,64). Several studies have therefore reported neurological and intellectual impairment and abnormalities on brain CT scan potentially related to PCI, but they are all retrospective and have analyzed a small number of patients. Only two recent prospective trials have included a neurological assessment in their study (13,46). Several patients had an initial neuropsychological examination (before PCI could possibly have been administered) that was abnormal (40–60%). The results within the first years of follow-up did not show any significant difference in neuropsychological modifications between treated and untreated patients. Longterm follow-up is, however, necessary to better evaluate late neurotoxicity. PCI seems to have an adverse effect on the quality of life only in a minority of patients, provided smaller fractions are used (⬍3 Gy) and no concomitant chemotherapy is given. OTHER INDICATIONS FOR PROPHYLACTIC CRANIAL IRRADIATION Should PCI be restricted to patients in complete remission? In the study by Nugent et al., PCI seemed to effectively prevent brain metastasis in patients with liver and bone marrow metastasis even if they had a short life expectancy (3). Several studies have indicated that if the aim is to reduce the incidence of brain recurrences, then all patients should receive PCI, whereas if the aim is to improve survival, then only patients with a favorable prognosis should receive PCI (12,44). CONCLUSION For many years, PCI was a controversial issue with opponents arguing that none of the published reports of randomized trials on PCI showed an effect on overall survival and that the late-occurring neurological effects would clearly outweigh its benefits. However, a number of studies during the past 20 years have reported a lower incidence of brain metastases with PCI, with an accompanying decrease in the risk of associated morbidity and the social consequences of brain failure. Not only have recent trials shown that brain metastases could really be prevented and not just delayed with PCI in complete responders, but the recent metaanalysis has demonstrated that PCI leads to an absolute increase of 5.4% in the 3-year survival rate (from 15.3% observed in the control group to 20.7%). This benefit conferred on overall survival can be added to the effect of thoracic radiotherapy, which has about the same value.
72
Le Pe´choux et al.
Selecting the optimal dose for PCI that would lead to a further decrease in the incidence of brain metastasis with minimal toxicity is one of the challenges identified by the meta-analysis as well the ideal timing of PCI. Future trials are therefore warranted that will require cooperation worldwide. Prophylactic cranial irradiation should now be considered as part of the standard treatment of patients with SCLC. ACKNOWLEDGMENT The authors wish to thank Lorna de Saint-Ange for editorial assistance. REFERENCES 1. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 1997:911–949. 2. Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep 1981; 65:811–814. 3. Nugent J, Bunn P, Matthews M, Ihde DC, Cohen MH, Gazdar A, Minna J. CNS metastases in small brochogenic carcinoma. Increasing frequency and changing pattern with lengthening of survival. Cancer 1979; 44:1885–1893. 4. Hansen HH. Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation? Cancer Chemother Rep 1973; 4:239–241. 5. Einhorn LH. The case against prophylactic cranial irradiation in limited small cell lung cancer. Semin Radiat Oncol 1995; 5:57–60. 6. Wagner H. Prophylactic cranial irradiation for patients with small cell lung cancer. An enduring controversy. Chest Surg Clin North Am 1997; 7:151–166. 7. Turrisi AT. Brain irradiation and systemic chemotherapy for small-cell lung cancer: dangerous liaisons? Editorial. J Clin Oncol 1990; 8:196–199. 8. Fleck JF, Einhorn LH, Lauer RC, Schultz SM, Miller ME. Is prophylactic cranial irradiation indicated in small-cell lung cancer? J Clin Oncol 1990; 8:209–214. 9. Sculier JP, Feld R, Evans WK, De Boer G, Sheperd FA, Payne DG, Pringle JF, Yeoh JL, Quirt IC, Curtis JE. Neurologic disorders in patients with small cell lung cancer. Cancer 1987; 60:2275–2283. 10. Hirsch FR, Paulson OB, Hansen HH. Intracranial metastases in small cell carcinoma of the lung. Correlation of clinical and autopsy findings. Cancer 1982; 50:2433– 2437. 11. Bunn PA, Nugent JL, Matthews MJ. Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol 1978; 5:314–322. 12. Rosen ST, Makuch RW, Lichter AS, Ihde DC, Matthews MJ, Minna JD, Glastein E, Bunn PA. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. Am J Med 1983; 74:615–624. 13. Arriagada R, Le Chevalier T, Borie F, Rivie`re A, Chomy P, Monnet I, Tardivon A,
Prophylactic Cranial Irradiation: Pro
14. 15. 16.
17. 18. 19. 20.
21.
22.
23.
24.
25. 26.
27.
28. 29.
73
Viader F, Tarayre M, Benhamou S. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183–190. Ball DL, Matthews JP. Prophylactic cranial irradiation: more questions than answers. Semin Radiat Oncol 1995; 5:61–68. Postmus PE, Sleijfer DT, Haaxma-Reiche H. Chemotherapy for central nervous system metastases from SCLC. A review. Lung Cancer 1989; 5:254–263. Kristjansen PE, Soelberg SP, Skov HM, Hansen HH. Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 1993; 4:579–583. Lee JS, Murphy WK, Glisson BS, et al. Primary chemotherapy of brain metastases in small-cell lung cancer. J Clin Oncol 1989; 7:916–922. Kristensen CA, Kristjansen PEG, Hansen HH. Systemic chemotherapy of brain metastases from small cell lung cancer. A review. J Clin Oncol 1992; 10:1498–1502. Baglan RJ, Marks JE. Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung. Cancer 1981; 47:41–45. Cox JD, Komaki R, Byhardt RW, Kun LE. Results of whole brain irradiation for metastases from small cell carcinoma of the lung. Cancer Treat Rep 1980; 64:957– 961. Carmichael J, Crane JM, Bunn PA, Glatstein E, Ihde DC. Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 14: 455–459. Hagerdorn HE, Haaxma-Reiche H, Canrimus AA, Vermey J, Smit EF, Postmus PE. Results of whole-brain radiotherapy for brain metastases of small cell lung cancer. Lung Cancer 1993; 8:293–300. Eagan RT, Frytak S, Lee RE, Creagan ET, Ingle JN, Nichols WC. A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small cell lung cancer. Cancer Clin Trials 1981; 4:261–266. Shaw EG, Su JQ, Eagan RT, Jett JR, Maksymiuk AW, Deigert FA. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol 1994; 12:2327–2332. Van Hazel GA, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small cell lung cancer. Cancer 1983; 51:933–937. Feletti R, Souhami RL, Spiro SG, Geddes DM, Tobias JS, Mantel BS, Harper PG, Trask C. Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol 1985; 4:335–339. Rosenman J, Choi N. Improved quality of life in patients with small cell carcinoma of the lung by elective irradiation of the brain. Int J Radiat Oncol Biol Phys 1982; 8:1041–1043. Neijstrom ES, Capizzi RI, Rudnick SA. High-dose methotrexate in small cell lung cancer: lack of efficacy in preventing CNS relapse. Cancer 1981; 51:1056–1061. Hardy J, Smith I, Cherryman G, Vincent M, Judson I, Perren T, Williams M. The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell cancer. Br J Cancer 1990; 62: 684–686.
74
Le Pe´choux et al.
30. Moore TN, Livingstone R, Heilbrun L. The effectiveness of prophylactic brain irradiation in small cell carcinoma of the lung. Cancer 1978; 41:2149–2153. 31. Le Chevalier T, Arriagada R, Dewar JA, Ruffie´ P, Martin M. Prophylactic cranial irradiation in small cell lung cancer. Lancet 1985; 8430:692–693. 32. Beiler DD, Kane RC, Bernath AM, Cashdollar MR. Low dose elective brain irradiation in small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1979; 5:941– 945. 33. Cox JD, Petrovich Z, Paig C, Stanley K. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Preliminary report of a cooperative trial. Cancer 1978; 42:1135–1140. 34. Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rygard J. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer 1980; 46:279–284. 35. Jackson DV, Richards F, Cooper MR, Feree C, Muss HB, White DR, Spurr CL. Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. JAMA 1983; 237:2730–2733. 36. Katsenis AT, Karpasitis N, Giannakakis D, Maragoudakis N, Kiparissiadis P. Elective brain irradiation in patients with small cell carcinoma of the lung: a preliminary report. Lung Cancer Int Congress Series. 558. Amsterdam: Excerpta Medica 1982: 277–284. 37. Niiranen A, Holsti P, Salmo M. Treatment of small cell lung cancer. Two-drug vs four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. Acta Oncol 1989; 28:501–505. 38. Perez CA, Krauss S, Bartolucci AA, Durant JR, Lowenbraun S, Salter MM, Storadoli J, Kellermeyer R, Comas F for the Southeastern Cancer Study Group. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung. Cancer 1981; 47: 2407–2413. 39. Seydel HG, Creech R, Pagano M, Salazar O, Rubin P, Concannon J, Carbone P, Mohuiddin M, Perez C, Matthews M. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol 1985; 8:218–223. 40. Aroney RS, Aisner J, Wesley MN, Whitacre MY, Van Echo DA, Slaeson RG, Wiernik PH. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983; 67:675–682. 41. Rosenstein M, Armstrong J, Kris M, Kris M, Shank B, Scher H, Fass D, Harrison L, Fuks Z, Leibel S. A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:43–48. 42. Rubenstein JH, Dosoretz DE, Katin MJ, Blitzer PH, Salenius SA, Floody PA, Harwin WN, Teufel TE, Raymond MG, Reeves JA. Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1995; 33:329–337. 43. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Richardson RL, Creagan ET, Eagan RT, Su JQ. Prophylactic cranial irradiation in limited-stage small cell lung cancer. Cancer 1995; 75:1302–1309. 44. Work E, Bentzen SM, Nielsen OM, Fode K, Michalski W, Palshof T. Prophylactic
Prophylactic Cranial Irradiation: Pro
45. 46.
47.
48.
49.
50.
51.
52. 53.
54.
55.
56.
57.
75
cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics. Eur J Cancer 1996; 32A:772–778. Pedersen AG, Kristjansen PE, Hansen HH. Prophylactic cranial irradiation and small cell lung cancer. Cancer Treat Rev 1988; 15:85–103. Gregor A, Cull A, Stephens RJ, Kirkpatrick JA, Yarnold JR, Girling DJ, Macbeth FR, Stout R, Machin D. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997; 33:1752–1758. Laplanche A, Monnet I, Santos-Miranda JA, Bardet E, Le Pe´choux C, Tarayre M, Arriagada R. Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer 1998; 21: 193–201. Ohnoshi T, Ueoka H, Kawahara S, Kiura K, Kamei H, Hiraki Y, Segawa Y, Hiraki S, Kimura I. Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993; 10:47–54. Wagner HJ, Kim K, Turrisi A, Jiroutek M, Shaw EG, Einhorn LH, Eisert D, Johnson D. A randomized phase III study of prophylactic cranial irradiation vs observation in patients with small cell lung cancer achieving a complete response: final report of an incomplete trial by the ECOG and RTOG. Proc Am Soc Clin Oncol 1996; 15:376. Aupe´rin A, Arriagada R, Pignon JP, Le Pe´choux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341(7):476–484. Brewster AE, Hopwood P, Stout R, Burt PA, Thatcher N. Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung. Radiother Oncol 1995; 34:132–136. Withers HR, Peters LJ, Taylor JMG. Dose-response relationship for radiation therapy for subclinical disease. Int J Radiat Oncol Biol Phys 1995; 31:353–359. Suwinski R, Lee SP, Withers HR. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1998; 40: 797–806. Lee JS, Umsawasdi T, Barkley HT, Murphy WK, Welch S, Valdivieso M. Timing of elective brain irradiation: a critical factor for brain metastasis-free survival in small cell lung cancer. Int J Radiat Oncol Biol Phys 1987; 13:697–704. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki J, Ayoub J, Maroun JA, Wilson KS for the National Cancer Institute of Canada Clinical Trials Group. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336–344. Bleehen NM, Bunn PA, Cox JD, Dombernowsky P, Fox RM, Host H, Joss R, White JE, Wittes RE. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep 1983; 67:11–19. Catane R, Schwade JG, Yarr I, Lichter AS, Tepper JE, Dunnick NR, Brody L, Brereton HD, Cohen M, Glatstein E. Follow-up and neurological evaluation in patients
76
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
Le Pe´choux et al. with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int J Radiat Oncol Biol Phys 1981; 7:105–109. Craig J, Jackson D, Moody D, Cruz JM, Pope EK, Powell BL, Spurr CL, Capizzi RL. Prospective evaluation of changes in computerized cranial tomography (CCT) in patients with small cell carcinoma (SCLC) treated with chemotherapy and cranial irradiation. J Clin Oncol 1984; 2:1151–1156. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994; 12:627–642. Cull A, Gregor A, Hopwood P, Macbeth F, Karnicka-Mlodkowska H, Thatcher N, Burt P, Stout R, Stepniseska K, Stewart M. Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer 1994; 8:1067– 1074. Frytak S, Shaw JN, O’Neill BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989; 12:27–33. Johnson BE, Becker B, Goff WB, Patronas N, Krehbel MA, Makuch RW, McKenna G, Glastein E, Ihde DC. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small cell lung cancer. J Clin Oncol 1985; 3:1659–1667. Johnson BE, Patronas N, Hayes W, Grayson J, Becker B, Gnepp D, Rowland J, Anderson A, Glastein E, Ihde DC, Frank JA. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small cell lung cancer: further follow-up to 6- to 13-year survivors. J Clin Oncol 1990; 8:48– 56. Lee JS, Umsawasdi T, Lee YY, Barkley HT, Murphy WK, Welch S, Valdivieso M. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 1986; 12:313–321. Laukkanen E, Klonoff H, Allan B, Graeb D, Murray N. The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 1988; 14:1109–1117. Lishner M, Feld R, Payne DG, Sagman U, Sculier JP, Pringle JF, Yeoh JL, Evans WK, Sheperd FA, Maki E. Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience. J Clin Oncol 1990; 8:215–221. Twijnstra A, Boon PJ, Lormans ACM, Ten Velde GPN. Neurotoxicity of prophylactic cranial irradiation in patients with small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1987; 23:983–986. Constine LS, Konski A, Ekholm S, McDonald S, Rubin P. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 1988; 15:319–330. Komaki R, Meyers CA, Shin DM, Garden AS, Byrne K, Nickens JA, Cox JD. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995; 33:179–182. Van Oosterhout AGM, van de Pol M, ten Velde GPM, Twijnstra A. Neurologic
Prophylactic Cranial Irradiation: Pro
71.
72. 73. 74.
75.
77
disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer 1996; 77:1434–1441. Erlington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764–767. Hill R. Residual effects of cigarette smoking on cognitive performance in normal aging. Psychol Aging 1989; 4:251–254. Komaki R. Prophylactic cranial irradiation for small cell carcinoma of the lung. Cancer Treat Symp 1985; 2:35–39. Bleyer W, Griffin T. White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukaemia: associations with central nervous system irradiation and methotrexate therapy. In: Gilbert HA, Kagan AR, eds. Radiation Damage to the Nervous System. New York: Raven Press, 1980:155–174. Van Oosterhout AG, Ganzevles PG, Wilmink JT, De Geus BW, Van Vonderen RG, Twijnstra A. Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 34:1037–1044.
6 The Role of Prophylactic Cranial Irradiation: Con Alan Sandler Vanderbilt University, Nashville, Tennessee
INTRODUCTION Lung cancer has become the leading cause of cancer death in the United States and is a leading cause of cancer-related mortality throughout the world. Small cell lung cancer (SCLC) accounts for approximately 20% of all cases of lung cancer. Staging for SCLC divides patients into two groups. The first group is limited-stage patients (LS), defined as patients with disease confined to the ipsilateral chest, including supraclavicular or scalene lymph nodes, without the presence of a malignant pleural effusion. With cisplatin-based chemotherapy and concurrent radiotherapy, these patients can expect a median survival of 20–22 months and a 5-year survival of 20–25%. The second group is those patients with disease outside the chest, and/or a malignant pleural effusion, who are staged as extensive SCLC. These patients are considered incurable and make up the majority of patients with SCLC, representing approximately two-thirds of patients diagnosed with SCLC. Combination chemotherapy has improved median survival from several weeks for the untreated patient to a median survival of approximately 9 months. 79
80
Sandler
Despite improvements in the treatment of SCLC, the vast majority of patients with SCLC will succumb to their disease. As described earlier, SCLC is a disease that has a high degree of systemic dissemination, both at presentation and at subsequent relapse. To postulate that a local prophylactic therapy, such as cranial irradiation, is effective in improving survival, several theories must be true: 1. 2.
3.
4. 5. 6.
Evidence that successful eradication of systemic micrometastatic disease has been attained Evidence that isolated central nervous system (CNS) relapse plays a significant role in this setting (i.e., is it merely a ‘‘forme fruste’’ of ultimate systemic failures) Evidence that cranial irradiation can provide successful ‘‘sterilization’’ of the CNS—at least in the micrometastatic setting (i.e., as prophylactic therapy) Evidence that the successful systemic chemotherapy has not already provided CNS sterilization Evidence that prophylactic CNS radiotherapy does not result in significant toxicity, both short-term and long-term Evidence for a survival advantage for prophylactic cranial irradiation in patients with SCLC
I will attempt to address these issues with respect to the role of prophylactic cranial irradiation (PCI) in SCLC. Although some data may be compelling favoring PCI, there are still issues that are not fully addressed. EVIDENCE FOR SUCCESSFUL ERADICATION OF SYSTEMIC MICROMETASTATIC DISEASE Perhaps the best results to date in the literature for limited-stage SCLC come from a recently published ECOG/RTOG/SWOG trial (1). The study randomized 419 patients with limited SCLC to receive cisplatin and etoposide with either once-daily thoracic radiation (45 Gy/25 fractions/5 weeks) or twice-daily fractionation (45 Gy/30 fractions/3 weeks). In both arms, thoracic radiotherapy was given concurrently with chemotherapy commencing with the first day of cycle 1 and prophylactic cranial radiation was administered to all patients with a complete response to chemoradiation. The twice-daily radiotherapy arm significantly improved survival when compared with the once-daily arm ( p ⫽ 0.04). With a median follow-up of almost 8 years, the median survival was 23 months for the twice-daily radiotherapy and 19 months for the once-daily arm. The survival rates were 26% at 5 years for the twice-daily arm compared to 16 at 5 years for the once-daily arm. This survival advantage appeared related to improved local failure rates in the twice-daily thoracic radiotherapy arm. Local failure rate was 52%
Prophylactic Cranial Irradiation: Con
81
in the once-daily arm and 36% in the twice-daily arm ( p ⫽ 0.06). The rate of simultaneous local and distant failure was also significantly different in the oncedaily arm and 6% in the twice-daily arm, p ⫽ 0.01. The results of this trial provide evidence that systemic chemotherapy and thoracic irradiation can successfully eliminate micrometastases resulting in long-term survival of 20–25%. Even with state-of-the-art therapy, however, the vast majority (75%) of patients unfortunately succumb to this disease and thus probably do not derive any long-term survival advantage with the addition of PCI. EVIDENCE THAT ISOLATED CNS RELAPSE PLAYS A SIGNIFICANT ROLE IN THIS SETTING (OR IS IT MERELY A ‘‘FORME FRUSTE’’ OF ULTIMATE SYSTEMIC FAILURE?) To surmise that PCI can affect survival, there must be evidence that a significant number of patients with SCLC who achieve a complete remission ultimately relapse in the CNS alone. There is an inherent difficulty in quantifying the incidence of isolated CNS relapse. Patients presenting with symptomatic brain metastases undergo variable degrees of further evaluation. Those patients undergoing more aggressive forms of evaluation (i.e., CT scans and bone scans) will most likely manifest other sites of systemic failure compared to those patients undergoing fewer diagnostic tests. This information is not often specifically reported in the literature and, as such, the available data would appear to reflect this lack of consistency. Ball and Matthews (2) reviewed the data for 17 clinical trials involving 1202 patients who did not receive PCI. There were 655 patients for whom data describing the crude incidence of cerebral relapse as a first or sole site of progression was available. Of these 655 patients, brain metastases occurred in 166 patients (25%). However, when reported as an isolated site of progression, this number decreased to 14%. Firsch et al. (3) reported the results of a large autopsy series in which only 3% of patients with SCLC manifested CNS as the sole site of relapse. It would appear that the incidence of isolated brain metastases is ⱕ15% in patients not receiving PCI. Ultimately, based on the effectiveness of PCI, the maximum survival benefit that PCI could achieve would be a fraction of that number. EVIDENCE THAT PCI CAN PROVIDE SUCCESSFUL ‘‘STERILIZATION’’ OF THE CNS Having established that there is a small but finite subset of patients who may relapse with isolated CNS metastases, the next logical question is whether cranial irradiation is effective in eradicating micrometastatic disease. Table 1 lists the
82
TABLE 1 Randomized Trials of PCI in SCLC Achieving a Complete Response to Induction Chemotherapy or Chemoradiation CNS failure Author Aroney (4) Ohonoshi (5) Wagner (6) Gregor (7) Laplanche (8) Arriagada (9)
Patients 32 46 32 314 211 300
PCI
Median survival No PCI
27% 0 52% 22% 53% 18% Hazard ratio 0.41 51% @ 4 yr 44% @ 4 yr 67% @ 2 yr 40% @ 2 yr
PCI
No PCI
p value
NR 21 mo 15.3 NR 22% @ 4 yr 29% @ 2 yr
NR 15 mo 8.8 NR 16% @ 4 yr 21.5% @ 2 yr
NR 0.097 0.249 NR 0.25 0.14
Sandler
Prophylactic Cranial Irradiation: Con
83
results of randomized trials of PCI that included only patients in complete remission. In all trials, the incidence of CNS relapse is lower in the PCI arm thus providing evidence that PCI can affect the subsequent development of overt CNS metastases (⬃20–60% absolute reduction in development of CNS metastases). EVIDENCE THAT PROPHYLACTIC CNS RADIOTHERAPY DOES NOT RESULT IN SIGNIFICANT TOXICITY, EITHER SHORT-TERM OR LONG-TERM The predominant deleterious effects of cranial radiotherapy typically occur from 9 to 12 months after treatment, but may occur years later (10,11). The most serious of these events is brain necrosis resulting from high doses of radiation therapy. More important in the setting of PCI is a potential decrease in a patient’s functional capability following treatment. These effects, seen in long-term follow-up, are manifested by memory impairment, cognitive deficits, and personality changes. Subtle motor effects may occur as well. Late effects on cognitive function are obviously more subtle than the dramatic effects of overt brain necrosis and thus more difficult to document and/or discriminate from other organic processes. These effects may or may not be associated with radiographic findings (12,13). Another problem is that the majority of the data has been generated from retrospective analyses (14,15). Evaluating a patient with SCLC for potentially subtle cognitive deficits is complicated by a number of potential mitigating factors: (1) Age—The median age of a patient with SCLC is approximately 65 years. These patients may be undergoing subtle personality and psychological changes from aging or other unrelated processes such as Alzheimer’s disease. (2) Tobacco use—It is possible that the long-term hypoxemia associated with smoking may contribute to subtle cognitive deficits. (3) Other illnesses—Patients with SCLC typically have other tobacco-related illnesses that may contribute, i.e., chronic obstructive lung disease, coronary artery disease with resultant cardiopulmonary impairment. Clearly, prospective, randomized trials evaluating patient’s cognitive function pre- and postradiotherapy are needed. Fortunately, over the past few years there have been several illustrative trials. Ahles et al. reported on the findings of the Cancer and Leukemia Group B trial 8534 (16). This trial randomized 347 patients with limited SCLC to three cycles of ACE chemotherapy (doxorubicin, cyclophosphamide, and etoposide). This was followed by two cycles of PCE chemotherapy (cisplatin, cyclophosphamide, and etoposide). Concurrent with PCE, all patients received thoracic radiotherapy (RT) and PCI. Following PCE and RT, patients went on to receive an additional three cycles of ACE, but this was discontinued after 179 patients were entered, secondary to excessive pulmonary toxicity. Patients were randomized
84
Sandler
to receive warfarin or no warfarin starting on day 1 of the induction chemotherapy. Of the 347 patients entered on study, 295 (85%) patients were recruited for the psychological study at baseline, and 224 (65%) and 177 (51%) patients, respectively, completed the pre-RT and post-RT assessments. This study employed the POMS (Profile of Mood States) and Trail Making B Test (Trails B) as psychological and neuropsychological assessment tools (17,18). The authors noted stable POMS scores pre- and post-RT (stable emotional pattern) but decreased Trails B scores (cognitive function), suggesting that the treatment had a negative impact on cognitive function. The results of this study are confounded by at least two factors: (1) The evaluation was only 1 month postRT, and (2) the patients received chemotherapy and concurrent thoracic RT at the time of their PCI. Another important message from this trial, which emphasizes the need for pre- and post-PCI evaluations, is that all patients evaluated pre-PCI performed in the 25th percentile, when compared with age-matched norms. In other words, three-fourths of the general population in this age range performed better than patients in the SCLC study. Komaki et al. (19) reported on a small study of 30 patients with limited SCLC who underwent neuropsychological testing pre- and post-PCI. They also noted baseline cognitive deficits. Eleven patients underwent testing 6–20 months after PCI. No significant differences were noted. Only two trials evaluating the role of PCI have prospectively evaluated the potential neurotoxicity associated with the effects of PCI. Arriagada et al. (9) reported on a prospective trial of 300 patients with SCLC in complete remission after induction therapy. In this trial, patients underwent neuropsychological examination and computerized tomography scan of the brain at the time of randomization and at 6, 18, 30, and 48 months. A total of 294 patients were eligible for study and of these, 65 patients (34 patients in the control group and 31 patients in the PCI group) were not fully evaluable for neurotoxicity (no baseline neuropsychological evaluation or the development of brain metastases within 1 month of randomization). Of the 229 patients (115 patients in the control arm and 114 in the PCI arm) who underwent initial neuropsychological testing, only 41% (50 patients/control group and 44 patients/PCI group) had a normal baseline neuropsychological evaluation. Patients were evaluated for cognitive (orientation, memory, judgment, language, and praxis), sensory, mood, walking, cerebellar, and cranial nerve functions; and tendon reflexes. The testing was performed by the same neurologist at each treatment site. Within the first 5 years of follow-up, there was no statistical difference in the 2-year cumulative incidence of abnormalities in any of these parameters. Gregor et al. (7) reported on a large European randomized trial of 314 patients with LS-SCLC in complete remission randomized to PCI at variable doses determined by the individual investigator versus observation. Prospective
Prophylactic Cranial Irradiation: Con
85
neuropsychometric and quality-of-life assessments were part of this trial in selected institutions and involved 136 patients (43%). In this trial too, the large majority of patients (78%) undergoing evaluation evidenced some neuropsychological deficit prior to PCI. Patients who underwent repeat testing at 6 and 12 months revealed some new impairments. No evidence of sustained deterioration over time was noted and no statistically significant difference was noted between the two groups. The authors commented on the fact that the number of patients undergoing prospective evaluation was small and that follow-up was limited. One final word of caution regarding the potential neurotoxicity of PCI must be raised. Looper et al. (20) reported on a series of 120 patients with SCLC treated with CAV-based (cyclophosphamide, doxorubicin, and vincristine) chemotherapy with or without thoracic radiotherapy, all of whom received PCI. The authors noted that of 18 patients (15%) alive and disease-free at ⱖ3 years, 14 patients (78%) experienced significant neurological sequelae felt to be related to PCI. These complications occurred an average of 4–7 years after completing PCI. Indeed, some investigators have suggested that the neurocognitive sequelae of RT may be underestimated in long-term survivors (11). EVIDENCE FOR A SURVIVAL ADVANTAGE FOR PCI IN PATIENTS WITH SCLC As discussed earlier, given the relatively low incidence of patients with isolated CNS failures, one can expect a similar small difference in survival when comparing patients treated with PCI to those patients undergoing observation. Table 2 shows the results of recent randomized trials in patients achieving a complete remission with induction therapy. None of these randomized trials demonstrated a survival advantage to PCI. As most of these trials were relatively small, however, a meta-analysis was conducted by the Prophylactic Cranial Irradiation Overview Collaborative Group. This meta-analysis included 987 patients with SCLC in complete remission enrolled in seven randomized trials assessing the role of prophylactic irradiation (21) (Table 2). The results of this analysis revealed a statistically significant, albeit small, improvement in the relative risk of death favoring PCI (RR ⫽ 0.84, p ⫽ 0.01). This difference resulted in a 5.4% absolute increase in survival at 3 years from 15.3% to 20.7%. The authors again noted a decrease in cumulative incidence of brain metastases (relative risk of 0.46, p ⬍ 0.001). The authors commented on the fact that higher doses of PCI led to relatively greater decreases in the risk of brain metastases (8 Gy vs. 24–25 Gy vs. 30 Gy vs. 36 Gy, p ⫽ 0.02) but no additional impact on survival (Table 3).
86
TABLE 2 Randomized Phase III Trials Included in Meta-Analysis
Trial UMCC (4) Okayama (5) PCI-85 (9) Danish-NCI (21) UKCCCR-EORTC (7) PCI-88 (8) ECOG-RTOG (6) a
Enrollment period
No. of patients
PCI dose/fractions
Survival advantage?
Evaluation for cognitive deficits
1977–80 1981–86 1985–93 1985–91 1987–95 1988–94 1991–94
29 46 300 55 314 211 32
30 Gy/10 40 Gy/20 24 Gy/8 24 Gy/8 8–36 Gy/1–18 a 24 Gy/8 25 Gy/10
No No No No No No No
No No Yes No Yes No No
Initially designed with three treatment groups (no PCI, 24 Gy/12, and 36 Gy/18; subsequently changed to no PCI versus PCI at variable doses).
Sandler
Prophylactic Cranial Irradiation: Con
87
TABLE 3 Meta-analysis of Randomized Phase III Trials of PCI No. of patients
Survival Cumulative rate of brain metastases DFS Cumulative rate of other metastases
PCI
No PCI
Hazard ratio
p value
Rate in control group (%)
Absolute benefit at 3 yr (%)
526 524
461 457
0.84 0.46
0.01 ⬍0.0001
15.3 58.6
⫹5.4 ⫺25.3
526 325
461 332
0.75 0.89
⬍0.0001 0.37
13.5 45.6
⫹8.8 ⫺3.8
SUMMARY It would appear that while several of the issues surrounding the use of PCI have been addressed, others remain unanswered. Although there appears to be a small percentage of patients with limited SCLC who are cured with chemotherapy and thoracic irradiation and remain at risk for relapse with isolated brain metastases, we are not able, at this time, to identify these patients upfront. Thus, for every 20 patients who receive PCI, only one benefits. Should we perhaps focus our priorities elsewhere, such as on other systemic issues? The potential benefit in survival from PCI is so small (⬃5%) that a meta-analysis became necessary to identify any impact at all. Although meta-analyses have achieved recent popularity, not all statisticians are convinced of their accuracy (22,23). There are many other unanswered questions. If PCI is to be utilized, what is the optimal dose, schedule, and timing of PCI? Is there any role in patients with extensive disease in complete response? Most importantly, however, is the unresolved issue of the full extent of CNS toxicity. Scant prospective data are currently available and continued follow-up is warranted. This information is critical before we can accurately assess the benefit/risk ratio of PCI. While, based on the current information, PCI should be offered at this time as part of the therapeutic regimen in patients with LS-SCLC who achieve a good response to chemoradiation, it is critical that the full implications of this strategy be reassessed over time as more information regarding long-term neurotoxicity becomes available. REFERENCES 1. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265–271.
88
Sandler
2. Ball DL, Matthews JP. Prophylactic cranial irradiation: more questions than answers. Semin Radiat Oncol 1995; 5:61–68. 3. Firsch FR, Paulson OB, Hansen HH, et al. Intracranial metastases in small cell carcinoma of the lung. Correlation of clinical and autopsy findings. Cancer 1982; 50: 2433–2437. 4. Aroney RS, Aisner J, Wesley MN, Whitacre MY, Van Echo DA, Slaeson RG, Wiernik PH. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983; 67:675–682. 5. Ohnoshi T, Ueoka H, Kawahara S, Kiura K, Kamei H, Hiraki Y, Segawa Y, Hiraki S, Kimura I. Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993; 10:47–54. 6. Wagner H. Prophylactic cranial irradiation for patients with small cell lung cancer. An enduring controversy. Chest Surg Clin North Am 1997; 31:353–359. 7. Gregor A, Cull A, Stephens RJ, Kirkpatrick JA, Yarnold JR, Girling DJ, Macbeth FR, Stout R, Machin D. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial. Eur J Cancer 1997; 33:1752–1758. 8. Laplanche A, Monnet I, Santos-Miranda JA, Bardet E, Le Pechoux C, Tarayre M, Arriagada R. Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer 1998; 21:193–201. 9. Arriagada R, Le Chevalier T, Boric F, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183–190. 10. Mahler P, Griffin B, Geyer JR, et al. Chemoradiotherapy interactions and the bloodbrain barrier. In: Nieuwalt EA, ed. Implications of the Blood-Brain Barrier and Its Manipulation. New York: Plenum Press, 1989:373–387. 11. Crossen JR, Garwood D, Glatstein E., et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Chin Oncol 1994; 12:627–642. 12. Johnson BE, Becker B, Goff WB, Patronas N, Krehbel MA, Makuch RW, McKenna G, Glatstein E, Ihde DC. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small cell lung cancer. J Clin Oncol 1985; 3:1659–1667. 13. Johnson BE, Patrons N, Hayes W, Grayson J, Becker B, Gnepp D, Rowland J, Anderson A, Glatstein E, Ihde DC, Frank JA. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small cell lung cancer: further follow-up to 6- to 13-year survivors. J Clin Oncol 1990; 8:48– 56. 14. Catane R, Schwade JG, Yarr I, Lichter AS, Tepper JE, Dunnick NR, Brody L, Brereton HD, Cohen M, Glatstein E. Follow-up and neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int J Radiat Oncol Biol Phys 1981; 7:105–109. 15. Lee JS, Umsawasdi T, Lee YY, Barkley HT, Murphy WK, Welch S, Valdivieso M. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 1986; 12:313–321.
Prophylactic Cranial Irradiation: Con
89
16. Ahles TA, Silberfarb PM, Herndon J II, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 1998; 16:1954–1960. 17. McNair DM, Lorr M, Droppleman LF. Profile of Mood States. San Diego, CA: Educational and Testing Service, 1971. 18. Reitan RM, Davison LA. Clinical Neuropsychology: Current Status and Applications. New York: Wiley, 1974. 19. Komaki R, Meyers CA, Shin DM, Garden AS, Byrne K, Nickens KJA, Cox JD. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995; 33:179–182. 20. Looper JD, Einhorn LH, Garcia SA, et al. Severe neurological problems following successful therapy for small cell lung cancer. Proc ASCO 1984; 3:31. 21. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens R, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476– 484. 22. LeLorier J, Gregore G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536– 542. 23. Bailar JC. The promise and problems of meta-analysis. N Engl J Med 1997; 337: 559–561.
7 Dose Intensification of Chemotherapy in SCLC: Pro Anthony Elias Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts
RATIONALE FOR DOSE-INTENSIVE THERAPY IN SCLC The principles of dose and combination therapy are strongly supported by preclinical and clinical evidence. Increased dose intensity of certain chemotherapeutic agents can yield greater cytotoxicity against the overall tumor cell population and is more likely to kill drug-resistant tumor cells. Which agents are chosen depends on pharmacology/mode of action and schedule/dose relationships to cytotoxicity. For these reasons, alkylating agents usually form the backbone of most high-dose regimens since near-log-linear dose-response relationships are consistently demonstrated for the alkylating agents and radiation in preclinical in vitro and in vivo experiments (1–4). Clinical success requires eradication of all clonogenic tumor if solely cytotoxic strategies are employed. The kinetics of tumor regrowth (Gompertzian models) suggest that near-eradication might yield fairly similar clinical outcomes compared with more modest antitumoral effects delivered over longer periods. The ability to detect clinical benefits from high-dose therapy would be greatest in clinical settings with high risk of systemic relapse but low tumor burden. In91
92
Elias
creased cytotoxicity may be irrelevant if tumor burden is great. Chemosensitivity, particularly the shape of the dose-response relationship for the drug-resistant tumor cell subpopulations, is also critical. Dose escalation of agents inactive against a particular disease is not likely to prove a fruitful strategy in generating significant clinical success. Many established chemotherapeutic agents including etoposide or teniposide, cisplatin or carboplatin, ifosfamide, cyclophosphamide, vincristine, and doxorubicin have major activity against small cell lung cancer (SCLC). Many of these agents, particularly the oxazaphosphorines, nitrosoureas, and the platinums, have strong preclinical rationales for dose escalation. There is also extensive clinical evidence to support a dose-response relationship with these agents against a variety of tumor types including SCLC. The major controversy surrounding dose-intensive therapy is whether an increase in tumor response can translate into prolonged survival and whether this benefit can outweigh the enhanced toxicities generated. Methods to deliver dose-intensive therapy include shortening cycle length, increasing dose and/or number of agents over multiple cycles, or increasing dose as consolidation of clinical response. On review of the phase II trials evaluating high-dose therapy with hematopoietic cellular support, outcomes are frequently better than those reported by conventional dose approaches. However, patient selection (low patient comorbidity) and staging biases clearly contribute to these results. Even if randomized data support the use of high-dose therapy, one may still ask whether the benefit is generalizable to the entire population of patients with that disease and/or stage of disease, or if the treatment strategy is applicable only for the most physiologically fit. In most cases, if the treatment is deemed worthwhile, technological advances in supportive therapy will develop to increase feasibility. A further question concerning dose-intensive strategies is whether they can be combined with other modalities. Assuming dose-intensive therapy improves overall response and complete response rates, this approach may serve as a suitable foundation to generate minimal residual tumor burdens and potentially render other therapeutic strategies more effective. The use of combinations of treatment modalities becomes more compelling given the generic properties of tumors, namely plasticity, adaptability, and heterogeneity. CONVENTIONAL-DOSE THERAPY IN SCLC Approximately 15–20% of all bronchogenic carcinomas, SCLC are the fourth leading cause of death from cancer in both men and women in the United States (5). Systemic metastatic disease is present in almost all patients at diagnosis: overt in two-thirds (extensive stage, ED) and subclinical in a third (limited stage, LD). Established chemotherapeutic agents include etoposide, cisplatin, carboplatin, ifosfamide, cyclophosphamide, vincristine, and doxorubicin. By general
Dose Intensification of Chemotherapy: Pro
93
consensus, conventional dose treatment consists of four to six cycles of platinum/ etoposide alone for extensive-stage disease or with concurrent chest radiation therapy for the third of patients with limited-stage disease (6). Complete response rates are 50–70% for LD and 10–20% for ED patients. However, by 2 years 20– 40% of LD and fewer than 5% of ED patients remain alive (7,8). Five-year survival is about half that at 2 years. Although ifosfamide has improved survival in ED patients in conjunction with cisplatin and etoposide (9), this lead has not yet been tested in LD patients. New agents with promising activity include the taxanes, gemcitabine, and the topoisomerase I inhibitors. The role of these new agents is being evaluated in ongoing first-line therapy trials. The underlying cardiovascular and pulmonary comorbidity typical of this population, median age 60–65 years, and enhanced risk of secondary smoking-related malignancies inherent in lung cancer patients contribute to an increased risk when applying doseintensive therapy. DOSE INTENSITY: WITHOUT CELLULAR SUPPORT Klasa et al. analyzed dose intensity (expressed in drug dose administered per square meter per week) of individual agents or regimens delivered in ED SCLC trials (10). Higher dose intensities of cyclophosphamide and doxorubicin with vincristine (CAV) and with etoposide (CAE), but not etoposide and cisplatin (EP), were associated with a longer median survival. The relative range of doses administered and the response and survival advantages were small (10). Six randomized trials have evaluated dose intensity in ED SCLC with or without cytokine support (11–16). The actual delivered doses, when reported, were significantly less different between the arms than the planned dose intensity differences (1.2–2-fold). Two of these trials showed a modest survival advantage for the higher-dose therapy. Arriagada et al. treated LD patients with six cycles of conventional-dose chemotherapy wherein the first cycle only was randomly assigned conventional dose versus modest intensification (17). A complete response and survival advantage for the patients receiving the intensified chemotherapy was observed. This result was somewhat unexpected, since the relative difference in the two groups was so small. It is possible that dose intensity, particularly if given early in the course of treatment, may be more effective in limited SCLC rather than extensive SCLC. Early intensification and treatment of earlierstage disease are two themes to consider when designing new trials. Multidrug cyclical weekly therapy was designed to increase the dose intensity of treatment by taking into account the differing toxicities of the weekly agents. Early phase II results were promising, although patient selection effects were evident (18,19). However, none of the cooperative group randomized trials demonstrated survival benefits (20–23), perhaps owing to the greater morbidity, dose reductions, and delays required for the weekly schedules; thus the actual
94
Elias
delivered dose intensities were not that different. Moreover, not only were doses and schedules varied, but so were the regimens, leading to interpretation obstacles (24). Currently established cytokines (e.g., GM-CSF and G-CSF) were able to maintain dose intensity across multiple cycles (25). Fukuoka et al. documented a statistically significant survival advantage for the use of G-CSF to support the CODE regimen (59 vs. 32 weeks) (26). With cytokine use, a modest increment in dose intensity, limited by cumulative thrombocytopenia, can be achieved (1.5– 2-fold). But the effectiveness of various thrombopoietins or other cytokines to increase achievable dose intensity remains uncertain. DOSE INTENSITY: WITH CELLULAR SUPPORT Trials reported prior to 1995 of patients with SCLC undergoing autologous bone marrow transplantation (ABMT) were reviewed by Elias and Cohen (27) if specifics about their response status (relapsed or refractory; untreated; or responding to first-line chemotherapy—partial or complete response) and their extent of disease (limited or extensive stage) had been provided. Patients in these various categories were pooled for aggregated relapse-free and overall survival characteristics. Complete and overall responses in 52 patients with relapsed or refractory disease were 19% and 56% (28–41), respectively, but lasted only 2–4 months. While combination chemotherapy, especially those containing multiple alkylating agents, produced slightly higher response rates, these regimens were more toxic (18% vs. 6% deaths). The high complete response rate substantiated a doseresponse relationship, but was insufficient for cure. Complete and overall responses in 103 patients with untreated SCLC (71% limited disease) who received single- or double-cycle high-dose therapy as initial treatment were 42% and 84%, respectively (42–48). Relapse-free, 2-year, and overall survivals were comparable to those with treatment with conventional multicycle regimens. Transplantation in the newly diagnosed SCLC setting is potentially hazardous because of the frequency of life-threatening complications from uncontrolled disease, and the likelihood of tumor cell contamination in untreated autografts. Theoretically, early intensification may have greater impact on the disease. High-dose chemotherapy with autologous hematopoietic support as consolidation has been given to approximately 466 patients responding to first-line chemotherapy (49–68). About 40–50% of partial responders converted to complete response, but without durable effect. Of patients with limited disease in complete response at the time of high-dose therapy, about 35% remained progression-free at a median follow-up ⬎ 3 years at the time of publication.
Dose Intensification of Chemotherapy: Pro
95
Brugger et al. administered two cycles of mobilization chemotherapy to 18 LD patients. Thirteen (72%) received high-dose ifosfamide, carboplatin, and etoposide (ICE) with epirubicin as consolidation (64,65). Event-free survival was 56% (median follow-up 44 months). About 25% had stage I or II SCLC, and surgical resection was performed in seven patients. Peripheral blood progenitor cells (PBPCs) collected after the second cycle of mobilization chemotherapy contained no microscopic tumor cells as measured by immunocytochemistry using keratin and EMA-125 antibodies. At the Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, over 55 patients with limited-stage and over 30 with extensive-stage SCLC have been treated with high-dose combination alkylating agents [highdose cyclophosphamide, carmustine, and cisplatin (CBP), or ICE] following response to conventional dose induction therapy. Of the original cohort of 36 patients with limited-stage SCLC (stages IIIA or B), 29 were in or near CR prior to treatment with high-dose CBP with marrow ⫾ PBPC support and subsequent chest and prophylactic cranial radiotherapy (62,66). For this group, the 5-year event-free survival is 53% (minimum follow-up 40 months, range to 11 years). By multivariate analysis, response to induction was most important (CR/near CR best vs. PR), but short induction ⱕ four cycles and the use of ifosfamide during induction also imparted better prognosis. Of the extensive-stage patients, about 17% remain progression free greater than 2 years after high-dose therapy, largely confined to patients with oligometastatic disease. Humblet et al. performed the only randomized trial to be reported (60). Five cycles of conventional chemotherapy with prophylactic cranial irradiation were given to 101 patients with SCLC. Of these, 45 were randomized to one further cycle of either high- or conventional-dose therapy using cyclophosphamide, etoposide, and carmustine (60). Dose response was demonstrated. Complete response was achieved in 77% of partial responders after high-dose therapy, but in none after conventional-dose treatment. High-dose therapy enhanced disease-free survival and trended to improve survival. However, because overall outcomes were mediocre, with an 18% toxic death rate on the high-dose arm, the investigators concluded that dose-intensive therapy should not be considered a standard therapy in SCLC. In addition, almost all patients experienced disease recurrence in the chest, reflecting the fact that chest radiotherapy was not given in this trial. Sites of prior tumor involvement, particularly the chest, are most likely to be sites of first relapse owing to a number of factors. These include increased tumor burden and/or drug-resistant clones in the chest; poorer drug delivery; intratumoral resistance factors such as hypoxia in areas of bulk tumor; or, in the case of autograft contamination, the possibility of homing with microenvironmental support for the tumor in local-regional sites (48,56). Chest relapse is re-
96
Elias
duced by conventional-dose radiotherapy (50 Gy), from 90% to 60%. Thus, highdose curative treatment approaches should include ‘‘consolidative’’ radiotherapy to sites of bulky disease. In many of the older trials, doses were attenuated and treatment-related morbidity and mortality was higher than currently expected. Many trials employed either single high-dose chemotherapeutic agents (⫾low-dose agents in addition) (47–52,67,68) or single alkylating agents (41,44,47,54–57). Combination alkylating agents were employed in a minority of patients (29,32,38,43,58– 66).
FUTURE DIRECTIONS Intensify Involved-Field Radiotherapy Thoracic radiotherapy (TRT) provides a 25–30% improvement in local-regional control and a 5% increase in long-term progression-free survival for limited-stage SCLC (69,70). Local-regional relapse still remains high (about a 60% actuarial risk of local relapse by 3 years) with the typical 45–50 Gy TRT (71–73), and may be underestimated due to the competing risk of systemic relapse (74). Further enhancement of local-regional control might increase the proportion of long-term survivors. Dose intensity of chest radiotherapy has not been sufficiently studied. The Eastern Cooperative Oncology Group (ECOG) and the Radiation Therapy Oncology Group (RTOG) compared 45 Gy TRT given either daily over 5 weeks or twice daily over 3 weeks concurrent with cisplatin and etoposide chemotherapy (75). Tumor recurrence in the chest was reduced from 61% to 48% at 2 years with the more intense TRT. A survival advantage for the more intensive radiotherapy has been reported (76). Many investigators have pointed to this trial as establishing a new benchmark for SCLC treatment outcomes. However, similar to high-dose trials, a patient selection bias is evident. Patients who were too sick (not suited for upfront combined modality therapy) or who had bilateral bulky mediastinal adenopathy (too large a radiotherapy port) were not generally enrolled onto the trial. Thus, a full 40% of patients enrolled in this trial had no apparent mediastinal adenopathy on computerized tomography—distinctly unusual for SCLC populations. This observation in no way undermines the demonstrated benefit of more intense radiotherapy, but does require caution before applying this advance to the general population of SCLC, even those with limited SCLC. Using a shrinking-field technique, Choi et al. gave escalating doses of TRT concurrently with cisplatin and etoposide either as daily 180-cGy fractions or as twice-daily 150-cGy fractions in LD SCLC (77). The maximal tolerated dose defined by acute esophagitis was 45 Gy for twice daily administration and 70⫹
Dose Intensification of Chemotherapy: Pro
97
Gy when given once daily. Intensification of TRT dose is feasible and should be evaluated in a randomized setting. Since most relapses occur in-field, a more focused port may be feasible to reduce morbidity of more intense TRT. Here too, there may be a role for 3-D conformal planning. Intensify Induction Induction therapy may reduce tumor burden, stabilize rapidly progressive systemic and local symptoms from SCLC, select patients possessing chemosensitive tumors for subsequent intensification, and diminish micrometastases in the autograft sources. On the other hand, chemoresistant tumor cells might proliferate or even be induced across treatment, and might blunt these putative benefits. The Arriagada trial supports initial intensification of induction (17). A logical extension of this concept is the administration of multicycle dose-intensive combination therapies supported by cytokines and PBPCs (78–85). Pettengell et al. treated good-performance-status SCLC patients with conventional-dose ICE supported by autologous whole blood cells given on day 3 of chemotherapy for six cycles (80). Cycle length could be shortened to 2 weeks using either pheresis products or 750 ml whole blood stored at 4°C. Cycles were repeated upon platelet recovery to 30,000/µl, rather than the usual 100,000/µl. In this phase I trial of 25 patients, the full planned dose intensity for each of the arms was reached across the first three cycles, and 56% completed all six. Mortality was 12% and complete response rate was 64%. The authors note that the collection of whole blood without cryopreservation reduced the cost and complexity of cellular support for nonablative therapy substantially (80). In a subsequent randomized phase II study, 50 ‘‘good prognosis’’ patients were given ICE either every 2 or 4 weeks (79). The median dose intensity delivered over the first three cycles was 1.8 (0.99–1.97) versus 0.99 (0.33–1.02) for the 2-week versus 4-week cycles, respectively. Paradoxically, more hematopoietic and infectious events occurred on the standarddose 4-week arm. A phase III trial is ongoing. In the European Bone Marrow Transplant (EBMT) group, 47 patients underwent mobilization with epirubicin and G-CSF followed by three cycles of moderately intensive ICE (81). Radiation to chest and head was recommended. Of 35 evaluable, the complete and near-complete response rate was 69%. Mortality was 14%. A phase III trial is ongoing. Using an innovative trial design, Humblet et al. treated 37 limited-stage patients with four intensive alternating cycles of etoposide with either ifosfamide or carboplatin with stem cell support (85). To integrate early chest radiotherapy, bursts of 10 Gy TRT in five fractions were given concurrently with each chemotherapy administration (total dose 40 Gy). Mortality was 3%. The median eventfree survival was 18 months, and 80% remain alive at 30 months. Eight of 13 relapses occurred in the brain, perhaps because no PCI was given.
98
Elias
Minimal Residual Tumor/Autograft Involvement Autograft contamination by tumor cells may cause relapse. Gene-marking studies have definitively proven that residual tumor cells directly contribute to relapse in certain hematological malignancies and neuroblastoma (86–88). However, this has not been adequately tested in solid tumors (89). These cells also serve to indicate the patient has increased systemic chemotherapy-resistant tumor burden. In SCLC, the marrow is a common metastatic site. Subclinical micrometastatic disease is detected in marrow in 13–54% of newly diagnosed limited- and 44–77% of newly diagnosed extensive-stage SCLC (90–94) using immunohistochemical techniques with sensitivities of ⬃1/104 cells. Two-thirds of patients in CR may have subclinical disease in marrow (95,96), and residual tumor appears to predict relapse (96). Brugger et al. detected circulating tumor cells in patients with metastatic SCLC or breast cancer mobilized with G-CSF and IPE chemotherapy (97), but not after the second cycle of chemotherapy. In the short term, in vivo chemotherapy induction may ‘‘purge’’ the patient and the autologous stem cell source (67). In our unpublished data using a technique with a sensitivity of 1–10/106, up to 77% of limited-disease patients in or near complete response prior to high-dose therapy have detectable tumor cells in their marrow by keratin staining (98). Molecular and antigenic characterization of these residual cancer cells may guide strategies for further treatment. We are utilizing a fluorescence microscope with automated computerized scanning with one set of fluorescent probes for detection and a second set with different fluorophores for biological characterization to analyze patterns of coexpression of various markers in these cells (98). Prospective trials to determine the clinical significance of marrow or peripheral blood tumor contamination and the impact of novel stem cell sources to support high-dose therapy are underway.
CONCLUSION Two major complementary strategies to administer high-dose therapy for SCLC include dose-intensive multicycle approach as initial treatment and ‘‘late’’ intensification in responders. Advantages for each approach are evident. The multicycle approach can achieve early dose intensity and maintain it for about three to four cycles. Disadvantages to this approach include subtransplant doses, high mortality rates, late administration of chest radiotherapy (except for the recent Humblet trial), and the collection of stem cells early in treatment when they have a higher potential to be contaminated with tumor cells. Advantages to later intensification include a patient with decreased tumor burden and decreased tumor-related symptoms with consequent improved performance status and a partial purge of the autograft. Early-dose intensive thoracic radiotherapy can be
Dose Intensification of Chemotherapy: Pro
99
given before high-dose therapy. The drawback of later administration of the doseintense cycles can be surmounted in part by intensification and shortening of induction chemoradiotherapy. The optimum may be to merge the two strategies into one: a brief dose-intensive induction followed by a single or double cycle of stem-cell-supported therapy followed by TRT and PCI. Ultimately, a randomized trial in patients with limited comorbid disease will be necessary to determine whether the increased toxicity is worthwhile and for which subsets of patients this approach is curative. High-dose therapy has a strong scientific basis: it kills more tumor cells and achieves minimal tumor burden in most. In clinical situations in which toxicity has been acceptable, it typically results in prolonged progression-free survival in a subset of patients. An additional group of patients may be near cure. Highdose therapy may have increased value if additional targets of residual tumor cells can be identified for novel treatment strategies and modalities. Most biological strategies such as active or adoptive immunotherapy, gene function replacement (retinoblastoma gene and/or p53), or interruption of autocrine or paracrine growth loops work best against minimal tumor burden. REFERENCES 1. Teicher BA. Preclinical models for high-dose therapy. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore, Williams & Wilkins. 1992:14–42. 2. Frei E III. Combination cancer chemotherapy: presidential address. Cancer Res 1972; 32:2593–2607. 3. Frei E III, Canellos GP. Dose, a critical factor in cancer chemotherapy. Am J Med 1980; 69:585–594. 4. Frei E III, Antman KH. Combination chemotherapy, dose, and schedule: section XV, Principles of Chemotherapy. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine. Philadelphia: Lea & Febiger, 1993:631–639. 5. Boring CC, Squires TS, Tong TT. Cancer statistics, 1993. CA—Cancer Journal for Clinicians 1994; 44:19–51. 6. Johnson DH, Kim K, Sause W, et al. Cisplatin and etoposide plus thoracic radiotherapy administered once or twice daily in limited stage small cell lung cancer: final report of intergroup trial 0096. Proc ASCO 1996; 15:374 (Abstract 1113). 7. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15(3):278–299. 8. Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Anderson PK. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4(9):1307–1313. 9. Loehrer PJ, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13:2594–2599.
100
Elias
10. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9:499–508. 11. Cohen MH, Creaven PJ, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61:349–354. 12. Brower M, Ihde DC, Johnston-Early A, et al. Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 1983; 75:993–1000. 13. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5:1731–1738. 14. Mehta C, Vogl SE. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: minor improvements in rate of remission and survival. Proc AACR 1982; 23:155. 15. Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3:54–64. 16. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, Johnson BE. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022–2034. 17. Arriagada R, Le Chevalier T, Pignon J-P, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329:1848–1852. 18. Miles DW, Earl HM, Souhami RL, Harper PG, Rudd R, Ash CM, James L, Trask CWL, Tobias JS, Spiro SG. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991; 9:280–285. 19. Murray N, Gelmon K, Shah A, Grafton C, Tsang V, McKenzie M, Goddard K, Morris J, Karsai H, Page R. Potential for long-term survival in extensive stage smallcell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy. Lung Cancer 1994; 11(suppl 1):99 (377). 20. Furuse K, Kubota K, Nishiwaki Y, et al. Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (GCSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC). Proc ASCO 1996; 15:375 (1117). 21. Murray N, Livingston RB, Shepard FA, et al. Randomized study of CODE versus alternating CAV/EP for limited stage small cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17:2300–2308. 22. Sculier JP, Paesmans M, Bureau G, et al. Multiple drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11:1858–1865. 23. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12:1806–1813.
Dose Intensification of Chemotherapy: Pro
101
24. Johnson DH, Carbone DP. Editorial. Increased dose-intensity in small cell lung cancer: a failed strategy. J Clin Oncol 1999; 17:2297–2299. 25. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164–170. 26. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with or without granulocyte colony stimulating factor in small cell lung cancer. Br J Cancer 1997; 75: 306–309. 27. Elias A, Cohen BF. Dose intensive therapy in lung cancer. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd edition. Baltimore: Williams & Wilkins, 1995:824–846. 28. Phillips GL, Fay JW, Herzig GP, et al. Nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I– II Study. Cancer 1983; 52:1792–1802. 29. Stahel RA, Takvorian RW, Skarin AT, Canellos GP. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU, and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol 1984; 20:1233–1238. 30. Wolff SW, Fer MF, McKay CM, et al. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1983; 1:701–705. 31. Pico JL, Beaujean F, Debre M, et al. High dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in small cell carcinoma of the lung (SCCL) in relapse. Proc ASCO 1983; 2:206. 32. Pico JL, Baume D, Ostronoff M, et al. Chimiotherapie a hautes doses suivie d’autogreffe de moelle osseuse dans le traitement du cancer bronchique a petites cellules. Bull Cancer 1987; 74:587–595. 33. Postmus PE, Mulder NH, Elema JD. Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow. Eur J Cancer 1988; 24:889–894. 34. Rushing DA, Baldauf MC, Gehlsen JA, et al. High-dose BCNU and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell carcinoma of the lung (SCCL). Proc ASCO 1984; 3:217. 35. Spitzer G, Dicke KA, Verma DS, Zander A, McCredie KB. High-dose BCNU Therapy with autologous bone marrow infusion: preliminary observations. Cancer Treat Rep 1979; 63:1257–1264. 36. Spitzer G, Dicke KA, Latam J, et al. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 1980; 45:3075–3085. 37. Eder JP, Antman K, Shea TC, Elias A, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Critchlow J, Flaherty M, Mick R, Schnipper LE, Frei E III. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 1988; 80:1221–1226. 38. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E III, Antman KH. A phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15:373–379.
102
Elias
39. Douer D, Champlin RE, Ho WG, et al. High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 1981; 71: 973–976. 40. Harada M, et al. Combined-modality therapy and autologous bone marrow transplantation in the treatment of advanced non-Hodgkin’s lymphoma and solid tumors: the Kanawaza experience. Transplant Proc 1982; 4:733–737. 41. Lazarus HM, Spitzer TR, Creger RT. Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer. Am J Clin Oncol 1990; 13:107–112. 42. Lange A, Kolodziej J, Tomeczko J, Toporski J, Sedzimirska M, Jazwiec B, Bochenska J, Mroz E, Bielecka E, Was A, Glejzer O, Tomaszewska-Toporowska B, Jagas M, Zukowska B, Spaltenstein A, Bieranowska D, Klimczak A. Aggressive chemotherapy with autologous bone marrow transplantation in small cell lung carcinoma. Arch Immunol Ther Exp 1991; 39:431–439. 43. Nomura F, Shimokata K, Saito H, Watanabe A, Saka H, Sakai S, Kodera Y, Saito H. High dose chemotherapy with autologous bone marrow transplantation for limited small cell lung cancer. Jpn J Clin Oncol 1990; 20:94–98. 44. Spitzer G, Farha P, Valdivieso M, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4:4–13. 45. Johnson DH, Hande KR, Hainsworth JD, Greco FA. High-dose etoposide as singleagent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67:957–958. 46. Littlewood TJ, Spragg BP, Bentley DP. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide? Clin Lab Haematol 1985; 7:213–218. 47. Littlewood TJ, Bentley DP, Smith AP. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer—a negative report Eur J Respir Dis 1986; 68:370–374. 48. Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM, Goldstone AH, Spiro SG, Geddes DM, Tobias JS. Intensive chemotherapy with autologous bone marrow transplantation for small cell lung cancer. Cancer Chemother Pharmacol 1989; 24:321–325. 49. Smith IE, Evans BD, Harland SJ, et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14:120–124. 50. Banham S, Burnett A, Stevenson R, et al. Pilot study of combination chemotherapy with late dose intensification and autologous bone marrow rescue in small cell bronchogenic carcinoma. Br J Cancer 1982; 42:486. 51. Banham S, Loukop M, Burnett A, et al. Treatment of small cell carcinoma of the lung with late dosage intensification programmes containing cyclophosphamide and Mesna. Cancer Treat Rev 1983; 10(suppl A):73–77. 52. Burnett AK, Tansey P, Hills C, et al. Haematologic reconstitution following high dose and supralethal chemoradiotherapy using stored non-cryopreserved autologous bone marrow. Br J Haematol 1983; 54:309–316. 53. Jennis A, Levitan N, Pecora AL, Isaacs R, Lazarus H. Sequential high dose chemo-
Dose Intensification of Chemotherapy: Pro
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
103
therapy (HDC) with filgrastim/peripheral stem cell support (PSCS) in extensive stage small cell lung cancer (SCLC). Proc ASCO 1996; 15:349 (1021). Ihde DC, Diesseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small-cell lung cancer. J Clin Oncol 1986; 4:1443–1454. Cunningham D, Banham SW, Hutcheon AH, et al. High-Dose Cyclophosphamide and VP-16 as late dosage intensification therapy for small cell carcinoma of lung. Cancer Chemother Pharmacol 1985; 15:303–306. Sculier JP, Klastersky J, Stryckmans P, et al. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol 1985; 3:184–191. Klastersky J, Nicaise C, Longeval E, et al. Cisplatin, adriamycin and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma: evaluation of efficacy and toxicity and pilot study of a ‘‘late intensification’’ with autologous bone marrow rescue. Cancer 1982; 50:652–658. Cornblett M, Gregor A, Allen S, Leonard R, Smyth J. High dose melphalan as consolidation therapy for good prognosis patients with small cell carcinoma of the bronchus (SCCB). Proc ASCO 1984; 3:210. Wilson C, Pickering D. Stewart S, Vallis K, Kalofonos H, Cross A, Snook D, Goldman JM, McKenzie CG, Epenetos AA. High dose chemotherapy with autologous bone marrow rescue in small cell lung cancer. In Vivo 1988; 2:331–334. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5:1864–1873. Stewart P, Buckner CD, Thomas ED, et al. Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67:1055–1059. Elias AD, Ayash L, Frei E III, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, McCauley M, Herman T, Schnipper L, Antman KH. Intensive combined modality therapy for limited stage small cell lung cancer. J Natl Cancer Inst 1993; 85:559–566. Tomeczko J, Pacuszko T, Napora P, Lange A. Treatment intensification which includes high dose induction improves survival of lung carcinoma patients treated by high-dose chemotherapy with hematopoietic progenitor cell rescue but does not prevent high rate of relapses. Bone Marrow Transplant 1996; 18(suppl 1):S44–S47. Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1995; 22(suppl 2):3–8. Brugger W, Fetscher S, Hasse J, et al. Multimodality treatment including early highdose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1998; 25(suppl 2):42–48. Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E III. Dose intensive therapy for limited stage small cell lung cancer: long-term outcome. J Clin Oncol 1999; 17:1175–1184. Farha P, Spitzer G, Valdivieso M, et al. High-dose chemotherapy and autologous
104
68.
69. 70.
71.
72.
73.
74.
75.
76.
77.
78.
Elias bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 1983; 52:1351–1355. Marangolo M, Rosti G, Ravaioli A, et al. Small cell carcinoma of the lung (SCCL): high-dose (HD) VP-16 and autologous bone marrow transplantation (ABMT) as intensification therapy: preliminary results. Int J Cell Cloning 1985; 3:277. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618–1624. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890–895. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner C, Comis R, Green MR. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912–918. Bunn PA, Lichter AS, Makuch RW, Cohen MH, Veach SR, Matthews MJ, Anderson AJ, Edison M, Glatstein E, Minna JD, Ihde DC. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. Ann Intern Med 1987; 106:655–662. Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA, Ward JH, Livingston RB. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol 1987; 5: 592–600. Arriagada R, Kramar A, Le Chevalier T, De Cremoux H. Competing events determining relapse-free survival in limited small-cell lung carcinoma. J Clin Oncol 1992; 10:447–451. Turrisi AT, Kim K, Johnson DH, Komaki R, Sause W, Curran W, Livingston R, Wagner H, Blum R. Daily (qd) v twice-daily (bid) thoracic irradiation (TI) with concurrent cisplatin-etoposide (PE) for limited small cell lung cancer (LSCLC): preliminary results on 352 randomized eligible patients. Lung Cancer 1994; 11(suppl 1):172 (667). Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265–271. Choi NC, Herndon II JE, Rosenman J, et al. Phase I study to determine the maximum tolerated dose (MTD) of radiation in standard daily and hyperfractionated accelerated twice daily radiation schedules with concurrent chemotherapy for limited stage small cell lung cancer (Cancer and Leukemia Group B 8837). J Clin Oncol 1998; 16:3528–3536. Tepler I, Cannistra SA, Frei E III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH. Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993; 11:1583–1591.
Dose Intensification of Chemotherapy: Pro
105
79. Woll PJ, Lee SM, Lomax L, Hodgetts J, Stout R, Burt PA, Sims T, Kitchin R, Thatcher N. Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC). Proc ASCO 1996; 15:333 (957). 80. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13:148–156. 81. Perey L, Rosti G, Lange A, Pampallona S, Bosquee L, Pasini F, Humblet Y, Hamdan O, Cetto GL, Marangolo M, Leyvraz S. Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study. Bone Marrow Transplant 1996; 18(suppl 1):S40–S43. 82. Crown J, Wasserheit C, Hakes T, et al. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral bloodderived hematopoietic progenitor cells. J Natl Cancer Inst 1992; 84:1935–1936. 83. Gianni AM, Siena S, Bregni M, et al. Prolonged disease-free survival after highdose sequential chemo-radiotherapy and hemopoietic autologous transplantation in poor prognosis Hodgkin’s disease. Ann Oncol 1991; 2:645–653. 84. Ayash L, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12:37–44. 85. Humblet Y, Bosquee L, Weynants P, Symann M. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Bone Marrow Transplant 1996; 18(suppl 1):S36–S39. 86. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Brossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for Bcell lymphoma. N Engl J Med 1991; 325:1525–1533. 87. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85–86, and verbal communication, Stem Cell Conference, San Diego, March, 1993. 88. Brenner MK, Rill DR. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother 1994; 3:33–36. 89. O’Shaughnessy JA, Cowan KH, Cottler-Fox M, Carter CS, Doren S, Leitman S, Wilson W, Moen R, Nienhuis AW, Dunbar CE. Autologous transplantation of retrovirally-marked CD34-positive bone marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. Proc ASCO 1994; 13:296 (963). 90. Stahel RA, Mabry M, Skarin AT, Speak J, Bernal SD. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol 1985; 3: 455–461. 91. Canon JL, Humblet Y, Lebacq-Verheyden AM, Manouvriez P, Bazin H, Rodhain J, Prignot J, Symann M. Immunodetection of small cell lung cancer metases in bone marrow using three monoclonal antibodies. Eur J Cancer Oncol 1988; 24:147–150. 92. Trillet V, Revel D, Combaret V, Favrot M, Loire R, Tabib A, Pages J, Jacquermet P, Bonmartin A, Mornex JF, Cordier JF, Binet R, Brune J. Bone marrow metastases
106
93.
94.
95.
96.
97.
98.
Elias in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. Br J Cancer 1989; 60:83–88. Berendsen HH, De Leij L, Postmus PE, Ter Haar JG, Popperna S, The TH. Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. J Clin Pathol 1988; 41:273–276. Beiske K, Myklebust AT, Aamdal S, Langhom R, Jakobsen E, Fodstad O. Detection of bone marrow metases in small cell lung cancer patients. Am J Pathol 1992; 141: 531–538. Hay FG, Ford A, Leonard RCF. Clinical applications of immunocytochemistry in the monitoring of the bone marrow in small cell lung cancer (SCLC). Int J Cancer 1988; (suppl 2):8–10. Leonard RCF, Duncan LW, Hay FG. Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. Cancer Res 1990; 50:6545–6548. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83:636–640. Elias A, Li Y, Wheeler C, Richardson P, Ayash L, McCauley M, Newquist E, Cap B, Tuchin J, Webb I, Schnipper L, Frei E III, Skarin AT, Chen LB. CD34-selected peripheral blood progenitor cell (PBPC) support in high dose therapy of small cell lung cancer (SCLC): use of a novel detection method for minimal residual tumor (MRT). Proc ASCO 1996; 15:341 (991).
8 Dose Intensification of Chemotherapy in SCLC: Con Russell F. DeVore III* Vanderbilt–Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, Tennessee
INTRODUCTION Small cell lung cancer (SCLC) is a chemosensitive malignancy in which high overall and complete response rates can be achieved. Despite the presence of systemic micrometastases in virtually all patients at the time of presentation (1), a proportion of patients with limited-stage disease can be cured with a combination of chemotherapy and thoracic radiotherapy (2). Therefore, SCLC is an excellent model for testing strategies to overcome drug resistance in an effort to increase long-term survival rates (3). In preclinical tumor models, one of the simplest methods used to overcome drug resistance is dose escalation (3). Testing of dose escalation strategies in SCLC began in the late 1970s when Cohen and colleagues undertook a randomized trial in which SCLC patients were randomly assigned to receive either standard dosages of cyclophosphamide, methotrexate, and lomustine or higher-dose cyclophosphamide, lomustine, and standard-dose methotrexate (4). These investigators observed both a higher overall response rate and a prolonged survival in the high-dose-chemotherapy group. Long-term survivors were observed only *Current affiliation: East Tennessee Oncology/Hematology, Knoxville, Tennessee.
107
108
DeVore
among those patients given high-dose chemotherapy. By today’s standards, the ‘‘high dose’’ regimen used by Cohen and his colleagues would be considered relatively modest. Nevertheless, this trial spawned a series of studies aimed at overcoming drug resistance through dose escalation. A number of strategies have been employed to dose-intensify therapy in SCLC. These include high-dose induction chemotherapy, weekly chemotherapy, use of hematopoeitic growth factors, and late intensification with bone marrow rescue. To date no randomized trial has demonstrated a survival advantage to increasing dose intensity beyond that of the best conventional regimens. Increasing dose intensity in patients with extensive-stage SCLC is harmful and only increases the rate of serious toxicities. In limited-stage patients, results of randomized trials suggest that maintaining dose intensity at or near the maximally tolerated dose of a given regimen is important, but intensifying induction therapy beyond conventional doses has not been well addressed. In this chapter the various trials investigating the importance of dose intensity in SCLC are reviewed. Emphasis is placed on randomized controlled trials and a distinction is made between results in extensive- versus limited-stage patients. An argument is made to discontinue work testing this strategy, which has been extensively studied with overwhelmingly negative results.
HIGH-DOSE INDUCTION CHEMOTHERAPY Extensive SCLC Several randomized trials have tested the concept of high-dose induction therapy in SCLC (Table 1) (5–10). Based on pilot data demonstrating the feasibility of high-dose induction therapy (11), the Southeastern Cancer Study Group (SECSG) undertook a prospective study in which patients with extensive-stage SCLC were randomized to receive either high-dose cyclophosphamide, doxorubicin, and vincristine (CAV) for the initial three cycles of therapy or standard doses of the same regimen (6). No dose attenuation was allowed during the initial three cycles of therapy. Patients received a mean of ⱖ95% of the planned dosages of cyclophosphamide and doxorubicin during the first three treatment cycles resulting in a 15% and 67% dose escalation of each drug, respectively. Although the complete remission rate was higher in the high-dose arm (22% and 12%; p ⬍ 0.05), overall response rates (63% and 53%) and median survival duration (29.3 weeks and 34.7 weeks) were not significantly different between the two treatment groups. Moreover, the high-dose CAV regimen was substantially more toxic with a large percentage of patients experiencing life-threatening toxicities (grade 4 neutropenia: 79% and 40%; p ⬍ 0.05). Virtually identical results were reported by Figueredo and colleagues in a Canadian trial (9).
Regimen a
Patient number
Overall response
cd MCDVEH hd MCDVEH
21 21
67% 74%
9 months 9 months
10% b 7% b
Figueredo (9)
cd CDV hd CDV
51 52
61% 71%
7 months c 9 months c
— —
Johnson (6)
cd CDV hd CDV
174 124
53% 63%
34.7 weeks 29.3 weeks
20% 20%
cd PE hd PE
46 44
83% 86%
10.7 months 11.4 months
48% 45%
cd PCDE hd PCDE
50 d 55 d
54% e 67% e
.14 months .18 months
26% f 43% f
Ref. Hande (8)
Ihde (7) Arriagada (10)
Median survival
1-Year survival
Dose Intensity in SCLC
TABLE 1 Randomized Trials of High-Dose Versus Conventional-Dose Induction Chemotherapy
Methotrexate (M); cyclophosphamide (C); doxorubicin (D); vincristine (V); etoposide (E); hexamethylmelamine (H); cisplatin (P). a Conventional dose ⫽ cd; high-dose ⫽ hd. b Survival at 18 months. c Median duration of response. d All patients limited stage. e Complete remission rate. f Survival at 24 months.
109
110
DeVore
Hong and associates randomly assigned limited- and extensive-stage SCLC patients to receive either high-dose cyclophosphamide (2000 mg/m2) plus vincristine (CV), standard dose CAV, or standard-dose etoposide plus cyclophosphamide and vincristine (CEV) (5). A total of 353 patients were studied. In limitedstage patients the complete response rates and median survivals for dose-intensive CV, standard-dose CAV, and standard-dose CEV were 31% and 41 weeks, 42% and 55 weeks, and 38% and 58 weeks, respectively. Because the agents employed in the various regimens were not identical, factors other than dose intensity may have affected survival outcomes. Indeed, the median survival duration for all patients was superior in the standard-dose CEV arm ( p ⫽ 0.01), suggesting that the inclusion of etoposide may have been more important to efficacy than dose intensification. More recently, Ihde and colleagues compared ‘‘standard-dose’’ etoposide (80 mg/m2 /day ⫻ 3 days) plus cisplatin (80 mg/m2 /day 1) to ‘‘high-dose’’ etoposide (80 mg/m2 /day ⫻ 5 days) plus cisplatin (27 mg/m2 /day ⫻ 5 days) (7) in patients with extensive disease. Both regimens were administered every 21 days. The degree of myelosuppression with high-dose therapy was approximately twice that observed with the standard dose. Despite 68% higher doses and a 46% higher dose-rate intensity actually given to patients in the high-dose group, there was no difference in response rates (85% and 81%), median survival (12 months and 11 months), or 1-year survival rates (50% and 46%). The Johnson and Ihde trials were well designed; they tested dose intensification of induction therapy with two widely used conventional regimens; and they had similar findings. Both groups were able to approximate their planned increase in dose intensity in the ‘‘high dose’’ treatment arms but not even a statistically insignificant trend suggesting a survival benefit was observed. It might be argued that the degree of dose intensification achieved by these investigators was not sufficient to impact clinical outcomes. Indeed, preclinical studies indicate that a survival benefit may not be observed until the dose of an active agent is increased twofold or more (3). Furthermore, in animal models the most convincing evidence for a survival benefit to dose intensification comes from models with curative potential (12). Therefore, extensive-stage SCLC may not be a good model for testing dose intensification even if a twofold increase in dose intensity can be achieved. Limited SCLC Efforts to exploit any biological or clinical advantage to dose intensification might better be pursued in patients with limited-stage disease. To this end Arriagada and colleagues performed a retrospective analysis of 131 consecutively treated limited-stage SCLC patients and observed a survival benefit for patients who received higher initial doses of cyclophosphamide and cisplatin (13,14).
Dose Intensity in SCLC
111
Based on this observation, they undertook a phase III trial in which limited-stage patients were randomly assigned to receive either conventional-dose cisplatin, cyclophosphamide, etoposide, and doxorubicin alternating with thoracic radiotherapy, or the identical treatment regimen, except 20% higher doses of cyclophosphamide and cisplatin were given in the first treatment cycle only (10). The complete response rate (67% vs. 54%, p ⫽ 0.16) and 2-year survival (43% vs. 26%, p ⫽ 0.02) were superior in the dose-intensive group. These results are astounding given the minor degree to which chemotherapy doses were intensified and suggest that a twofold increase in dose intensity might not be necessary to impact survival outcomes in the clinical setting. A more recent report by Steward and colleagues also suggests that dose intensification might effect superior survival outcomes in early-stage patients (15). These investigators enrolled patients with ‘‘good- or intermediateprognosis’’ SCLC to a prospective multicenter study that involved a 2 ⫻ 2 factorial design, randomizing patients to conventional versus dose-intensified VICE chemotherapy (vincristine, ifosfamide, carboplatin, etoposide). Patients were randomly assigned to receive identical doses of all four drugs on either an every3-week or every-4-week schedule. Therefore, dose intensification was attempted by decreasing the dosing interval rather than increasing chemotherapy doses. Both treatment groups underwent a second randomization to receive either granulocyte-macrophage colony-stimulating factor (GM-CSF) or no growth factor support. Eligibility required that patients be classified as good- or intermediateprognosis as defined by Cerny and colleagues (16). A total of 178 of 300 patients (59%) had limited-stage disease. Although there were greater proportions of limited-stage patients and patients with more favorable prognostic scores in the dose-intensive group, these differences were not statistically significant. The addition of GM-CSF neither reduced the incidence of complications from myelosuppression, nor did it improve survival. However, patients in the 3-weektreatment arm experienced statistically superior median and 2-year survivals (443 vs. 351 days and 33% vs. 18%, respectively). The dose-intensive patients in the Arriagada and Steward trials experienced 2-year survival rates of 43% and 33%, respectively. Although the treatment regimens used in these trials varied significantly, an indirect estimate of the relative dose intensity of the two regimens can be made by comparing the incidence of dose-limiting toxicity, that being grade IV neutropenia 59% and 65%, respectively. Turrisi and colleagues recently described the highest long-term survival rates ever observed in a multicenter phase III trial in limited-stage SCLC (2). Patients were treated with etoposide and cisplatin and concurrent thoracic radiotherapy by either a conventional once-daily or a twice-daily schedule. For the entire patient group, the 2-year survival rate was 44% and the grade IV neutropenia rate was 63%, results almost identical to those observed in the ‘‘doseintensive’’ patients from the Arriagada and Steward trials. The control regimens
112
DeVore
used in the latter trials resulted in grade IV neutropenia rates of only 23% (cycle 1 only) and 49%, respectively. The dose intensity of the latter regimens might better be considered suboptimal rather than standard. Similar to the experience of Cohen and colleagues in patients with extensive-stage disease (4), the Arriagada and Steward trials demonstrated that reducing chemotherapy dose intensity below the optimum of a given induction regimen leads to inferior survival outcomes. It is safe to conclude that dose intensification of induction therapy is of no benefit to patients with extensive-stage disease. Optimal therapy for limited-stage disease should include doses at or near the maximal tolerated doses of the induction regimen. Compromising dose intensity in these patients may negatively impact long-term survival rates. Whether a survival benefit can be derived by intensifying induction therapy beyond the maximally tolerated doses of conventional outpatient therapy is unknown at this time and is a reasonable area for continued investigation in limited-stage patients. WEEKLY CHEMOTHERAPY As described in the preceding section, Steward and colleagues were able to effect a significant improvement in median survival in good- or immediate-prognosis SCLC patients by decreasing the treatment interval from 4 to 3 weeks. This suggests that increasing dose intensity by more frequent dosing might be beneficial. This may be even better achieved with weekly chemotherapy using standard chemotherapy doses but alternating between myelosuppressive and nonmyelosuppressive agents. Early pilot trials testing this approach have produced very promising results leading to a number of phase III trials comparing weekly chemotherapy to conventional regimens (Table 2) (17–20). The EORTC conducted a large phase III study comparing a weekly multidrug chemotherapy regimen (doxorubicin, etoposide, cyclophosphamide, cisplatin, vindesine, vincristine, and methotrexate) to a standard chemotherapy regimen (cyclophosphamide, doxorubicin, and etoposide) administered every 3 weeks (17). Both limited- and extensive-stage patients were enrolled. Although the response rate in the weekly regimen was higher in limited-stage patients, there was no difference in overall response rate, median survival, and 2-year survival. The total relative dose intensity for the drugs common to both regimens was significantly less in the weekly chemotherapy arm due to frequent treatment delays. This study failed to directly address the question of dose intensity but suggests increasing dose intensity or dose density with weekly chemotherapy may not be possible without hematopoietic support because of excessive toxicity. Souhami and colleagues, reporting for the Cancer Research Campaign of the United Kingdom, also found no survival benefit when they compared a weekly multidrug regimen to a standard every-3-week approach (18). In the U.K.
Ref.
Regimen
Patient number
Sculier (17)
a
Weekly Every 3 weeks b
98 101
69 62
Souhami (18)
Weekly c Every 3 weeks d
221 217
82.3 81.1
Murray (19)
CODE CAV/EP
110 109
Furuse (20)
CODE, GCSF CAV/EP
114 113
Overall response (%)
Median survival
2-Year survival (%)
49 weeks 43 weeks
8.5 7.9
10.8 months 10.6 months
11.8 11.7
87 70
0.98 years 0.91 years
10 e 10 e
84 77
11.6 months 10.9 months
8.5 12
Dose Intensity in SCLC
TABLE 2 Randomized Trials of Weekly Versus Every-Three-Week Chemotherapy
a
Doxorubicin, etoposide, cyclophosphamide, cisplatin, vindesine, vincristine, methotrexate. Cyclophosphamide, doxorubicin, etoposide. c Ifosfamide, doxorubicin alternating with cisplatin, etoposide. d Cyclophosphamide, doxorubicin, vincristine alternating with cisplatin and etoposide. e Progression-free survival. b
113
114
DeVore
trial, 438 patients with either limited disease or ‘‘good prognosis’’ extensive disease were randomized to receive 12 weekly cycles of ifosfamide and doxorubicin alternating weekly with cisplatin and etoposide or six cycles of CAV alternating every 3 weeks with EP. Thoracic irradiation was administered only to limitedstage patients in complete or partial response. There were no reported differences in overall response rates (82.3% and 81.1%), median survival (10.8 months and 10.6 months), or 2-year survival rates (11.8% and 11.7%). Hematological toxicity was greater in the weekly-chemotherapy arm and the ratio of intended/delivered dose intensity was greater in the standard arm. In both the EORTC and U.K. trials the chemotherapeutic agents differed between the two treatment arms. Although the ability to deliver full intended doses was superior in the standard regimens, it was not possible to directly compare dose intensity between the regimens. Canadian investigators reported promising results from a pilot study of a weekly regimen referred to as CODE: cisplatin (25 mg/m2 for 9 consecutive weeks); vincristine (1 mg/m2 weeks 1, 2, 4, 6, 8); doxorubicin (40 mg/m2 weeks 1, 3, 5, 7, 9); and etoposide (80 mg/m2 days 1–3, weeks 1, 3, 5, 7, 9) (21). Excluding cyclophosphamide, the CODE regimen contained the same agents and same total cumulative doses as the conventional alternating CAV/EP regimen but therapy was completed in 9 rather than 18 weeks. Thoracic and prophylactic cranial radiation therapy was also given to selected patients. These investigators were able to deliver close to full intended doses, thus achieving the goal of an approximately twofold increase in dose intensity for the four drugs common to the two regimens. A 2-year survival rate of 30% was observed, far superior to the historical rate of ⬍5% in extensive-stage patients. NCI Canada and SWOG collaborated on a phase III trial comparing CODE to conventional alternating CAV/EP in patients with extensive-stage SCLC (19). Greater than 70% of intended doses were delivered for both regimens. CODE patients received slightly higher cumulative doses of each of the four common agents but completed their therapy as intended in just 9 weeks rather than the 18 weeks targeted for control patients. Therefore, a twofold increase in the dose intensity of the four common agents was again achieved. Although rates of neutropenia and fever were similar, 10/110 CODE patients versus 1/109 CAV/EP patients died during chemotherapy. Response rates were higher for the CODE patients but progression-free and overall survival were not statistically different. In view of the increased mortality and a lack of survival benefit, CODE was not recommended. In the Canadian pilot and intergroup phase III trials, CODE patients received aggressive supportive care but were not routinely treated with prophylactic colony-stimulating factor (CSF). Japanese investigators conducted a small randomized trial of CODE with or without granulocyte-colony stimulating factor (G-CSF) in patients with extensive-stage SCLC (22). Use of G-CSF resulted in
Dose Intensity in SCLC
115
increased mean total received dose intensity for all drugs, reduced neutropenia and neutropenic fever, and a significant improvement in survival. This led to a phase III trial designed almost identical to that of the NCI Canada/SWOG trial (20). A total of 227 patients with extensive-stage SCLC were randomized to receive either CODE ⫹ G-CSF or conventional alternating CAV/EP. CODE patients received G-CSF on nontreatment days. The achieved dose intensity for CODE ⫹ G-CSF was twice that of the CAV/EP regimen. The incidence of leukopenia was not different but anemia and thrombocytopenia were significantly increased in the CODE ⫹ G-CSF patients. The incidence of neutropenic fever was 18.8% versus 8.8% of patients in the CODE ⫹ G-CSF and CAV/EP arms, respectively, and 4/114 (3.5%) of CODE ⫹ G-CSF patients died from therapyrelated causes. The response rate was slightly higher (77% vs. 84%) in the CODE ⫹ G-CSF arm, but there was no survival difference. Even with a twofold increase in dose intensity and growth factor support, dose intensification with the CODE regimen yielded no survival benefit in extensive-stage patients. As demonstrated in the induction therapy trials, dose intensification with weekly therapy leads to excessive toxicity rates and no therapeutic advantages. Dose intensification has been well tested in patients with extensive-stage SCLC and no evidence for benefit has been observed. COLONY STIMULATING FACTORS As outlined in the preceding sections, the addition of a CSF allowed for dose intensification of the VICE and CODE regimens (15,22). Decreasing the dosing interval of VICE improved survival, but the addition of GM-CSF had no independent impact on this outcome. The initial Japanese CODE ⫹ G-CSF trial, reported by Fukuoka and colleagues, was designed to address dose intensity as the primary endpoint rather than survival. Therefore, only 63 patients were accrued, but median survival was superior for patients who received G-CSF (59 vs. 32 weeks, p ⫽ 0.0004). Several phase III trials have investigated the impact of CSFs on SCLC chemotherapy (Table 3) (15,22–29). The primary endpoint of most trials was the incidence of neutropenia and associated sequelae. Most were not designed to directly address the relationship between dose intensity and therapeutic outcomes. In the study described above by Steward and colleagues, dose intensity was increased by adding GM-CSF to the regimen but the addition of growth factor had no independent impact on survival (15). Likewise, when Woll and colleagues added G-CSF to the VICE regimen, they were able to increase dose intensity but the trial was not powered to accurately address survival endpoints (28). Pujol and colleagues treated 125 patients with extensive-stage SCLC with either a dose-intensive regimen containing high doses of cyclophosphamide, epidoxorubicin, etoposide, and cisplatin plus GM-CSF or the same chemotherapy at conventional doses without GM-CSF (24). Despite their attempt to improve
116
TABLE 3 Randomized Trials of Chemotherapy With and Without Colony-Stimulating Factors (CSF) in SCLC Ref.
CSF
LD/ED
Attempt ↑ DI a
Pujol (24) Steward (15) Fukuoka (22) Bunn (23) Hamm (25)
GM GM G GM GM
ED 59% LD ED LD Both
Miles (26) Crawford (27) Trillet-Lenoir (29) Woll (28)
G G G G
Both Both Both 92% LD
Effect on DI
Effect on toxicity
Yes Yes No No No
Decreased Increased Increased Decreased Increased
No No No Yes
None NA Increased Increased
Increased None Decreased Increased ↓ Neutropenia ↑ Thrombocytopenia Decreased Decreased Decreased Increased deaths
Effect on median survival Decreased None Increased None None None None None None
a
An attempt was made to increase either doses or dose frequency in the CSF patients. Dose intensity (DI); granulocyte-colony stimulating factor (G); granulocyte-macrophage-stimulating factor (GM); limited disease (LD); extensive disease (ED).
DeVore
Dose Intensity in SCLC
117
survival by increasing dose intensity with the aid of GM-CSF, these investigators reported decreased dose intensity, worse hematological toxicities, and inferior median survival (10.8 vs. 8.9 months, p ⫽ 0.0005) for the high-dose chemotherapy/GM-CSF-treated patients. The Pujol data further corroborate the overwhelming evidence that attempting to intensify chemotherapy for extensive-stage patients is not beneficial, but is, in fact, harmful. However, the Arriagada and VICE data suggest dose intensification might be beneficial in limited-stage patients. Although the trial by Woll and colleagues was not designed to address a primary survival endpoint, they did demonstrate a statistically significant increase in 2-year survival (32 vs. 15%) in primarily limited-stage patients receiving dose-intensified VICE ⫹ GCSF, even though median survival was not improved (69 vs. 65 weeks). Bunn and colleagues conducted a phase III trial in 230 limited-stage SCLC patients to determine whether GM-CSF could be used to reduce the incidence of neutropenic fever and hematological toxicities of combined chemoradiotherapy (23). All patients initially received etoposide 80 mg/m2 and cisplatin 40 mg/m2 days 1–3. Thoracic radiotherapy consisted of 45 Gy total delivered in 25 daily fractions of 1.8 Gy, 5 days per week, given simultaneously with the chemotherapy over the first 5 weeks. GM-CSF was dosed at 250 µg/m2 subcutaneously twice daily on days 4–18 of each cycle of therapy. There was a statistically significant increase in the frequency and duration of life-threatening thrombocytopenia ( p ⬍ 0.001), more nonhematological toxicity, more days of hospitalization, a higher incidence of intravenous antibiotic usage, more transfusions, and more toxic deaths in the patients receiving GM-CSF. There was no significant difference in median survival. In summary, the addition of CSFs to chemotherapy in patients with SCLC can reduce the incidence of hematological side effects if chemotherapy is given at conventional doses. Chemotherapy dose escalation or the addition of concurrent radiotherapy to CSFs has resulted in increased toxicity and death rates in some studies. Considering the expense and inconveniences associated with the use of CSFs, the lack of benefit from dose intensification, and the intolerability of concurrent use with radiotherapy, the routine use of these agents in the management of SCLC cannot be recommended (30–32). This represents yet a third failed strategy to improve treatment outcomes with dose intensification. LATE INTENSIFICATION CHEMOTHERAPY Of the dose intensification strategies discussed thus far, only the CODE regimen yields a greater-than-twofold increase in dose intensity. Some type of hematopoietic stem cell support is needed to intensify therapy further. Late intensification has both scientific and clinical appeal (33,34). Because SCLC patients are often quite ill at the time of presentation they are often poor candidates for highly
118
DeVore
aggressive approaches upfront. Patients are generally in better medical condition to be considered for high-dose therapy following induction. Consolidation with high-dose therapy also allows for the prospective identification and selection of patients who are most likely to benefit—those with limited-stage disease, good performance status, and those who obtained a major remission with induction chemoradiotherapy (34). This approach has been studied by a number of investigators albeit rarely in a randomized trial. Humblet and colleagues reported the results of the only published multicenter randomized study testing late intensification chemotherapy in patients responding well to induction therapy (35). Autologous bone marrow transplantation was used to rescue patients from hematological toxicities. Of 101 patients receiving standard induction chemotherapy, 45 patients with chemotherapy-sensitive disease were randomized to receive one additional cycle of either high-dose cyclophosphamide, carmustine (BCNU), and etoposide or conventional doses of the same drugs. In this highly selected group of patients, median overall survival after induction therapy was 68 weeks for the intensified group compared to 55 weeks for the conventional therapy group, a difference that proved not to be statistically significant ( p ⫽ 0.13). In a large phase II study, the Southwest Oncology Group treated 58 limitedstage SCLC patients with induction chemoradiotherapy followed by high-dose cyclophosphamide (150 mg/kg) intensification and autologous bone marrow rescue (36). Only 21 patients completed the entire course of therapy, and there were seven treatment-related deaths, four of which occurred during late-intensification chemotherapy. Median survival for all patients was 11.1 months. Nine of the 21 patients receiving late intensification were alive in complete remission with a median survival of 27 months. Dana Farber Cancer Center investigators employed high-dose consolidation chemotherapy in patients with limited-stage SCLC in partial or complete remission following conventional first-line chemotherapy (37). Patients received cumulative doses of 5625 mg/m2 cyclophosphamide, 165 mg/m2 cisplatin, and 480 mg/m2 carmustine followed by thoracic and prophylactic cranial irradiation. Of the 36 patients treated in this phase II trial, 29 of whom were in complete or near-complete remission before high-dose therapy, 14 remained disease free at a median of 21 months after treatment. Actuarial 2- and 5-year disease-free survival rates were 53% and 41%, respectively. Morbidity was relatively low and most patients were able to return to full-time work. Although the results of this trial are provocative, patients were highly selected and accrued over a 9-year period. Furthermore, the median age of patients entered into this trial was 49 years, several years below the typical age of SCLC patients. There are few reports of similarly selected patients from which historical control data can be derived and compared. However, the SECSG reported a phase III trial involv-
Dose Intensity in SCLC
119
ing a similar subset of selected patients (38). Patients with limited-stage SCLC were randomly assigned to receive either six cycles of induction chemotherapy with CAV or the same therapy with concurrent radiotherapy. Good-performancestatus patients who had achieved an objective remission at the end of induction therapy were randomized to receive two cycles of consolidation etoposide and cisplatin or no further therapy. Twenty-six patients had received induction chemotherapy and radiotherapy and consolidation with etoposide and cisplatin. From the time of consolidation therapy initiation, these patients achieved a 2-year survival rate of 55%, almost identical to the results reported by the Dana Farber group. The results with high-dose consolidation therapy in patients with SCLC have not been sufficiently promising to justify phase III testing. More compelling data are needed to generate enthusiasm for more extensive testing of this costly and toxic therapy in a disease that occurs primarily in elderly patients with significant comorbidities. CONCLUSIONS Dose-intensive induction therapy, weekly chemotherapy, attempts to intensify therapy with CSFs, and high-dose consolidation therapy have all failed to show a survival benefit for patients with SCLC. Intensification of therapy beyond that of conventional regimens has generally been harmful. A large body of clinical evidence indicates that further study of dose intensification strategies in extensive-stage SCLC is not justified and ethically questionable given the high rates of morbidity and mortality observed with this approach to date. For patients with limited-stage SCLC, the available data suggest that survival is compromised when induction chemotherapy is given below the maximally tolerated doses of conventional combined-modality regimens. Intensification of induction therapy beyond this level in limited-disease patients has not been well studied and remains a legitimate area of research. The utility of late intensification therapy for limited-stage SCLC is still not well addressed in randomized controlled studies. However, it is questionable whether pilot trials have generated sufficiently promising clinical evidence to justify phase III testing of this approach. Based on an extensive body of clinical data, we can safely conclude that dose intensification with current agents is of no benefit and may even be harmful to patients with SCLC. Early intensification of therapy in limited-stage disease remains a legitimate area of research, but it is difficult to be optimistic given the futility of this approach in other disease settings. Unless new and significantly more active and non-cross-resistant agents are identified, substantial additional effort in this area of research is largely a waste of valuable patient resources.
120
DeVore
REFERENCES 1. Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative resection for lung cancer. Cancer Chemother Rep 1973; 4(part 3):63–67. 2. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340(4):265–271. 3. Schabel FM, Griswold DP, Corbett TH, Laster R, Mayo JG, Lloyd HH. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors in man. In: DeVita VT, Busch H, eds. Methods in Cancer Research. Cancer Drug Development Part B. Vol. XVII. New York: Academic Press, 1979: 4–52. 4. Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston A, Williams CL, Minna JD. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61:349–354. 5. Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Leudke D, Hurtubise M, Lanzotti V, Goodlow J, Rozencweig M. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 1989; 7:450–456. 6. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, Omura G, Greco FA. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5:1731– 1738. 7. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, Johnson BE. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022–2034. 8. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 1982; 73:413–419. 9. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small cell lung cancer. J Clin Oncol 1985; 3:54–64. 10. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329(25):1848–1852. 11. Lowenbraun S, Birch R, Buchanan R, Krauss S, Durant J, Perez C, Mill W, Vollmer R, Ogden L. Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens. Cancer 1984; 54:2344–2350.
Dose Intensity in SCLC
121
12. Murray N. Importance of dose and dose intensity in the treatment of small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40 (suppl):S58–S63. 13. Arriagada R, de The H, Le Chevalier T, Thomas F, Ruffie P, de Cremoux H, Martin M, Duroux P, Dewar J, Sancho-Garnier H. Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses. Bull Cancer 1989; 76(6):604–615. 14. De Vathaire F, de The H. Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung carcinoma. Lung Cancer 1993; 8:301– 308. 15. Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998; 16(2):642–650. 16. Cerny T, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987; 89(February):146–149. 17. Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, Van Cutsem O, Berchier MC, Ries F, Michel J, Sergysels R, Mommen P, Klastersky J. Multiple drug weekly chemotherapy versus combination regimen in small cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11:1858–1865. 18. Souhami RL, Rudd R, Ruiz de Elvira M-C, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C, Spiro SG. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12:1806–1813. 19. Murray N, Shepherd F, James K, Zee B, Lantgleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. A randomized study of CODE versus alternating CAV/EP for extensive stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17: 2300–2308. 20. Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998; 16(6):2126–2132. 21. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairley R, Voss N. Intensive weekly chemotherapy for the treatment of extensive-stage small cell lung cancer. J Clin Oncol 1991; 9:1632–1638. 22. Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75(2):306–309. 23. Bunn PA, Jr., Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase
122
24.
25.
26.
27.
28.
29.
30.
31.
32.
33. 34. 35.
DeVore III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13(7): 1632–1641. Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P, BardonnetComte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15(5):2082–2089. Hamm J, Cuffie C, Oken M, Risher R, Shepherd F, Kaiser G. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in smallcell lung carcinoma. J Clin Oncol 1994; 12:2667–2676. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12(1):77–82. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325:164–170. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13(3):652–659. Trillet-Lenoir GJ, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur Cancer 1993; 29A:319–324. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhom LH. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colonystimulating factor. J Clin Oncol 1994; 12(6):1245–1250. Chouaid C, Fuhrman C, Monnet I, Housset B. Routine use of granulocyte colonystimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998; 16(August):2700–2707. Messori A, Tnendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996; 21(April):57–63. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61:1307–1317. Elias A. Dose-intensive therapy in lung cancer. In: Armitage JAK, ed. High-Dose Cancer Therapy. Baltimore: Williams & Wilkins, 1995:824–846. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Doyen C, Weynants P, Longueville J, Prignot J. Late intensification chemotherapy
Dose Intensity in SCLC
123
with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5:1864–1873. 36. Goodman GE, Crowley J, Livingston RB, Rivkin SE, Albain K, McCulloch JH. Treatment of limited small cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. J Clin Oncol 1991; 9:453–457. 37. Elias A, Skarin A, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman K, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome. J Clin Oncol 1999; 17(April):1175–1184. 38. Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993; 11(7):1223–1229.
9 The Role of Surgery in SCLC Frances A. Shepherd University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada
HISTORICAL PERSPECTIVE Twenty to twenty-five percent of all primary bronchogenic carcinomas are of the small cell subtype. However, since dissemination to regional lymph nodes and/ or distant metastatic sites can be identified in more than 90% of patients at the time of initial presentation (1), these tumors represent less than 5% of cases in most surgical series. Furthermore, in the patients with apparently ‘‘limited’’-stage or operable tumors, widespread micrometastic disease is likely present, and these subclinical deposits have the potential to proliferate if only local therapeutic modalities, such as surgery or radiotherapy, are employed. This explains why almost all surgical series from the prechemotherapy era reported 5-year survival rates approaching zero for patients with small cell carcinoma (2,3). To assess the role of surgery in the treatment of small cell lung cancer, a prospective randomized trial was mounted by the Medical Research Council of Great Britain (4,5). Seventy-one patients were randomized prospectively to undergo surgery, and 73 to receive thoracic irradiation (30 Gy or more over 20– 40 days). The median survivals for patients in the surgical and radiotherapy arms were 199 and 300 days, respectively (Figure 1). At 5 years, one surgical and three radiotherapy patients were alive (p ⫽ 0.04), and at 10 years, only the three patients in the radiotherapy arm remained alive. It was concluded from this study 125
126
FIGURE 1
Shepherd
Survival in the two treatment series (all patients). (From Ref. 4.)
that radical radiotherapy was preferable to surgery, but that neither of the treatment policies was really effective. The investigators stated that it would be improbable that any advance in therapy could exert a significant effect on the death rate from this disease in the absence of successful smoking prevention programs. How true these words are, even today! The results of this study led to trials of preoperative radiotherapy followed by surgery for patients with small cell lung cancer. Several prospective phase II trials showed that it was possible to combine these two local treatment modalities safely, but few patients achieved long-term survival (6–8). The observation in the 1970s that patients with small cell lung cancer were dying from systemic metastases led to the hypothesis that chemotherapy might add to the effects of local radiotherapy. Bergsagel et al. from the Princess Margaret Hospital were the first to show a modest survival advantage with the addition of single-agent, low-dose cyclophosphamide (9). The British Medical Research Council Lung Cancer Working Party also showed that adding low-dose cyclophosphamide and 1-(2-chloroethyl)-3 cyclohexyl-1-nitrosourea (CCNU) to radiotherapy resulted in a significant prolongation of progression-free, but not overall, survival (10). At the same time, other investigators were applying the same adjuvantchemotherapy principles to surgical patients. In 1977, Shields reviewed the results of four Veterans Administration Surgical Adjuvant Group (VASOG) adjuvant chemotherapy studies, and undertook a separate analysis of the 148 patients (47%) in those trials who had small cell lung cancer (11). No survival advantage
The Role of Surgery in SCLC
127
was seen for the patients in the chemotherapy arms of either of the trials that evaluated single-agent nitrogen mustard or single-agent cyclophosphamide. A small survival advantage was seen for patients in the chemotherapy arm of a three-arm trial in which patients were randomized to receive prolonged intermittent courses of CCNU and hydroxyurea or no further therapy (Figure 2).
FIGURE 2 (A) Survival of treated and control patients with undifferentiated small cell carcinoma in the nitrogen mustard (HN2) and cyclophosphamide (Cytoxan) adjuvant chemotherapy VASOG lung trials. (B) Survival of treated and control patients with undifferentiated small cell carcinoma in the prolonged intermittent cyclophospharide (Cytoxan, CTX) and methotrexate (MTX) adjuvant chemotherapy VASOG lung trials. (C) Survival of treated and control patients with undifferentiated small cell carcinoma in the CCNU and hydroxyurea adjuvant chemotherapy VASOG lung trials. (From Ref. 12.)
128
Shepherd
Shields and his colleagues also made other important observations from their analysis of the small cell patients in the VASOG trials (12). They demonstrated the importance of tumor, node, metastasis (TNM) staging, which has long been recognized to have prognostic significance for non–small cell lung cancer. Sixty percent of patients with T1 N0 M0 tumors were alive at 5 years, whereas there were almost no 5-year survivors among the patients who presented either with T2–3 tumors or with mediastinal lymph node involvement (Figure 3). Patients with small stage II tumors had an intermediate 5-year survival of approximately 30%. These observations suggested that there could be a small subpopulation of patients with small cell lung cancer for whom it might be appropriate to consider a surgical approach. In a retrospective review of 40 patients with small cell lung cancer who underwent potentially curative resection between 1959 and 1972, Shore and Paneth reported an overall 5-year survival rate of 25%. Four of 10 patients (40%) without nodal involvement achieved long-term survival compared to nine of 26 patients (25%) who had hilar or mediastinal nodal involvement (13).
FIGURE 3 Survival, computed by the life table method, from postoperative day 30 (early trials) or from randomization (recent trials) by TNM classification for patients with undifferentiated small cell carcinoma who had undergone a ‘‘curative’’ resection in the VASOG lung trials. (From Ref. 12.)
The Role of Surgery in SCLC
129
Small cell lung cancer usually presents with a central mass associated with hilar and mediastinal adenopathy. Lennox et al. observed that patients who had large proximal tumors and who required a pneumonectomy were less likely to achieve long-term survival. The 2- and 5-year survival rates for patients who required only a lobectomy were 32% and 18%, respectively, compared to 14.4% and 7.2% for pneumonectomy patients (14). It is unusual for small cell lung cancer to present as a solitary pulmonary nodule. In the VASOG review of solitary pulmonary nodules, only 15 patients (4%) were found to have small cell pathology, and 11 were able to undergo surgery (15). One-, 5-, and 10-year survival rates for those 11 patients were 63.6%, 36.4%, and 18.2%, respectively. Since most of these patients underwent surgery before the chemotherapy era, it may be assumed that approximately one-third were cured by their surgery alone as measured by survival at the 5-year mark. From this historical review it is clear that local treatment, whether surgery, or radiation, or both, is inadequate therapy for small cell lung cancer. If surgery is to play a role, it must be in the context of a combined-modality treatment program with systemic combination chemotherapy.
RATIONALE FOR SURGERY Improved Control at the Primary Site Response rates of 80% or more are achieved with current chemotherapy combinations for small cell lung cancer, and complete clinical response is seen in approximately 50% of patients with limited-stage disease (16). However, most patients relapse shortly after discontinuing treatment, and the 2-year survival rate is 20% or less in most series. For patients with limited disease, the most frequent site of failure is the primary tumor and the hilar or mediastinal lymph nodes. In total, up to 50% of patients fail at the primary site, and for half of those patients, the primary site may be the only area of failure. Similar results have been found at autopsy. In a review by Elliott et al., residual tumor was identified at autopsy in the primary site in 64%, and in the hilar and mediastinal lymph nodes in 53% of patients with limited disease who had at some time achieved a complete clinical response (17). Two meta-analyses of thoracic radiotherapy for small cell lung cancer have been published (18,19). The survival data for almost 2000 patients in 16 trials were available, and data on local control rates were available for nine studies. Both meta-analyses showed that thoracic irradiation resulted in a reduction in local relapse rate from 47.9% to 23.3% (p ⬍ 0.0001) (18). They also demonstrated a small but significant survival benefit for patients who received radiotherapy (18,19). Based on the results of these meta-analyses, the standard therapy for patients with limited small cell lung cancer now consists of combination chemother-
130
Shepherd
apy and thoracic irradiation with or without prophylactic cranial irradiation. Median survival longer than 20 months and 5-year survival rates of approximately 20% have been reported (16,20). However, even the most successful combinedmodality treatment programs report isolated initial relapse at the primary site in 20–25% of patients, and a cumulative risk of recurring locally of 50% (20). This high local failure rate led several investigators to question whether surgical resection would result in improved local control. They postulated that control of bulk disease in the chest by surgery and eradication of low-volume micrometastatic disease by systemic chemotherapy would result in an increased cure rate. Small studies from several centers suggested that this might, indeed, be the case. The University of Toronto Lung Oncology Group reported only two local recurrences in 35 patients treated with combined-modality therapy that included surgical resection (21). Similar results were reported by Comis et al., who observed no local recurrences in 16 patients who underwent adjuvant surgical resection after induction chemotherapy (22). Mixed Histology Tumors In approximately 5–10% of cases, small cell lung cancer is found in combination with other histologies such as adenocarcinoma or squamous cell carcinoma (23). Investigators for the Eastern Cooperative Oncology Group reported that mixedhistology tumors were more likely to present as peripheral lesions on chest xray, although they found that all other clinical characteristics were similar to those of the pure small cell lung cancer patients (24). Surgical series of small cell lung cancer report higher percentages of mixed histological tumors. The University of Toronto Lung Oncology Group reported mixed histology in 14 of 79 patients (17.7%) who underwent initial surgery followed by adjuvant chemotherapy, and in three of 40 patients (7.5%) who had surgical resections after induction chemotherapy (25). Since non–small cell lung cancers are relatively insensitive to chemotherapy, they are not likely to be controlled by systemic treatment. Thus, it may be appropriate to consider a combined-modality treatment program for patients with mixed-histology tumors if they meet standard surgical criteria and have no evidence of extrathoracic spread. Late Recurrence After Successful Treatment of Small Cell Lung Cancer Several reviews have now suggested that long-term survivors of small cell lung cancer are at high risk of developing second primary tumors, in particular second primary lung cancers (26–30). Although the patient population at risk for these second tumors is low because of the low cure rate for small cell lung cancer, clinicians seeing patients in follow-up must be aware that a new lesion on chest x-ray may not represent relapse, but may be a new tumor of different histology.
The Role of Surgery in SCLC
131
Such patients should be investigated as any other patient who is presenting with a lung mass for the first time. Histological or cytological confirmation of malignancy should be obtained, and if non–small cell lung cancer pathology is found, further workup should be directed at determining operability since surgical resection has the potential to be curative for some patients. ADJUVANT CHEMOTHERAPY FOLLOWING SURGICAL RESECTION The favorable results reported in Shields’s review of the VASOG trials led several investigators to administer combination chemotherapy to all patients following complete resection of small cell lung cancer. A summary of 11 such trials is shown in Table 1 (12,31–42). All of the studies were retrospective reviews and suffer from the inherent weaknesses of any retrospective assessment of a treatment policy. Frequently surgery was undertaken for patients in these series because a preoperative diagnosis of small cell lung cancer had not been made. For some, it had not been possible to obtain adequate tissue for any malignant diagnosis, and for others a preoperative diagnosis of non–small cell lung cancer had been made. Some of those patients were found subsequently to have mixed-histology tumors, whereas others had pure small cell tumors that had been incorrectly diagnosed preoperatively. Maassen and Greschuchna (36) reported that only 18 of 24 patients had a correct histological diagnosis of small cell lung cancer preoperatively. Similarly, the University of Toronto Group (37) found that a correct preoperative diagnosis of small cell cancer was found in only 18 of 63 patients. Postoperatively small cell lung cancer was seen in 54 patients and mixed-histology tumors in nine. Most of the series in Table 1 included patients seen over a 10-or-moreyear period, and frequently, multiple-chemotherapy protocols were employed. However, with the exception of the early trials reported by Shields et al. (12) and Hayata et al. (31), all patients were treated with combinations of drugs that would be considered adequate even today. The duration of chemotherapy treatment was also variable, and ranged from a single course of postoperative therapy, to multiple courses for up to 18 months. Most groups administered approximately six cycles of treatment. In addition to postoperative chemotherapy, some centers also administered thoracic radiotherapy as well as prophylactic cranial irradiation. In view of the variability in radiation treatment, and incomplete reporting in several series, no conclusions can be drawn concerning the advisability of trimodality therapy. Because so few patients with small cell lung cancer are surgical candidates, the TNM staging system is not generally applied to this subtype of lung cancer, and instead, patients are classified simply as having limited or extensive disease. The patients in the reviews summarized in Table 1 differ from limited-stage small
Author Hayata, 1978 (31) Shields, 1982 (12) Meyer, 1983, 1984 (32,33) Wada, 1995 (34) Osterlind, 1986 (35) Maassen, 1986 (36) Shepherd, 1988 (37) Karrer, 1990, 1991 (38,39) Macchiarini, 1991 (40) Hara, 1991 (41)
a
Stage I and II combined.
Stage
Number of patients
I
II
Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival Number Survival
27 26% 49 51% 6 ⬎50% 5 37%a 18 22% 41 34% 19 48% 63 61% 26 52% 13 64% 11 50%
6 17% 55 20% 4 50% 5 — 8 ? 19 21% 24 24% 54 35% — — 10 42% 16 35%
III 39 0% 28 3% 10 0 7 33% 10 ? 64 11% 20 24% 40 35% 15 (T 3N0) 13% 14 10.7% 5 21%
Total 72 11% (5 yr) 132 28% (5 yr) 30 ? (5 yr) 17 32% 36 25% (3.5 yr) 124 20% (3 yr) 63 31% (5 yr) 157 ? (4 yr) 42 36% (5 yr) 37 ? (5 yr) 32 36% (5 yr)
Shepherd
Davis, 1993 (42)
132
TABLE 1 Survival by Pathological Stage for Patients Treated with Adjuvant Chemotherapy After Surgery for Small Cell Lung Cancer
The Role of Surgery in SCLC
133
cell lung cancer patients overall in that they all underwent pretreatment surgical resection, and therefore detailed pathological staging is available. The results show clearly that the TNM staging system is highly prognostic for patients with limited small cell lung cancer. In every study, the best survival was achieved by patients who had pathological stage I tumors, and the poorest survival was seen for patients with pathological stage III tumors (Figures 4 and 5) (38,39). For stage I patients, survival ranged from 22% at 3.5 years in the Danish series (35) to 61% at 4 years in the International Society of Chemotherapy LCSG. On average, it would appear that approximately 50% of patients with pathological stage I small cell lung cancer may be cured with a combined-modality approach that includes surgical resection and adjuvant combination chemotherapy. In the early trials, virtually no patients with stage III tumors achieved long-term survival. In the later reviews in which more aggressive combination chemotherapy regimens were employed, long-term survival ranged from 11% (36,43) to 35% (38,39). In all series, the survival of stage II patients was intermediate between that of patients with stages I and III. In fact, stage for stage, the survival rates are very similar to those seen after surgical resection of non–small cell lung cancer. All of the studies that employed intensive combination chemotherapy reported survival rates that appear to be superior to the survival rates seen in patients
FIGURE 4 Life table survival curves for small cell lung cancer patients according to lymph node involvement. Patients with stage pT, N0, M0 disease (solid line), n ⫽ 63; pT, N1, M0 (dotted line), n ⫽ 51: pT, N2, M0 (dashed line), n ⫽ 32. (From Ref. 39.)
134
Shepherd
FIGURE 5 A comparison of survival by stage for patients treated with adjuvant chemotherapy after surgical resection for small cell lung cancer. (From Ref. 37.)
following surgery without adjuvant chemotherapy. Since it is likely that the improved survival is attributable to the postoperative chemotherapy treatment and not to improvements in surgical techniques or supportive care, it seems appropriate to recommend that chemotherapy be given to all patients who have undergone resection for limited small cell lung cancer. The short-term toxicity of such treatment is usually quite manageable and reversible, and the long-term toxicity is minimal. The Toronto Group recommend no more than six treatment cycles (37), since survival does not seem to be superior for patients in the retrospective studies who received 12–18 months of postoperative treatment (34,35). Whether fewer than six cycles may also be adequate is unknown. In the study reported by Hara et al. (41), 11 patients treated before 1981 received only one postoperative course of combination chemotherapy, and 26 patients treated from 1982 to 1989 received two courses followed by consolidation radiotherapy. Although the 5-year survival rates for patients with stage I and II tumors were excellent, only 10.7% of patients with stage III tumors were alive at 5 years. These results appear to be somewhat poorer than those achieved by other groups who administered a more prolonged course of adjuvant chemotherapy, although firm conclusions cannot be drawn from these retrospective analyses. Littlewood et al. (44) treated two young patients by pneumonectomy followed by a single course of very-highdose chemotherapy and autologous bone marrow transplantation. Both patients relapsed, 118 and 80 weeks after treatment. It would appear, therefore, that a brief course (maximum six treatment cycles) of standard-dose combination chemotherapy should be the treatment of choice for patients.
The Role of Surgery in SCLC
135
It is not possible to state with certainty whether it is necessary to administer adjuvant chemotherapy to all patients. Shah et al. (45) reported 43.3% actual 5year survival for 28 patients who underwent complete surgical resection without postoperative chemotherapy. More than half the patients in this study had peripheral tumors, and their survival was better than that of the patients who had central tumors. However, peripheral stage I small cell lung cancer is uncommon, as shown by the VASOG study of solitary pulmonary nodules in which only 15 of 309 patients were found to have small cell cancer (15). Their 5-year and 10-year survivals were 36.4% and 18.2%, respectively. The details of postoperative therapy, if any, for these patients were not provided, but it is likely that they did not receive aggressive combination chemotherapy. The 5-year survival rate is less than that reported by Shah et al. (45), and one can only speculate whether superior survival might have been achieved with the addition of combination chemotherapy. It is not, on the other hand, possible to draw firm conclusions concerning the contribution of the surgery to the overall survival of these patients. It must be remembered that these surgical series included only a select subgroup with limited disease from which patients with adverse prognostic factors, such as supraclavicular adenopathy, bulky primary tumors with superior vena caval obstruction, and/or pleural effusions, were specifically excluded. Surgery, if it does play a role in the treatment of small cell lung cancer, will do so by improving control at the primary site. Relapse patterns were reported in only seven of the trials reviewed (32,37,40–44), but the results from those studies suggest that surgery did, indeed, contribute to local control, since isolated local relapse was seen in only eight of the 201 patients in those studies (Table 2). It is still possible, however, that this high rate of local control was due only
TABLE 2 Pattern of Relapse for Patients with Small Cell Lung Cancer Treated with Surgery Followed by Adjuvant Chemotherapy No. of patients with relapse Investigators Meyer, 1983 (32) Friess, 1985 (43) Littlewood, 1987 (44) Shepherd, 1988 (37) Macchiarini, 1991 (40) Hara, 1991 (41) Davis, 1993 (42) Total
No. of patients
Local only
Distant only
Both
10 15 2 63 42 37 32
— 1 1 2 2 2 —
1 5 1 26 24 ? 15
— 1 — 5 — — 2
201
8
72
8
136
Shepherd
to the fact that the patients in these series had less locally advanced tumors and that the local control rate might have been equivalent with a combination of systemic chemotherapy and thoracic irradiation.
PROSPECTIVE TRIALS OF INDUCTION CHEMOTHERAPY FOLLOWED BY SURGICAL RESECTION FOR SMALL CELL LUNG CANCER Phase II Trials The encouraging results achieved with initial surgery followed by adjuvant chemotherapy led several groups to undertake prospective studies of systemic chemotherapy followed by surgery for certain patients with limited small cell lung cancer. The results of nine prospective phase II trials are summarized in Table 3 (46–54). In all studies, patients received multiple courses of combination chemotherapy that included agents considered, even today, to be active against small cell lung cancer (cyclophosphamide, doxorubicin, vincristine, etoposide, and cisplatin). The number of preoperative chemotherapy courses ranged from two to six, and the overall response rate was greater than 88% in all studies except that of Baker et al. (49) in which only two preoperative courses of chemotherapy were given. This perhaps suggests that a longer course of induction chemotherapy is advisable, although in the small study reported by Benfield et al. (51) 88% of patients responded to treatment, and 100% were able to undergo complete surgical resection after only two courses of chemotherapy. Not all responding patients in this series were eligible for thoracotomy after chemotherapy. On average, approximately 60% of patients were considered to have responded adequately enough for surgical exploration, and of those, more than 80% could be resected completely. When calculated from the total number of patients who entered the studies, however, the overall complete surgical resection rate was only approximately 50%. Not all studies reported surgical toxicity, but it does not appear that the postoperative death rate or complication rate was significantly increased by the preoperative chemotherapy. Only three postoperative deaths were reported (50,52,54), all in patients who had required a complete pneumonectomy. Other postoperative complications included infection, bronchopleural fistula formation, and reversible supraventricular tachycardias. As would be expected, the complete pathological response rate was considerably lower than the clinical response rate. The rate ranged from 4% (50) to 37% (48) and on average was approximately 10%. It is of interest that this complete pathological response rate is very similar to that which has been reported in studies of induction chemotherapy followed by surgery for patients with locally advanced (stage IIIA or IIIB) non–small cell lung cancer (58).
Investigators Prager, 1984 (46) Williams, 1987 (47) Johnson, 1987 (48) Baker, 1987 (49) Shepherd, 1989 (50) Benfield, 1989 (51) Zatopek, 1991 (52) Hara, 1991 (53) Eberhardt, 1997 (54)
Clinical stage
No. of patients
I
II
III
39 38 24 37 72 8 25 17 46
2 — 3 — 21 — 10 4 6
12 — 7 — 16 5 1 6 2
CAVE ⫻ 2–4 25 ⫻3 — CAE 14 CAV ⫻ 6 ⫾ EP — CAE ⫻ 2 CAV ⫻ 6 ⫾ EP 35 3 CAEV ⫻ 2 24 COPE ⫻ 3 7 Various 38 EP
Chemotherapy
Response CR/PR (ORR%)
Surgery: thoracotomy /CSR (%)
13/21 (88) 5/26 (82) ? (100) 1/19 (54) 27/30 (80) 5/2 (88) 10/14 (96) 4/10 (82) 15/28 (94)
11/8 25/21 23/15 20/20 38/33 8/8 14/10 17/17 32/23
(21) (55) (62) (54) (36) (100) (40) (100) (50)
Complete pathological response (%)
The Role of Surgery in SCLC
TABLE 3 Prospective Phase II Trials of Induction Chemotherapy Followed by Surgery for Limited Small Cell Lung Cancer
2 4 9 2 3
(5) (11) (37) (5) (4) 0 5 (20) ? 11 (24)
CR, complete response; PR, partial response; ORR, overall response rate; CSR, complete surgical resection; V, vincristine; E, etoposide; O, vincristine; P, cisplatin; C, cyclophosphamide; A, doxorubicin.
137
138
Shepherd
All investigators reported that survival was strongly dependent on TNM stage (Figure 6). Patients with stage I (T1–2 N0) tumors had the best prognosis with 5-year survival rates that approached 70% for completely resected patients. Stage II and III patients fared less well, but all series reported a small number of patients with stage IIIA tumors (N2) who achieved long-term survival and appeared to be cured by their combined-modality treatment program. The median survival for the entire group of patients who entered the trials (including those who did not proceed to thoracotomy) was reported for only six studies, and ranged from 13 to 33 months (47,48,50–52,54). Several authors reported the highest cure rate for patients who required only a lobectomy (47,54), although this was not confirmed by all authors (46,48). Almost no long-term survival was seen in patients who had unresectable tumors at the time of thoracotomy. Patients who achieved a complete pathological response and who had no viable tumor identified at thoracotomy had the best survival. Williams et al. (47) reported that all patients who had pathological complete response (five) were cured of their tumors compared to only 20% of patients who were operable but had gross or microscopic evidence of residual cancer. Local relapse rates ranged from 0% (46) to 40% of completely resected patients (49). Most series reported local failure rates that ranged from 10 to 20% for patients who were able to undergo successful resection (Table 4) (46–48,50– 53,55,56,59). Local control was found to correlate with the degree of response to chemotherapy and the completeness of the surgical resection. If the 15% of
FIGURE 6 Comparison of survival by pathological stage for 38 patients with small cell lung cancer treated with adjuvant surgical therapy after chemotherapy. (From Ref. 50.)
The Role of Surgery in SCLC
139
TABLE 4 Pattern of Relapse for Patients with Small Cell Lung Cancer Treated with Induction Chemotherapy Followed by Surgerya Relapse pattern Investigators Prager, 1984 (46) Williams, 1987 (47) Johnson, 1987 (48) Shepherd, 1989 (50) Benfield, 1989 (51) Zatopek, 1991 (52) Hara, 1991 (53) Yamada, 1991 (55) Muller, 1992 (56) Total
Thoracotomy/ CSR
None
Local only
Distant only
Both
11/8 25/21 23/15 38/33 8/8 14/10 17/17 20/18 48/45
4 12 2 10 2 5 10 13 26
— 3 3 3 — — 3 3 4
4 6 7 20 6 5 7 7 15
— — 3 — 0 — — — —
204/175
106
19
70
6
a
Excluding patients who did not have complete surgical resection (CSR) at time of thoracotomy.
patients who had unresectable tumors are added to those who relapsed locally, the real local failure rate rises to over 25% of the surgical patients. These phase II trials led to observations that were important in the design of subsequent randomized trials of surgery for limited small cell lung cancer (57). They showed that combined-modality treatment was feasible and that the preoperative administration of chemotherapy did not result in excessive postoperative morbidity or mortality. It was recognized by all investigators that the favorable survival achieved in these trials might be due to patient selection. The Toronto group emphasized the importance of selection bias after their review of all limited-stage small cell lung cancer patients treated at their institutions over a 10-year period (58). They reported a significant survival advantage for patients who had no clinical evidence of mediastinal node involvement or pleural effusion. This group, which would be typical of patients who might be considered for surgery protocols, had a 20% cure rate with standard chemotherapy and radiation alone, compared to no long-term survival for patients with more advanced tumors. Randomized Trials In an attempt to determine whether the addition of surgery to combination chemotherapy and radiotherapy could prolong survival and improve the cure rate for patients with limited small cell lung cancer, the LCSG initiated a prospective randomized trial of adjuvant surgical resection in 1983 (59). Most patients with
140
Shepherd
limited-stage tumors were eligible for this trial, even those with clinically evident mediastinal lymph node involvement. Induction chemotherapy initially consisted of cyclophosphamide, doxorubicin, vincristine, and etoposide but was changed to cyclophosphamide, doxorubicin, and vincristine alone in the later phase. In the absence of toxicity or progressive disease, patients received five preoperative cycles of chemotherapy. They were then restaged and medically assessed to determine their suitability for thoracotomy. At that point, eligible patients were randomized to receive either surgical resection followed by radiotherapy to the chest and prophylactic cranial irradiation or the same radiotherapy alone. A total of 340 patients entered the trial. Although the clinical response rate to chemotherapy was 68% (28% CR, 37% PR), only 144 (42%) of patients were randomized, 68 to receive surgery and radiotherapy, and 76 to receive radiotherapy alone. Of the 68 patients who were randomized to surgery, six did not undergo thoracotomy, but eight patients in the nonsurgical arm had off-study surgery, so a total of 70 thoracotomies were performed. Fifty-eight patients had some resection of tumor (83%) but only 54 had a pathological complete resection (77%). A complete pathological response was documented for 18% of patients who underwent surgery. Non–small cell pathology was found in 11% of patients. All randomized patients received radiotherapy to the chest, 50 Gy delivered over 5 weeks, and prophylactic cranial irradiation, 30 Gy over 3 weeks. The median survival from enrollment for all patients was 14 months, and for the randomized patients it was 18 months, with no difference seen between the groups in either median survival or long-term survival (Figure 7). Because only half of the randomized patients in this study underwent surgical resection, it is not possible to compare survival based on pathological stage or TNM subgroup. The Toronto group were the first to draw attention to the discrepancy between clinical staging and pathological staging for patients with small cell lung cancer (25,50); they showed that clinical staging could not identify subgroups of patients with different prognoses (Figure 8). Similar results were found in the LCSG study in which patients were staged very carefully at the time of surgery. Clinical and surgical TNM stages after chemotherapy were the same in only 20 patients (29%) and most frequently patients moved into a more advanced stage (59). For the surgical group, no difference in resectability was identified for patients in any T or N subgroup although there seemed to be a trend toward unresectability for patients with T3 tumors (p ⫽ 0.08). All pathological T and N subsets in the surgical patients had similar survival. Why was survival not improved by surgery, and how should the results of this LCSG trial be interpreted? The survival curves shown in Figure 9 were generated on an ‘‘intent to treat’’ basis, which is, of course, mandatory for any prospective randomized trial. It should be noted, though, that 10% of the patients did not receive protocol-specified therapy. Six patients randomized to surgery declined operation, and of perhaps even greater significance, eight patients in the nonsurgi-
The Role of Surgery in SCLC
141
FIGURE 7 A comparison of survival for patients randomized to thoracotomy and radiation or radiation alone. (From Ref. 62.)
cal arm underwent thoracotomy and surgical resection. In such a small study, a 10% protocol violation of this nature may have masked a small, but significant, survival advantage between the treatment arms. The next question to be asked is why complete surgical resection was possible for only three-quarters of the patients subjected to thoracotomy. Although the combination of cyclophosphamide, doxorubicin, and vincristine was considered standard therapy at the time, a disappointingly low response rate of only 65% was seen in this study. With newer regimens that incorporate etoposide and cisplatin and concurrent radiotherapy administered early in the course of the disease, response rates of 90% or more are standard (16,20). One might speculate, therefore, that a more complete response to chemotherapy might have resulted in a higher complete surgical resection rate. Seventeen percent of patients underwent ‘‘open and closed’’ procedures with no attempt at surgical resection. For some patients the residual tumor was clearly unresectable at the time of thoracotomy. For other patients, though, the decision not to proceed to resection was based on scar tissue formation at the area of the primary tumor and in the mediastinum. Response to chemotherapy is often accompanied by an intense local scirrhous reaction, which makes surgical resection more difficult. Tumors that may appear initially unresectable because of fibrosis may, in fact, be resected safely with careful dissection of the tumor
142
Shepherd
FIGURE 8 A comparison of survival by pretreatment clinical stage for 119 patients who underwent surgery for limited small cell lung cancer. (From Ref. 25.)
FIGURE 9 Survival of 28 patients who underwent salvage operations for small cell lung cancer. (From Ref. 60.)
The Role of Surgery in SCLC
143
bed and mediastinum. Because this was an international multi-institutional study, any individual surgeon operated on only a few patients. It is possible that had this been a larger study, the overall resectability rate might have been higher. This is suggested by the observation that the resectability rate was higher for LCSG surgeons than it was in other centers that joined the trial at a later date. This may have been due to their greater experience in operating on both small cell and non–small cell patients after induction chemotherapy. Finally, patient selection undoubtedly played a large role in the ultimate results of this trial. All patients with limited disease were eligible to enter this study, with the exception of those who had supraclavicular lymph node involvement or pleural or pericardial effusions. Therefore, the majority of patients had stage III tumors. It has long been recognized that surgery has a limited role in the management of stage III patients with non–small cell lung cancer, and this trial suggests that the same is true for patients with small cell lung cancer. Since many, if not most, patients with limited small cell lung cancer have mediastinal node involvement (often bulky) at the time of initial diagnosis, it is clear that surgical resection will have very little role to play for the majority of patients with this disease. Nonetheless, it still remains possible that patients with earlystage disease (T1–2 N0, and perhaps nonbulky stage II) may benefit from a combined-modality approach that includes surgery. Because so few patients fall into this subgroup (likely less than 10%) it will probably never be possible to undertake a prospective randomized trial to prove or disprove that surgery is appropriate in this setting. SALVAGE SURGERY FOR PATIENTS WITH SMALL CELL LUNG CANCER There are few treatment options for patients with small cell cancer who fail to respond to initial therapy, or who relapse after a primary response. Typically, only brief periods of palliation or prolongation of survival are achieved with second-line chemotherapy or radiation. This has led some investigators to evaluate whether surgery might be useful as salvage therapy for certain patients with limited small cell lung cancer. Yamada et al. (55) operated on nine patients, two who had failed to respond to chemotherapy, six who had achieved partial response, and one complete responder. Four patients achieved long-term disease-free survival, which ranged from 3 to 11⫹ years. The Toronto group performed salvage operations on 28 patients, only 18 of whom were found on pathological examinations to have pure small cell tumors (60). Overall median survival of the 28 patients was 105 weeks, but only two pure small cell patients survived beyond 5 years (Figure 9). In view of these results, surgery cannot be recommended for patients with pure small cell tumors who fail to respond or who relapse after initial standard therapy.
144
Shepherd
Mixed-histology tumors are reported more frequently in surgical series (25,61). In the series of salvage operations reported by the Toronto group (60) 10 patients had mixed-histology or non–small cell tumors, and their median survival was 108 weeks. Four of the 10 patients (three stage I) achieved long-term survival after operation. Because a small number of patients with tumors of mixed histological type may be cured by surgical treatment, consideration should be given to a second biopsy for patients who have localized resistant small cell lung cancer. Several authors have now reported that long-term survivors of small cell lung cancer are at increased risk of developing second primary tumors (26–30). In fact, a long-term survivor is more likely to have a second primary malignancy than a relapse of small cell lung cancer, and many of these tumors arise in the lung. In the University of Toronto series, eight patients underwent surgical resection at the time of ‘‘relapse’’ following a long disease-free interval after initial treatment for small cell lung cancer. Two were found to have non–small cell tumors, and both achieved long-term survival after surgery. It is recommended, therefore, that a biopsy should be undertaken for long-term survivors of small cell lung cancer who develop a new lung lesion. If non–small cell pathology is documented, the patient should be staged completely, and surgery should be considered if the standard medical and surgical criteria for resection that would be applied to all patients with non–small cell tumors are met. SUMMARY It has now been shown that combined-modality therapy with surgery and chemotherapy is feasible, the toxicity is manageable, and the postoperative morbidity and mortality rates acceptable. Patient selection is important and the results of the LCSG trial indicate that surgical resection will not benefit the majority of patients with limited small cell lung cancer. The chances of long-term survival and cure are strongly correlated with pathological TNM subgroup, and the results suggest that consideration of surgery for patients with small cell lung cancer should be limited to those with stage I and perhaps some stage II patients. Therefore, before surgery is undertaken, patients should undergo full staging of the mediastinum including mediastinoscopy. Surgery may be considered for patients with T1–2 N0 small cell tumors, and whether it is offered as the initial treatment or after induction chemotherapy does not seem to be important, as shown by Wada et al. (34) and the University of Toronto group (28). If a small cell tumor is identified unexpectedly at the time of thoracotomy, complete resection and mediastinal lymph node resection should be undertaken if possible. Chemotherapy should be administered postoperatively to all patients, even those with pathological stage I tumors.
The Role of Surgery in SCLC
145
Surgery likely has very little role to play for most stage II patients and virtually no role for patients with stage III tumors. Even though chemotherapy can result in dramatic shrinkage of bulky mediastinal tumors, the addition of surgical resection does not contribute significantly to long-term survival for the majority of patients as shown conclusively by the LCSG trial. The final group of patients who may benefit from surgical resection are those with combined small cell and non–small cell tumors. If a mixed-histology cancer is identified at diagnosis, the initial treatment should be with chemotherapy to control the small cell component of the disease, and surgery should be considered for the non–small cell component. For patients who demonstrate an unexpectedly poor response to chemotherapy, and for patients who experience localized late relapse after treatment for pure small cell tumors, a repeat biopsy should be performed. Surgery may be considered if non–small cell pathology is confirmed. REFERENCES 1. Hansen HH, Dombernowsky P, Hirsch FR. Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma. Semin Oncol 1978; 5:280–287. 2. Martini N, Wittes RE, Hilaris BS, et al. Oat cell carcinoma of the lung. Clin Boll 1975; 5:144–148. 3. Mountain C. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol 1978; 5:272–279. 4. Working-party on the evaluation of different methods of therapy in carcinoma of the bronchus comparative trial of surgery and radiotherapy for the primary treatment of small cell, or oat-cell carcinoma of the bronchus. Lancet 1966; 2:979–986. 5. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small cell or oat-cell carcinoma of the bronchus. Ten-year follow-up. Lancet 1973; 2:63–65. 6. Bates M, Levison V, Hurt R, Sutton M. Treatment of oat-cell carcinoma of bronchus by pre-operative radiotherapy and surgery. Lancet 1975; 1:1134–1135. 7. Levison V. Pre-operative radiotherapy and surgery in the treatment of oat-cell carcinoma of the bronchus. Clin Radiol 1980; 31:345–348. 8. Sherman DM, Neptune W, Weichselbaum R, Order SE, Piro AJ. An aggressive approach to marginally resectable lung cancer. Cancer 1978; 41:2040–2045. 9. Bergsagel DE, Jenkin RDT, Pringle JF. Lung cancer: Clinical trial of radiotherapy alone versus radiotherapy plus cyclophosphamide. Cancer 1972; 30:321. 10. Medical Research Council Lung Working Party. Radiotherapy alone or with chemotherapy in the treatment of small cell carcinoma of the lung. Br J Cancer 1979; 40: 1–10. 11. Shields TW, Humphrey EW, Eastridge CE, Keehn RJ. Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer 1977; 40:2057–2062. 12. Shields TW, Higgins GA, Matthews MG, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982; 84: 481–488.
146
Shepherd
13. Shore DF, Paneth M. Survival after resection of small cell carcinoma of the bronchus. Thorax 1987; 35:819–822. 14. Lennox SC, Flavell G, Pollock DJ, Thompson VC, Wilkins JL. Results of resection for oat-cell carcinoma of the lung. Lancet 1968; 2:925–927. 15. Higgins GS, Shields TW, Keehn RJ. The solidary pulmonary nodule. Ten-year follow-up of Veteran’s Administration–Armed Forces Co-operative study. Arch Surg 1975; 110:570–575. 16. Shepherd FA, The role of chemotherapy in the treatment of small cell lung cancer. Chest Surg Clin North Am 1997; 7:113–133. 17. Elliott JA, Osterlind K, Hirsch FR, Hansen HH. Metastatic patterns in small cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol 1987; 5:246–254. 18. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890–895. 19. Pingnon J-P, Arriagada R, Ihde D, Johnson DH, Perry MC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327:1618– 1624. 20. Murray N, Coy P, Pater J, Hodson I, Arnold A, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. J Clin Oncol 1993; 11:336–344. 21. Shepherd FA, Ginsberg RJ, Evans WK, Feld R, Cooper JD, et al. Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. J Thorac-Cardiovasc Surg 1983; 86:498–504. 22. Comis R, Meyer J, Ginsberg S, et al. The impact of TNM stage on results with chemotherapy and adjuvant surgery in small cell lung cancer. Proc Am Soc Clin Oncol 1984; 3:226 (abstr C-884) 23. Hirsch FR, Osterlind K, Hansen H. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. Cancer 1983; 52:2144–2150. 24. Magnum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small cell and non–small cell lung cancer. J Clin Oncol 1989; 7:607–612. 25. Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small cell lung cancer. J Thorac Cardiovasc Surg 1991; 101:385–393. 26. Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long-term survivors of small cell lung cancer. J Clin Oncol 1992; 10:1519–1524. 27. Tucker MA, Murray N, Shaw EG, Shepherd FA, et al. Second cancers related to smoking and treatment for small cell lung cancer. J Natl Cancer Inst 1997; 89(23): 1782–1788. 28. Sagman U, Lishner M, Maki E, Shepherd F, Haddad R, et al. Second primary malignancies following diagnosis of small cell lung cancer. J Clin Oncol 1992; 10:1525– 1533. 29. Ihde DC, Tucker MA. Second primary malignancies in small cell lung cancer: a major consequence of modest success. J Clin Oncol 1992; 10:1511–1513. 30. Osterlind K, Hansen HH, Hansen M, et al. Mortality and morbidity in long-term
The Role of Surgery in SCLC
31.
32.
33.
34. 35.
36. 37.
38.
39.
40.
41.
42.
43.
44. 45. 46.
147
surviving patients treated with chemotherapy with or without irradiation for small cell lung cancer. J Clin Oncol 1986; 4:1044–1052. Hayata Y, Funatsu H, Suemasu K, Yoneyama T, Hashimoto K, Doi O, Ohota M. Surgical indications for small cell carcinoma of the lung. Jpn J Clin Oncol 1978; 8:93–100. Meyer J, Comis RL, Ginsberg SJ, Burke WA, Ikins PM, DiFino S, et al. The prospect of disease control by surgery combined with chemotherapy in stage I and stage II small cell carcinoma of the lung. Ann Thorac Surg 1983; 36:37–43. Meyer JA, Gullo JJ, Ikins PM, Comis RL, Burke WA, DiFino SM, Parker FB. Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1984; 88:495–501. Wada H, Yokomise H, Tanaka F et al. Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13:45–56. Osterlind K, Hansen M, Hansen HH, Dombernowsky P. Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. Eur J Cancer Clin Oncol 1986; 22:589–593. Maassen W, Greschuchna D. Small cell carcinoma of the lung—to operate or not? Surgical experience and results. Thorac Cardiovasc Surg 1986; 34:71–76. Shepherd FA, Evans WK, Feld R, Young V, Patterson GA, Ginsberg R, Johansen E. Adjuvant chemotherapy following surgical resection for small cell carcinoma of the lung. J Clin Oncol 1988; 6:832–838. Karrer K, Denck H, Karnicka-Mlodkowska H, Drings P, Salzer GM, et al. The importance of surgery as the first step in multimodality treatment of small cell bronchial carcinoma. Int J Clin Pharm Res 1990; 10:257–263. Ulsperger E, Karrer K, Denck H, ISC-Lung Cancer Study Group. Multi-modality treatment for small cell bronchial carcinoma. Eur J Cardio-Thorac Surg 1991; 5: 306–310. Macchiarini P, Hardin M, Basolo F, Bruno J, Chella A, Angeletti CA. Surgery plus adjuvant chemotherapy for T1–3N0M0 small cell lung cancer. Am J Clin Oncol 1991; 14:218–224. Hara N, Ichinose Y, Kuda T, Asoh H, Yano T, Kawasaki M, Ohta M. Long-term survivors in resected and non-resected small cell lung cancer. Oncology 1991; 48: 441–447. Davis S, Crino L, Tonato M, Darwish S, Pelicci PG, Grignani F. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small cell lung cancer. Am J Clin Oncol 1993; 16:93–95. Friess GG, McCracken JD, Troxell ML, Pazdur R, Coltman CA, Eyre HG. Effects of initial resection of small cell carcinoma of the lung: a review of Southwest Oncology Group study 7628. J Clin Oncol 1985; 3:964–968. Littlewood TH, Smith AP, Bentley DP. Treatment of small cell lung cancer by pneumonectomy and single course high dose chemotherapy. Thorax 1987; 42:315–316. Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of small cell lung cancer. Ann Thorac Surg 1992; 54:498–501. Prager RL, Foster JM, Hainsworth JD, Hande KR, Johnson DH, Wolff SN, Greco FA, Bender HW. The feasibility of adjuvant surgery in limited-stage small cell carcinoma: a prospective evaluation. Ann Thorac Surg 1984; 38:622–627.
148
Shepherd
47. Williams CJ, McMillan I, Lea R, Mead DJ, Thompson J, Sweetenham J, Herbert A, et al. Surgery after initial chemotherapy for localized small cell carcinoma of the lung. J Clin Oncol 1987; 5:1579–1588. 48. Johnson DH, Einhorn LH, Mandelbaum I, Williams SD, Greco FA. Post chemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest 1987; 92:241–246. 49. Baker RR, Ettinger DS, Ruckdeschel JD, Eggleston JC, McKneally MF, Abeloff MD, Woll J, Adelstein DJ. The role of surgery in the management of selected patients with small cell carcinoma of the lung. J Clin Oncol 1987; 5:697–702. 50. Shepherd FA, Ginsberg RJ, Patterson GA, Evans WK, Feld R. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. J Thorac Cardiovasc Surg 1989; 97:177–186. 51. Benfield GFA, Matthews HR, Watson DCT, Colling FJ, Cullen MH. Chemotherapy plus adjuvant surgery for local small cell lung cancer. Eur J Surg Oncol 1989; 15: 341–344. 52. Zatopek N, Holoye P, Ellerbroek NA, Hong WK, Roth JA, Ryan B, Komaki R, et al. Resectability of small cell lung cancer following induction chemotherapy in patients with limited disease (stage II–IIIb). Am J Clin Oncol 1991; 14:427–432. 53. Hara N, Ohta M, Ichinose Y, Motohiro A, Kuda T, Asoh H, Kawasaki M. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 1991; 47:53–61. 54. Eberhardt W, Wilke H, Stamatis G, et al. Preliminary results of a stage oriented multimodality treatment including surgery for selected subgroups of limited disease small cell lung cancer. Lung Cancer 1997; 18(suppl 1):61 (abstr 235). 55. Yamada K, Saijo N, Kojima A, Ohe Y, Tamura T, Sasaki Y, Euguchi K, et al. A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer. Jpn J Clin Oncol 1991; 21:39–46. 56. Muller LC, Salzer GM, Huber H, Prior C, Ebner I, Frommhold H, Prauer H-W. Multimodal therapy of small cell lung cancer in TNM stages I–IIIa. Ann Thorac Surg 1992; 54:493–497. 57. Shepherd FA. Induction chemotherapy for locally advanced non–small cell lung cancer. Ann Thorac Surg 1993; 55:1585–1592. 58. Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small cell lung cancer: a valuable system to separate prognostic subgroups. J Clin Oncol 1993; 8:1592–1597. 59. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; (suppl 6):3205–3235. 60. Shepherd FA, Ginsberg RJ, Patterson GA, Feld R, Goss PE, Pearson FG, Todd TJR, et al. Is there ever a role for salvage operations in limited small cell lung cancer? J Thorac Cardiovasc Surg 1991; 101:196–200. 61. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small cell and non–small cell lung cancer. J Clin Oncol 1989; 7:607–612. 62. Shields TW, ed. General Thoracic Surgery, 4th edition. Baltimore: Williams & Wilkins, 1994.
10 Adjuvant Therapy for Resected Stages II and IIIA NSCLC: Pro Ritsuko Komaki University of Texas M.D. Anderson Cancer Center, Houston, Texas
INTRODUCTION The role of adjuvant radiation therapy for completely resected non–small cell lung cancer (NSCLC) remains controversial. This is due to differences in the behavior of tumors and the extent of metastasis depending on the histology, adequacy of staging, and extent of surgery. These variations make it difficult to compare the results of local control, survival, and failure patterns. Nevertheless, in certain circumstances, radiation therapy does have a distinct role in the adjuvant treatment of selected patients with NSCLC. Much of the published data includes outdated staging workup (without imaging of the brain, CT of the chest and upper abdomen), as well as suboptimal radiation therapy equipment (e.g., Co-60 or low-energy Linac accelerators), without postoperative CT planning. Without reviewing isodose curves, suboptimal doses delivered to the target volume may cause sublethal damage on malignant cells leading to tumor recurrence and/or excessive doses to the normal surrounding tissue, such as the lung, heart, esophagus, or spinal cord, possibly contributing to intercurrent death. Evaluating the benefit of adjuvant treatment requires long follow-up. There is little published data to date with adequate follow149
150
Komaki
up after thorough staging workup, modern surgical techniques, advanced radiotherapy with CT-based planning, and/or 3-D conformal techniques, as well as efficacious chemotherapeutic agents, in carefully selected patients who require postoperative adjuvant treatment. RATIONALE FOR ADJUVANT RADIATION THERAPY FOR NSCLC Surgery and radiation therapy (RT) can eradicate cancer cells if the cancer is localized and patients can tolerate aggressive treatment. However, since patients with lung cancer usually have a smoking history with compromised cardiopulmonary function, radical cancer surgery is not feasible for many patients. Adjuvant RT instead of reoperation is a reasonable treatment choice for these patients who have microscopic residual tumor in the form of positive margins or positive lymph nodes after surgery. In theory, hypoxic conditions exist in large epithelial tumors, making RT less effective in patients with these tumors (1). However, as surgery can remove hypoxic cells, the remaining microscopic cancer cells are potentially better oxygenated, and these can be eradicated by adjuvant radiation therapy. A more detailed explanation of the role of hypoxia in lung cancer is provided in another chapter. In addition, as long as the volume and fractionation are reasonable, adjuvant RT for epithelial tumors is relatively free of serious side effects. This combination of factors makes adjuvant RT a reasonable choice in patients with possible residual tumor. FAILURE PATTERNS AFTER SURGERY Approximately one-third of patients with NSCLC undergo surgery, and only onequarter of these patients are completely resected (with negative lymph nodes) and do not require adjuvant treatment. The rest are candidates for adjuvant treatment due to positive margins, hilar lymph node involvement (stage II), or mediastinal nodal involvement (N2 , stage IIIA disease), according to the recent staging system (2). Patients with mediastinal lymph node involvement (N2 ) have a 5year survival rate of 15–30% (3,4). Patients with stage II disease (hilar or peribronchial nodal involvement) have a 5-year survival rate of 30–60% (5,6). Most recurrences following curative complete resections are distant metastases. Adjuvant radiation therapy to the hilar or mediastinal lymph nodes has not, however, led to an improvement in overall survival, according to the Lung Cancer Study Group (LCSG) trial, although locoregional control was significantly improved by postoperative RT compared with surgery alone (7). There are no published clinical trials or retrospective studies, except for some limited autopsy-based studies, documenting the cause of death. This stems from the
Pattern of failure (%) Investigators
Tumor stage
Kotlyarov and Rukosuyev, 1991 (15) Martini and Beattie, 1977 (10) Immerman et al., 1981 (13)
All T1–2 N0 T1–2N 0 T1–2N 1 T1N 0 T2N 0 T1N 1 T1N 0 T1N 1 T2N 0 N1–2 T1–2N 0–1 T1–2N 1–2 T1–3N 0–2
Pairolero et al., 1984 (11)
Feld et al., 1984 (12)
Lung Cancer Study Group, 1986 (7) Ludwig Lung Cancer Study Group, 1987 (14) Medical Research Council, 1996 (25) The Groupe d’Etude et de Traitemant des Cancers Bronchiques, 1999 (24)
No. of patients
Local
Distant
542 110 77 22 170 158 18 162 32 196 108 1012 154 355
12 0 12 41 6 6 28 9 9 11 20 17 47 28
18 18 27 23 15 23 39 17 22 30 30 22 67 26
Adjuvant Therapy for NSCLC: Pro
TABLE 1 Pattern of Failure After Surgery for Lung Cancer
151
152
Komaki
fact that meticulous workup to detect all possible sites of recurrence after surgical resection for NSCLC is not routinely done at the time of follow-up. Instead, physicians tend to document only the first site of failure on the basis of obvious changes in radiological images or in symptoms or signs of the recurrence. A further difficulty in assessing the patterns of failure in patients with resected NSCLC is that autopsies are done on few patients. Matthews and colleagues in 1973 reported the autopsy findings in 202 patients who died within 30 days after a curative resection of lung cancer. Interestingly, 22 of 24 patients who had residual cancer within the thorax had squamous cell carcinoma. This suggests that failure in the thorax occurs more frequently in patients with squamous cell carcinoma than in those with adenocarcinoma (8). In a series of 227 patients who underwent surgery for lung cancer, Rasmussen (9) reported autopsy data for 64 patients who died at least 2 months after surgery. Fifty-four (84%) of the 64 had residual cancer in the thorax. Twenty-three of the 57 patients with N 2 disease had autopsies, and residual cancer was found in the thorax in 20 (87%). Several clinical studies (7,10–15) have analyzed the failure patterns after surgery in patients who did not receive adjuvant treatment for lung cancer; the findings are summarized in Table 1. According to these series, distant metastases appear to be a problem in most patients, although these were not autopsy series and these patients were not evaluated by computed tomography (CT) of the chest to investigate locoregional recurrence. The local recurrence rate reported was likely lower than reality because it is difficult to detect minimal or asymptomatic local recurrence on routine follow-up chest x-ray studies. When the patient develops symptoms or signs of locoregional recurrences, the disease is usually too advanced to be controlled. On the other hand, the incidence of distant metastases has likely been overestimated. Locoregional failure is not an uncommon event, and the risk of such failure appears to be related to the nodal status (7,10– 12,14,15). Indeed, many studies do not report locoregional recurrences when patients die of distant metastases. EFFICACY OF SALVAGE TREATMENT FOR LOCOREGIONAL RECURRENCE If the salvage treatment for locoregional recurrence were efficacious, adjuvant treatment would not be a critical issue. However, to date, no efficacious salvage treatment exists for locoregional recurrence in the chest, whether additional surgery or a curative type of RT (with or without chemotherapy) has been attempted. Some authors have, however, reported that RT can be efficacious in controlling local recurrence after curative resection for lung cancer (16–18). The 2-year survival rate reported by these authors ranged from 5% to 28%. Most patients, however, had progression in the locoregional areas as the first site of failure after radiation therapy. Their cause of death after RT was locoregional progression, although no
Adjuvant Therapy for NSCLC: Pro
153
attempt was made to detect distant metastases (DM) at the time of death, if they were asymptomatic from DM. Patients with recurrences at the bronchial resection site had a better outcome, with a 2-year survival rate of 50% compared with patients with locoregional recurrence in the hilar or mediastinal nodal area.
PROSPECTIVE RANDOMIZED CLINICAL TRIALS Adjuvant Radiotherapy Table 2 compares the patient data reported for seven prospective randomized trials of postoperative RT versus observation (7,19–24). The majority of these studies were conducted in the pre-CT era, and many patients were treated with cobalt 60 or orthovoltage therapy. Paterson and Russell (19) studied the efficacy of postoperative RT after pneumonectomy in 202 patients with or without lymph node involvement. After the pneumonectomy, patients were randomized to receive either 45 Gy in 4 weeks versus observation. The authors did not stratify patients by the tumor stage, nodal stage, or histological type. They also included node-negative patients treated by cobalt 60 or orthovoltage using large fields that encompassed a portion of the heart and the opposite side of the lung. Their 3-year survival rates were 36% without postoperative RT versus 33% with RT. In the trial conducted by Bangma, patients were alternately (rather than prospectively) randomized to receive either postoperative RT or observation alone. All patients had early-stage cancer, and two-thirds had negative lymph nodes. Survival in patients who received postoperative RT (45 Gy over 5 weeks) was not statistically different from survival in the observation-alone group (20). In 1979, Israel et al. (21) published interim results of the trial conducted by the European Organization for Research and Treatment of Cancer (EORTC). This trial included two arms in which patients were consecutively randomized to receive either adjuvant local treatment or systemic treatment. This trial included only patients with squamous cell carcinoma with or without postoperative thoracic RT (total dose of 45 Gy over 4.5 weeks to the mediastinum). After the completion of thoracic RT, patients were randomized to undergo observation or to receive one of the following systemic treatments: chemotherapy, such as cyclophosphamide, methotrexate, and lomustine; immunotherapy, such as bacille Calmette Gue´rin; or chemotherapy and immunotherapy together. The 1979 interim analysis showed that patients receiving adjuvant chemotherapy had a significantly lower survival than those in the immunotherapy or observation groups. Although postoperative RT did not improve survival, it did reduce locoregional relapses, especially in patients with nodal involvement. Specifically 12 of the 104 patients (11.5%) who received postoperative RT developed local relapse compared with 26 of 126 patients (20.6%) who had surgery alone.
154
TABLE 2 Postoperative Radiotherapy for Lung Cancer: Prospective Randomized Trials Investigators Paterson and Russell, 1962 (19) Bangma, 1972 (20) Israel et al., 1979 (21) van Houtte et al., 1980 (22) Lung Cancer Study Group, 1986 (7) MRC, 1996 (25) GETCB, 1999 (24)
Radiation dose
Equipment
No. of patients
Pathology
Surgery
Patient selection
Survival
45 Gy/4 wk
Ortho
202
All
Pneumo
N0 , N⫹
NI
45 Gy/4 wk
Co-60
73
All
All
N 0 , N⫹
NI
45 Gy/4.5 wk
Co-60
392
Sq
All
N 0 , N⫹
NI
60 Gy/6 wk
Co-60
224
All
All
N0
NI
50 Gy/5 wk
Co-60
230
Sq
All
N⫹
LCI
40 Gy/3 wk
Co-60/LA
308
NSC
All
N⫹
LCI
60 Gy/6 wk
Co-60/LA
728
All
All
N 0 , N⫹
NI
NSC: non–small cell; Sq: squamous cell; NI: no improvement; LCI: local control improved; MRC: Medical Research Council Lung Working Party; GETCB: Groupe d’Etude et de Traitemant des Cancers Bronchiques; Ortho: orthovoltage; LA: linear accelerator.
Komaki
Adjuvant Therapy for NSCLC: Pro
155
Van Houtte and colleagues conducted a randomized study in patients without lymph node metastasis (N 0 ) who had T1, T2, or T3 lesions and underwent complete surgical resection of the primary tumor. Postoperative RT was associated with a slight decrease in the rate of locoregional recurrence within the irradiated field from 18% to 13%. Survival, however, was inferior in the patients who received postoperative RT, especially those patients who had a pneumonectomy. There was also a high rate of radiation-induced late effects, such as cardiac toxicity. This adverse effect appeared to be related to use of a cobalt 60 unit that delivered 60 Gy in 6 weeks employing a three-field technique, without correction for lung inhomogeneity. Very large fields were also used to irradiate mediastinal nodes, including a large portion of the heart. A further problem was that there was no CT-based treatment planning capability available at that time (22). The LCSG conducted a randomized study to evaluate postoperative radiation therapy in patients with completely resected stage II and stage IIIA squamous cell carcinoma of the lung. Patients were randomized after complete resection to an observation-only group or a RT group that received a total tumor dose of 50 Gy in 5 weeks (7). Only patients with squamous cell carcinoma who had disease in either the hilar lymph nodes (N1 ) or the mediastinal lymph nodes (N 2 ) were included in the study. Patients received 50 Gy in 5 weeks using a cobalt 60 unit or a Linac accelerator. Although there was no difference in overall survival between the two groups, the patients who received postoperative RT had a significant reduction in the incidence of local recurrence (1%) compared with those who were observed postoperatively (19%) ( p ⫽ 0.05). The reduction in the incidence of locoregional recurrence was especially pronounced in patients with N 2 disease. The British Medical Research Council (MRC) (25) conducted a randomized study in 308 patients with pathologically staged T1 or T2 NSCLC who had positive hilar or mediastinal lymph nodes. They were randomized either to undergo observation or to receive a total dose of postoperative RT to 40 Gy in 3 weeks using a cobalt 60 or low-energy linear accelerator. Postoperative RT was associated with improved locoregional recurrence-free survival in a subset group (106 patients) with T2 N2 NSCLC. The 2-year survival rate in the group was 46% as compared with 27% in the observation group. However, there was no significant difference in overall survival rate between the two groups. The most significant difference between the observation and postoperative RT groups was in the incidence of distant metastases. There was a highly significant increase in the incidence of bone metastases in N2 patients in the observation group over the 3– 4 years following treatment. There was no significant difference in the incidence of local recurrence among the patients with pathological N1 disease with or without postoperative RT. A prospective multicenter randomized trial assessed the value of postoperative RT after complete tumor resection in patients with NSCLC in Europe (24).
156
Komaki
There were 728 patients with NSCLC (221 stage I, 180 stage II, and 327 stage III) in the study, and they were randomized to receive either postoperative RT or observation only. There were 303 patients who had a pneumonectomy and 425 patients who were treated by lobectomy. Patients were assigned to a study group within 1 month of complete resection, although it is not clear exactly when the RT was initiated. The RT was administered by cobalt 60 or higher energy for a total dose of 60 Gy over 6 weeks. The total dose was prescribed at the isocenter, without inhomogeneity calculation. The daily fraction was also higher than the usual fraction size (1.8–2.0 Gy per fraction) at 2.5 Gy per fraction, when a high-energy photon source (of more than 10 MV) was used. The first 40 Gy in the initial 4 weeks encompassed the bronchial stump, ipsilateral hilum, upper and middle mediastinum, and supraclavicular area. This was followed by 20 Gy in 2 weeks delivered by lateral or oblique fields to avoid the spinal cord. Computer dosimetry was recommended but not required. At the conclusion of the study period, 218 of 355 patients (61%) in the observation group and 262 of the 373 patients (70%) in the postoperative RT group had died. The 5-year overall survival was 43% in the observation group and 30% in the RT group (p ⫽ 0.002). This result was not altered following adjustment for potential prognostic factors. The excessive mortality rate in the postoperative RT group was due to excess of intercurrent deaths owing to a high incidence of intercurrent cardiac or respiratory complications, which accounted for 31% of the deaths in the RT group and 8% of the deaths in the observation group over 5 years (p ⫽ 0.0001). This study suggests that unnecessary and technically limited RT can cause treatment-related deaths rather than conferring any benefit. More than half of the patients did not need any postoperative RT since they had undergone resection and had stage I or II disease. Adjuvant Radiotherapy With or Without Chemotherapy One randomized trial (26) from the LCSG evaluated adjuvant therapy in patients with incompletely resected stage II or III NSCLC of all histological types. Incomplete resection was defined by the finding of either disease in the highest resected mediastinal node or positive surgical margins. A total of 172 patients were randomized to undergo either postoperative thoracic RT (40 Gy in a split course) or cyclophosphamide (Cytovan), doxorubicin (Adriamycin), and cisplatin (CAP) chemotherapy plus RT. CAP was administered every 4 weeks for six courses. Chemotherapy improved the median survival from 13 months to 20 months and improved the median time to recurrence from 8 months to 14 months. Also, the survival rate at 1 year improved by 14%, from 54% to 68%, in the adjuvant chemotherapy/RT group. Although the differences in median and 1-year overall survivals were not statistically significant, death due to cancer in the first postoperative year was significantly less in the group that received the combination of chemotherapy and RT (p ⫽ 0.02) (26).
Adjuvant Therapy for NSCLC: Pro
157
In Intergroup Study 0015 (RTOG 91-05), patients with resected stage II (N1 ) and stage III (N2 ) NSCLC were randomized to receive postoperative RT alone or concurrent RT and chemotherapy. In this study, 488 patients were randomized between April 1991 and February 1997. Chemotherapy consisted of four cycles of cisplatin (60 mg/m 2 /day 1) and etoposide (VP-16, 120 mg/m 2 / day 1–3), and RT was delivered to a total dose of 50.4 Gy in 28 fractions (in a daily dose of 1.8 Gy). Patients were stratified by weight loss, histological type, nodal biopsy technique, and stage (N1 vs. N2). A total of 351 patients were eligible for analysis at a median follow-up of 37 months. A total of 121 of the 183 (66%) patients in the combination therapy group received four cycles of chemotherapy, while 139 of the 183 patients (76%) in the RT group received the planned RT. Treatment-associated mortality was 2.2% in the chemotherapy/RT arm and 2.4% in the RT arm. The median survival in the RT arm was 41.1 months, and it was 38.6 months in the chemotherapy/RT arm (p ⫽ 0.99). Analysis of the stratified subgroups showed no statistically significant advantage for either treatment arm. The conclusion was that adjuvant chemotherapy in combination with RT does not prolong survival in patients with completely resected stage II or III NSCLC over that in patients treated with RT alone (27). RETROSPECTIVE STUDIES AND META-ANALYSIS Retrospective studies have shown some benefit from postoperative RT in selected groups of patients. For example, postoperative RT proved beneficial in patients with locoregionally advanced disease (T3 , N1 , N2 , or N3 ) from the standpoint of survival and locoregional control (Table 3). None of the studies listed demonstrated any significant benefit from postoperative RT (28,29) for patients who underwent complete resection of an early-stage tumor without positive lymph nodes (T1 or T2 , N0 ). In retrospective comparisons of outcome in patients treated with surgery alone versus postoperative RT, Green and Kern (16), Ennuyer (28), and Chung et al. (30) observed a trend toward improvement in the 5-year survival rate in patients treated with postoperative RT. Green (29), Choi (32), and Sawyer (31), and their colleagues, reported a benefit from postoperative RT in patients with adenocarcinoma, suggesting that locoregional adjuvant treatment improves survival. The findings from these studies contrast to those from a more recent metaanalysis conducted by PORT (33) in which adjuvant RT was associated with a decrement in survival. From the retrospective studies, it appears that mostly patients with T3 disease or positive lymph nodes benefited from postoperative RT. One of many drawbacks to the PORT meta-analysis is that it included mostly early stage and N 0 patients (7,10,13,14,16,28,30–32,34–40). Table 4 summarizes survival data reported in the literature for patients with more locally advanced disease (T3 disease and positive lymph nodes) and shows a wide range in survival depending on the treatment (surgery alone vs. postopera-
158
TABLE 3 Postoperative Radiotherapy for Locally Advanced Lung Cancer (T3, N⫹): Results of Uncontrolled Studies Postoperative radiation therapy
Surgery Investigators Ennuyer, 1963 (28) Martini and Beattie, 1977 (10) Green and Kern, 1978 (16) Chung et al., 1982 (30) Kirsh and Sloan, 1982 (34) Astudillo and Conill, 1990 (37) Durci et al., 1991 (38) Reinfuss et al., 1993 (39) Emami et al., 1997 (40) Sawyer et al., 1997 (31) a
Dose (Gy) 60–65 40–45 50–60 46 50–55 45–50 50–60 50–60 50–60 45–55
Pathology Sq Sq All All All All All All Sq All
No. pts.
Survival (%)
No. pts.
Survival (%)
Survival @ year #
42
26
30 29 20 60 41
3 9 0 12 25
35
4
37 25 66 38 105 86 48 37 62 27
40 44 35 39 24 19 30 38 29 37
2 3 5 3 5 5 5 5 5 4
Sq: squamous cell. a High-risk group for recurrence.
Komaki
Postoperative radiation therapy
Surgery Investigators Choi et al., 1980 (32) Immerman et al., 1981 (13) Chung et al., 1982 (30) Iascone et al., 1986 (35) Lung Cancer Study Group, 1986 (7) Ludwig Lung Cancer Study, 1987 (14) Herskovic et al., 1988 (36) Astudillo and Conill, 1990 (37) Durci et al., 1991 (38) Emami et al., 1997 (40) Sawyer et al., 1997 (31)
No. pts.
Local relapse (%)
32 22 29 59 108 253
53 41 48 20 20 30
60 41
12 36
136
LR 37 IM 58 HR 100
No. pts.
Local relapse (%)
41
31
38
8
102
1
64 71 38 150 88
19 19 45 20 LR 20 IM 15 HR 11
Adjuvant Therapy for NSCLC: Pro
TABLE 4 Postoperative Radiation Therapy for Lung Cancer: Locoregional Relapses (T3, N⫹)
LR: low risk; IM: intermediate risk; HR: high risk.
159
160
Komaki
tive RT), histology, and the series. For example, Choi et al. (32) reported that postoperative RT was associated with a significant increase in survival in patients with adenocarcinoma, but not squamous cell carcinoma. In their 29 patients with squamous cell carcinoma who had positive lymph nodes but did not receive postoperative RT, the 5-year survival rate was 33%, identical to the survival rate in 46 patients with squamous cell carcinoma and positive mediastinal lymph nodes treated with postoperative RT. However, the 5-year survival rate in the 21 patients with adenocarcinoma treated with surgery alone was 8%, versus 43% in the 40 patients with adenocarcinoma treated with postoperative RT, with doses ranging from 40 to 56 Gy (32). Martini et al. (41) also suggested that postoperative RT was more beneficial for patients with positive regional lymph nodes who had adenocarcinoma than in those with positive nodes who had squamous cell carcinoma. The average local relapse rate for the 11 studies summarized in Table 4 was 30% (ranging from 12% to 53%) in patients who underwent surgery alone (7,13,14,30–32,35–38) and 12% (ranging from 1% to 31%) in those who received postoperative RT (7,13,14,30–32,35–38,40). The key question as to whether local control will translate into an improvement in survival remains controversial. It is critical to assess biomarkers and underlying risk factors in such patients to determine which patients will potentially benefit most from postoperative RT (10,16,28,30,32,34,37–39,42,43). Despite these findings, a recent meta-analysis of nine randomized trials from the same group revealed a significant survival decrement in patients who received postoperative RT (33). However, this meta-analysis included nodenegative patients in whom postoperative radiation is not indicated. Indeed, the use of postoperative RT in such node-negative patients adversely affected survival, especially when cobalt 60 teletherapy was utilized with large fields (22). Few, if any, contemporary clinical investigators would now prescribe RT for such patients with negative nodes. Another problem in interpreting the findings from some of the trials included in this meta-analysis is that, in the absence of CT of the chest, it would have been difficult to localize the positive nodal area in the mediastinum or hilar region, in patients status postpneumonectomy. In addition, anterior/posterior rectangular fields with cobalt 60 were often employed, leading to potential ‘‘hot spots’’ over the spinal cord and esophagus, as well as the anterior portion of the heart (Figure 1A). Indeed, cobalt 60 is no longer considered an acceptable modality for the treatment of patients with thoracic malignancies due to the inhomogeneous dose distribution compared to higher-energy linear accelerators (Linac) (Figure 1B). This meta-analysis also incorporated patients who were treated in the 1960s when adequate staging was not done (33). Without adequate staging, including CT of the chest and upper abdomen, CT or MRI of the brain, and bone scan, it is difficult to evaluate the efficacy of local control from the standpoint of survival. It is often difficult to ascertain the exact cause of death in a meta-analysis, owing to inconsistency in the reporting or analysis of the data.
(A)
(B) FIGURE 1 (A) Sagittal section of the thorax showing isodose curves from AP/PA fields delivered by cobalt 60. The target volume was not encompassed by the maximum dose curve, and the patient received a 7% higher dose to the heart and spinal cord compared with the dose to the target volume (tumor). (B) Sagittal section of the thorax shown by AP/PA fields delivered by 18-MV photons, which did not cause as much of the inhomogeneous dose distribution as seen for cobalt-60 treatment. A higher dose to the heart and spinal cord was avoided by using 18-MV photons.
162
Komaki
The timing of the postoperative RT is also an important factor that impacts on local control and survival in patients with epithelial carcinoma. For example, if RT is not initiated within approximately 6 weeks of surgery in patients with positive lymph nodes, local control and survival may be reduced, according to the results from a study of patients with head and neck cancer (44). Observations in breast cancer patients have also shown that local control is an important factor influencing survival once systemic treatment improves. In breast cancer, the role of RT after mastectomy has been evaluated in several randomized trials, and these have shown there is a significant reduction in locoregional recurrences with postoperative RT. Once adequate adjuvant chemotherapy became available, the role of postoperative RT became more important in the control of locoregional disease, which ultimately influenced overall survival (45,46).
TECHNICAL CONSIDERATIONS OF POSTOPERATIVE RT Equipment and Target Volume It is very important to utilize adequate treatment equipment for postoperative RT to avoid the inhomogeneous dose distribution and large penumbra associated with the use of orthovoltage or cobalt units, compared to high-energy linear accelerators. For example, in some patients treated on the trial conducted by the Medical Research Council (MRC), the RT technique was suboptimal owing to the use of a midline block, resulting in suboptimal dose to the mediastinum. A further drawback in the randomized or retrospective studies listed in Tables 1 and 2 was that none utilized planning CT to identify the shift of the mediastinum postoperatively to ensure delivery of an adequate dose to the mediastinal lymph nodes or ipsilateral hilar lymph nodes. At the same time, an overdose of radiation may have been delivered to the heart and residual lungs. Figure 1A shows the sagittal section of the thorax and the isodose curve in the anteroposterior/posteroanterior (AP/PA) fields given by cobalt 60. The target volume was not encompassed by the high-dose area, and the patient received a 7% higher dose to the heart and spinal cord compared to the dose to the target volume. Higher-energy sources (Figure 1B) do not cause this inhomogeneous dose distribution or the delivery of higher doses to the heart and spinal cord. The difference between the maximum dose and target volume becomes more significant when parallel opposed oblique or lateral fields are used because of the distance from the surface of the skin to the target volume, which is at midline. Philips et al. (47) reviewed the efficacy and toxicity of postoperative RT using cobalt 60 versus linear accelerator in patients who had undergone a pneumonectomy. Fifty-one patients were treated with 60 and 25 patients by a linear accelerator. Twenty-seven patients who had T1, T2 , or T3 disease without any positive lymph nodes did not receive any postoperative RT, and these 27 patients
Adjuvant Therapy for NSCLC: Pro
163
were used as the control group. Twenty of 51 patients who were treated by cobalt 60 had positive lymph nodes and 17 of 25 who were treated by the linear accelerator had positive lymph nodes. The 5-year survival rate in patients treated with cobalt 60 was significantly lower at 8% compared to 30% in those treated by a linear accelerator. The 5-year survival rate in the control group was 31%. Those patients who were treated with cobalt 60 developed more cases of respiratory insufficiency and cardiac complications, with a 12% rate of lethal complications due to treatment compared to only a 4% incidence of lethal complications in patients treated by the linear accelerator. However, the incidence of distant metastases was higher in those patients treated by the linear accelerator than in those treated with cobalt 60. The authors concluded that poor treatment led to treatment-related deaths and that locoregional control did not confer a survival benefit (47). Figure 2 shows the shift of the mediastinum after pneumonectomy creating a 1.5-cm margin lateral to the vertebral body on the opposite side, leading to
FIGURE 2 The mediastinum shifted after pneumonectomy, placing a 1.5-cm margin lateral to the vertebral body on the opposite side and causing the inclusion of a fairly large amount of the opposite side of the lung.
164
Komaki
inclusion of a fairly large volume of the opposite lung. Because of the shift of the mediastinum after left pneumonectomy, an AP/PA field delivered by cobalt may cause more severe cardiac damage in those patients who already have borderline cardiovascular problems (Figure 2). When the AP/PA field was set up without a computerized plan, the right hilum and a portion of the mediastinum were partially missed from the RT ports, owing to the shift of the mediastinum after bilobectomy on the right side (Figure 3, A and B). This problem could be corrected by a computerized system (Figure 4, A and B). CT-based treatment planning, the linear accelerator with tissue inhomogeneity correction, and three-dimensional conformal treatment planning are helpful tools to define the target volume and avoid radiation to the surrounding normal tissue (22,47). However, the CT scan for the treatment plan must be performed with the patient in the treatment position. The formulation of an optimal treatment plan to define the target volume and avoid critical structures is essential, especially in patients who have had a pneumonectomy or bilobectomy (Figure 4, A and B), which limits lung capacity and compromises cardiac function (48). At the same time, while tighter margins are necessary for these patients, it is essential not to miss the target volume due to respiratory motion or movement of the heart and aorta. The target volume for postoperative RT needs to include the bronchial resection line, the ipsilateral hilum, and the mediastinum usually 5 cm below the carina and supraclavicular fossa if the lesion is in the upper lobe. We place the lower border 3 cm below the carina if there were no involved subcarinal nodes and the patient is receiving concurrent chemotherapy and RT. More recently, the contralateral hilum and supraclavicular regions are not routinely treated. If the primary tumor was in the lower lobe and the patient has positive mediastinal lymph nodes, the lower mediastinum, ipsilateral hilum, and an area several centimeters above the carina in the mediastinum are typically irradiated. The arrangement of the beam for postoperative RT has been well documented by Emami et
FIGURE 3 (A) When the AP/PA field was configured without a computerized plan postoperatively, the right hilum and a portion of the mediastinum were missed from the radiation therapy ports due to the shift of the mediastinum after right middle and lower lobectomy. This is shown by a horizontal line in the circle, which was the center. This was corrected by a computerized system, and the new center became the cross in the middle of the circle, marked to cover the right hilum and mediastinum adequately and to avoid the medial portion of the left lung. The black outline shows 4500 cGy, which was set up by AP/PA fields without a CT plan. The white outline shows a 5000-cGy isodose curve that is missing the right hilum. (B) Coronal section of the isodose curve without a CT plan. The margin is too tight around the right hilum.
Adjuvant Therapy for NSCLC: Pro
(A)
(B)
165
166
(A)
(B)
Komaki
Adjuvant Therapy for NSCLC: Pro
167
(C)
(D) FIGURE 4 (A) Axial section of the CT plan. The white circle is the old central axis, the black circle is the new central axis, and the shaded gray part indicates motion, which was recognized. The motion of the hilum depended on breathing and pulsation of the heart. (B) Coronal section showing inclusion of the same margin and the shaded area representing respiration and motion of the heart. The white circle is the old isocenter, and the black circle is the new isocenter. (C) Dose-volume histogram without planning CT. (D) Dose-volume histogram with planning CT and with an inhomogeneity correction.
168
Komaki
al. (40). No longer are the generous treatment fields of the past utilized, which included the bilateral hilum and bilateral upper, mid-, and lower portions of the mediastinum (32,42). Optimal Postoperative RT Dose The optimal radiation dose to be prescribed after complete resection to control microscopic residual tumor has not been well defined, but is currently between 50 Gy and 60 Gy for conventional RT (delivered in fractions of 1.8–2 Gy). Emami et al. (40) recommend 60 Gy for positive margins and 50 Gy for subclinical nodal disease. This was confirmed by the LCSG, which administered 50 Gy over 5 weeks postoperatively with a local recurrence rate of 1%. According to Emami’s data, local control was achieved in 75% of patients with positive margins given 50–60 Gy and there was no difference in the local control rate associated with doses in this range. However, locoregional control was achieved in only 45% of the patients who received less than 50 Gy. There was improvement in the survival rate in patients with positive margins who received 60 Gy or higher, compared with the rate in patients given lower doses. Emami and colleagues also emphasized the importance of adequate portal coverage for achieving local control. As long as the portal and target volumes were adequately covered, there was no significant difference in the local control with doses between 50 and 60 Gy. However, there was a significant decrease in the local control rate in patients who received ⬍50 Gy or those given ⱖ60 Gy if the portal did not adequately cover the target volume. Emami et al. recommend 50 Gy for microscopic residual disease, 60 Gy for positive margins, and 70 Gy for macroscopic residual disease (2 Gy/fraction) to 90% of the dose line. Adequate coverage was also associated with significant improvement in the actuarial survival rate compared with the rate in patients who received inadequate coverage regardless of the dose level (i.e., ⬍50 Gy, 50–60 Gy, ⬎60 Gy). A study by Choi and colleagues (32) showed that all patients with local relapse had received a dose of ⬍50 Gy. COMPLICATIONS RELATED TO POSTOPERATIVE RT Clinical and experimental studies have shown that the total dose and fraction size of the RT are associated with pericardial and myocardial complications (49). According to the GETCB study, intercurrent death was related to the fraction size of radiation therapy (24). Seven percent of the patients in their study died of intercurrent disease in the control group. However, of those who received RT, 16% of the patients who received less than 2 Gy per fraction, 18% of patients who received 2 Gy per fraction, and 26% of patients who received more than 2 Gy per fraction died of intercurrent disease. These authors did not, however, find any correlation between the intercurrent death rate and the total tumor dose (24).
Adjuvant Therapy for NSCLC: Pro
169
An increased rate of intercurrent deaths in patients who received RT was documented in the van Houtte trial (22) and also by the LCSG (7). According to the LCSG, 14 intercurrent deaths (14%) occurred in the RT group, compared with seven (7%) in the control group. These intercurrent deaths were mainly due to cardiovascular failure and infections. It is important to recognize this potential complication in patients at high risk of cardiovascular disease prior to the initiation of postoperative RT. Usually acute toxicity during RT does not predict for intercurrent death or late effects. Radiation Effects on the Lung The pulmonary effects of irradiation depend on an interplay of host and treatment factors, especially the volume of the radiated lung, the site of the irradiated lung, the total dose and fraction schedule, and the different chemotherapeutic regimens. Rubin (50) noted that when the whole lung is irradiated, there is a steep upward dose-response curve at a threshold of 7 Gy and a rapid rise to a cell lethality of 80% due to pulmonary toxicity at 11 Gy (Figure 5). No pneumonitis was manifest when ⱖ20 Gy was delivered to ⬍22% of the lung volume. However, there is a steep increase in the extent of radiation pneumonitis if 20 Gy is given to ⬎40% of the total lung, and this was observed to cause 23% of the cases of grade 3 (severe) to 5 (lethal) pneumonitis, as calculated by dose-volume histograms (51). The late or fibrotic changes may begin to occur at 3–6 months and are characterized by sclerosis of the alveolar wall and damage to small blood vessels, replacement of alveolar spaces by fibrotic tissue, and functional loss. Interstitial fibrosis, pleural thickening, and increased lung density are seen on radiographs with gradual volume loss (52). Patients are usually not symptomatic, however, even with fibrotic changes on the CT scan, because the volume of the sclerotic area is less than 20% and because the patient’s pretreatment condition obscures the development of subsequent symptoms. To prevent pneumonitis and other pulmonary complications, it is important to assess a dose-volume histogram to reduce lung volume irradiated by ⱖ20 Gy to ⬍40% (Figure 5). Of further concern is the wellknown fact that certain types of chemotherapy such as bleomycin, actinomycin D, cyclophosphamide, methotrexate, BCNU, and possibly CPT-11 and paclitaxel (Taxol) have pulmonary toxicities that may increase pulmonary injury, especially when they are administered concurrently with radiation therapy (50,52–55). Radiation Effects on the Heart The cardiac effects of radiation have been best studied in patients who received RT for Hodgkin’s disease, breast cancer, or lung cancer. For example, a radiation effect on the coronary vessels (56–58) and myocardium (59,60) has been reported, although these were not solely due to radiation. Usually the cardiac tolerance dose is 40 Gy in 4–5 weeks when the entire heart is irradiated. Among
170
Komaki
FIGURE 5 Incidence of pneumonitis correlated with dose of radiation. (From Ref. 50.)
patients who received a total dose of 40 Gy in 4–5 weeks to the entire heart, 4–7% developed symptoms of radiation pericarditis (61–63). Symptomatic pericarditis typically develops within 12–24 months of the completion of radiation therapy (64), and the manifestations are usually chest pain, fever, friction rub, and pericardial effusion. Coronary occlusion is only manifest many years later. A total radiation dose of 35 Gy to the heart reduced the ventricular ejection fraction in more than one-half of irradiated patients (65). This was mainly subclinical, however, in those patients with Hodgkin’s disease who received radiation to the mediastinum. None of the patients who received this amount of radiation to the heart presented with congestive heart failure or constrictive pericarditis. Electrocardiographic changes have been observed, as well as transient and clinically silent perimyocarditis following cardiac radiation in breast cancer patients receiving internal mammary radiation on the left side (66). Not surprisingly, there were reports of deaths due to cardiac disease in node-negative patients who received 60 Gy using cobalt 60 in the study conducted by van Houtte and Dautzenberg (22,24). With careful CT-based planning, however, it should
Adjuvant Therapy for NSCLC: Pro
171
now be possible to minimize radiation to the heart so that less than 30% of the cardiac volume receives a dose of 50 Gy or higher (67,68). Radiation Effects on the Esophagus The effects of radiation on the esophagus may either be acute (e.g., esophagitis during radiation therapy to the mediastinum) or chronic (e.g., stricture of the esophagus months after radiation therapy). The germinal layer of the epithelium is most sensitive to radiation, especially if chemotherapy is given concurrently as a sensitizer for radiation. Acute esophagitis causes dysphagia usually around 2 weeks after the initiation of radiation therapy (at a dose of ⬃20 Gy or higher). It is very difficult, however, to avoid acute esophagitis when patients require mediastinal RT. However, an esophageal stricture may be avoided by reducing the length of the irradiated area and limiting the total esophageal dose to less than 60 Gy. There have been reports of severe stricture in less than 5% of patients given a total dose of 60–70 Gy of radiation to the esophagus (69). If less than 10 cm of the esophagus is irradiated and the total radiation dose is 50 Gy in 5 weeks, the risk of an esophageal stricture is less than 2% (70). Many chemotherapeutic agents are known to augment the radiation effect on the esophagus, especially doxorubicin (71–73), cyclophosphamide (50), bleomycin (74), fluorouracil and dactinomycin (75), and etoposide (76). At present, we are conducting a randomized study of radioprotectors in patients (WR-2721) for unresectable NSCLC who are being treated with concurrent chemotherapy and radiation therapy. Similarly, the Radiation Therapy Oncology Group has a randomized trial to determine if amifostine (WR-2721) can reduce esophagitis from intensive chemoradiation in locally advanced NSCLC (RTOG 98-01). WR-2721 has been shown to protect normal tissue from radiation chemotherapy effects (77,78). Radiation Effects on the Spinal Cord A transient radiation myelopathy may be seen weeks to months following RT to the cervical or upper thoracic spinal cord. Lhermitte’s sign of electrical paresthesias is the only clinical feature of this subacute effect, which does not translate into a higher risk of developing myelopathy. Affected patients experience electric-like shocks that radiate down the extremities, especially the buttocks and legs, on ventral flexion of the neck. This is most likely to be the result of transient demyelination of the spinal cord (79). This transient myelopathy has been noted in 3–15% of patients who receive RT to the thoracic spinal cord (80,81). Late radiation effects on the spinal cord include a progressive radiation myelopathy, often presenting with clumsiness and weakness of the legs. A common early finding is the Brown-Se´quard syndrome. The onset of the myelopathy
172
Komaki
is around 6 months or longer after the completion of RT, and symptoms may begin 3 or more years after treatment. Permanent spinal cord damage from RT is rare if the total dose is limited to less than 50 Gy in 5 weeks with standard fractionation such as less than 2 Gy per fraction. The fraction size to the spinal cord is an important factor related to permanent radiation myelitis (82). This damage to the spinal cord can be avoided by using careful CT-based treatment planning and by fractionating the radiation therapy. Effects on Peripheral Nerves When postoperative RT is given to the apex of the thorax in patients with positive margins or positive lymph nodes, there is always a concern regarding damage to the brachial plexus. However, peripheral nerves have a relatively high tolerance to ionizing radiation, and the incidence of damage to the peripheral nerves from the RT itself is rare. There are no recognized acute or subacute effects, and damage to peripheral nerves from radiation is manifested late, usually a few years or more after RT. Stoll and Andrews (83) reported the symptoms and signs related to brachial plexus damage among patients who received radiation to the supraclavicular area with 4-MV photons. However, patients with involvement of the brachial plexus by supraclavicular lymph nodes were not consistently excluded. Thomas and Colby (84) observed injury in only 1.2% (14/1202 patients) of those treated to supraclavicular area by RT. Stoll and Andrews reported that radiationinduced brachial plexus lesions were correlated with the dose-time-fraction size, as well as with the volume included within the radiation fields. They also suggested that the equipment that caused an inhomogeneous dose distribution, such as low-energy kilovoltage equipment, would more likely cause brachial plexus damage. DISCUSSION AND RECOMMENDATION Postoperative RT for Resected N 2 (Stage IIIA) NSCLC It is obvious that survival is significantly lower in patients with positive mediastinal lymph nodes. This is borne out by findings such as those reported by Wilkins et al. (85), who reported 5-year survival rates of 42% in patients without mediastinal lymph node involvement compared with only 16% in patients with positive mediastinal lymph nodes. Mountain (86) also pointed out a significant reduction in the 5-year survival rate when there was mediastinal lymph node involvement. However, the preoperative staging in these studies was not uniform. For example, it did not include CT scan of the chest and upper abdomen, MRI of the brain, bone scan, etc., since these studies were performed before CT was applied to all lung cancer patients. A further difficulty in interpreting the results of some of the studies is that gross N2 disease versus microscopic residual N2 disease was not
Adjuvant Therapy for NSCLC: Pro
173
documented. A further consideration is that the nodal level determines a different outcome, according to Naruke et al. (87) and Pearson et al. (88). A number of retrospective studies have been interpreted to show that postoperative RT is beneficial to patients with mediastinal lymph node involvement (29,30,32,34,89). However, these retrospective studies usually had a fairly small sample size, and comparisons were made with historical controls or with controls in other studies conducted by different investigators. Nevertheless, it cannot be ignored that an improvement in local control was found in most of the randomized studies in patients with N2 disease. As well, local control will only become more important for improvement in survival once an efficacious systemic treatment is developed (54). A major problem in interpreting the cited studies is that many patients died of intercurrent disease stemming from inadequate planning and treatment equipment as well as inadequate staging, making it difficult to assess the true value of postoperative RT in these patients. Among patients with N2 NSCLC, squamous cell carcinoma will more likely recur locally and postoperative RT will reduce local recurrence without influencing survival, compared with adenocarcinoma in which postoperative RT might reduce the risk of local recurrence, as well as improve survival (29,30,32). Sawyer et al. (31) analyzed 224 patients who had N2 NSCLC and underwent surgery and postoperative RT. Eighty-eight of the 224 patients had at least one positive mediastinal lymph node and received postoperative RT (50.4 Gy in 5.5 weeks). These investigators separated patients into three groups: a low-risk group with no nodal involvement, N1 nodal involvement, T1 or T2 disease, and discordant T3–4 lesions without superior or inferior mediastinal lymph node involvement; an intermediate-risk group with negative N1 nodes and discordant T3–4 lesions with superior or inferior mediastinal lymph node involvement or positive N1 lymph nodes with superior or inferior mediastinal lymph node involvement; and a high-risk group with superior and inferior mediastinal lymph node involvement. According to their analysis, those patients in the high-risk group had a significant benefit from the adjuvant postoperative RT in terms of freedom from local recurrence and survival. This was also the case for patients of intermediate risk, although the benefit from RT was moderate. There was no improvement with regard to freedom from local recurrence or survival among those patients who were in the low-risk group. Sawyer et al. therefore advocated that patient selection is important to identify those patients with N2 disease who benefit from postoperative RT. Postoperative RT in Resected T3 , N0, M0 (New Staging System Stage IIB) Disease Involving the Chest Wall Patients with resected T3 tumors involving the chest wall, such as the parietal pleura, intercostal muscle, and ribs, need postoperative RT (90). However, Piehler
174
Komaki
and colleagues (91) made contrasting observations in 93 patients operated on from 1960 through 1980 for lung cancer invading the chest wall. Sixty-six had complete en bloc resection, and of those, 31 had T3 N0 NSCLC. Sixteen of these 31 patients received postoperative RT; their actuarial survival at 5 years was the same as for those who did not receive postoperative RT (53.3% vs. 54.4%). Patterson and colleagues (92) reported on 35 patients treated between 1969 and 1981, 83% of whom had en bloc resection. Twenty-one patients with T3 N0M0 disease had a complete resection. Unlike the findings in Piehler and associates’ study, seven of their nine patients (78%) who received postoperative RT were alive at 5 years compared with only three of the 14 (21%) who received no postoperative RT. None of the 13 patients who received postoperative RT had a recurrence locally, while six of the 22 (27%) who did not receive postoperative RT failed locally. However, the role of postoperative RT in patients with T3 N0M 0 NSCLC whose tumor has been completely resected has been controversial. This has been compounded by the fact that there has not been any randomized study to compare postoperative RT with no postoperative RT for completely resected T3 N0 M0 NSCLC. In the study of Gould et al. (93), 92 patients underwent complete resection for T3 N0 M0 NSCLC. They reviewed prognostic factors, including histological type, tumor size, location, grade, patient age, adjuvant RT, and type of surgical procedure. The actuarial local control rate at 4 years in their patients was 94%, with or without additional postoperative RT. Superior sulcus tumors are a special consideration with regard to postoperative RT as there is typically not an adequate margin, even if patients had a complete resection. The majority of patients will have microscopic residual tumor without any preoperative RT. Whether resectable T3 N0M0 superior sulcus tumors need to be treated with RT preoperatively or postoperatively has been controversial. Recently, the effectiveness of preoperative versus postoperative RT for superior sulcus tumors was analyzed, but there was no significant difference in the outcome of the patients (Komaki, unpublished observations). In stage IIB (T3 N0 ) or stage IIIA patients with the superior sulcus tumors, the 2-year survival rate was 46.5% compared with 20.6% in stage IIIB patients with superior sulcus tumors (94). Postoperative RT for T1–2, N0–1 NSCLC Patients with squamous cell carcinoma and completely resected stage I–II disease should have less of a survival benefit from postoperative RT according to retrospective studies (16,34,95). For example, in a study of 134 patients with N1 squamous cell carcinoma, the LCSG (7) showed a significant improvement in the local control rate in those who received postoperative RT compared with those
Adjuvant Therapy for NSCLC: Pro
175
who received surgery alone, but there was no significant improvement in overall survival. According to our analysis of patients with pathologically confirmed N1 squamous cell carcinoma who underwent complete resection, patients did extremely well without any adjuvant treatment (96,97). The original study included 173 patients who had complete resection of their NSCLC that was clinically graded as N0. However, at surgery, patients were found to have hilar lymph node involvement. There were 86 patients with squamous cell carcinoma and 73 patients with adenocarcinoma; the other histological types were large cell or unclassified. The 5-year survival rate in patients with squamous cell carcinoma was 43% compared with 21% in the non–squamous cell cases ( p ⫽ 0.03). A further finding was that the apoptosis and mitosis indices in the squamous cell group predicted a significantly better survival (96). When other prognostic biomarkers were studied (S ⫹ G2M, p53 status, Ki-67, DNA index) in addition to the apoptosis and mitosis indices, apoptosis and Ki-67 proved to be significant prognostic factors in squamous cell carcinoma for less distant metastasis and better overall survival. Multivariate analysis showed that the DNA index and Ki-67 status were significant predictors. In patients with non–squamous cell carcinoma of the lung, only the mitotic index was a significant predictor of overall survival (97). Postoperative RT and Chemotherapy Although the recent Intergroup Study showed no benefit to the addition of cisplatin and etoposide to postoperative radiation, the Radiation Therapy Oncology Group (RTOG) and other groups have decided to test newer systemic agents such as carboplatin and paclitaxel (98). In a recent Eastern Cooperative Oncology Group (ECOG) study of multiple cisplatin analogs in combinations, initial therapy with carboplatin and paclitaxel produced the best long-term survival, with a p value of ⱕ0.001 (99). Several studies (100–104) have indicated that paclitaxel is an active chemotherapeutic agent for NSCLC and that chemoradiation therapy with paclitaxel and carboplatin is well tolerated in patients with inoperable, locally advanced NSCLC. This approach was thus adapted to the adjuvant setting in patients who do not have bulky disease, i.e., in a setting where cure rates may be substantially enhanced. In the RTOG 97-05 phase III study (98), adjuvant therapy with paclitaxel, carboplatin, and concurrent thoracic RT was evaluated in patients with completely resected stage II and IIIA NSCLC. A total of 93 patients were entered, and toxicity data were available for 62 patients. Overall, the treatment regimen was reasonably well tolerated, with only one patient death secondary to sepsis and grade IV respiratory toxicity after completion of four cycles of chemotherapy. There was one grade IV esophagitis after two cycles of
176
Komaki
chemotherapy. Overall, there was a 16% rate of grade III/IV acute esophagitis and two late grade III toxicities. While waiting for mature data from RTOG 9705, RTOG would like to build on this experience by exploring a promising approach that could be added to this regimen without risking increased toxicity. The adjuvant approach selected for this study is active immunotherapy with vaccines directed against tumor-associated antigens. These antigens are seen as selfantigens by the immune system and thus the patient is typically immunologically tolerant to them.
CONCLUSIONS Postoperative RT will be more effective once more efficacious systemic treatment and better prognostic predictors become available. Further advances will come with improvements in CT-based planning and equipment and once we are better able to determine the volume to be irradiated, dose-time-fractionation schedule, and total dose. The role of postoperative chemotherapy will also need to be reinvestigated as better sensitizers to radiation and better systemic agents become available.
REFERENCES 1. Hall EJ. Radiobiology for Radiologist, 4th edition. Philadelphia: Lippincott, 1994: 141–145. 2. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997:1718–1723. 3. Pearson FG. Management of stage III disease: mediastinal adenopathy—the N2 lesion. In: Delarue NC, Eschapasse H, eds. International Trends in General Thoracic Surgery, Vol 1, Lung Cancer. Philadelphia: WB Saunders, 1985:104–107. 4. Martini N, Flehinger BJ, Bains MS, McCormack P. Alternate approaches to the management of mediastinal adenopathy. In: Delarue NC, Eschapasse H, eds. International Trends in General Thoracic Surgery, Vol. I, Lung Cancer. Philadelphia: WB Saunders, 1985:108–120. 5. Martini N, Flehinger BJ, Nagasaki F, Hart B. Prognostic significance of N1 disease in carcinoma of the lung. J Thorac Cardiovasc Surg 1983; 86:646–653. 6. Ferguson M, Little AG, Golomb HM, Hoffman PC, DeMeester TR, Beveridge R, Skinner DB. The role of adjuvant therapy after resection of T1 N0 M0 and T2 N0 M0 nonsmall cell lung cancer. J Thorac Cardiovasc Surg 1986; 99:344–349. 7. Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377–1381. 8. Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 1973; 4:63–67.
Adjuvant Therapy for NSCLC: Pro
177
9. Rasmussen PS. The incidence of local recurrence and distant metastases in surgically treated cases of lung cancer. Acta Pathol Microbiol Scand 1964; 62:145–150. 10. Martini N, Beattie EJ Jr. Results of surgical treatment in stage I lung cancer. J Thorac Cardiovasc Surg 1977; 74:499–505. 11. Pairolero PC, Williams DE, Bergstrahl EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38:331–338. 12. Feld R, Rubenstein LV, Weisenberger TH. The Lung Cancer Study Group: sites of recurrence in resected stage I nonsmall cell cancer: a guide for future studies. J Clin Oncol 1984; 2:1352–1357. 13. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II nonsmall cell carcinoma of the lung. Ann Thorac Surg 1981; 32:23–27. 14. Ludwig Lung Cancer Study Group. Patterns of failure in patients with resected stage I and II nonsmall cell carcinoma of the lung. Ann Surg 1987; 205:67–71. 15. Kotlyarov EV, Rukosuyev AA. Long-term results and patterns of disease recurrence after radical operations for lung cancer. J Thorac Cardiovasc Surg 1991; 102: 24–28. 16. Green N, Kern W. The clinical course and treatment results of patients with postresection locally recurrent lung cancer. Cancer 1978; 42:2478–2482. 17. Kopelson G, Choi N. Radiation therapy for postoperative loco-regionally recurrent lung cancer. Int J Radiat Oncol Biol Phys 1980; 6:1503–1506. 18. Curran WJ, Herbert SH, Stafford PM, Sandler HM, Rosenthal SA, McKenna WG, Hughes E, Dougherty MJ, Keller S. Should patients with postresection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 1992; 24:25–30. 19. Paterson R, Russell MH. Clinical trial in malignant disease. IV. Lung cancer. Value of postoperative radiotherapy. Clin Radiol 1962; 13:141–144. 20. Bangma PJ. Postoperative radiotherapy. In: Deeley TJ, ed. Carcinoma of the Bronchus: Modern Radiotherapy. New York: Appleton-Century-Crofts, 1972:163– 170. 21. Israel L, Bonadonna G, Sylvester R. Controlled study with adjuvant radiotherapy, chemotherapy, immunotherapy and chemoimmunotherapy in operable squamous cell carcinoma of the lung. In: Muggia FM, Rozencweig M, eds. Lung Cancer: Progress in Therapeutic Research. New York: Raven Press, 1979:443–452. 22. van Houtte P, Rocmans P, Smets P, Goffin J-C, Lustman-Marechal J, Vanderhoeft P, Henry J. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980; 6:983–986. 23. Bleehen NM, British Medical Research Council Lung Cancer Working Party. Randomized trial of surgical resection with or without post-operative radiotherapy (RT) in nonsmall cell lung cancer NSCLC. Lung Cancer 1994; 11(suppl 1):148. 24. Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K, Lagrange JL, Le Pechoux C, Lebeau B, Chastang C. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999; 86:265–273. 25. Medical Research Council Lung Cancer Working Party. The role of postoperative
178
26.
27.
28. 29. 30.
31.
32.
33.
34.
35.
36.
37. 38.
39.
40.
Komaki radiotherapy in nonsmall cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1 –T2 , N1 –N2 , M0 disease. Br J Cancer 1996; 74:632– 639. Holmes EG, Gail M for the LCSG. Surgical adjuvant therapy for stage II and III adenocarcinoma and large cell undifferentiated carcinoma. J Clin Oncol 1986; 4: 710–715. Keller SM, Adak S, Wagner H, Herskovic A, Bruke JB, Perry MC, Livingston RB, Johnson DH. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIa non-small cell lung cancer: an intergroup trial (E3590). Proc Am Soc Clin Oncol 1999; 18:465a. Ennuyer A. L’irradiation du mediastin apras pneumectomie pour cancer bronchique. Poumon Coeur 1963; 9:1093–1098. Green N, Kurohara SS, George FW. Postresection irradiation for primary lung cancer. Radiology 1975; 116:405–407. Chung CK, Stryker JA, O’Neil M, DeMuth WE Jr. Evaluation of adjuvant postoperative radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1982; 8:1877– 1880. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, Pairolero PC, Allen MS, Lange CM, Li H. Effectiveness of postoperative irradiation in stage IIIA non–small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997; 64:1402–1408. Choi NC, Grillo HC, Gardiello M, Scannell JG, Wilkins EW Jr. Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1980; 6:31–35. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in nonsmall cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257–263. Kirsh M, Sloan H. Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell types and location. Ann Thorac Surg 1982; 33: 459–463. Iascone C, DeMeester TR, Albertucci M, Little AG, Golomb HM. Local recurrence after resectable non-oat cell carcinoma of the lung. A warning against conservative treatment for N0 and N1 disease. Cancer 1986; 57:471–476. Herskovic A, Bauer M, Seydel HG, Yesner R, Doggett RLS, Perez CA, Durbin LM, Zinninger M. Post-operative thoracic irradiation with or without levamisole in non–small cell lung cancer: results of a radiation therapy oncologic group study. Int J Radiat Oncol Biol Phys 1988; 14:37–42. Astudillo J, Conill C. Role of postoperative radiation therapy in stage IIIA nonsmall cell lung cancer. Ann Thorac Surg 1990; 50:618–623. Durci ML, Komaki R, Oswald MJ, Mountain CF. Comparison of surgery and radiation therapy for nonsmall cell carcinoma of the lung with mediastinal metastasis. Int J Radiat Oncol Biol Phys 1991; 21:629–636. Reinfuss M, Glinski B, Mitus J, Kowalska T, Rzepecki W. Radiotherapie postoperatoire des cancers bronchopulmonaires non petites cellules. A propos de 75 cas. Bull Cancer Radiother 1993; 80:163–167. Emami B, Kaiser L, Simpson J, Shapiro S, Roper C, Lockett MA. Postoperative
Adjuvant Therapy for NSCLC: Pro
41.
42.
43. 44.
45.
46.
47.
48.
49. 50. 51.
52.
53.
54. 55.
179
radiation therapy in non–small cell lung cancer. Am J Clin Oncol 1997; 20:441– 448. Martini H, Flehinger BJ, Zaman M, Beattie, Jr, EJ. Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 1980; 80:390–399. Emami B, Kim T, Roper C, Simpson JR, Pilepich MV, Hederman MA. Postoperative radiation therapy in the management of lung cancer. Radiology 1987; 164: 251–253. van Houtte PJ. Personal communication. Marcus RB Jr, Million RR, Cassisi NJ. Postoperative irradiation for squamous cell carcinomas of the head and neck: analysis of time-dose factors related to control above the clavicles. Int J Radiat Oncol Biol Phys 1979; 5:1943–1949. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadsberg CC, Mouridsen HT, Jensen M-B, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337; 949–955, 1997. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 1995; 333:1444–1455. Philips P, Rocmans P, Vanderhoeft P, van Houtte P. Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 1993; 27:525–529. Rosenzweig KE, Hanley J, Mychalczak B, Raben A, Fuks Z, Mageras G, Mah D, Ling CC, Burman C, Kutcher G, Ginsberg R, Rusch V, Downey R, Bains M, Kris M, Leibel S. Final report of the 70.2 and 75.6 Gy dose levels of a phase I dose escalation study using three dimensional conformal radiotherapy in the treatment of inoperable lung cancer. Proc Am Soc Ther Radiat Oncol 1998; 42:165. Stewart JR, Fajardo LF, Gilette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31:1205–1211. Rubin P. The Franz Buschke Lecture: Late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys 1984; 10:5–34. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non–small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323– 329. Travis EL, Komaki R. Treatment-related lung damage. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven, 1996:285–301. Phillips TL, Margolis L. Radiation pathology and the clinical response of lung and esophagus. In: Vaeth JM, ed. Frontiers of Radiation Therapy and Oncology, vol 6, Radiation Effects and Tolerance, Normal Tissue, Baltimore: University Park Press, 1972:254–273. Wara WM, Phillips TL, Margolis LW, Smith V. Radiation pneumonitis: a new approach to the derivation of time-dose factors. Cancer 1973; 32:547–552. Einhorn L, Krause M, Hornback N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 1976; 37:2414–2416.
180
Komaki
56. Dollinger MR, Lavine DM, Foye LV, Jr.: Myocardial infarction due to postirradiation fibrosis of the coronary arteries: case of successfully treated Hodgkin’s disease with lower esophageal involvement. JAMA 1966; 195:316–319. 57. McReynolds RA, Gold GL, Roberts WC. Coronary heart disease after mediastinal irradiation for Hodgkin’s disease. Am J Med 1976; 60:39–45. 58. Brosius FC, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15–33 years) necropsy patients who received over 3500 rads to the heart. Am J Med 1981; 70:519–530. 59. Ruckdeschel JC, Chang P, Martin RG, Byhardt RW, O’Connell MJ, Sutherland JC, Wiernik PH. Radiation-related pericardial effusions in patients with Hodgkin’s disease. Medicine 1975; 54:245–259. 60. Kaplan HS. Hodgkin’s Disease. Cambridge: Harvard University Press, 1980. 61. Cohn KJE, Stewart JR, Fajardo LF, Hancock EW. Heart disease following radiation. Medicine 1967; 46:281–285. 62. Stewart JR, Fajardo LF. Radiation-induced heart disease. Radiol Clin North Am 1971; 9:511–531. 63. Dana M, Colombel P, Bayle-Weisgerber G, Tiellet F, Desperez-Curely JP, Bernard J, Chotin G. Pericarditis after wide field mediastinal irradiation for Hodgkin’s disease. J Radiol Electrol Med Nucl 1978; 59:335–341. 64. Byhardt RW, Brace K, Ruckdeschel JC, Chang P, Martin RG, Wiernik PH. Dose and treatment factors in radiation related pericardial effusion associated with a mantle technique for Hodgkin’s disease. Cancer 1975; 35:795–802. 65. Gomez GA, Park JJ, Panahon AM, Parthasarathy KL, Pearce J, Reese P, Bakshi S, Henderson ES. Heart size and function after radiation therapy to the mediastinum in patients with Hodgkin’s disease. Cancer Treat Rep 1983; 67:1099–1103. 66. Wehr M, Rosskopf BG, Pittner PM, Schwenk D, Prignitz R. The effect of radiation therapy on the heart in patients with left-sided mammary carcinoma. In Proceedings of the International Association for Breast Cancer Research, March 20–24, 1983, Denver, CO. 67. Applefeld MM, Cole JF, Pollock SH, Sutton FJ, Slawson RG, Singleton RT, Wiernik PN. The late appearance of chronic pericardial disease in patients treated by radiation therapy for Hodgkin’s disease. Ann Intern Med 1981; 94:338– 341. 68. Mill WB, Baglan RJ, Kurichety P, Prasad S, Lee JY, Moller R. Symptomatic radiation induced pericarditis in Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1984; 10:2061–2065. 69. Roswit B. Complications of radiation therapy: the alimentary tract. Semin Roentgenol 1974; 9:51–63. 70. Morichau-Beauchant M, Touchard G, Battandier D, Maire P, Fontanel JP, Daban A, Babin P, Matuchansky C. Chronic radiation-induced esophagitis after treatment of oropharyngeal cancer: a little known anatomo-clinical entity. Gastroenterol Clin Biol 1983; 7:843–850. 71. Greco FA, Brereton HD, Kent CH, Zimbler H, Merrill J, Johnson RE. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85:294–298. 72. Chabora BM, Hopfan S, Wittes R. Esophageal complications in the treatment of
Adjuvant Therapy for NSCLC: Pro
73.
74.
75. 76.
77.
78.
79. 80.
81. 82. 83. 84. 85.
86. 87.
88.
89.
181
oat cell carcinoma with combined irradiation and chemotherapy. Radiology 1977; 123:185–187. Schenken LL, Burholt DR, Kovacs CJ. Adriamycin, radiation combination: drug induced delayed gastro-intestinal radiosensitivity. Int J Radiat Oncol Biol Phys 1979; 5:1265–1269. Soreide O, Janssen CW, Kvam G, Hartveit F. Aorto-oesophageal fistula complicating carcinoma of the oesophagus. Scand J Thorac Cardiovasc Surg 1976; 10:79– 84. Philips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976; 37:1186–1200. Giever RJ, Heuskinveld RS, Manning MR, Bowden GT. Enhanced radiation reaction following combination chemotherapy for small cell carcinoma of the lung, possibly secondary to VP16-213. Int J Radiat Oncol Biol Phys 1982; 8:921– 923. Milas L, Hunter N, Stephens LC, Peters LJ. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1992; 44:5567–5569. Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella T, Schiller JH. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15:2850–2857. Jones A. Transient radiation myelopathy (with reference to Lhermitte’s sign of electrical paresthesia). Br J Radiol 1964; 37:727–744. Hutchinson G. Survival and complications of radiation therapy following involved and extended field therapy of Hodgkin’s disease, stages I and II. Cancer 1976; 38: 288–305. Carmel RH, Kaplan HS. Mantle irradiation in Hodgkin’s disease. Cancer 1976; 37: 2813–2826. Wollin M, Kagan AR. Modification of biological dose to normal tissue by daily fractionation. Acta Radiol Ther 1976; 15:481–492. Stoll BA, Andrews JT. Radiation-induced peripheral neuropathy. Br Med J 1966; 1:834–839. Thomas JE, Colby MY. Radiation-induced or metastatic brachial plexopathy? A diagnostic dilemma. JAMA 1972; 222:1392–1395. Wilkins EW, Scannell JG, Craver JG. Four decades of experience with resection for bronchogenic carcinoma in Massachusetts General Hospital. J Thorac Cardiovasc Surg 1978; 76:364–368. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 2255–2335. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76: 832–839. Pearson FG, De Larue NC, Ilves R, Todd, TRJ, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83:1–11. Newman SB, Demeester TR, Golomb HM, Hoffman PC, Little AG, Raghaven V.
182
90. 91.
92.
93.
94.
95.
96.
97.
98. 99.
100.
101.
102.
Komaki Treatment of modified stage II (T1 N1 M0 , T2 N1 M0 ) non–small cell bronchogenic carcinoma. J Thorac Cardiovasc Surg 1983; 86:180–185. Grillo HC. In: DeLarue NC, Eschapasse H, eds. International Trends in General Thoracic Surgery, vol 1, Lung Cancer. Philadelphia: WB Saunders, 1985:134–138. Piehler JM, Weiland LH, Offard KP, Payne WS, Bernatz PE. Bronchogenic carcinoma with chest wall invasion: factors reflecting survival following en bloc resection. Ann Thorac Surg 1982; 34:684–691. Patterson GA, Ilves R, Ginsberg RJ, Cooper JD, Todd TRJ, Pearson FG. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann Thorac Surg 1982; 34:692–697. Gould PM, Bonner JA, Sawyer TE, Deschamps C, Lange CM, Li H. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non– small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 45:91–95. Komaki R, Mountain CF, Holbert JM, Garden AS, Shallenberger R, Cox JD, Maor MH, Guinee VF, Samuels B. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (M0 ) at presentation. Int J Radiat Oncol Biol Phys 1990; 19:31–36. Chang AY, Kim K, Glick J Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone and piroxantrone in stage IV nonsmall cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388– 394. Komaki R, Fujii T, Perkins P, Ro JY, Allen PK, Mason KA, Mountain CF, Milas L. Apoptosis and mytosis as prognostic factors in pathologically staged N1 non– small cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 36:601–605. Komaki R, Milas L, Ro JY, Fujii T, Perkin P, Allen P, Sikes CR, Mountain CF, Ordonez NG. Prognostic biomarker study in pathologically staged N1 non–small cell lung cancer. Int J Radiat Oncol Biol Phys 1998; 40:787–796. Ettinger. Personal communication. Bonomi P, Finkelstein D, Ruckdeschel J, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV nonsmall cell lung cancer, a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602–1613. Murphy WK, Fosella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK. Phase II study of taxol in patients with untreated advanced nonsmall cell lung cancer. J Natl Cancer Inst 1993; 85:384–388. Langer CJ, Leighton JC, Comis RL, O’Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF. Paclitaxel and carboplatin in combination in the treatment of advanced nonsmall cell lung cancer: phase II toxocity, response and survival analysis. J Clin Oncol 1995; 13:1860–1870. Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable locally advanced nonsmall cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol 1997; 24: S12–S89.
Adjuvant Therapy for NSCLC: Pro
183
103. Belani CP, Aisner J, Day R, Ramanathan R, Jett J, Capozzoli MJ, Bahri S, Hiponia D. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced nonsmall cell lung cancer: three-year followup. Proc Am Soc Clin Oncol 1997; 16:448a. 104. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced nonsmall cell lung cancer. J Clin Oncol 1998; 16:3316–3322.
11 Adjuvant Therapy for Resected Stages II and IIIA NSCLC: Con Steven M. Keller* Beth Israel Medical Center, New York, New York, and Albert Einstein College of Medicine, Bronx, New York
Zvi Small Albert Einstein College of Medicine, Bronx, New York
INTRODUCTION Following resection of pathological stages II and IIIA non–small cell lung cancer (NSCLC), 5-year survival approximates 40% and 20%, respectively (1–4). Recurrent disease presumably originates in deposits of intrathoracic and extrathoracic micrometastatic tumor foci that were present at the time of surgery. Theoretically, the minimal residual disease present following surgery should be much less likely to harbor treatment-resistant cells and would, therefore, represent an optimal scenario for the administration of curative local and systemic therapies. Unfortunately, unlike breast cancer, adjuvant therapy has not proved successful in improving patient survival. Numerous phase II and phase III adjuvant therapy trials utilizing thoracic
*Current affiliation: Montefiore Medical Center, Bronx, New York.
185
186
Keller and Small
radiotherapy and/or systemic chemotherapy have been reported. The biases associated with phase II trials are well known. Though the results of these nonrandomized trials are frequently intriguing and may form the basis for future phase III trials, they cannot be employed to determine patient care standards. Therefore, only the results of phase III trials will be analyzed. Furthermore, though ‘‘neoadjuvant’’ trials have been designed with substantial adjuvant therapy components, the preoperative therapy confounds the interpretation of the specific contribution of the adjuvant therapy. These trials will also not be included in this discussion. PHASE III TRIALS Three adjuvant phase III trials of patients with stage II and III NSCLC have been reported by the former Lung Cancer Study Group (LCSG) (5–7). CAP chemotherapy (cyclophosphamide 400 mg/m2, adriamycin 40 mg/m2, cisplatin 40 mg/ m2) administered in six 1-month cycles was compared to a control arm of intrapleural BCG (single injection within 14 days of surgery) and levamisole 2.5 mg/kg orally daily ⫻ 3 days every other week for 18 months in 57 patients with either adenocarcinoma or large cell undifferentiated T2N1 NSCLC (LCSG #772) (5). An additional 73 patients had stage III disease. When both stages were analyzed together, a 7-month median survival advantage (15 months vs. 22 months, p ⬍ .05) was identified in those patients who received chemotherapy. Though no stage-specific analysis was presented, the authors stated that adjustment for stage did not affect statistical significance. The results of this study were not widely accepted because the survival of patients in the treatment arm approximated that of untreated patients from previous trials, while the survival of patients in the control arm was worse than expected. The poor survival of the patients randomized to the immunotherapy arm was attributed by some to an (unproven) detrimental effect of levamisol. Moreover, long-term survival data were not reported; so it was never clear if the differences observed in median survival were sustained over time. In a second study (LCSG #773), 210 patients with resected stages II or III squamous NSCLC received either radiotherapy (5000 cGy, 180–200 cGy daily fractions) or no further treatment (6). 136 patients had T2N1 disease. Among the remaining 74 patients, 44 were stage IIIA by virtue of metastases to the N2 lymph nodes. Once again, the two stages were analyzed together. Though the median survival of patients in the control and treatment arms was 33 months and 20 months, respectively, the survival curves largely overlapped and no significant difference was found (p ⫽ 0.618). Subgroup analysis reportedly showed no effect of stage on the result. Radiotherapy significantly decreased local recurrence and although radiation reduced overall recurrence in patients with N2 disease, survival was not affected.
Adjuvant Therapy for NSCLC: Con
187
The third LCSG study (#791) compared split-course radiotherapy (400 cGy ⫻ 5 days repeated after a 3-week rest) and CAP chemotherapy (cyclophosphamide 400 mg/m2, adriamycin 40 mg/m2, cisplatin 40 mg/m2) to radiotherapy alone in 164 patients (7). Three patients were stage I, 10 were stage II, and 151 were stage III. Among the latter group, 119 had N2 disease. Though the time to recurrence was significantly greater in the treatment arm than in the control arm (p ⫽ .004, median 14 months vs. 8 months), the time to death was not significantly different (p ⫽ .133). The apparent biological effect did not translate into improved survival, although the study may have been underpowered to detect a significant survival difference. Subset analysis demonstrated a slight advantage for those patients with N2 disease who received both radiation and chemotherapy. A recent phase III trial by a French cooperative group compared radiotherapy (6000 cGy) alone to three cycles of chemotherapy (cycles 1 and 3: doxorubicin 40 mg/m2, vincristine 1.2 mg/m2, cisplatin 75 mg/m2, lomustine 80 mg on days 3 and 4; cycle 2: vincristine 1.2 mg/m2, cisplatin 75 mg/m2, cyclophosphamide 600 mg/m2 day 1) followed by radiotherapy (RT) in 267 patients with resected NSCLC (8). Eight patients had stage I disease, 70 stage II, and 189 stage III. N2 disease was present in 137 of the stage III patients. No disease-free or overall survival differences were detected (p ⫽ .68). Median survival in the RT group was 15.4 months; it was 14.9 months in the combined arm. Though analysis by stage was not performed, subset analysis of the 137 patients with N2 disease revealed a significant improvement in disease-free survival (p ⫽ .002) and a decrease in the number of deaths in the combined treatment arm when compared to the radiotherapy only arm (p ⫽ .003). This was attributed to a decrease in the number of metastatic occurrences. However, patients with N0 and N1 disease who received both radiotherapy and chemotherapy actually had a statistically significant poorer survival than those patients who received radiotherapy alone (p ⫽ .03). Once again, though some biological effect may have been present, convincing survival benefit was lacking. Three phase III trials from Japan have appeared in the English language literature (9–11). In a study coordinated by the National Kyushu Cancer Center (9), 209 patients with completely resected stage IIIA NSCLC were randomized to either observation or three cycles of monthly vindesine (3 mg/m2, days 1 and 8) and cisplatin (80 mg/m2 day 1). A total of 119 of the 181 eligible patients had N2 disease. Neither the disease-free interval nor the overall survival was different between the two groups. The remaining two Japanese trials incorporated long-term therapy with uracil and futrafur, a unique chemotherapy combination not yet investigated in patients with NSCLC in the United States and Europe. Futrafur (tegafur, FT) is an orally administered fluorourcil derivative that is converted in vivo to 5-FU. Degradation of the 5-FU is inhibited by the concomitant administration of uracil.
188
Keller and Small
The combination is known as UFT. The results of these trials are difficult to interpret because of the vagaries of the staging systems utilized and the manner in which the data were analyzed. Wada et al. reported the results of a three-arm adjuvant chemotherapy trial for the West Japan Study Group for Lung Cancer Surgery (10). A total of 323 patients with NSCLC were randomized to either surgery alone, surgery ⫹ UFT (400 mg daily ⫻ 1 year) or surgery ⫹ cisplatin (50 mg/m2 ⫻ 1) and vindesine (2–3 mg/kg ⫻ 3 at 2-week intervals) followed by UFT (400 mg daily ⫻ 1 year). The majority of patients (n ⫽ 210) had stage I disease, while 36 patients had stage II disease and 55 had stage IIIA disease. The 5-year survival for those patients who received cisplatin-vindesine-UFT, UFT alone, or no postoperative treatment was 60.6%, 64.1%, and 49.0%, respectively. The differences among the three groups approached statistical significance (log-rank p ⫽ .053, Wilcoxon p ⫽ .044). The difference between the UFT group and the control arm was statistically significant, though the difference between the cisplatin-vindesine-UFT arm and the no-treatment arm approached, but did not reach, significance. Unfortunately, analysis by stage was not presented, so it remains unknown whether these findings hold for patients with stages II and IIIA NSCLC. The Study Group of Adjuvant Chemotherapy for Lung Cancer from Chuba, Japan conducted a two-arm trial in which 383 patients with resected NSCLC were randomized to either surgery alone or surgery ⫹ cisplatin 66 mg/m2 ⫻ 1, adriamycin 26 mg/m2 ⫻ 1, and oral UFT 8 mg/kg/day ⫻ 6 months (11). 29 patients had stage II disease and 78 patients were stage III, the remainder were pathological stage I. When all 309 eligible patients were analyzed by treatment arm, no significant difference in survival was apparent. The authors noted, however, that there existed a statistically significant greater number of patients with nodal metastases in the treatment arm. They consequently reanalyzed the data using Cox’s proportional hazard model to adjust for this imbalance and found a significant improvement in survival for the patients treated with chemotherapy (p ⫽ .044). However, the authors later stated that this apparent survival advantage was limited to node-negative patients and was not present for those patients with nodal metastases. In fact, survival was actually worse for those patients with N2 disease who were treated with chemotherapy. A phase III adjuvant radiotherapy trial was recently reported by Mayer et al. from Austria (12). A total of 155 patients with NSCLC who had undergone complete resection and mediastinal lymph node dissection were randomized to either no further treatment or radiotherapy (50–56 Gy in 2-Gy daily fractions, 5 ⫻/week). The 116 patients with N1 or N2 disease received the higher dose. No significant difference was present between the two arms or among the nodal subgroups. Local recurrence, however, was significantly decreased in those patients who had received radiotherapy.
Adjuvant Therapy for NSCLC: Con
189
The Eastern Cooperative Oncology Group conducted a randomized, prospective phase III trial of adjuvant therapy in patients with resected stages II and IIIA NSCLC (13). The objectives of the study were to determine if concomitant chemoradiotherapy was superior to radiotherapy alone in prolonging survival and preventing local tumor recurrence. A total of 488 patients who had undergone complete resection of the primary tumor and a thorough mediastinal lymph node sampling or dissection were randomized between April 1991 and February 1997 to receive either four cycles of cisplatin (60 mg/m2, day 1) and VP-16 (120 mg/ m2, days 1–3) administered concurrently with RT (5040 cGy in 28 daily 180cGy fractions) or RT alone. Patients were stratified by weight loss (⬍5% vs. ⬎5%), histology (squamous vs. other), nodal biopsy technique (sampling vs. complete lymph node dissection), and stage (II vs. IIIA). A total of 351 patients were eligible for analysis with a median follow-up of 37 months; 121/183 (66%) of patients in the chemoradiotherapy arm received all four cycles of chemotherapy, while 139 (76%) received the planned radiotherapy, and 83% (139/168) of patients in the radiotherapy-only arm received the requisite radiotherapy. Grades 3 or 4 toxicity consisting largely of leukopenia and esophagitis occurred in 8.8% and 1.3% of patients who received radiotherapy alone, and 25% and 65% of patients who received chemoradiotherapy. Treatment-associated mortality was 2.2% in the chemoradiotherapy arm and 2.4% in the radiotherapy arm. Median survival in the radiotherapy arm was 41.1 months and 38.6 months in the combined-modality arm (p ⫽ .99). Analysis of the stratified subgroups showed no statistically significant survival advantage for either treatment arm. Similarly, comparison of the eligible and ineligible patients revealed no survival difference. META-ANALYSIS The previously summarized adjuvant phase III trials are those that employed modern treatment modalities and contained sufficient data regarding TNM staging, drug administration, and radiotherapy techniques to permit accurate analysis. Though the trials required the participation of multiple investigators and numerous years to reach their accrual goals, each individual study contained insufficient numbers of patients to permit detection of fine differences between the treatment arms. In an effort to overcome this problem, which is common to most areas of clinical research, the statistical methods of meta-analysis were applied. Appropriate trials were identified via literature searches and personal communication with experts in the subject of interest. Data from disparate studies were collected, updated, and collated. The resulting large number of patients permits a greater statistical power to identify small differences among treatment groups. Though meta-analysis has achieved recent popularity and widespread utilization, not all statisticians are convinced of its accuracy or utility (14,15). Indeed, it is our
190
Keller and Small
opinion that the subtleties of clinical trials render the conclusions of meta-analyses suspect. With these caveats stated, the published meta-analyses of adjuvant chemotherapy and radiotherapy can be reviewed. The Non–Small Cell Lung Cancer Collaborative Group published a metaanalysis of chemotherapy trials that were conducted between 1965 and 1991 (16). Among the 52 randomized studies containing 9387 patients with the requisite details regarding staging, treatment, and survival were 14 adjuvant therapy trials containing 4357 patients who were randomized to postoperative chemotherapy or observation, and seven studies containing 807 patients who received either adjuvant radiotherapy or combination chemoradiotherapy. The 14 adjuvant-chemotherapy trials were further divided into three groups: five containing alkylating agents (2145 patients), eight containing cisplatin (1394 patients), and four containing other drugs, principally tegafur or UFT (918 patients). (Note: some of the publications contained the results of more than one chemotherapy trial and are counted twice.) The utilization of alkylating agents proved detrimental to survival, causing a 15% increased risk of death and decreasing survival at 2 and 5 years by 4% and 5%, respectively (p ⫽ .005). However, the cisplatin-containing regimens proved beneficial, producing a 13% decrease in the risk of death and improving survival at 2 and 5 years by 3% and 5%, respectively. This improved survival approached, but did not reach, statistical significance (p ⫽ .08). The trials containing ‘‘other’’ drugs demonstrated no significant survival difference between the study arms (p ⫽ .30). Six of the seven trials comparing adjuvant radiotherapy to chemoradiotherapy employed a cisplatin-containing regimen. Analysis demonstrated a 6% reduction in the risk of death favoring combined chemoradiotherapy, though the 2% improved survival at 2 and 5 years was not statistically significant (p ⫽ .46). The authors stated that analysis of each chemotherapy group by stage failed to identify a subgroup that either sustained a greater benefit or was more adversely affected by treatment. The PORT Meta-analysis Trialists Group recently reported their meta-analysis of nine adjuvant trials containing 2128 patients with resected stages I–IIIa NSCLC who were randomized to either radiotherapy or no further treatment (17). Postoperative radiotherapy was associated with a 21% relative increase in the risk of death and 7% decrease in 2-year survival (55% vs. 48%, p ⫽ .001). Local and distant recurrence-free survival were also adversely affected by radiotherapy (p ⫽ .005, p ⫽ .007, respectively). Similarly, analysis of overall recurrence-free survival demonstrated a 13% relative increase in the risk of recurrence or death and a 4% reduction in the 2-year recurrence-free survival (46% vs. 50%, p ⫽ .018). Subgroup analysis by stage revealed that the greatest adverse effect of postoperative radiotherapy occurred in patients with stage I disease. A less unfavorable effect was demonstrated in patients with stage II disease, and neither a beneficial nor a detrimental effect was seen in patients with stage III disease.
Adjuvant Therapy for NSCLC: Con
191
TABLE 1 ECOG 3590 Morbidity RT n ⫽ 230 Grade 3 Leukopenia Granulocytopenia Thrombocytopenia Anemia Nausea Emesis Esophagitis
4
⬍1% 1% ⬍1% 1% ⬍1% 1%
RT ⫹ chemo n ⫽ 232 Grade 3
4
41% 14% 13% 13% 20% 10% 14%
38% 60% 5% 1% 5% 3%
MORBIDITY AND MORTALITY The extent and severity of adjuvant-therapy-induced morbidity and mortality are difficult to assess owing to a lack of uniform definitions and reporting. The LCSG documented only one death among the 543 patients entered in the three adjuvant trials previously cited (5–7). The majority of hematological, gastrointestinal, and pulmonary toxicities were grade 3 or less. As expected, the morbidity for those patients who received combined treatment was greater than for those who received radiotherapy alone. The Japanese reported similar data, with no treatmentrelated deaths among the 837 patients included in the three adjuvant-therapy trials (9–11). However, Dautzenberg et al. reported 17 (6.4%) treatment-related deaths among the 267 patients in the French trial (five in the radiotherapy arm and 12 in the radio/chemotherapy arm) (8). Three patients in the radiotherapy arm and two patients in the combined arm developed bronchopleural fistula. In addition, grade 3–4 hematological toxicity was present in 6% of patients, gastrointestinal in 8%, and other organ systems in 2%. Keller et al. (13) documented seven deaths (1.4%) among the 488 patients registered in the ECOG trial (Table 1). Treatment morbidity was, as expected, worse in the combined-treatment arm. Grade 4 granulocytopenia and leukopenia occurred in 60% and 38% of patients, respectively.
ADJUVANT THERAPY—WHY IS IT NOT MORE SUCCESSFUL? Radiation and chemotherapy have been utilized both individually and in combination as adjuvant treatments following complete resection of NSCLC. These cyto-
192
Keller and Small
TABLE 2 Administration of Chemotherapy Trial LCSG 772 (5) LCSG 791 (7) Ohta (9) Wada (10) SGACLC (11) Dautzenberg (8) Keller (13)
Planned cycles
% of patients who received the planned cycles
6 6 3 1c 1b 3 4
58%a 51% 41% 75%d 85% 76% 66%
a
Average cumulative dose of all patients randomized to receive chemotherapy. One initial dose followed by daily oral drug for 6 months (see text). c One initial dose followed by daily oral drug for 1 year (see text). d All patients received the initial chemotherapy dose. This figure represents the percentage of planned daily drug actually received. b
toxic modalities are thought to be most effective with small numbers of rapidly dividing cells. Yet, despite the presence of only micrometastatic disease following complete resection of the primary tumor, and laboratory evidence that documents the entry of those micrometastases into a growth phase following resection of the primary tumor (18,19), adjuvant therapy has proven ineffective. Other theoretical considerations regarding the timing of treatment in relation to operation, the number of drugs, and their mechanisms of action, as well as the order in which the two modalities are administered, have also not yet proven clinically relevant (20,21). Practical aspects of adjuvant-therapy administration have, however, proved significant. Following surgery, many of the patients are unable to receive all the planned chemotherapy cycles (Table 2). Concomitant chemotherapy and radiotherapy compounds this problem. CURRENT TRENDS Though adjuvant therapy for resected stages II and IIIA NSCLC has proved disappointing, new studies with different drugs and dosage schedules are being investigated. Following operation, patients with N1 (stage II) disease are eligible for participation in the National Cancer Center of Canada adjuvant trial NCIC BR.10. Patients are randomized to either observation or chemotherapy (four cycles of monthly cisplatin and weekly vinorelbine). The principal clinical objectives of the trial are: (1) to compare the duration of overall survival between completely resected patients who have received either adjuvant chemotherapy or
Adjuvant Therapy for NSCLC: Con
193
TABLE 3 Current Adjuvant Therapy Trialsa Group b
NCIC CALGBf CALGBf EUe EUe EUe EORTCc GETCBd GETCBd
Protocol number
Therapy
Accrual goal
Eligibility
BR10 9633 9734 94043 96010 97010 08861 04CB86 05CB88
CT/observation CT/observation CT/CT ⫹ RT CT/observation CT/observation CT/observation RT/observation RT/observation RT/observation
600 504 480 1840 3300 750 106 189 539
T2N0,T1–2N1 T2N0 Stage IIIA Stages I–IIIA Stages I–IIIA Stages I–IIIA Stage II–III Stage I–III Stage I–III
a
See text for details. National Cancer Institute of Canada. c European Organization for Research and Treatment of Cancer. d Groupe d’Etude et de Traitement des Cancers Bronchiques. e European Union. f Cancer and Leukemia Group B. b
observation alone and (2) to measure and compare health-related quality of life in both treatment arms throughout the study period. Accrual of the 600 necessary patients is underway and is expected to require 5.5 years. A CALGB trial, limited to stage IB patients, uses a similar approach in resected patients, comparing four cycles of adjuvant carboplatin-paclitaxel to observation. In another CALGB trial, patients with resected stage IIIa disease are randomized to chemotherapy (carboplatin/paclitaxel) versus chemotherapy (same agents) followed by mediastinal radiation. A number of European adjuvant therapy trials include patients with stages I–IIIA NSCLC (Table 3). Following resection of stages I–IIIA NSCLC, the European Union is randomizing 1840 patients to receive either chemotherapy consisting of mitomycin, vindesine, and cisplatin or no further therapy (EU 94043). Radiotherapy may be administered at the discretion of each institution. If employed, it will be given in both study arms. In another study with similar stages (EU 96010), 3300 patients will be randomized to receive three cycles of chemotherapy consisting of cisplatin and either a vinca alkaloid or etoposide or no further therapy. Individual institutions have the option to administer sequential radiotherapy. Finally, 750 patients with resected stages I–IIIA will be randomized to receive three cycles of cisplatin and etoposide or no further treatment (EU 97010). Radiation may be administered at the discretion of the treating physician. Three additional trials evaluating adjuvant radiotherapy have been completed, but not yet reported (17).
194
Keller and Small
The introduction of new chemotherapeutic agents with increased effectiveness has raised the hope of prolongation of life in patients with NSCLC. The decreased toxicity associated with these drugs has permitted their use after surgery with little or no increase in surgical morbidity or mortality. In addition, improvements in radiotherapy techniques have enabled more accurate and less toxic administration following operation. To conclusively demonstrate the role of adjuvant therapy, patients should be encouraged to participate in controlled, randomized prospective trials. REFERENCES 1. Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ. Survival after resection of stage II non–small cell lung cancer. Ann Thorac Surg 1992; 54: 460–466. 2. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non–small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1994; 107:1398–1402. 3. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non– small cell lung cancer with ipsilateral mediastinal node metastases (N2 disease). J Thorac Cardiovasc Surg 1994; 107:19–28. 4. Dalton R, Keller S. Survival following resection of clinically occult N2 non small cell lung cancer. J Cardiovasc Surg 1994; 35(suppl. 1 to no. 60):13–17. 5. Holmes EC, Gail M, The Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4:710–715. 6. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377–1381. 7. The Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988; 6:9–17. 8. Dautzenberg B, Chastang C, Arriagado R, Le Chevalier T, Belpomme D, Hurdebrourcq M, Lebeau B, Fabre C, Charvolin P, Guerin RA, for the GETCB (Groupe d’Etude et de Traitement des Cancers Bronchiques). Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non–small cell lung carcinoma. Cancer 1995; 76:779–786. 9. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, Suemasu K, Watanabe Y, Tomita M, Terashima M, and the Japan Clinical Oncology Group. Adjuvant chemotherapy for completely resected stage III non–small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106:703–708. 10. Wada H, Hitomi S, Teramatsu T, the West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection on non–small-cell lung cancer. J Clin Oncol 1996; 14:1048–1054. 11. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chuba, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995; 21:69–77.
Adjuvant Therapy for NSCLC: Con
195
12. Mayer R, Smoole-Juettner FM, Szolar D, Stuecklschweiger GF, Quehengerger F, Friehs G, Hackl A. Postoperative radiotherapy in radically resected non–small cell lung cancer. Chest 1997; 112:954–959. 13. Keller SM, Adak S, Wagner H, Kerskovic A, Brooks BJ, Perry MC, Livingston RB, Johnson DH. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIA non-small cell lung cancer: an intergroup trial (E3590). Proc ASCO 1999; 18:465a. 14. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536–542. 15. Bailar JC. The promise and problems of meta-analysis. N Engl J Med 1997; 337: 559–560. 16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non–small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899–909. 17. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 1998; 352:257–263. 18. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal of the growth and kinetics of residual tumor. Cancer Res 1979; 39:3861–3865. 19. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43:1488–1492. 20. Surbone A, Gilewski TA, Norton L. Cytokinetics. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR eds. Cancer Medicine. Baltimore: Williams Wilkins, 1997:769–798. 21. Goldie JH, Coldman AJ, Gudauskes GA. Rationale for the use of alternating noncross-resistant chemotherapy. Cancer Treat Rep 1982; 66:439–449.
12 Surgery for Potentially/Marginally Resectable Pathological N 2 NSCLC: Pro William H. Warren Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois
INTRODUCTION Complete surgical resection has provided the best local control and the best 5year survivals for stage I and stage II carcinoma of the lung. Many studies have failed to prove a survival advantage with the addition of immunotherapy, chemotherapy, or radiotherapy, either alone, or in any combination. Surgical resection alone is adequate for these stages of malignancy and reflects the relative ineffectiveness of other modes of therapy. Stage III lung cancer, however, presents a different clinical challenge. While, by definition, the tumor is still localized to the thorax, complete surgical extirpation is much more difficult to accomplish. Even in patients assessed to have undergone a complete resection (as determined by a pathological assessment of the specimen), the development of local/regional recurrence and/or distant metastases is a frequent occurrence. Early data documented that the 5-year survival of all stage III patients undergoing resection alone is only 5%. This sobering statistic has instigated a nihilistic approach to this stage of disease with the advo197
198
Warren
cation of palliative radiotherapy alone as an alternative to surgical resection. This attitude may still persist. Nevertheless, surgeons have continued to advise that, within the entire population of stage III patients, there is a subset for which surgical resection plays an important role. Recognizing that stage III was simply too heterogeneous to address this controversy, the early TNM staging system was modified in 1986 (1). Stage III was subdivided into stage IIIA and stage IIIB on the basis of ‘‘resectability’’ versus ‘‘unresectability’’ using the conventional criteria of the day. Many T4 tumors (stage IIIB), by virtue of involvement of the carina, superior vena cava, and left atrium, can now be resected safely with a long-term survival advantage over nonoperative care. Nevertheless, most patients with stage IIIB lung disease are not surgical candidates, particularly those with N 3 nodal involvement (2–5). Over the past 25 years, several studies have been published to attempt to define the best management of patients with stage IIIA lung carcinoma. The result of surgical therapy alone, while better than that of stage IIIB, has still been disappointing regardless of the scope of the resection. While generally the unaltered natural history of stage IIIA disease may be the same, evidence suggests that not all subtypes of this stage respond equally to therapeutic intervention. Encouraging results have been reported in surgically resected stage IIIA disease particularly in the absence of N 2 involvement (3,6,7). Many authors have demonstrated that T3 N 1 tumors (be they peripheral or central T3 carcinomas) respond better to surgical resection, with or without adjuvant therapy, than T1–2 N 2 , and especially T3 N 2 tumors, even though all are staged as IIIA tumors (8). Ichinose et al. observed that the 5-year survival after resection of stage IIIA (N 0 , N 1 ) tumors was 62.1% versus a 5-year survival of only 22.7% after resection of stage IIIA (N 2 ) tumors (9). The focus on stage IIIA (N 2 ) as a specific subset within stage IIIA is a more recent development and this distinction is increasingly being adopted in current clinical reports (10). This functional refinement in staging has realized that the majority of cases of surgically resected stage IIIA (N 2 ) recur with distant metastatic spread. Moreover, completely resected patients had an unacceptably high local/regional recurrence rate. These features have led to the incorporation of various local and systemic adjuvant therapies attempting to modify patterns of failure and/or to improve the long-term survival. The interpretation of the results of the many clinical trials has been problematic. The subject matter derives from many disciplines including radiation biology, pharmacokinetics, and immunology, and the trials are often retrospective, nonrandomized, and subject to considerable selection bias. Earlier reports failed to address specifically the subpopulation of stage IIIA disease with N 2 involvement. Nevertheless, many observations
Surgery for Pathological N 2 NSCLC: Pro
199
were made that help to define the role of surgical resection in this particular subset. PREDICTORS FOR FAVORABLE PROGNOSIS FOR SURGICAL RESECTION OF STAGE IIIA (N 2 ) DISEASE Over the past 25 years, several reports have attempted to define features that predict favorable outcome after surgical resection (11–17). These include patient characteristics, the scope of the surgical resection, and various tumor parameters, including mediastinal lymph node involvement. The performance status and overall health of a patient may determine whether a patient may participate in a given therapeutic intervention. This is important when comparing results of a trial of preselected patients and historical results of a patient population. In a radiotherapy series of ‘‘inoperable’’ patients considered to be ‘‘favorable’’ (i.e., Karnofsky Performance Status of 70 or greater and little or no weight loss), favorable patients had a better response to therapy than ‘‘unfavorable’’ patients (18). In a series comparing combined chemotherapy and radiotherapy with resection in patients identified as ‘‘eligible’’ or ‘‘ineligible’’ for resection, ‘‘eligible’’ and resected patients had a 3-year survival of 39% versus ‘‘ineligible’’ patients denied a resection with a 3-year survival of 18% (19). Another report compared the outcomes of patients receiving combined therapy with or without surgery, assessing patients eligible for surgery versus patients considered initially ineligible for surgery. In patients eligible for surgery who elected to undergo surgery, the 3-year survival was 52%; in contrast, those eligible, but who declined surgery, had a 3-year survival, no different than those ineligible for surgery (25% vs. 19%) (20). In these series, however, stage III (N 2 ) was not separately analyzed. Intuitively, patients with a better performance status present a lower operative risk and have a better long-term prognosis, even among patients with the same TNM stage. The selection bias to enlist only the favorable patients for aggressive therapy confounds interpretation of the results of most nonrandomized and randomized clinical trials. Complete surgical resection is also an important prognostic factor. Complete resection mandates that all microscopic margins are free of tumor after a complete mediastinal lymph node dissection. Sabanathan et al. demonstrated a 5-year survival of 42% in stage III patients undergoing a complete surgical resection, and a 0% 5-year survival in those undergoing ‘‘incomplete’’ resections (21). In two similar series of patients with stage IIIA (N 2 ) disease, the 5-year survival in patients undergoing a complete resection was significantly better than in those undergoing an incomplete resection (16,17). Suzuki et al. observed that complete resection (vs. incomplete resection) was one of four statistically significant and independent prognostic factors (15). The Lung Cancer Study Group (LCSG) ex-
200
Warren
tended the definition of complete resection to include the absence of metastatic tumor in the highest mediastinal lymph node. In a LCSG trial of preoperative chemoradiotherapy, Weiden and Piantadosi observed that the best local control was achieved after complete resection (vs. incomplete resection), especially if the tumor had undergone a complete histological response (22). The size and location of the primary tumor is another independent prognostic factor. Several series have reported that the T status impacts on prognosis, with T3 N 2 tumors having a 5-year survival of 0–20% (11–14,21,23,24). Size and location of the primary tumor may reflect the extent of the operation required for its removal. One study observed that patients with stage III (N 2 ) tumors requiring a pneumonectomy to accomplish complete resection had a worse prognosis that those undergoing a lobectomy (16). Some authors have been unable to confirm that the size of the primary tumor influences the long-term survival (25,26). According to Asamura et al., peripheral T1 tumors with N 2 metastases have a 44.5% 5-year survival after a complete resection (27). Additionally, Daly et al. found that patients with microscopically positive N 2 disease and whose primary tumor was peripheral had a survival advantage over similar patients in whom the tumor was central (28). Most investigators have recognized that the size and number of involved mediastinal lymph nodes impact on the results of surgical resection and longterm outcome. Several authors have distinguished between ‘‘clinically’’ positive, bulky or grossly involved nodes and ‘‘microscopically’’ positive or occult metastases discovered at the time of routine mediastinoscopy or surgical resection (10,29,31). Pearson et al. reported that in patients who had positive mediastinal nodes at the time of resection and negative nodes by mediastinoscopy, the 5-year survival after a complete resection was 41%; those who had positive nodes by mediastinoscopy and a ‘‘curative’’ resection had a 5-year survival of 15% (32). Nakanishi et al. reported a 21% 5-year survival in a group of patients with radiologically unsuspicious, but surgically discovered stage III (N 2 ) disease (17). Martini et al. and Watanabe et al. both reported a 33% 5-year survival in patients whose N 2 disease first became apparent at the time of thoracotomy and underwent a curative resection (11,33). Cybulsky et al. reviewed the preoperative CT scans of patients with completely resected stage IIIA (N 2 ) disease. In those patients found to have mediastinal nodes greater than or equal to 1 cm, the 5-year survival was 6.6% compared to 13.5% in those patients with mediastinal nodes 1 cm or less (34). Several authors have found that patients with disease limited to the lower mediastinal nodes had a better prognosis than those with disease in the upper mediastinal nodes. Patients with multiple levels of involvement had the worse survival (35–38). Upon reviewing their experience with surgical resection of stage IIIA (N 2 ) lung carcinoma, other investigators discovered that patients who had involvement at only one level had a significantly better 3-year survival
Surgery for Pathological N 2 NSCLC: Pro
201
than those with involvement at multiple levels (11,37,39,40). However, in all of these studies, there was no significant difference in survival 4 years after surgery. Patients with N 2 metastatic disease confined to the subaortic nodes (level 5,6) have a better prognosis than those with any other single level of mediastinal nodal involvement. Patterson et al. reported 23 patients undergoing a complete resection with N 2 disease confined to the subaortic nodes and the 5-year survival was 42% (41). Cybulsky et al. and Nakanishi et al. also reported that patients with carcinomas in the left upper lobe and N 2 nodal involvement limited to the subaortic nodes had a significantly better 5-year survival than other patients with more extensive N 2 disease (17,34). Others have been unable to validate this observation (25). On the other hand, patients with subcarinal nodal involvement (level 7) have a worse prognosis than other patients with N 2 disease in other locations (36). Naruke et al. observed that in patients with resected N 2 disease the 5-year survival was 29% with uninvolved subcarinal nodes and 9% if the subcarinal nodes were involved (42). Several histological characteristics have been identified as having prognostic significance. In an early report, Pearson et al. recognized that if the tumor had squamous differentiation, was intracapsular, and was microscopic, the 5-year survival of patients undergoing radiotherapy followed by complete resection was 31% (31). The distinction between intracapsular and extracapsular disease is easier to make on a mediastinal node dissected at the time of thoracotomy as opposed to nodal biopsy by mediastinoscopy (43). While the above data support the position that there are patients with stage IIIA (N 2 ) who would predictably do better in the short term with a complete surgical resection than with palliative radiotherapy, the overall long-term survival statistics after surgery alone are poor. The patterns of failure, site of first recurrence, and 5-year survival have all been documented and considered in devising adjuvant therapies. Over the last 25 years, numerous clinical trials have been conducted to attempt to improve these results. The outcomes of these trials will be outlined. ADJUVANT RADIOTHERAPY Preoperative external-beam radiotherapy was the first adjuvant therapy to be used in conjunction with surgical resection. In 1975, a large cooperative study was published that compared the results of 40-Gy external-beam radiotherapy to the mediastinum and primary tumor followed by surgical resection to surgical resection alone. Although no staging system was in use, survival in the two groups was almost identical (44). Another part of this study assessed the value of preoperative therapy in patients initially thought to be unresectable. Those patients who responded to radiotherapy and upon reassessment were considered to be potentially
202
Warren
resectable were randomized to surgery versus no surgery. Survival in these two groups was also not significantly different (44). In 1990, a similar, but nonrandomized trial was performed. Patients with stage III tumors underwent preoperative 40 Gy to the primary tumor and mediastinum over a 4-week period. Patients with (N 2 ) disease had a 5-year survival of 20%. Of the cases considered to be inoperable after radiotherapy, there were no 5-year survivors (45). Postoperative radiotherapy after complete resection for stage IIIA disease has also been studied. In 1990, Astudillo and Conill studied 146 patients with stage IIIA carcinoma treated by complete resection. Some patients were treated with postoperative radiotherapy in a nonrandomized fashion. The incidence of local/regional recurrence was marginally lower with the addition of postoperative radiotherapy, but there was no impact on survival (23). In 1980, Van Houtte reported on the effect of the administration of 60 cGy to the mediastinum after a complete resection. Not only was survival unaffected, but there was an additional detrimental effect in patients with squamous carcinoma undergoing a pneumonectomy (46). Nevertheless, others continued to find some improvement in local/ regional control and improvement in 3-year survival (47). In 1986, another trial for completely resected stage IIIA (N 2 ) disease randomized patients to receive 50 cGy radiation postoperatively to the mediastinum versus no additional therapy. There was some benefit with local/regional recurrence but there was no survival advantage with radiotherapy (48). All of these trials conclude that survival in completely resected stage III (N 2 ) patients was primarily determined by recurrence at distant sites, and that future trials should encompass effective systemic adjuvant therapy. ADJUVANT CHEMOTHERAPY The poor survival statistics for patients with stage IIIA (N 2 ) disease with local therapies of surgical resection and radiation, either in concert or alone, was a reflection of the high incidence of tumor recurrence at distant sites, often after good local control had been achieved. This is assumed to be on the basis of subclinical micrometastases at the time of diagnosis and unaffected by local therapies. This naturally led to the search for effective systemic therapy. Although immunotherapy has had many proponents and many theoretical advantages over conventional chemotherapy, the vast majority of the studies to date, especially those pertaining to patients with stage III carcinomas, have failed to demonstrate any survival benefit. In fact, several studies found a deleterious effect upon combining immunotherapy with conventional chemotherapy (49,50). Numerous studies have assessed the value of postoperative chemotherapy after complete resection of lung cancer (51–54). Unfortunately, many early trials failed to stratify for the TNM stage. Moreover, the agents available were only
Surgery for Pathological N 2 NSCLC: Pro
203
marginally effective against primary lung cancer. The mid-1980s marked a new era with the more consistent application of clinical staging and reporting. Furthermore, clinical trials focused on more uniform patient subpopulations. In addition, this period marks the advent of newer and more effective systemic agents. The combination of cyclophosphamide, doxorubicin, and cisplatin (CAP), or cisplatin, etoposide, and 5-FU evolved as standards against which other regimens have come to be measured. In the early 1980s, the LCSG assessed the potential benefit of adding cisplatin-based multiagent chemotherapy to radiotherapy after ‘‘incomplete’’ resections versus postoperative radiotherapy alone (55). A total of 119/151 patients had been identified as having stage IIIA (N 2 ) tumors, but this population was not analyzed separately. Although there was a survival advantage and a decrease in distant metastases at 1 year in the arm combining postoperative chemotherapy and radiotherapy, the advantage abated after 3 years. Other trials utilizing postoperative chemotherapy, either alone or in combination with radiotherapy, have also reported no long-term survival advantage over complete surgical resection alone (51,52). PREOPERATIVE ADJUVANT CHEMOTHERAPY WITH/WITHOUT RADIOTHERAPY Early experience with neoadjuvant chemotherapy (with or without radiotherapy) was disappointing, owing to the ineffective chemotherapeutic agents available prior to the advent of cisplatin. In contrast to the experience of postoperative adjuvant therapy, the administration of induction cisplatin-based chemo/ radiotherapy preoperatively has yielded encouraging results (6,14,30,56–70). There are several theoretical advantages in administering chemoradiotherapy in the preoperative setting. Chemotherapy treats not only the primary tumor, but also subclinical micrometastatic disease. In addition, several agents, including cisplatin and 5-FU, have been shown to have radiosensitizing properties, enhancing the effect of a given dose of radiotherapy. The addition of radiotherapy is designed to reduce the size of the primary tumor to provide a wider resection margin, and in some cases, to provide the opportunity to perform more conservative resections. Studies have shown that an excellent radiological response does not necessarily correlate with a complete pathological response. On the other hand, patients with only a partial or minimal radiological response may have undergone a complete histological response with only scar tissue remaining in the lung and mediastinal nodes (6,30). In other instances, metastatic disease evolves during the course of adjuvant therapy, often only discovered by restaging the patient prior to surgery. Hence, it is important to routinely reassess these patients with CT scan of the brain, chest, and upper abdomen, and with a nuclear
204
Warren
bone scan after adjuvant therapy and prior to resection. The exclusion of patients developing metastatic disease introduces a selection process that undoubtedly has helped to improve the results in the surgical arm. A multitude of phase I and II trials have documented that patients can tolerate these regimens with acceptable toxicity and operative mortality (56,58). In every study where patients with stage IIIA (N 2 ) carcinomas could be evaluated, the results favored the use of preoperative cisplatin-based adjuvant chemotherapy. Encouraging reports documented a higher rate of complete resection at the time of thoracotomy than historical controls of surgery with or without preoperative radiotherapy. The incidence of complete resection was also higher than seen historically with surgery alone. Complete surgical resection was found to be an important prognostic factor (5,6,8,10,15–17,19,21,22,30,56,70). The incidence of local/regional recurrence after a complete resection was also lower even though most patients died with distant recurrent disease (71–73). The brain was not only a common site for distant metastatic disease, but it was the most frequent site when distant metastatic disease was limited to a solitary site (56,60,74). Although this incidence could be reduced with prophylactic cranial radiotherapy, it did not seem to influence the long-term survival. Several phase III prospective randomized trials comparing induction chemotherapy and surgery to surgery alone have yielded encouraging results in stage IIIA N 2 disease (22,75–77). Rosell et al. did not separately analyze patients with N 2 disease, but the majority of patients in both treatment arms had documented stage III (N 2 ) carcinomas (78). There were no 3-year survivors in the surgeryalone arm compared with 7/30 patients surviving beyond 3 years undergoing preoperative chemotherapy. In a small study of remarkably uniform patients, Pass et al. also demonstrated a trend toward increased disease-free interval and survival time in patients treated with preoperative cisplatin-based chemotherapy and postoperative radiotherapy versus surgical resection and postoperative radiotherapy alone (75). Roth et al. compared cisplatin-based chemotherapy followed by surgical resection with surgical resection alone (79). Unfortunately, the course of stage IIIA (N 2 ) patients was not analyzed separately, but they represented the majority of cases in both arms of the trial. This trial, also, showed a clear advantage in favor of preoperative chemotherapy. Insight into the role of surgical resection in N 2 disease has been provided in a phase II study that identified 12 patients who had undergone preoperative chemoradiotherapy and were assessed to be resectable, but who refused surgery. Seven of the 12 patients refusing a thoracotomy underwent additional nonoperative therapy. Their clinical course was compared with that of 62 similar patients who completed the neoadjuvant therapy and underwent a thoracotomy (20). Approximately one-half of the patients in the study were assessed to have mediastinal nodal involvement. Although conclusions are soft from this small number of patients, the 3-year survival in those patients electing to have surgery was 52%
Surgery for Pathological N 2 NSCLC: Pro
205
compared with 25% in those patients who refused. Unfortunately, such followup and analysis of patients refusing surgery has been uncommon. PROGNOSTIC FACTORS IN STAGE IIIA (N 2 ) DISEASE AFTER PREOPERATIVE CHEMOTHERAPY (WITH OR WITHOUT RADIOTHERAPY) Those factors cited favoring a good prognosis after surgical resection alone presumably also apply after induction chemotherapy. Good performance status, underlying good health, smaller primary tumors, and minimal mediastinal node involvement can all be expected to favor a better long-term survival. A complete surgical resection has also been found to have prognostic significance after adjuvant preoperative chemotherapy. In addition, several reports have identified that patients with a complete pathological response (no viable tumor in specimen) have a better prognosis than similar patients found to have viable tumor in the resected specimen (45,56,80). The incidence of complete histological response among those subjected to thoracotomy after neoadjuvant therapy has ranged from 0 to 39% (5,6,22,30,62,68,69,81,82). Although complete response had occasionally been seen in patients undergoing preoperative radiotherapy alone, no survival advantage could be demonstrated in that setting, presumably because the patients had not undergone systemic therapy. Some authors have suggested that sterilization of previously involved mediastinal nodes (even with residual tumor in the lung and/or in N 1 nodes) may still have some prognostic significance (82). PROBLEMS ASSOCIATED WITH NEOADJUVANT CHEMORADIOTHERAPY Although the prognosis for patients with completely resected stage IIIA (N 2 ) carcinoma can be improved with the use of preoperative chemoradiotherapy, the operative morbidity and mortality may be increased. At thoracotomy the dissection may be tedious with tissue planes obliterated by an intense inflammatory reaction. Commonly the primary tumor has been ‘‘downstaged’’ by preoperative therapy, and a more conservative resection, including bronchial sleeve resection, can be performed provided it accomplishes a complete resection. Rendina et al. documented that the use of preoperative neoadjuvant therapy does not increase the incidence of complications with bronchial or vascular reconstruction (83). Nevertheless, there is an increase in postoperative morbidity, including pneumonia, atelectasis, deep venous thrombosis, atrial arrhythmias, and prolonged bronchopleural fistula. In the various phase II and III trials, the overall ‘‘treatment-related’’ mortality has been approximately 5% (1–15%). The incidence of ‘‘induction-related’’ mortality ranged from 0 to 7%; the 30-day perioperative mortality ranged from
206
Warren
0 to 10% (56). Of those patients who died in the postoperative period, most had undergone a pneumonectomy, and many developed ARDS and/or a bronchopleural fistula (6,84,85). In several series, the relatively high perioperative mortality has been linked to the incidence of pneumonectomy (66,84). An attempt to perform a curative resection with less than a pneumonectomy is preferable, especially after neoadjuvant therapy. Although the overall survival of patients with stage IIIA (N 2 ) carcinoma remains disappointingly low, complete surgical resection may still provide the best form of local/regional control. The incidence of local/regional recurrence is much lower than in those patients who have not undergone a resection. Other advantages of resection include obtaining tissue for tumor marker assay and chemosensitivity analysis. To date, neither of these has been found to be clinically valuable but may in the near future help determine prognosis and further management strategies. CONCLUSION Although the overall long-term prognosis for patients with stage IIIA (N 2 ) carcinoma of the lung remains poor, surgical resection (with or without adjuvant therapy) has certainly provided the best results for the minority of patients with minimal mediastinal lymphadenopathy. More effective systemic control is necessary, and at present, surgical resection offers the best local/regional control. Even with a large mediastinal tumor burden, ‘‘complete’’ surgical resection has provided the best means of local/regional control. It can be performed with acceptable morbidity and mortality. The long-term survival has been shown to be improved by the addition of chemoradiotherapy. The advantage of surgical resection in stage IIIA (N 2 ) patients after induction chemoradiotherapy over chemoradiotherapy alone remains to be proven. Currently, there are several prospective randomized clinical trials (RTOG 9309, CALGB 9531, CALGB 9592) comparing neoadjuvant chemoradiotherapy followed by surgical resection versus chemoradiotherapy alone. The results of these trials are anxiously awaited. REFERENCES 1. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225–233s. 2. Warren WH, Faber LP. Extended resections for locally advanced pulmonary carcinomas. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven, 1996:567–584. 3. Martini N, Yellin A, Ginsberg RJ, Bains MS, Burt ME, McCormack PM, Rusch VW. Management of non–small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg 1994; 58:1447–1451.
Surgery for Pathological N 2 NSCLC: Pro
207
4. Macchiarini P, Chapelier AR, Monnet I, Vannetzel JM, Rebischung JL, Cerrina J, Parquin F, Ladurie FLR, Lenot B, Dartevelle PG. Extended operations after induction therapy for stage IIIB (T4 ) non–small cell lung cancer. Ann Thorac Surg 1994; 57:966–973. 5. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R, Livingston RB, Griffin BR, Benfield JR. Surgical resection of stage IIIA and stage IIIB non–small cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993; 105:97– 106. 6. Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor IV SG, Reddy S, Lee MS. Preoperative chemotherapy and irradiation for stage III non–small cell lung cancer. Ann Thorac Surg 1989; 47:669–677. 7. Burt ME, Pomerantz AH, Bains MS, McCormack PM, Kaiser L, Hilaris BS, Martini N. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin North Am 1987; 67:987–1000. 8. Bonomi P, Faber LP. Neoadjuvant chemoradiation therapy in non-small lung cancer: the Rush University experience. Lung Cancer 1993; 9:383–390. 9. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non–small cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110: 601–605. 10. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE, Demedts MG. Survival and prognostic factors in resected N 2 non–small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997; 63:1441–1450. 11. Martini N, Flehinger BJ, Zaman MB, Beattie EJ. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198:386–397. 12. Martini N. Flehinger BJ, Zaman MB, Beattie EJ. Results of surgical treatment in N 2 lung cancer. World J Surg 1981; 5:663–666. 13. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non– small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46:603–610. 14. Cangemi V, Volpino P, D’Andrea N, Chiarotti F, Tomassini R, Piat G. Results of surgical treatment of stage IIIA non–small cell lung cancer. Eur J Cardio-thorac Surg 1995; 9:352–359. 15. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. The prognosis of surgically resected N 2 non–small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 1999; 118:145–153. 16. Miller DL, McManus KG, Allen MS, Ilstrup DM, Deschamps C, Trastek VF, Daly RC, Pairolero PC. Results of surgical resection in patients with N 2 non–small cell lung cancer. Ann Thorac Surg 1994; 57:1095–1101. 17. Nakanishi R, Osaki T, Nakanishi K, Yoshino I, Yoshimatsu T, Watanabe H, Nakata H, Yasumoto K. Treatment strategy for patients with surgically discovered N 2 stage IIIA non–small cell lung cancer. Ann Thorac Surg 1997; 64:342–348. 18. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Perex CA. N 2 (clinical) non– small cell carcinoma of the lung: prospective trials of radiation therapy with total
208
19.
20.
21. 22.
23. 24.
25.
26.
27.
28.
29.
30.
31.
32.
Warren doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 20:7–12. Taylor MA, Reddy S, Lee MS, Bonomi P, Taylor IV SG, Kaplan E, Faber LP, Warren W, Hendrickson FR. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer 1994; 73:2599– 2606. Reddy S, Lee MS, Bonomi P, Taylor IV SG, Kaplan E, Gale M, Faber LP, Warren WH, Kittle CF, Hendrickson FR. Combined modality therapy for stage III non– small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 24:17–23. Sabanathan S, Richardson J, Mearns AJ, Goulden C. Results of surgical treatment of stage III lung cancer. Eur J Cardio-thorac Surg 1994; 8:183–187. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non–small cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83:266–272. Astudillo J, Conill C. Role of postoperative radiation therapy in stage IIIA non– small cell lung cancer. Ann Thorac Surg 1990; 50:618–623. Inoue K, Sato M, Fujimura S, Sakurada A, Takahashi S, Usuda K, Kondo T, Tanita T, Handa M, Saito Y, Sagawa M. Prognostic assessment of 1210 patients with non– small cell lung cancer who underwent complete resection from 1980–1993. J Thorac Cardiovasc Surg 1998; 116:407–411. Riquet M, Manac’h D, Saab M, Le Pimpec-Barthes F, Dujon J, DeBesse B. Factors determining survival in resected N 2 lung cancer. Eur J Cardio-thorac Surg 1995; 9: 300–304. Skarin A, Jochelson M, Sheldon T, Malcolm A, Oliynyk P. Overholt R, Hunt M, Frei E. Neoadjuvant chemotherapy in marginally resectable stage III M 0 non–small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266– 274. Asamura H. Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence and prognosis in resected, small, peripheral, non– small cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 1996; 111:1125–1134. Daly DBT, Mueller JD, Faling LJ, Diehl JT, Bankoff MS, Karp DD, Rand WM. N 2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 1993; 105:904–911. Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N 2 disease) in non–small cell carcinoma of the lung. A commentary. J Thorac Cardiovasc Surg 1990; 99:48–53. Martini N, Kris MG, Gralla RJ, Bains MS, McCormack PM, Kaiser LR, Burt ME, Zaman MB. The effects of preoperative chemotherapy on the resectability of non– small cell lung carcinoma with mediastinal lymph node metastases (N 2 M 0 ). Ann Thorac Surg 1988; 45:370–379. Pearson FG, Nelems JM, Henderson RD, Delarue NC. The role of mediastinoscopy in the selection of treatment for bronchial carcinoma with involvement of the superior mediastinal nodes. J Thorac Cardiovasc Surg 1972; 64:382–390. Pearson FG, Delarue NC, Ilves R, Todd TRJ, Cooper JD. Significance of positive
Surgery for Pathological N 2 NSCLC: Pro
33.
34.
35. 36.
37.
38.
39.
40.
41.
42.
43.
44. 45.
46.
47. 48.
209
superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83:1–11. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Watanabe S. Tatsuzawa Y, Iwa T, Suzuki M, Takashima T. Aggressive surgical intervention in N 2 non–small cell cancer of the lung. Ann Thorac Surg 1991; 51:253–261. Cybulsky IJ, Lanza LA, Ryan B, Putnam JB, McMurtrey MM, Roth JA. Prognostic significance of computed tomography in resected N 2 lung cancer. Ann Thorac Surg 1992; 54:553–557. Mountain CF. Surgery for stage IIIA-N 2 non–small cell lung cancer. Cancer 1994; 73:2589–2598. Thomas PA, Piantadosi S, Mountain CF. Should subcarinal nodes be routinely examined in patients with non–small cell lung cancer? J Thorac Cardiovasc Surg 1988; 95:883–887. Maggi G, Casadio C, Mancuso M, Oliaro A, Cianci R, Ruffini E. Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg 1990; 75:17–21. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resection pN 2 non–small cell lung carcinomas: what is the significant node that affects survival? J Thorac Cardiovasc Surg 1999; 118:270–275. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non– small cell lung cancer with ipsilateral mediastinal node metastasis (N 2 disease). J Thorac Cardiovasc Surg 1994; 107:19–28. Conill C, Astudillo J, Verger E. Prognostic significance of metastases to mediastinal lymph node levels in resected non–small cell lung carcinoma. Cancer 1993; 72: 1199–1202. Patterson GA, Piazza D. Pearson FG, Todd TRJ, Ginsberg RJ, Goldberg M, Waters P, Jones D, Ilves R, Cooper JD. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg 1987; 43:155–159. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76: 832–839. Theunissen PHMH, Bollen ECM, Koustaal J, Thunnissen FBJM. Intranodal and extranodal tumor growth in early metastasised non–small lung cancer: problems in histological diagnosis. J Clin Pathol 1994; 47:920–923. Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial: a collaborative study. Cancer 1975; 36:914–925. Reddy S, Faber LP, Baumann LA, Lee MS, Jensik RJ, Kittle CF, Bonomi PD, Taylor SG IV, Hendrickson FR. Preoperative radiation therapy in regionally localized stage III non–small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys 1990; 19:287–292. Van Houtte P, Rocmans P, Smets P, Goffin JC, Lustman-Marechal J, Vanderhoeft P, Henry J. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980; 6:983–986. Chung CK, Stryker JA, O’Neill M, DeMuth WE. Evaluation of adjuvant postoperative radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1982; 8:1877–1880. Weisenburger TH, Gail M. Effects of postoperative mediastinal radiation on com-
210
49.
50.
51. 52.
53.
54. 55. 56.
57.
58.
59.
60.
61.
Warren pletely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377–1381. Anthony HM, Mearns AJ, Mason MK, Scott DG, Moghissi K, DeVerall PB, Rozycki ZJ, Watson DA. Levamisole in surgery of bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 1979; 34:4–12. Ruchdeschel JC, McNeally MF, Baxter DH, De Vore C, Kellar S, Killam D, Caradonna R, Sedransk N, McIlduff JB, Horton J. Regional immunotherapy has a detrimental effect on the response to combined irradiation and chemotherapy in locally advanced non–small cell lung cancer. Cancer Immunol Immunother 1981; 11:227– 282. Holms EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4:710–715. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, Suemasu K, Watanabe Y, Tomita M, Terashima M. Adjuvant chemotherapy for completely resected stage III non–small cell lung cancer. Results of a randomized prospective study. J Thorac Cardiovas Surg 1993; 106:703–708. Katsuki H, Shimada K, Koyama A, Okita M, Yamaguchi Y, Okamoto T. Longterm intermittent adjuvant chemotherapy for primary resected lung cancer. J Thorac Cardiovasc Surg 1975; 70:590–605. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non–small cell lung cancer. J Clin Oncol 1996; 14:1048–1054. Lad T, Rubenstein L, Sadeghi A. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988; 6:9–17. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non–small cell lung cancer. Mature results of a phase II trial. J Clin Oncol 1998; 16:622–634. Vokes EE, Bitran JD, Hoffman PC, Ferguson MK, Weichselbaum RR, Golomb HM. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a Phase II study. Chest 1989; 96:110–113. Bitran JD, Golomb HM, Hoffman PC, Albain K, Evans R, Little AG, Purl S, Skosey C. Protochemotherapy in non–small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report. Cancer 1986; 57:44–53. Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non–small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237–1244. Kim DH, Lynch TJ, Mentzer SJ, Lee TH, Strauss GM, Elias AD, Skarin A, Sugarbaker DJ. Multimodality therapy of patients with stage IIIA, N 2 non–small cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. J Thorac Cardiovasc Surg 1993; 106:696–702. Burkes RL, Ginsberg RJ, Shephard FA, Blackstein ME, Goldberg M, Waters PF, Patterson GA, Todd T, Pearson FG, Cooper JD, Jones D, Lockwood G. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable
Surgery for Pathological N 2 NSCLC: Pro
62.
63.
64.
65.
66. 67.
68.
69.
70.
71.
72. 73.
74.
211
non–small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10:580–586. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MH, Green MR. Results of Cancer and Leukemia Group B protocol 8935. A multiinstitutional phase II trimodality trial for stage III (N 2 ) non–small cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 473–485. Taylor IV SG, Murthy AK, Bonomi P, Reddy S, Lee MS, Faber LP, Mathisen DJ. Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non–small cell lung cancer. NCI Monogr 1988; 6:327–329. Takita H, Regal AM, Antkowiak JG, Rao UNM, Botsoglou NK, Lane WW. Chemotherapy followed by lung resection in inoperable non-small cell lung carcinomas due to locally far-advanced disease. Cancer 1986; 57:630–635. Bonomi P, Rowland K, Taylor IV SG, Reddy S, Lee MS, Faber LP, Warren W. Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non–small cell bronchogenic carcinoma. Semin Oncol 1986; 13(suppl 3):115–120. Rusch VW, Benfield JR. Neoadjuvant therapy for lung cancer: a note of caution. Ann Thorac Surg 1993; 55:820–821. Sridhar KS, Thurer R, Kim Y, Fountzilas G, Davila E, Donnelly E, Charyulu KKN, Saldana MJ, Thompson T, Benedetto P, Raskin N, Beattie EJ. Multimodality treatment of non–small cell lung cancer: response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy. J Surg Oncol 1988; 38:193–215. Recine D, Rowland K, Reddy S, Lee MS, Bonomi P, Taylor IV SG, Faber LP, Warren W, Kittle CF, Hendrickson FR. Combined modality therapy for locally advanced non–small cell lung cancer. Cancer 1990; 66:2270–2278. Rice TW, Adelstein DJ, Ciezki JP, Becker ME, Rybicki LA, Farver CF, Larto MA, Blackstone EH. Short-course induction chemoradiotherapy with paclitaxel for stage III non–small cell lung cancer. Ann Thorac Surg 1998; 66:1909–1914. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, Heelan R, McCormack PM, Pisters KMW, Rigas JR, Rusch VW, Ginsberg RJ. Preoperative chemotherapy for stage IIIA (N 2 ) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365–1374. Eagan RT, Ruud C, Lee RE, Pairolero PC, Gail MH. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M 0 non–small cell lung cancer. Cancer Treat Rep 1987; 71:895–900. Holmes EC. Surgical adjuvant therapy of non–small cell lung cancer. J Surg Oncol 1989; I(suppl):26–33. Ciriaco P, Rendina EA, Venuta F, DeGiacomo T, Della Rocca G, Flaishman I, Baroni C, Cortesi E, Bonsignore G, Ricci C. Preoperative chemotherapy and immunotherapy for locally advanced stage IIIA and IIIB non–small cell lung cancer. Preliminary results. Eur J Cardio-thorac Surg 1995; 9:305–309. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi III AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N 2 ) and IIIB non–small cell lung cancer: mature
212
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
Warren results of South Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880– 1892. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53: 992–998. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non–small cell lung cancer. N Engl J Med 1990; 323:940–945. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non–small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210–1215. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non–small cell lung cancer. N Engl J Med 1994; 330:153– 158. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, DeCaro L, Chasen M, McGavran M, Atkinson EN, Hong WK. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small cell lung cancer. J Natl Cancer Inst 1994; 86:673–680. Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non–small cell lung cancer following preoperative chemotherapy: implications for the design of future non–small cell lung cancer combined modality trials. J Clin Oncol 1993; 11:1757–1762. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T, Grossbard M, Grillo H. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non–small cell lung cancer. J Clin Oncol 1997; 15:712–722. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, Grossbard M, Lynch T, Grillo H. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N 2 ) non–small cell lung cancer. J Thorac Cardiovasc Surg 1996; 111:123–133. Rendina EA, Venuta F, DeGiacomo T, Flaishman I, Fazi P, Ricci C. Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer. J Thorac Cardiovasc Surg 1997; 114:830–837. Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, VanKirk MA, Taylor ME, Olencki TE, Peereboom D, Budd GT. Accelerated induction therapy and resection for poor prognosis stage III non–small cell lung cancer. Ann Thorac Surg 1995; 60: 586–592. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993; 55:986– 989.
13 Surgery for Potentially/Marginally Resectable Pathological N2 NSCLC: Con Elizabeth M. Gore and Roger W. Byhardt Medical College of Wisconsin, Milwaukee, Wisconsin
INTRODUCTION Patients with ipsilateral mediastinal lymphadenopathy (N2) non–small cell lung cancer (NSCLC) are a heterogeneous group with varying prognoses. When N2 disease is diagnosed preoperatively by CT scan or chest x-ray (clinical N2), the prognosis is worse than when N2 involvement is microscopic, diagnosed with mediastinoscopy or at the time of thoracotomy (minimal N2). Additional prognostic factors include extent of tumor within the nodes, extracapsular extension, multiple nodal levels, multiple nodes at a single level, nodal station, and histology (1,2). Controversy exists over the most appropriate management of N2 disease owing to inconsistent pathological documentation and grouping of patients with other T and N stages. The majority of patients with N2,M0 disease are grouped into stage IIIA, which is potentially resectable, locally advanced disease. T4, N2 (in addition to T4,N0–1, and N3) is IIIB disease. Subclassification of IIIA disease, based on T stage and degree of N2 involvement, has been proposed (3). Outcome with multimodality therapy differs between subsets making the distinctions relevant when choosing and comparing different therapies. 213
214
Gore and Byhardt
Comparing surgical and nonsurgical trials for NSCLC is particularly difficult. Generally patients treated with radiation are referred by surgeons not recommending resection because of disease bulk or medical contraindication. This group is clearly not comparable to those receiving an operation. Distant micrometastases are present in ⱖ60% of patients with N2 disease (3), emphasizing the need for effective systemic treatment. Adjuvant chemotherapy has been shown to decrease distant metastases. In addition, chemotherapy as part of multimodality therapy is effective in improving local control in both surgical and nonsurgical management of stage III disease. Studies with the most encouraging results use multimodality therapy. The current recommendation for minimal N2 disease is resection (1,4,5), but controversy exists over whether pre- or postoperative chemotherapy and/or radiation improves survival. This recommendation is based on superior surgical results compared to standard radiotherapy for unresectable or medically inoperable disease. For bulky or clinical N2 disease chemoradiotherapy is standard of care. One question must be addressed: does surgical resection after induction chemoradiotherapy in a select group of clinical N2 patients improve outcome over chemoradiotherapy alone? Intergroup trial 0139 is a phase III trial designed to assess whether concurrent chemotherapy and radiotherapy followed by surgical resection results in a significant improvement in progression-free, median, and long-term survival compared to the same chemotherapy plus standard radiotherapy in patients with biopsy-proven T1-3,N2 NSCLC. This study is currently accruing patients. The results should help resolve these controversies.
MINIMAL N2 DISEASE Surgery Surgical resection of minimal N2 NSCLC results in 5-year survival rates of 10– 34%. Martini and Flehinger reported 3- and 5-year survivals of 47 and 34% after complete resection of clinical N0–1 /pathological N2 disease (1). This was a retrospective review of 151 patients who had complete resections for N2 NSCLC. Of the original 404 patients surgically explored, 224 had clinical N0–1 disease. In 53% (119/224) complete resection was possible. Survival rates are based on this very select group of patients with completely resected tumors. Ninety percent of the patients were treated with postoperative radiation. Locoregional failure was only 20%. In the series reported by Naruke et al., the 5-year survival for resected N2 disease was 19.2% (4). Pearson et al. reported 9% and 24% 5-year survival after resection of N2 disease with positive and negative mediastinoscopy, respectively (6).
Surgery for Pathological N2 NSCLC: Con
215
Randomized combined modality trials for minimal N2 disease include a National Cancer Institute (NCI) trial reported in 1992 comparing pre- and postoperative chemotherapy and postoperative radiation alone (7) and a Japanese trial of preoperative chemoradiotherapy versus resection alone (8). Neither study showed a survival advantage with induction therapy. Two- to 3-year survival in the Japanese trial was 37–40% and 21–46% in the NCI trial. Radiation Therapy Patients without clinical N2 disease, medically unfit for surgery and referred for radiation, are, unfortunately, not routinely mediastinoscoped and therefore not accurately staged. The incidence of occult mediastinal lymphadenopathy in clinical T1–3, N1 disease is approximately 25%. Radiation results in patients with clinically occult N2 disease are difficult to obtain. In ‘‘higher’’-performance-status patients and clinical N1 disease, treated with ‘‘standard’’ radiation (60 Gy given in 30 daily fractions 5 days per week), 5-year survival of 28% has been reported (9). Local control rates with ‘‘standard’’ radiation are poor. Evidence suggests that increasing the biological total dose of radiation improves local control. This can theoretically be accomplished with hyperfractionated radiation (10), threedimensional conformal radiation, and noncytotoxic radiosensitizers or low-dose cytotoxic chemotherapy given with radiation. It is expected that with conformal radiation, total doses can safely be escalated, improving local control while avoiding unacceptable doses to normal tissue volumes. This is now being evaluated by the RTOG. Hyperfractionated radiation can be used to increase the total dose of radiation given to the tumor without increasing normal tissue toxicity. With optimal radiation therapy in good-performance-status patients, local control and survival may be similar to that achieved with surgery and postoperative irradiation. As with surgical series, effective systemic therapy is necessary to improve the rate of response of distant metastases. CLINICAL N2 DISEASE As with minimal N2 disease, there is no completed prospective randomized trial that identifies whether surgery is beneficial after induction chemotherapy or chemoradiotherapy. Available studies have used heterogeneous patient populations. The surgical series include patients who are medically fit for surgery and have less bulky, technically resectable disease. Other patients with clinical N2 disease are generally referred for radiation. Historically, owing to poor results, radiation is frequently considered palliative. With the introduction of effective systemic chemotherapy, radiosensitizing chemotherapy, and new radiotherapy techniques,
216
Gore and Byhardt
more patients are receiving preoperative chemotherapy or chemoradiotherapy for downstaging followed by resection or various combinations of chemotherapy and radiation as definitive treatment. Surgery alone and radiation alone will be discussed to emphasize the similar poor results with single-modality therapy. Multimodality therapy with and without surgery will then be discussed. Surgery Martini and Flehinger have reported survival rates for clinical N2 disease, detected radiographically or by mediastinoscopy, treated with surgery and postoperative irradiation (1). In this retrospective review, 179 patients with clinical N2 disease were considered to have operable tumors. Only 32 (18%) had complete resections producing 3- and 5-year survival rates of 9%. Two small prospective randomized trials comparing surgery to preoperative chemotherapy and surgery for IIIA disease have been published (11,12). Ipsilateral mediastinal lymphadenopathy was clinically obvious on CT scans. Pathological confirmation of N2 disease was not required. It is important to note that as many as 35% of patients with positive mediastinal lymph nodes on CT scan will have negative nodes by mediastinoscopy (13). Median survivals for surgery alone were 8 and 11 months in both studies and 3-year survivals were 15% and 15% (Table 1). Both studies showed a survival advantage with preoperative chemotherapy.
TABLE 1 Single Modality Therapy Survival Standard RT Perez (14) Dillman (16) Sause (15) Cox (17) Hyperfractionated RT Sause (15) Cox (10) Cox (17) Surgery Martini (1) Rosell (11) Roth (12)
Median
1 year
9.6 11.4
40% 46% 30%
12.3 13
51%
2 year 20% 13% 19%
5 year
10% 6% 7%
6%
29% 58%
8 11
3 year
20%
25%
9% 15% 15%
9%
Surgery for Pathological N2 NSCLC: Con
217
In the study reported by Rosell et al. 60 patients with stage II and III NSCLC were randomly assigned to either three cycles of preoperative chemotherapy (mitomycin and cisplatin) or surgery alone (11). Eighty-three percent of patients in the chemotherapy arm had clinical N2 disease and 63% in the surgeryalone group. There was one pathological complete response to chemotherapy. Complete resection rate was 76% in the chemotherapy group and 90% in the surgery-only group. Median survival with preoperative chemotherapy was 26 months and 8 months with surgery alone. Three-year survival was 30% for preoperative chemotherapy and 0% for surgery alone. Prevalence of mutated K-ras oncogene was 15% in patients receiving preoperative chemotherapy and 42% in those treated with surgery alone. This may partly explain the different outcomes between the two groups. At MDACC 60 patients with stage IIIA NSCLC were randomized to surgery alone or six cycles of perioperative chemotherapy (cyclophosphamide, etoposide, and cisplatin) (12). Three cycles were given preoperatively and three cycles postoperatively in responders. Sixty-nine percent of the surgery-only group and 71% of the chemotherapy group had clinical stage IIIA disease. Only 20/28 patients in the chemotherapy arm went on to thoracotomy. There was one complete responder and eight partial responders to preoperative chemotherapy. Complete resection rates were 61 and 66% and were not statistically different. Estimated median survival in the chemotherapy group was 64 months compared to 11 months in the surgery-alone arm (p ⬍ 0.008). Estimated 2- and 3-year survivals were 60% and 56% respectively, for the perioperative chemotherapy patients and 25% and 15% for those who had surgery alone. Most recurrences following resection were distant metastases. There was one local recurrence after complete resection in the chemotherapy arm and three in the surgery-alone arm. Including patients with unresectable disease, local control was not achieved in 43% (12/28) of patients in the chemotherapy arm and 44% (14/32) of patients in the surgery arm. Radiation Therapy The results of RTOG 73-01 established a ‘‘standard’’ for definitive radiation for medically inoperable or technically unresectable NSCLC (14). This study showed survival rates with continuous-course radiation to 60 Gy in 30 fractions to be superior to lower total doses. Survival at 2 years was 20% with a local control of 50%. The ‘‘standard’’ radiation-only arms of RTOG 88-08 and CALGB 8433 both reported similar results (15,16). Patients in these studies had IIIA or IIIB disease, KPS ⱖ 70, and ⬍5% weight loss in the 3 months prior to entry. In the RTOG study, median survival was 11.4 months and 1-year survival 46%. Fiftysix percent of patients had N2 disease, 20% had N3 disease, and only 24% had
218
Gore and Byhardt
N0–1 disease (15). In the CALGB study median survival was 9.6 months and 1-, 3-, and 5-year survivals were 40%, 10%, and 6%, respectively (16). Despite the more advanced stage in the radiation series the results are similar to those in the surgical series. Survival in these studies was superior in the induction chemotherapy arms due mostly to decreased distant metastases. Locoregional progression was high, emphasizing the need for more aggressive local treatment. A phase I/II dose escalation trial of hyperfractionated radiation with total doses of 60–79.2 Gy for unresectable NSCLC demonstrated a dose response for survival (10). Survival with 69.6 Gy given at 1.2 Gy per fraction twice daily was significantly better than with lower doses. Two-year survival was 29% and median survival was 13 months. These results were confirmed in the hyperfractionation arm of RTOG 88-08, showing a 1-year survival of 51% and median survival of 12.3 months (15). Cox et al. evaluated only patients with clinical N2 disease with ⬍5% weight loss and KPS ⱖ 70 treated with hyperfractionated radiation on RTOG 83-11 and compared them to similar patients treated with ‘‘standard’’ radiation on RTOG protocols 73-01, 78-11, and 79-11 (17). Patients treated with 1.2 Gy twice daily to 69.6 Gy had significantly longer 1- and 3-year survivals (58% and 20%, respectively) compared to 2 Gy per fraction to 60 Gy (30% and 7%). More than half of the patients had T3 or T4 primary tumors. Patients with technically unresectable disease were not excluded. Despite differences in patient population compared to surgical series, these results compare favorably to those with surgery alone or surgery plus postoperative radiation. They are also similar to those in surgical series using perioperative chemotherapy or chemoradiotherapy. Multimodality Therapy-Surgery Preoperative Chemotherapy Preoperative chemotherapy or chemoradiotherapy in responsive tumors can increase resectability rates and control micrometastases. It is important that studies evaluating induction therapy followed by surgery for N2 disease use pathological staging prior to induction therapy. Studies from Memorial Sloan-Kettering (18), the CALGB (19), and Toronto (20) used preoperative chemotherapy and postoperative irradiation in pathologically documented clinical N2 disease. Complete resection rates were 51–65%, locoregional relapse 25%, and median survivals 15–21 months (Table 2). The 136 patients in the Sloan-Kettering study had clinical N2 disease defined as bulky mediastinal lymph node metastases or multiple levels of lymph node involvement in the ipsilateral mediastinum or subcarinal space on chest xrays, computed tomographic scans, or mediastinoscopy (18). Patients received two to three cycles of MVP (mitomycin ⫹ vindesine or vinblastine ⫹ high-dose cisplatin) preoperatively. The complete resection rate was 65% and the complete
Surgery for Pathological N2 NSCLC: Con
219
TABLE 2 Multimodality Therapy Survival Preop CT Martini (1) Sugarbaker (19) Burkes (20) Preop CT/RT Strauss (22) Albain (21) Weiden (24) CT/RT Dillman (16) Sause (15) Byhard (27)
Median
1 year
2 year
19 15 21 15.5 15 13
58%
13.7 13.8 12.2
54% 60% 54%
3 year
5 year
28% 23% 34%
17%
26%
26%
24%
17%
28%
pathological response rate was 14%. After complete resection, local regional recurrences occurred only in patients who did not have complete pathological responses. Median survival was 19 months and overall 3- and 5-year survival rates were 28% and 17%, respectively. The CALGB used vinblastine and cisplatin preoperatively followed by postoperative irradiation (19) with a complete resection rate of 62%. Median survival was 15 months. Burkes et al. published a similar series from Toronto, using preoperative chemotherapy. The resection rate was 51% and the median survival 21 months (20). There was a plateau in overall survival between 3 and 5 years of 34% (21). In these studies, the majority of recurrences in patients with complete resections were distant metastases. Most patients with unresectable disease died of locoregional progression. Preoperative Chemoradiotherapy Preoperative chemoradiotherapy has been assessed in phase II studies by CALGB (22), SWOG (23), and LCSG (24). These studies were intended for marginally resectable or potentially unresectable disease. This may be the most appropriate group to compare to patients treated with definitive chemoradiation (Table 2). The CALGB trial treated 41 patients with histologically confirmed T3 and/ or N2 disease (22). Eighty percent of patients had N2 disease. Both preoperatively and postoperatively, patients were treated with two cycles of cisplatin, vinblastine, and 5-FU, and radiation starting concurrently with the first cycle of chemotherapy. Each cycle of radiation was 30 Gy given in 15 fractions. Resection rate was 57% with a complete response rate of 22.5%. Median survival was 15.5 months and 1-year survival 58%. There were six (14%) treatment-related deaths. In the SWOG study, eligible patients had histologically proven N2 or N3 nodal
220
Gore and Byhardt
disease or T4 primary lesions (23). Patients were treated with 45 Gy given at 1.8 Gy per fraction concurrently with two cycles of cisplatin and etoposide. Resectability was 83%. Locoregional relapse was 11%. Three-year survival was 26% and median survival 15 months. Treatment-related mortality was 10%. Median survival time and 3-year survival rate were significantly better if mediastinal nodes were negative in the surgical specimen (30 months vs. 10 months and 44% vs. 18%). The LCSG treated 85 patients with technically unresectable disease (24). They received two cycles of cisplatin and 5-FU with 30 Gy at 2 Gy per fraction starting concurrently with the first cycle of chemotherapy. Complete pathological response was 9%. Complete resection rate was 34%. Median survival was 13 months. Postoperative mortality was 7%. Treatment-related deaths with induction chemotherapy and chemoradiotherapy were between 4 and 10%. Multimodality Therapy—Radiation The CALGB 8433 and RTOG 8808 have established standard of care for patients with unresectable stage IIIA and IIIB NSCLC with KPS ⱖ 70 and ⬍5% weight loss. These trials demonstrated median and overall survival advantage of induction chemotherapy with two cycles of vinblastine and cisplatin followed by ‘‘standard’’ radiation over ‘‘standard’’ radiation alone or hyperfractionated radiation alone (Table 2). RTOG 8808 included medically or surgically inoperable clinical stage II, IIIA, and IIIB disease (15). This was a three-arm study comparing induction chemotherapy followed by 60 Gy radiation given at 2 Gy per fraction, 60 Gy radiation alone, and 69.9 Gy given at 1.2 Gy twice daily. Only 5–7% of patients in each arm were stage II, and 18–24% of patients had N0–1 disease. The remaining patients had N2 –N3 disease. One-year survival was 60% in the induction chemotherapy arm, 46% for standard radiation, and 51% for hyperfractionated radiation. Median survivals were 13.8, 11.4, and 12.3, respectively. These differences were significant. CALGB 8433 compared the same induction chemotherapy arm to standard radiation (16). Patients had to have clinical T3 or N2 disease with ⬍5% weight loss and Zubrod performance status of 0 or 1. Median survival for CT-RT was 13.7 months compared to 9.6 months for radiation alone. Threeand 5-year survival rates were 24 and 17%, respectively, in the chemotherapy arm and 10 and 6% in the radiation-only arm. Local failure rates in both trials were high, emphasizing the need for more aggressive local treatment. Concurrent chemotherapy and radiation has demonstrated promising local response rates. Radiosensitizing chemotherapy improves local control (25). The EORTC conducted a phase III trial with nonstandard radiation of 30 Gy in 10 fractions with a 3-week break followed by 25 Gy in 10 fractions with either weekly or daily cisplatin. Survival due to improved local control was superior in the radiotherapy-plus-weekly-cisplatin group. One-, 2-, and 3-year survival
Surgery for Pathological N2 NSCLC: Con
221
rates were 54%, 26%, and 16%, respectively. Two-year survival without local failure was 31% with weekly cisplatin compared to 19% without. Jeremic et al. randomized patients to 64.8 Gy at 1.2 Gy twice daily alone or with weekly or every-other-week carboplatin and VP16 (26). Five-year overall survival, median survival, and local control were improved with weekly chemotherapy. Five-year survival was 21% versus 4.9%, median survival 18 versus 8 months, and 5-year local recurrence-free survival 34% versus 12%. There was a plateau from 3 to 5 years in overall survival and local recurrence-free survival. RTOG conducted a phase II trial of hyperfractionated radiation given concurrently with cisplatin and vinblastine (27). Inoperable stage II, IIIA, and IIIB patients were eligible, the majority of whom had ⬎5% weight loss over 3 months prior to therapy. Concurrent chemotherapy and hyperfractionated radiation had more intense acute toxicity than hyperfractionation alone, but late toxicity was acceptable. One- and 2-year survival rates were 54% and 28%, respectively, and median survival was 12.2 months (27). RTOG 94-10 is a three-arm phase III study comparing induction chemotherapy followed by standard radiation to concurrent chemotherapy and daily radiation or concurrent chemotherapy and hyperfractionated radiation in ‘‘good risk’’ patients with medically inoperable stage II and IIIA or unresectable stage IIIA and IIIB NSCLC. This phase III trial with over 600 patients compared 3 arms: (1) induction CT (cisplatin/vinblastine) plus RT (60 Gy/qd); (2) the same regimen administered concurrently; and (3) concurrent cisplatin and oral VP-16 with hyperfractionated RT (BID to 69.6 Gy). The median survival times were 14.6 months, 17.0 months, and 15.6 months, respectively. These preliminary results demonstrated a trend (p ⫽ 0.08) supporting the benefit of concurrent chemo/ RT (using daily RT) (28). CONCLUSION The best chemoradiotherapy regimens in good-risk patients yield similar results to preoperative chemoradiotherapy trials, despite the fact that there is a selection bias with more extensive IIIA and IIIB being excluded form the surgical trials. Chemoradiotherapy alone results in significant myelosuppression, esophagitis, and pneumonitis. Morbidity from induction chemoradiotherapy followed by surgery is significant. The dissection may be more difficult after radiation and/or chemotherapy due to fibrosis in the tumor area, especially if there has been a dramatic response. Surgery following induction therapy increases the frequency of pulmonary complications over that expected for surgery alone, radiotherapy alone, or chemoradiotherapy. Quality of life is a necessary part of evaluating treatment outcomes in this population. Local control rates in patients undergoing complete resection after induction therapy are high. These are a select group of patients who have responded
222
Gore and Byhardt
to induction therapy. With the best available chemotherapy and radiotherapy combinations surgical resection may not further improve results in clinical N2 disease but may only serve to increase complications and have a negative impact on quality of life. In patients with minimal N2 disease, the best available chemotherapy and radiotherapy combinations in comparable patient groups may yield similar results as surgery. This may be an acceptable alternative to surgery in patients who refuse surgery or are medically unfit for surgery. REFERENCES 1. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67(5):1037–1049. 2. Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non–small cell carcinoma of the lung. A commentary. J Thorac Cardiovasc Surg 1990; 99:48–53. 3. Greco FA, Hainsworth JD. Multidisciplinary approach to potentially curable non– small cell carcinoma of the lung. Oncology 1997; 11(1):27–36. 4. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non– small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46:603–610. 5. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:856–911. 6. Pearson FG, DeLarue NC, Ilves R, Todd TR, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy. J Thorac Cardiovasc Surg 1982; 83:1–11. 7. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53: 992–998. 8. Yoneda S, Hibino S, Gotoh I, Sakai H, Noguchi Y, Yamamoto M, Nishimura H, Izumo T, Sakura M. A comparative trial on induction chemoradiotherapy followed by surgery (CRS) or immediate surgery (IS) for stage III non–small cell lung cancer (NSCLC). Proc Asco 1995; 14:367. 9. Rosenthal SA, Curran WJ, Herbert SH, Hughes EN, Sandler HM, Stafford PM, McKenna WG. Clinical stage II non–small cell lung cancer treated with radiation therapy alone. Cancer 1992; 70(10):2410–2417. 10. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with ⱖ69.6 Gy in favorable patients with radiation therapy oncology group stage III non–small cell lung carcinoma: report of radiation therapy oncology group 83-11. J Clin Oncol 1990; 8(9):1543–1555. 11. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skagel Z, Morera-Prat J, Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery
Surgery for Pathological N2 NSCLC: Con
12.
13.
14.
15.
16.
17.
18.
19.
20.
21. 22.
23.
223
alone in patients with non–small cell lung cancer. N Engl J Med 1994; 330(3):153– 158. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr. JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Kong WK. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non–small cell lung cancer. J Natl Cancer Inst 1994; 86:673–680. Jolly PC, Hutchinson BS, Detterbeck F, Guyton SW, Hofer B, Anderson RP. Routine computed tomographic scans, selective mediastinoscopy, and other factors in evaluation of lung cancer. J Thorac Cardiovasc Surg 1991; 102:266–271. Perez C, Stanley K, Rubin P, Kramer S, Brady L, Pere-Tamayo R, Brown GS, Concannon J, Rotman M, Seydel HG. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non–oat cell carcinoma of the lung. Preliminary report by the Radiation Oncology Therapy Group. Cancer 1980; 45(11):2744–2753. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, Dar AR, Cox JD. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advance, unresectable non–small cell lung cancer. J Natl Cancer Inst 1995; 87(3):198–205. Dillman RO, Herdon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non–small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88(17):1210–1215. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Perez CA. N2 (clinical) non– small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1991; 20:7–12. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, Heelan R, McCormack PM, Pisters KMW, Rigas JR, Rusch VW, Ginsberg RJ. Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365–1374. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR, Cancer and Leukemia Group B Thoracic Surgery Group. Results of Cancer and Leukemia Group B protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA non– small cell lung cancer. J Thorac Cardiovasc Surg 1995; 109:473–485. Burkes RL, Shepherd FA, Ginsberg RJ, Blackstein ME, Goldberg M, Todd T, Pearson FG, Jones C, Greenwood C. Induction chemotherapy with MVP for stage III (N2) unresectable non–small-cell lung cancer: results of Toronto phase II trial. J Clin Oncol 1992; 10:580–586. Albain KS. Induction chemotherapy with/without radiation followed by surgery in stage III non–small-cell lung cancer. Oncology 1997; 11(suppl 9):51–57. Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non–small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10(8):1237–1244. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ,
224
24.
25.
26.
27.
28.
Gore and Byhardt Beasley KR, Livingston RB. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13(8): 1880–1892. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non–small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83(4):266–272. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier J, van Zandwijk N, Bartelink H. Effects of concomitant cisplatin and radiotherapy on inoperable non–small-cell lung cancer. N Engl J Med 1992; 326(8):524–530. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non– small-cell lung cancer. J Clin Oncol 1995; 13(2):452–458. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RLS, Coughlin C, Scarantino C, Rotman M, Emami B. Concurrent hyperfractionated irradiation and chemotherapy for unresectable non–small cell lung cancer. Cancer 1995; 75(9):2337– 2344. Curran WJ, Jr, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wasserman TH, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non–small cell lung cancer (NSCLS): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc ASCO 2000; 19, 484a.
14 Management of Superior Sulcus Tumors Garrett L. Walsh, Sunil Gandhi, and Ritsuko Komaki University of Texas M. D. Anderson Cancer Center, Houston, Texas
INTRODUCTION Controversy and confusion are terms that appropriately describe the diagnosis, workup, and management of superior sulcus tumors, first described over a century and a half ago. As a relatively rare bronchogenic malignancy, accounting for less than 3% of all lung cancers, there have been no randomized, controlled trials evaluating treatment modalities. Most of the progress has been made through single-institution phase II trials using historical controls as a measure of success. Advances in surgical and radiation therapy techniques have improved local control and long-term survival to the point where the expected cure rates are comparable to those of non–superior sulcus lung cancers. Despite treatment advances, locoregional recurrence following treatment can cause debilitating problems from invasion into surrounding musculoskeletal and neurovascular structures that can lead to severe pain, often difficult to control with narcotics. Tumor growth can lead to the progressive loss of function of the upper extremity on the affected side. A thoracic surgeon need only encounter one such patient in his career, who has lost limb function, to serve as an impetus to develop aggressive surgical and multimodality treatments to deal both with the devastating local problems and the systemic metastatic disease that these tumors inflict. In this chapter we will 225
226
Walsh et al.
examine the clinical changes in evaluation, management, and multimodality approaches that have evolved over the past 50 years in caring for these patients. HISTORICAL CONTROVERSIES RELATED TO PRESENTATION AND ORIGIN A patient with a tumor involving the apex of the lung associated with localized pain and an ulnar neuropathy was first described by Edwin Hare in the London Medical Gazette in 1838 (1). The etiology of this mass was felt to be infectious. In 1924 and 1932, Henry Pancoast described a clinical syndrome that he had seen in seven patients with small opacities in their chest apices with local rib destruction and often vertebral infiltration (2,3). The clinical constellation of symptoms (Pancoast syndrome) included pain around the shoulder with or without radiation to the axilla, scapula, and down the arm, Horner’s syndrome, and atrophy of the muscles of the hand. Death occurred as a result of what seemed to be a comparatively trivial growth in the thoracic inlet without detectable metastases. He had attributed the etiology of the destructive radiographic process to an embryonic rest. It was not until 1932 that Tobias in Argentina correctly identified this process as a bronchogenic cancer (4). RADIOGRAPHIC CONTROVERSY: WHAT LESIONS ACTUALLY MEET THE CRITERIA OF A SUPERIOR SULCUS TUMOR? Pancoast in his original paper was very specific in his description of the superior pulmonary sulcus tumors as always occurring at a definite location in the thoracic inlet producing constant and the characteristic clinical presentation of pain in the eighth cervical and first and second thoracic root distribution. Pancoast, who was a radiologist and at that time the chairman of the section of radiology of the American Medical Association, described the lesion radiographically as ‘‘a small, homogeneous density at the extreme apex with more or less local rib destruction and often vertebral infiltration.’’ There was no description of involvement of the superior vena cava or the phrenic or recurrent laryngeal nerves (5). Large tumors with their epicenter in the center of the upper lobe with extension into the apex can also produce a clinical Pancoast syndrome but do not meet his strict radiographic definition. True superior sulcus tumors can often be overlooked as thickening of the apical pleura and are often small tumors, leading to a delay in diagnosis in many patients. Many series do not follow these strict definitions and therefore would include bulky upper-lobe tumors in their patient population. This often makes it difficult to compare one series results to the next. The larger tumors may be
Management of Superior Sulcus Tumors
227
associated with symptoms of cough, hemoptysis, and superior vena caval obstruction that are not typically associated with these smaller apical tumors, which produce pain and a subtle thickening of the apical pleura. Today, better clinical appreciation of these tumors often will lead to a diagnosis of a superior sulcus tumor prior to the development of advanced wasting of the hypothenar hand muscles or ulnar neuropathy as was seen 60 years ago. By definition, these tumors are T3 or T4 and therefore are associated with pain around the shoulder, axilla, or arm and varying degrees of neurological involvement or loss of function depending on the extent of nerve root, sympathetic nerve, rib, or vertebral body involvement. Similarly, an apical tumor without the clinical presentation of pain would not qualify as a superior sulcus tumor. INITIAL CONTROVERSIAL TREATMENT APPROACHES The opinion of the medical community in the 1930s and 1940s was that these lesions were uniformly fatal with no known 5-year survivors, with death usually occurring within 10–14 months from the time of diagnosis (6). Pancoast stated that these tumors were clearly not amenable to surgical resection and were also considered radioresistant. Fifty years later we know that both of these statements were incorrect. Surgeons had been reluctant to attempt resection because of the typical dense infiltration of the tumor into the surrounding tissue. While it was felt that radiation therapy could not cure a patient, in the early 1950s Haas et al. described a patient who had not only survived nearly 3 years after radiation therapy but also, more importantly, had significant improvement in symptoms (7). It was not until 1956 that Chardack and MacCallum published the first successful report of a combined-modality (surgery followed by 65-Gy radiation therapy) cure of a patient (8). In the 1960s, with higher dosage and wider portals including the mediastinum, vertebral bodies, and supraclavicular fossae, reports were published with 5-year survivors after radiation therapy alone. Shaw and colleagues in 1961 described a fortuitous case where a patient with an ‘‘unresectable’’ Pancoast tumor responded dramatically with a 50% decrease in the tumor volume after an initial 30 Gy of radiation therapy (9). This was sufficient to permit a complete resection of the lesion. This patient lived for 27 years without recurrence of the tumor. Their approach was popularized by Paulson and has remained the ‘‘standard’’ approach for this lesion for over 30 years in many centers (10). Surgical techniques have also evolved over the past 50 years, and tumors that involve the subclavian vessels or the vertebral body, previously considered an absolute contraindication to resection, can now be safely resected and reconstructed with minimal morbidity and mortality (11). We will now examine some of the specific details of these changing treatment modalities that have occurred and the present-day evaluation of these lesions.
228
Walsh et al.
EVALUATION OF A PATIENT The early diagnosis of a superior sulcus tumor often requires an astute clinician. The periscapular and shoulder pain is frequently misdiagnosed as bursitis or arthritis or cervical degenerative disc disease with secondary radicular pain into the arm. The mean delay in diagnosis is usually 5–7 months but can vary from 1 to 48 months (12). Pain or symptoms along an ulnar nerve distribution should prompt a chest radiograph regardless of the age of the patient and especially if there is a smoking history. We have seen advanced Pancoast tumors in individuals even in their twenties. Many have been erroneously diagnosed as ulnar entrapment syndrome or carpal tunnel syndrome and have undergone transposition and decompressive procedures on these nerves with persistent postoperative pain that usually prompts a more detailed evaluation. A good-quality plain chest radiograph with a special emphasis on the symmetry of the apices will often be the first step to appropriate diagnosis of the problem. Horner’s syndrome [ptosis, enophthalmos, and a meiotic (small) pupil because of unopposed parasympathetic innervation] and dryness and inability to sweat on the side of the face usually are seen in more locally advanced tumors that have invaded the stellate ganglion on the vertebral body. This usually occurs in 20–40% of the patients (11,13). Although recognized as a poor prognostic clinical sign, this does not necessarily rule out surgery (12). These patients, on presentation, are often debilitated because of chronic pain and have lost a fair amount of weight because of the secondary anorexia that results. While their presenting performance (Karnofsky) status can be so poor to the point that they are felt not to be a surgical candidate, an intense program of appropriately dosed narcotics, either orally or by patch administration, can dramatically improve their quality of life and appetite. We have used Megace over a short time frame as an appetite stimulant to help patients regain weight and muscle mass that they have lost over several months secondary to anorexia and pain. Some patients can be nutritionally optimized within 2–3 weeks to a point where a major resection can be performed safely. The medical history must also focus on other bone symptoms away from the tumor and a detailed review of systems trying to discern new neurological findings. The physical examination will focus on the general physical appearance of the patient, the supraclavicular fossa that often reveals the asymmetry and firmness on the side of the tumor, a search for palpable lymph nodes on both sides of the neck and axilla, and the degree of neurological changes in the arm. Sensory changes usually occur at the T1 level and can extend equally cephalad and caudally into the C8 and T2 levels and less commonly into the T3 and C7 levels. Progressive neurological changes occur as these lesions initially abut, displace, and finally invade these intercostal nerves and the roots of the brachial
Management of Superior Sulcus Tumors
229
plexus. Patients with more prolonged symptoms will also begin to show atrophy of the hypothenar muscles. Progressive motor loss in the hand, wrist, and arm usually indicates a more advanced tumor with progressive cephalad infiltration rather than displacement of the brachial plexus (14). We would view upper-trunk involvement with motor loss as a contraindication to a surgical approach. IS THE RADIOGRAPHIC WORKUP ANY DIFFERENT FROM THAT DONE FOR ROUTINE LUNG CANCERS? Most bronchogenic malignancies can be fully evaluated with a plain chest radiograph and a CT scan of the chest (which includes a few cuts of the upper abdomen) with bone scans and brain scans requested only if clinical symptoms exist. The chest radiograph is also very important in the initial diagnosis of a superior sulcus tumor. Special attention must be focused on the lung apices, above the medial portion of the clavicle within the arc of the first rib on the posteroanterior film. Asymmetrical pleural thickening is usually the first subtle radiographic finding. An elevation of the hemidiaphragm on the affected side may indicate a more advanced lesion that has involved the phrenic nerve. CT scans of the chest are important to assess for enlarged hilar or mediastinal nodes and for other parenchymal metastases. Patients with superior sulcus tumors in addition require MRI evaluations as the coronal and sagittal imaging techniques yield important details for surgical planning, including the involvement of the subclavian vessels, the extent of infiltration of the brachial plexus, and the number of bony structures invaded including the ribs, clavicle, sternum, and vertebral body. These details cannot be as readily appreciated by computed tomography. The extent of vertebral body involvement is critical for surgical planning including the extension into the neural canal, with or without epidural extension and dural sac compression. This anatomical location of a lung cancer is the only site where we routinely obtain an MRI for evaluation, which yields more information than a CT scan for preoperative evaluation. Positron emission tomography (PET) will likely be more frequently utilized in the workup and follow-up of patients following surgery and radiation therapy in the next 5 years but there is little information in this subset of lung cancer patients now. While the biological behavior of superior sulcus tumors is considered by some to remain more locally aggressive for a longer period of time prior to metastasis, many patients will eventually die from metastatic disease. As the brain is the most common site of systemic failure, we routinely perform MRI imaging of the brain prior to considering treatment options and embarking on major surgical resections. Bone scans are also done to complete the metastatic workup and help evaluate the extent of bony involvement of the ribs, clavicle, sternum, and vertebral bodies.
230
Walsh et al.
PHYSIOLOGICAL TESTING All patients undergo physiological pulmonary testing with a baseline spirometry, pre- and postbronchodilators, and diffusion capacity measurements. Exercise oxygen consumption testing can be performed in patients with marginal respiratory parameters (15). Xenon ventilation and perfusion scans help to predict if a formal lobectomy can be tolerated or if a more limited segmental or nonanatomical wedge resection is required. It is hard to predict the physiological compromise to a patient’s respiratory function following the en bloc resections that usually require one to three ribs and an extended posterolateral thoracotomy. Although the chest wall defect does not usually require formal reconstruction (as it is very well covered by the scapula and chest wall musculature), these patients seem to experience a fair amount of lung volume loss on the operative hemithorax. Resection of the scalene muscles and on occasion the clavicle further leads to rotation of the shoulder and loss of some of these accessory muscles of respiration. These are important considerations when trying to decide to proceed to an anatomical lobectomy in these patients. Many require assisted ventilation and are prone to collapse of the remaining lobe or lobes on the operative side for a few days, postoperatively, until better pulmonary mucous clearance and chest wall movement are possible on the operative side.
PRETREATMENT HISTOLOGICAL DIAGNOSIS: IS IT NECESSARY AND HOW SHOULD IT BE OBTAINED? There are several conditions, including fungal and bacterial infections (Staphylococcus, Cryptococcus, Echinococcus, and Actinomyces), lymphomas, and plasmacytomas, that can mimic a superior sulcus tumor; therefore, we feel it is essential to obtain tissue for diagnosis prior to treatment or enrollment on a protocol (16). Occasionally these tumors can be of small cell histology, which is better treated nonsurgically. Transthoracic fine-needle aspiration (FNA) has yielded the best results with a positive diagnostic yield in ⬎90% of patients (14). Pneumothorax is rare as these tumors are often invading the surrounding structures and the lung cannot fall away from the chest wall. If a pneumothorax does result and the tumor does in fact ‘‘fall away’’ from the thoracic apex, it is not a Pancoast tumor and will be at worst a T2 (visceral pleural involvement) lesion. Palpable scalene or supraclavicular nodes can be biopsied directly in the outpatient clinic. Because of the peripheral location, sputum cytology and bronchoscopy are usually less rewarding with positive results in only 20–40% of patients. Thoracoscopy, while useful for the evaluation of the pleural cavity, is not generally utilized to avoid tumor spill that may result from manipulation of the adhesions at the apex of the chest. Mediastinoscopy should be used in patients with clinically enlarged nodes
Management of Superior Sulcus Tumors
231
by CT scan (⬎1 cm) because of the poor outcome in many series in patients with N 2 disease with superior sulcus tumors. The histology of superior sulcus tumors in most series demonstrates 25– 40% squamous, 25–60% adenocarcinoma (with adenocarcinomas representing nearly twice the incidence of squamous histology in more recent studies over the past 10 years) with the remaining 5–15% large cell, mixed, and approximately 2–5% small cell histologies. NODAL INVOLVEMENT: SHOULD STANDARD N 2 AND N 3 NODAL DEFINITIONS APPLY TO SUPERIOR SULCUS TUMORS? All of the Pancoast tumors are at minimum T3 (parietal pleura, rib involvement) or T4 (vertebral body or mediastinal structure). Patients with N 2 disease are known to have a poor overall survival. Therefore, in the face of radiographically enlarged (⬎1 cm) mediastinal nodes, we would first proceed to mediastinoscopy prior to resection to confirm or rule out N 2 disease. Even in the setting of a normal mediastinum by CT scan, many would argue that mediastinoscopy should be routine as the long-term survival of these patients with N 2 disease is so poor that it would not be warranted to proceed with a major en bloc resection with no survival advantage (17). If positive paratracheal or subcarinal nodes were demonstrated preoperatively, then surgery would be abandoned as a treatment option in favor of radiation therapy. By definition, a supraclavicular node or scalene node on the same side of the tumor is an N 3 node. We would, however, consider a node in this setting to be more of a locoregional node and would not exclude a patient from surgery on this basis if the surgeon felt all disease could be resected at the time of surgery. Some studies show an obvious survival difference in N 1 disease versus N 2 or N 3 but no difference between N 2 and N 3 patients (18). Muscolino et al., however, have demonstrated that the presence of an ipsilateral supraclavicular metastasis was not a contraindication to operation (19). Hilaris et al. demonstrated improved survival in patients with N 0 , N 1 , or N 3 disease compared to N 2 (20). Other European authors, Grunenwald and Spaggiari, who have experience with radical resections for superior sulcus tumors, also adopt this philosophy toward cervical nodes (21). DIFFERENT SURGICAL APPROACHES AND WHEN THEY ARE USED A patient is considered to be a surgical candidate unless: (1) he has documented metastatic disease to the mediastinum or other organs, (2) he has pronounced
232
Walsh et al.
motor loss of the arm with MRI evidence of extensive brachial plexus, or (3) he has direct invasion of the trachea or esophagus. The CT scans and the MRI are extremely important in planning the surgical approach. A surgeon should consider an operation only in patients in whom he feels a complete surgical resection of all gross disease is possible. Debulking of Pancoast tumors is of no benefit and does not improve local control. We have utilized Dartevelle’s classification of tumor location along the first rib as anterior, middle, or posterior to guide our surgical approach (22,23). We utilize one of three surgical approaches to resect these lesions: (1) an anterior neck approach only, (2) a posterior approach only, or (3) a combined anterior and posterior approach. Anteriorly placed tumors often abut or invade the subclavian vessels. If the subclavian vein is involved by MRI, a hockey-stick incision is made along the anterior border of the sternocleidomastoid muscle and extended along the clavicle. The clavicle is resected with a Gigli saw to improve the exposure to the subclavian vessels (Figure 1). No attempt is made to salvage, plate, or reconstruct the clavicle. Removal of the clavicle affords excellent exposure of the thoracic inlet. Tumors that involve the vein have usually resulted in collateralization around the scapula and chest wall over many months; therefore, it is not necessary to reconstruct the subclavian vein and simple ligation of the subcla-
FIGURE 1 Initial dissection of an anteriorly positioned superior sulcus tumor with an L-shaped incision along the anterior border of the sternocleidomastoid and along the inferior margin of the right clavicle.
Management of Superior Sulcus Tumors
233
vian and usually the jugular vein is well tolerated. Occasionally, mild arm swelling can result if the vein was not previously fully obstructed, but this edema quickly improves once collaterals develop. On the left, the thoracic duct is carefully identified and ligated at its junction with the internal jugular and subclavian veins. This will prevent the development of a postoperative chyle leak, which will either drain into the neck wound or track into the chest requiring reoperation in most instances. When the tumor appears to displace rather than involve the subclavian vessels, the clavicle can often be left in place. We have modified Dartevelle’s anterior approach and have tried to maintain the clavicle as much as possible. The cosmetic and functional deformity that results when the clavicular support is removed, with the secondary internal rotation and drooping of the arm, can be avoided. If the oncological dissection is compromised, however, the clavicle is removed. The anterior scalene muscle requires division next and the course of the phrenic nerve along the anterior border of scalenus anterior is identified and preserved if uninvolved or transected if infiltrated with tumor. Dissection of the subclavian artery in the subadventitial plane often permits elevation of the subclavian artery away from the tumor mass. Care must be taken to divide the internal mammary artery to permit elevation of the subclavian artery off of the first rib. If the patient has been radiated prior to resection, care must be taken to ligate this vessel and avoid a suture cutting through the vessel, which is extremely soft and fragile (even in a nonradiated field). Dissection proximally of the right subclavian at its junction with the takeoff of the carotid from the innominate artery must avoid injury to the recurrent nerve, which branches from the vagus at this point and loops inferiorly around the subclavian artery. Significant morbidity can result if the recurrent is injured resulting in poor vocal cord apposition and a poor cough postoperatively increasing the risk of atelectasis and pneumonia. The thyrocervical trunk often requires ligation and the dissection proceeds laterally attempting to elevate the subclavian artery from the first rib. The vertebral artery may also require ligation. With the subclavian artery mobilized, it is possible to divide the anterior portion of the first and second ribs from the front (Figure 2). If the subclavian artery is invaded rather than displaced by the tumor, it is resected and primarily reanastomosed if the segment is short, or an interposition graft of PTFE utilized for the reconstruction if a greater length is resected. Invasion of the subclavian artery should not be considered a contraindication to resection as this vessel can easily be resected through this anterior approach (Figure 3). The brachial plexus can now be easily identified as it courses at an angle just lateral to the scalene anterior. Direct neurolysis is usually possible to free the plexus from the tumor. If required, the lower trunk of the plexus can be sharply divided if tumor infiltrates rather than displaces the nerve. In some patients with small tumors, it is possible to divide the ribs posteriorly from the front and deliver the specimen into the neck wound, amputating a
234
Walsh et al.
FIGURE 2 This dissection demonstrates the division of the first and second ribs from the anterior approach with resection of the subclavian vein and jugular vein. In this case the subclavian artery has been dissected along the plane of Leriche and spared. The brachial plexus is also demonstrated.
generous wedge of the upper lobe with a GIA or TA stapling device and allowing the lung to retract into the hemithorax. As such, a posterolateral thoracotomy is avoided. Anterior thoracotomies can also be performed with the patient supine and a formal lobectomy performed from the front. For tumors that are extensive involving both the vessels anteriorly and the spine posteriorly, following mobilization of the vessels and plexus, and anterior division of one or two ribs, the neck incision can be closed and the patient repositioned for the posterior resection and lobectomy. In patients with tumors that are posteriorly situated only, with a clear plane by MRI away from the subclavian vessels, the surgical approach can be in a standard manner, entirely from the back with an extended posterolateral thoracotomy. If the tumor involves the vertebral body and will require resection, the head
Management of Superior Sulcus Tumors
235
FIGURE 3 In this patient the tumor involved subclavian artery and required a 6mm PTFE interposition graft to reconstruct the resected subclavian artery resected en bloc with the tumor. The vagus nerve has been transposed with the recurrent nerve behind the stump of the subclavian artery. The phrenic nerve has been preserved.
is positioned in cervical tongs at the time of lateral positioning (Figure 4). A generous posterolateral thoracotomy, with extension to the base of the neck by dividing the latissimus dorsi, trapezius, and rhomboids, is performed. A chest spreader is placed beneath the scapula and stabilized into one of the interspaces inferiorly. This permits the scapula to be elevated away from the chest wall and provides superb exposure to the superior sulcus of the chest. An interspace is chosen one below those involved with tumor to obtain a clear inferior margin. If this is not clear from the external examination of the hemithorax, an anterior interspace is initially opened to permit digital palpation of the chest from within. The anterior ribs are first divided. If a previous anterior approach has been performed, it is now safer and quicker to divide the first rib, if it was not previously
236
Walsh et al.
FIGURE 4 Patient positioned for an extended posterolateral thoracotomy with a chest wall resection and vertebral body resection for a superior sulcus tumor. The head is held in place with cervical tongs during the procedure to avoid movement in the spinal axis.
divided, knowing that the neurovascular structures have been safely elevated and mobilized away from the first rib. Otherwise, care must be taken to stay precisely in the subperiosteal plane, to avoid injury to these vital structures. If the paraspinal muscles are not involved, they are elevated from the transverse processes. The ribs are disarticulated from each of the transverse processes and the vertebral body taking care not to place excessive traction on the nerve roots, which can result in a dural tear where the nerve root exits the dural sac. If this tear at the ‘‘axilla’’ of the nerve root goes unrecognized, this will result in a serious postoperative cerebrospinal fluid leak that generally does not seal with conservative maneuvers such as the placement of a lumbar drain. Often, a re-do thoracotomy, drilling out the neural foramen and direct suture repair of the dural sac and coverage with autogeneous tissue, is required. Each of the neurovascular bundles is individually ligated as one proceeds cephalad. Dissection of the T1 nerve root must proceed slowly. This is a large root that courses just above the angle of the second rib, and runs beneath the first rib to join the C8 root. The neck of the first rib essentially bisects these two nerve roots. To safely remove the first rib without injury to these nerves, it is sometimes easier to divide the first rib at its angle